{"date": "2024-12-31", "symbol": "PFE", "type": "income_statement_annual", "result": {"date": "2024-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-02-27", "acceptedDate": "2025-02-27 16:27:18", "fiscalYear": "2024", "period": "FY", "revenue": 63627000000, "costOfRevenue": 21781000000, "grossProfit": 41846000000, "researchAndDevelopmentExpenses": 10738000000, "generalAndAdministrativeExpenses": 11471000000, "sellingAndMarketingExpenses": 3300000000, "sellingGeneralAndAdministrativeExpenses": 14730000000, "otherExpenses": -105000000, "operatingExpenses": 25363000000, "costAndExpenses": 47144000000, "netInterestIncome": -2546000000, "interestIncome": 545000000, "interestExpense": 3091000000, "depreciationAndAmortization": 7013000000, "ebitda": 18127000000, "ebit": 11114000000, "nonOperatingIncomeExcludingInterest": 5369000000, "operatingIncome": 16483000000, "totalOtherIncomeExpensesNet": -8460000000, "incomeBeforeTax": 8023000000, "incomeTaxExpense": -28000000, "netIncomeFromContinuingOperations": 8051000000, "netIncomeFromDiscontinuedOperations": 11000000, "otherAdjustmentsToNetIncome": 0, "netIncome": 8020000000, "netIncomeDeductions": -11000000, "bottomLineNetIncome": 8031000000, "eps": 1.42, "epsDiluted": 1.41, "weightedAverageShsOut": 5664000000, "weightedAverageShsOutDil": 5700000000}}
{"date": "2023-12-31", "symbol": "PFE", "type": "income_statement_annual", "result": {"date": "2023-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-02-22", "acceptedDate": "2024-02-22 13:17:37", "fiscalYear": "2023", "period": "FY", "revenue": 59553000000, "costOfRevenue": 29213000000, "grossProfit": 30340000000, "researchAndDevelopmentExpenses": 10578000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 14470000000, "otherExpenses": 0, "operatingExpenses": 25048000000, "costAndExpenses": 54261000000, "netInterestIncome": -585000000, "interestIncome": 1624000000, "interestExpense": 2209000000, "depreciationAndAmortization": 6290000000, "ebitda": 9557000000, "ebit": 3267000000, "nonOperatingIncomeExcludingInterest": 2025000000, "operatingIncome": 5292000000, "totalOtherIncomeExpensesNet": -4234000000, "incomeBeforeTax": 1058000000, "incomeTaxExpense": -1114000000, "netIncomeFromContinuingOperations": 2172000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 2133000000, "netIncomeDeductions": 14000000, "bottomLineNetIncome": 2119000000, "eps": 0.3755, "epsDiluted": 0.3712, "weightedAverageShsOut": 5643000000, "weightedAverageShsOutDil": 5709000000}}
{"date": "2022-12-31", "symbol": "PFE", "type": "income_statement_annual", "result": {"date": "2022-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-02-23", "acceptedDate": "2023-02-23 14:12:53", "fiscalYear": "2022", "period": "FY", "revenue": 100330000000, "costOfRevenue": 38240000000, "grossProfit": 62090000000, "researchAndDevelopmentExpenses": 11426000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 13115000000, "otherExpenses": 0, "operatingExpenses": 24541000000, "costAndExpenses": 62781000000, "netInterestIncome": -987000000, "interestIncome": 251000000, "interestExpense": 1238000000, "depreciationAndAmortization": 5064000000, "ebitda": 41031000000, "ebit": 35967000000, "nonOperatingIncomeExcludingInterest": 1582000000, "operatingIncome": 37549000000, "totalOtherIncomeExpensesNet": -2820000000, "incomeBeforeTax": 34729000000, "incomeTaxExpense": 3328000000, "netIncomeFromContinuingOperations": 31401000000, "netIncomeFromDiscontinuedOperations": -1000000, "otherAdjustmentsToNetIncome": 0, "netIncome": 31365000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 31365000000, "eps": 5.5929, "epsDiluted": 5.471, "weightedAverageShsOut": 5608000000, "weightedAverageShsOutDil": 5733000000}}
{"date": "2021-12-31", "symbol": "PFE", "type": "income_statement_annual", "result": {"date": "2021-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-02-24", "acceptedDate": "2022-02-24 14:25:01", "fiscalYear": "2021", "period": "FY", "revenue": 81288000000, "costOfRevenue": 34413000000, "grossProfit": 46875000000, "researchAndDevelopmentExpenses": 13828000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 12254000000, "otherExpenses": 0, "operatingExpenses": 26082000000, "costAndExpenses": 60495000000, "netInterestIncome": -1255000000, "interestIncome": 36000000, "interestExpense": 1291000000, "depreciationAndAmortization": 5191000000, "ebitda": 30793000000, "ebit": 25602000000, "nonOperatingIncomeExcludingInterest": -4809000000, "operatingIncome": 20793000000, "totalOtherIncomeExpensesNet": 3518000000, "incomeBeforeTax": 24311000000, "incomeTaxExpense": 1852000000, "netIncomeFromContinuingOperations": 22459000000, "netIncomeFromDiscontinuedOperations": -268000000, "otherAdjustmentsToNetIncome": 1000000, "netIncome": 22147000000, "netIncomeDeductions": 1000000, "bottomLineNetIncome": 22146000000, "eps": 3.9539, "epsDiluted": 3.8798, "weightedAverageShsOut": 5601000000, "weightedAverageShsOutDil": 5708000000}}
{"date": "2025-09-28", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2025-09-28", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-11-04", "acceptedDate": "2025-11-04 07:03:48", "fiscalYear": "2025", "period": "Q3", "revenue": 16654000000, "costOfRevenue": 4172000000, "grossProfit": 12482000000, "researchAndDevelopmentExpenses": 3936000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 3186000000, "otherExpenses": 1810000000, "operatingExpenses": 8932000000, "costAndExpenses": 13104000000, "netInterestIncome": -514000000, "interestIncome": 138000000, "interestExpense": 652000000, "depreciationAndAmortization": 1662000000, "ebitda": 5648000000, "ebit": 3986000000, "nonOperatingIncomeExcludingInterest": -436000000, "operatingIncome": 3550000000, "totalOtherIncomeExpensesNet": -216000000, "incomeBeforeTax": 3334000000, "incomeTaxExpense": -216000000, "netIncomeFromContinuingOperations": 3550000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 3541000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 3541000000, "eps": 0.62, "epsDiluted": 0.62, "weightedAverageShsOut": 5685000000, "weightedAverageShsOutDil": 5714000000}}
{"date": "2025-06-29", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2025-06-29", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-08-05", "acceptedDate": "2025-08-05 07:16:27", "fiscalYear": "2025", "period": "Q2", "revenue": 14653000000, "costOfRevenue": 5233000000, "grossProfit": 9420000000, "researchAndDevelopmentExpenses": 2443000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 3402000000, "otherExpenses": 0, "operatingExpenses": 5845000000, "costAndExpenses": 11078000000, "netInterestIncome": -498000000, "interestIncome": 156000000, "interestExpense": 654000000, "depreciationAndAmortization": 1625000000, "ebitda": 5323000000, "ebit": 3698000000, "nonOperatingIncomeExcludingInterest": -123000000, "operatingIncome": 3575000000, "totalOtherIncomeExpensesNet": -531000000, "incomeBeforeTax": 3044000000, "incomeTaxExpense": 141000000, "netIncomeFromContinuingOperations": 2903000000, "netIncomeFromDiscontinuedOperations": 25000000, "otherAdjustmentsToNetIncome": 0, "netIncome": 2910000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 2885000000, "eps": 0.51, "epsDiluted": 0.51, "weightedAverageShsOut": 5685000000, "weightedAverageShsOutDil": 5706000000}}
{"date": "2025-03-30", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2025-03-30", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-05-05", "acceptedDate": "2025-05-05 16:00:34", "fiscalYear": "2025", "period": "Q1", "revenue": 13715000000, "costOfRevenue": 3888000000, "grossProfit": 9827000000, "researchAndDevelopmentExpenses": 2179000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 3024000000, "otherExpenses": 0, "operatingExpenses": 5203000000, "costAndExpenses": 9091000000, "netInterestIncome": -511000000, "interestIncome": 143000000, "interestExpense": 654000000, "depreciationAndAmortization": 1618000000, "ebitda": 5056000000, "ebit": 3438000000, "nonOperatingIncomeExcludingInterest": 1186000000, "operatingIncome": 4624000000, "totalOtherIncomeExpensesNet": -1840000000, "incomeBeforeTax": 2784000000, "incomeTaxExpense": -189000000, "netIncomeFromContinuingOperations": 2973000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 2967000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 2967000000, "eps": 0.5228, "epsDiluted": 0.5196, "weightedAverageShsOut": 5675000000, "weightedAverageShsOutDil": 5710000000}}
{"date": "2024-12-31", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2024-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-02-27", "acceptedDate": "2025-02-27 16:27:18", "fiscalYear": "2024", "period": "Q4", "revenue": 17763000000, "costOfRevenue": 4795000000, "grossProfit": 12968000000, "researchAndDevelopmentExpenses": 3017000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 4226000000, "otherExpenses": 0, "operatingExpenses": 7243000000, "costAndExpenses": 12038000000, "netInterestIncome": -569000000, "interestIncome": 170000000, "interestExpense": 739000000, "depreciationAndAmortization": 1791000000, "ebitda": 5143000000, "ebit": 3352000000, "nonOperatingIncomeExcludingInterest": 2373000000, "operatingIncome": 5725000000, "totalOtherIncomeExpensesNet": -5735000000, "incomeBeforeTax": -10000000, "incomeTaxExpense": -421000000, "netIncomeFromContinuingOperations": 411000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 403000000, "netIncomeDeductions": -7000000, "bottomLineNetIncome": 410000000, "eps": 0.0724, "epsDiluted": 0.0719, "weightedAverageShsOut": 5667000000, "weightedAverageShsOutDil": 5703000000}}
{"date": "2024-09-29", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2024-09-29", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-11-04", "acceptedDate": "2024-11-04 16:06:08", "fiscalYear": "2024", "period": "Q3", "revenue": 17702000000, "costOfRevenue": 6931000000, "grossProfit": 10771000000, "researchAndDevelopmentExpenses": 2565000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 3238000000, "otherExpenses": 0, "operatingExpenses": 5803000000, "costAndExpenses": 12734000000, "netInterestIncome": -667000000, "interestIncome": 116000000, "interestExpense": 783000000, "depreciationAndAmortization": 1755000000, "ebitda": 7253000000, "ebit": 5498000000, "nonOperatingIncomeExcludingInterest": -530000000, "operatingIncome": 4968000000, "totalOtherIncomeExpensesNet": -253000000, "incomeBeforeTax": 4715000000, "incomeTaxExpense": 234000000, "netIncomeFromContinuingOperations": 4481000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 4473000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 4473000000, "eps": 0.7893, "epsDiluted": 0.784, "weightedAverageShsOut": 5667000000, "weightedAverageShsOutDil": 5705000000}}
{"date": "2024-06-30", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2024-06-30", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-08-05", "acceptedDate": "2024-08-05 15:54:43", "fiscalYear": "2024", "period": "Q2", "revenue": 13283000000, "costOfRevenue": 5040000000, "grossProfit": 8243000000, "researchAndDevelopmentExpenses": 2676000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 3688000000, "otherExpenses": 0, "operatingExpenses": 6364000000, "costAndExpenses": 11404000000, "netInterestIncome": -648000000, "interestIncome": 130000000, "interestExpense": 778000000, "depreciationAndAmortization": 1731000000, "ebitda": 2405000000, "ebit": 674000000, "nonOperatingIncomeExcludingInterest": 1205000000, "operatingIncome": 1879000000, "totalOtherIncomeExpensesNet": -1982000000, "incomeBeforeTax": -103000000, "incomeTaxExpense": -134000000, "netIncomeFromContinuingOperations": 31000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 24000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 24000000, "eps": 0.0042, "epsDiluted": 0.0042, "weightedAverageShsOut": 5666000000, "weightedAverageShsOutDil": 5696000000}}
{"date": "2024-03-31", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2024-03-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-05-08", "acceptedDate": "2024-05-08 15:56:17", "fiscalYear": "2024", "period": "Q1", "revenue": 14879000000, "costOfRevenue": 4381000000, "grossProfit": 10498000000, "researchAndDevelopmentExpenses": 2480000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 3459000000, "otherExpenses": 0, "operatingExpenses": 5939000000, "costAndExpenses": 10320000000, "netInterestIncome": -661000000, "interestIncome": 129000000, "interestExpense": 790000000, "depreciationAndAmortization": 1736000000, "ebitda": 5948000000, "ebit": 4212000000, "nonOperatingIncomeExcludingInterest": 347000000, "operatingIncome": 4559000000, "totalOtherIncomeExpensesNet": -1138000000, "incomeBeforeTax": 3421000000, "incomeTaxExpense": 293000000, "netIncomeFromContinuingOperations": 3128000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 3120000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 3120000000, "eps": 0.5515, "epsDiluted": 0.5477, "weightedAverageShsOut": 5657000000, "weightedAverageShsOutDil": 5697000000}}
{"date": "2023-12-31", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2023-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-02-22", "acceptedDate": "2024-02-22 13:17:37", "fiscalYear": "2023", "period": "Q4", "revenue": 14570000000, "costOfRevenue": 8590000000, "grossProfit": 5980000000, "researchAndDevelopmentExpenses": 2773000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 4470000000, "otherExpenses": 0, "operatingExpenses": 7243000000, "costAndExpenses": 15833000000, "netInterestIncome": -80000000, "interestIncome": 609000000, "interestExpense": 689000000, "depreciationAndAmortization": 1670000000, "ebitda": -1770000000, "ebit": -3440000000, "nonOperatingIncomeExcludingInterest": 2177000000, "operatingIncome": -1263000000, "totalOtherIncomeExpensesNet": -2866000000, "incomeBeforeTax": -4129000000, "incomeTaxExpense": -794000000, "netIncomeFromContinuingOperations": -3335000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": -3343000000, "netIncomeDeductions": 26000000, "bottomLineNetIncome": -3369000000, "eps": -0.5966, "epsDiluted": -0.5966, "weightedAverageShsOut": 5647000000, "weightedAverageShsOutDil": 5647000000}}
{"date": "2023-10-01", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2023-10-01", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-11-08", "acceptedDate": "2023-11-08 16:00:02", "fiscalYear": "2023", "period": "Q3", "revenue": 13491000000, "costOfRevenue": 10603000000, "grossProfit": 2888000000, "researchAndDevelopmentExpenses": 2682000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 3212000000, "otherExpenses": 0, "operatingExpenses": 5894000000, "costAndExpenses": 16497000000, "netInterestIncome": -172000000, "interestIncome": 523000000, "interestExpense": 695000000, "depreciationAndAmortization": 1560000000, "ebitda": -1097000000, "ebit": -2657000000, "nonOperatingIncomeExcludingInterest": -349000000, "operatingIncome": -3006000000, "totalOtherIncomeExpensesNet": -346000000, "incomeBeforeTax": -3352000000, "incomeTaxExpense": -964000000, "netIncomeFromContinuingOperations": -2388000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": -2394000000, "netIncomeDeductions": 0, "bottomLineNetIncome": -2394000000, "eps": -0.424, "epsDiluted": -0.424, "weightedAverageShsOut": 5646000000, "weightedAverageShsOutDil": 5646000000}}
{"date": "2023-07-02", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2023-07-02", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-08-09", "acceptedDate": "2023-08-09 16:11:52", "fiscalYear": "2023", "period": "Q2", "revenue": 13007000000, "costOfRevenue": 4595000000, "grossProfit": 8412000000, "researchAndDevelopmentExpenses": 2629000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 3432000000, "otherExpenses": 0, "operatingExpenses": 6061000000, "costAndExpenses": 10656000000, "netInterestIncome": -192000000, "interestIncome": 316000000, "interestExpense": 508000000, "depreciationAndAmortization": 1573000000, "ebitda": 4351000000, "ebit": 2778000000, "nonOperatingIncomeExcludingInterest": -427000000, "operatingIncome": 2351000000, "totalOtherIncomeExpensesNet": -82000000, "incomeBeforeTax": 2269000000, "incomeTaxExpense": -71000000, "netIncomeFromContinuingOperations": 2340000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 2329000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 2329000000, "eps": 0.4125, "epsDiluted": 0.4077, "weightedAverageShsOut": 5646000000, "weightedAverageShsOutDil": 5713000000}}
{"date": "2023-04-02", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2023-04-02", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-05-10", "acceptedDate": "2023-05-10 15:53:31", "fiscalYear": "2023", "period": "Q1", "revenue": 18486000000, "costOfRevenue": 5950000000, "grossProfit": 12536000000, "researchAndDevelopmentExpenses": 2494000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 3357000000, "otherExpenses": 0, "operatingExpenses": 5851000000, "costAndExpenses": 11801000000, "netInterestIncome": -141000000, "interestIncome": 177000000, "interestExpense": 318000000, "depreciationAndAmortization": 1487000000, "ebitda": 8076000000, "ebit": 6589000000, "nonOperatingIncomeExcludingInterest": 96000000, "operatingIncome": 6685000000, "totalOtherIncomeExpensesNet": -415000000, "incomeBeforeTax": 6270000000, "incomeTaxExpense": 715000000, "netIncomeFromContinuingOperations": 5555000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 5542000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 5542000000, "eps": 0.9837, "epsDiluted": 0.9677, "weightedAverageShsOut": 5634000000, "weightedAverageShsOutDil": 5727000000}}
{"date": "2022-12-31", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2022-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-02-23", "acceptedDate": "2023-02-23 14:12:53", "fiscalYear": "2022", "period": "Q4", "revenue": 24290000000, "costOfRevenue": 10900000000, "grossProfit": 13390000000, "researchAndDevelopmentExpenses": 3615000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 4427000000, "otherExpenses": 0, "operatingExpenses": 8042000000, "costAndExpenses": 18942000000, "netInterestIncome": -176000000, "interestIncome": 137000000, "interestExpense": 313000000, "depreciationAndAmortization": 1519000000, "ebitda": 7064000000, "ebit": 5545000000, "nonOperatingIncomeExcludingInterest": -197000000, "operatingIncome": 5348000000, "totalOtherIncomeExpensesNet": -117000000, "incomeBeforeTax": 5231000000, "incomeTaxExpense": 230000000, "netIncomeFromContinuingOperations": 5001000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 4993000000, "netIncomeDeductions": 2000000, "bottomLineNetIncome": 4991000000, "eps": 0.889, "epsDiluted": 0.8692, "weightedAverageShsOut": 5615000000, "weightedAverageShsOutDil": 5743000000}}
{"date": "2022-10-02", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2022-10-02", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-11-09", "acceptedDate": "2022-11-09 16:05:15", "fiscalYear": "2022", "period": "Q3", "revenue": 22638000000, "costOfRevenue": 6989000000, "grossProfit": 15649000000, "researchAndDevelopmentExpenses": 2696000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 3254000000, "otherExpenses": 0, "operatingExpenses": 5950000000, "costAndExpenses": 12939000000, "netInterestIncome": -241000000, "interestIncome": 70000000, "interestExpense": 311000000, "depreciationAndAmortization": 1183000000, "ebitda": 10495000000, "ebit": 9312000000, "nonOperatingIncomeExcludingInterest": 387000000, "operatingIncome": 9699000000, "totalOtherIncomeExpensesNet": -698000000, "incomeBeforeTax": 9001000000, "incomeTaxExpense": 356000000, "netIncomeFromContinuingOperations": 8645000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 8630000000, "netIncomeDeductions": 1000000, "bottomLineNetIncome": 8629000000, "eps": 1.539, "epsDiluted": 1.5091, "weightedAverageShsOut": 5607000000, "weightedAverageShsOutDil": 5718000000}}
{"date": "2022-07-03", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2022-07-03", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-08-10", "acceptedDate": "2022-08-10 16:26:18", "fiscalYear": "2022", "period": "Q2", "revenue": 27742000000, "costOfRevenue": 9066000000, "grossProfit": 18676000000, "researchAndDevelopmentExpenses": 2815000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 2914000000, "otherExpenses": 0, "operatingExpenses": 5729000000, "costAndExpenses": 14795000000, "netInterestIncome": -263000000, "interestIncome": 30000000, "interestExpense": 293000000, "depreciationAndAmortization": 1175000000, "ebitda": 12914000000, "ebit": 11739000000, "nonOperatingIncomeExcludingInterest": 1208000000, "operatingIncome": 12947000000, "totalOtherIncomeExpensesNet": -1500000000, "incomeBeforeTax": 11447000000, "incomeTaxExpense": 1570000000, "netIncomeFromContinuingOperations": 9877000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 9871000000, "netIncomeDeductions": -1000000, "bottomLineNetIncome": 9872000000, "eps": 1.7651, "epsDiluted": 1.7283, "weightedAverageShsOut": 5593000000, "weightedAverageShsOutDil": 5712000000}}
{"date": "2022-04-03", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2022-04-03", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-05-11", "acceptedDate": "2022-05-11 16:19:49", "fiscalYear": "2022", "period": "Q1", "revenue": 25661000000, "costOfRevenue": 10798000000, "grossProfit": 14863000000, "researchAndDevelopmentExpenses": 2301000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 2519000000, "otherExpenses": 0, "operatingExpenses": 4820000000, "costAndExpenses": 15618000000, "netInterestIncome": -308000000, "interestIncome": 14000000, "interestExpense": 322000000, "depreciationAndAmortization": 1187000000, "ebitda": 10560000000, "ebit": 9373000000, "nonOperatingIncomeExcludingInterest": 670000000, "operatingIncome": 10043000000, "totalOtherIncomeExpensesNet": -993000000, "incomeBeforeTax": 9050000000, "incomeTaxExpense": 1172000000, "netIncomeFromContinuingOperations": 7878000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 1000000, "netIncome": 7873000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 7873000000, "eps": 1.4016, "epsDiluted": 1.3673, "weightedAverageShsOut": 5617000000, "weightedAverageShsOutDil": 5758000000}}
{"date": "2021-12-31", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2021-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-02-24", "acceptedDate": "2022-02-24 14:25:01", "fiscalYear": "2021", "period": "Q4", "revenue": 23838000000, "costOfRevenue": 10678000000, "grossProfit": 13160000000, "researchAndDevelopmentExpenses": 5915000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 3965000000, "otherExpenses": 0, "operatingExpenses": 9880000000, "costAndExpenses": 20558000000, "netInterestIncome": -301000000, "interestIncome": 14000000, "interestExpense": 315000000, "depreciationAndAmortization": 1277000000, "ebitda": 5418000000, "ebit": 4141000000, "nonOperatingIncomeExcludingInterest": -861000000, "operatingIncome": 3280000000, "totalOtherIncomeExpensesNet": 547000000, "incomeBeforeTax": 3827000000, "incomeTaxExpense": 249000000, "netIncomeFromContinuingOperations": 3578000000, "netIncomeFromDiscontinuedOperations": -187000000, "otherAdjustmentsToNetIncome": 0, "netIncome": 3393000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 3393000000, "eps": 0.6042, "epsDiluted": 0.5883, "weightedAverageShsOut": 5616000000, "weightedAverageShsOutDil": 5768000000}}
{"date": "2021-10-03", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2021-10-03", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2021-11-12", "acceptedDate": "2021-11-12 06:06:57", "fiscalYear": "2021", "period": "Q3", "revenue": 24035000000, "costOfRevenue": 10855000000, "grossProfit": 13180000000, "researchAndDevelopmentExpenses": 2681000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 2749000000, "otherExpenses": 0, "operatingExpenses": 5430000000, "costAndExpenses": 16285000000, "netInterestIncome": -315000000, "interestIncome": 10000000, "interestExpense": 325000000, "depreciationAndAmortization": 1341000000, "ebitda": 9509000000, "ebit": 8168000000, "nonOperatingIncomeExcludingInterest": -418000000, "operatingIncome": 7750000000, "totalOtherIncomeExpensesNet": 93000000, "incomeBeforeTax": 7843000000, "incomeTaxExpense": -328000000, "netIncomeFromContinuingOperations": 8171000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": 0, "netIncome": 8159000000, "netIncomeDeductions": 13000000, "bottomLineNetIncome": 8146000000, "eps": 1.4546, "epsDiluted": 1.4252, "weightedAverageShsOut": 5609000000, "weightedAverageShsOutDil": 5725000000}}
{"date": "2021-07-04", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2021-07-04", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2021-08-12", "acceptedDate": "2021-08-12 16:01:31", "fiscalYear": "2021", "period": "Q2", "revenue": 18899000000, "costOfRevenue": 7845000000, "grossProfit": 11054000000, "researchAndDevelopmentExpenses": 2239000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 2827000000, "otherExpenses": 0, "operatingExpenses": 5066000000, "costAndExpenses": 12911000000, "netInterestIncome": -303000000, "interestIncome": 13000000, "interestExpense": 316000000, "depreciationAndAmortization": 1308000000, "ebitda": 8572000000, "ebit": 7264000000, "nonOperatingIncomeExcludingInterest": -1276000000, "operatingIncome": 5988000000, "totalOtherIncomeExpensesNet": 961000000, "incomeBeforeTax": 6949000000, "incomeTaxExpense": 1123000000, "netIncomeFromContinuingOperations": 5826000000, "netIncomeFromDiscontinuedOperations": 0, "otherAdjustmentsToNetIncome": -1000000, "netIncome": 5799000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 5799000000, "eps": 1.0359, "epsDiluted": 1.0213, "weightedAverageShsOut": 5598000000, "weightedAverageShsOutDil": 5678000000}}
{"date": "2021-04-04", "symbol": "PFE", "type": "income_statement_quarter", "result": {"date": "2021-04-04", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2021-05-13", "acceptedDate": "2021-05-13 11:32:26", "fiscalYear": "2021", "period": "Q1", "revenue": 14516000000, "costOfRevenue": 4998000000, "grossProfit": 9518000000, "researchAndDevelopmentExpenses": 1994000000, "generalAndAdministrativeExpenses": 0, "sellingAndMarketingExpenses": 0, "sellingGeneralAndAdministrativeExpenses": 2713000000, "otherExpenses": 0, "operatingExpenses": 4707000000, "costAndExpenses": 9705000000, "netInterestIncome": -336000000, "interestIncome": 0, "interestExpense": 336000000, "depreciationAndAmortization": 1207000000, "ebitda": 7236000000, "ebit": 6029000000, "nonOperatingIncomeExcludingInterest": -1218000000, "operatingIncome": 4811000000, "totalOtherIncomeExpensesNet": 881000000, "incomeBeforeTax": 5692000000, "incomeTaxExpense": 808000000, "netIncomeFromContinuingOperations": 4884000000, "netIncomeFromDiscontinuedOperations": 1000000, "otherAdjustmentsToNetIncome": 1000000, "netIncome": 4877000000, "netIncomeDeductions": 0, "bottomLineNetIncome": 4877000000, "eps": 0.8734, "epsDiluted": 0.8614, "weightedAverageShsOut": 5584000000, "weightedAverageShsOutDil": 5662000000}}
{"date": "2024-12-31", "symbol": "PFE", "type": "balance_sheet_annual", "result": {"date": "2024-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-02-27", "acceptedDate": "2025-02-27 16:27:18", "fiscalYear": "2024", "period": "FY", "cashAndCashEquivalents": 1043000000, "shortTermInvestments": 19434000000, "cashAndShortTermInvestments": 20477000000, "netReceivables": 14777000000, "accountsReceivables": 11463000000, "otherReceivables": 3314000000, "inventory": 10851000000, "prepaids": 0, "otherCurrentAssets": 4253000000, "totalCurrentAssets": 50358000000, "propertyPlantEquipmentNet": 18393000000, "goodwill": 68527000000, "intangibleAssets": 55412000000, "goodwillAndIntangibleAssets": 123939000000, "longTermInvestments": 2227000000, "taxAssets": 8662000000, "otherNonCurrentAssets": 9817000000, "totalNonCurrentAssets": 163038000000, "otherAssets": 0, "totalAssets": 213396000000, "totalPayables": 10980000000, "accountPayables": 5633000000, "otherPayables": 5347000000, "accruedExpenses": 0, "shortTermDebt": 6946000000, "capitalLeaseObligationsCurrent": 356000000, "taxPayables": 0, "deferredRevenue": 1511000000, "otherCurrentLiabilities": 23202000000, "totalCurrentLiabilities": 42995000000, "longTermDebt": 57405000000, "capitalLeaseObligationsNonCurrent": 2286000000, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 2122000000, "otherNonCurrentLiabilities": 20091000000, "totalNonCurrentLiabilities": 81904000000, "otherLiabilities": 0, "capitalLeaseObligations": 2642000000, "totalLiabilities": 124899000000, "treasuryStock": -114763000000, "preferredStock": 0, "commonStock": 480000000, "retainedEarnings": 116725000000, "additionalPaidInCapital": 93603000000, "accumulatedOtherComprehensiveIncomeLoss": -7842000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 88203000000, "totalEquity": 88497000000, "minorityInterest": 294000000, "totalLiabilitiesAndTotalEquity": 213396000000, "totalInvestments": 21661000000, "totalDebt": 66993000000, "netDebt": 65950000000}}
{"date": "2023-12-31", "symbol": "PFE", "type": "balance_sheet_annual", "result": {"date": "2023-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-02-22", "acceptedDate": "2024-02-22 13:17:37", "fiscalYear": "2023", "period": "FY", "cashAndCashEquivalents": 2853000000, "shortTermInvestments": 9837000000, "cashAndShortTermInvestments": 12690000000, "netReceivables": 15544000000, "accountsReceivables": 11566000000, "otherReceivables": 3978000000, "inventory": 10189000000, "prepaids": 0, "otherCurrentAssets": 4910000000, "totalCurrentAssets": 43333000000, "propertyPlantEquipmentNet": 18940000000, "goodwill": 67783000000, "intangibleAssets": 64900000000, "goodwillAndIntangibleAssets": 132683000000, "longTermInvestments": 15368000000, "taxAssets": 3706000000, "otherNonCurrentAssets": 12471000000, "totalNonCurrentAssets": 183168000000, "otherAssets": 0, "totalAssets": 226501000000, "totalPayables": 11431000000, "accountPayables": 6710000000, "otherPayables": 4721000000, "accruedExpenses": 0, "shortTermDebt": 10346000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 2349000000, "deferredRevenue": 2700000000, "otherCurrentLiabilities": 23317000000, "totalCurrentLiabilities": 47794000000, "longTermDebt": 60499000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 640000000, "otherNonCurrentLiabilities": 28280000000, "totalNonCurrentLiabilities": 89419000000, "otherLiabilities": 0, "capitalLeaseObligations": 2626000000, "totalLiabilities": 137213000000, "treasuryStock": -114487000000, "preferredStock": 0, "commonStock": 478000000, "retainedEarnings": 118353000000, "additionalPaidInCapital": 92631000000, "accumulatedOtherComprehensiveIncomeLoss": -7961000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 89014000000, "totalEquity": 89288000000, "minorityInterest": 274000000, "totalLiabilitiesAndTotalEquity": 226501000000, "totalInvestments": 25205000000, "totalDebt": 70845000000, "netDebt": 67992000000}}
{"date": "2022-12-31", "symbol": "PFE", "type": "balance_sheet_annual", "result": {"date": "2022-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-02-23", "acceptedDate": "2023-02-23 14:12:53", "fiscalYear": "2022", "period": "FY", "cashAndCashEquivalents": 416000000, "shortTermInvestments": 22316000000, "cashAndShortTermInvestments": 22732000000, "netReceivables": 14529000000, "accountsReceivables": 10952000000, "otherReceivables": 3577000000, "inventory": 8981000000, "prepaids": 0, "otherCurrentAssets": 5017000000, "totalCurrentAssets": 51259000000, "propertyPlantEquipmentNet": 16274000000, "goodwill": 51375000000, "intangibleAssets": 43370000000, "goodwillAndIntangibleAssets": 94745000000, "longTermInvestments": 15069000000, "taxAssets": 6693000000, "otherNonCurrentAssets": 13163000000, "totalNonCurrentAssets": 145944000000, "otherAssets": 3000000, "totalAssets": 197206000000, "totalPayables": 10699000000, "accountPayables": 6809000000, "otherPayables": 3890000000, "accruedExpenses": 0, "shortTermDebt": 2934000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 1587000000, "deferredRevenue": 2520000000, "otherCurrentLiabilities": 25985000000, "totalCurrentLiabilities": 42138000000, "longTermDebt": 31925000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 1023000000, "otherNonCurrentLiabilities": 26203000000, "totalNonCurrentLiabilities": 59151000000, "otherLiabilities": 0, "capitalLeaseObligations": 2597000000, "totalLiabilities": 101289000000, "treasuryStock": -113969000000, "preferredStock": 0, "commonStock": 476000000, "retainedEarnings": 125656000000, "additionalPaidInCapital": 91802000000, "accumulatedOtherComprehensiveIncomeLoss": -8304000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 95661000000, "totalEquity": 95917000000, "minorityInterest": 256000000, "totalLiabilitiesAndTotalEquity": 197206000000, "totalInvestments": 37385000000, "totalDebt": 34859000000, "netDebt": 34443000000}}
{"date": "2021-12-31", "symbol": "PFE", "type": "balance_sheet_annual", "result": {"date": "2021-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-02-24", "acceptedDate": "2022-02-24 14:25:01", "fiscalYear": "2021", "period": "FY", "cashAndCashEquivalents": 1944000000, "shortTermInvestments": 29125000000, "cashAndShortTermInvestments": 31069000000, "netReceivables": 15745000000, "accountsReceivables": 11479000000, "otherReceivables": 4266000000, "inventory": 9059000000, "prepaids": 0, "otherCurrentAssets": 3820000000, "totalCurrentAssets": 59693000000, "propertyPlantEquipmentNet": 14882000000, "goodwill": 49208000000, "intangibleAssets": 25146000000, "goodwillAndIntangibleAssets": 74354000000, "longTermInvestments": 21526000000, "taxAssets": 3341000000, "otherNonCurrentAssets": 7679000000, "totalNonCurrentAssets": 121782000000, "otherAssets": 2000000, "totalAssets": 181477000000, "totalPayables": 9093000000, "accountPayables": 5578000000, "otherPayables": 3515000000, "accruedExpenses": 0, "shortTermDebt": 2241000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 1266000000, "deferredRevenue": 3067000000, "otherCurrentLiabilities": 28270000000, "totalCurrentLiabilities": 42671000000, "longTermDebt": 34757000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 349000000, "otherNonCurrentLiabilities": 26237000000, "totalNonCurrentLiabilities": 61343000000, "otherLiabilities": 0, "capitalLeaseObligations": 2510000000, "totalLiabilities": 104014000000, "treasuryStock": -111361000000, "preferredStock": 0, "commonStock": 473000000, "retainedEarnings": 103394000000, "additionalPaidInCapital": 90591000000, "accumulatedOtherComprehensiveIncomeLoss": -5897000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 77201000000, "totalEquity": 77463000000, "minorityInterest": 262000000, "totalLiabilitiesAndTotalEquity": 181477000000, "totalInvestments": 50651000000, "totalDebt": 36998000000, "netDebt": 35054000000}}
{"date": "2025-09-28", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2025-09-28", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-11-04", "acceptedDate": "2025-11-04 07:03:48", "fiscalYear": "2025", "period": "Q3", "cashAndCashEquivalents": 1343000000, "shortTermInvestments": 13641000000, "cashAndShortTermInvestments": 14984000000, "netReceivables": 14260000000, "accountsReceivables": 14260000000, "otherReceivables": 0, "inventory": 11468000000, "prepaids": 0, "otherCurrentAssets": 6212000000, "totalCurrentAssets": 46924000000, "propertyPlantEquipmentNet": 18880000000, "goodwill": 69101000000, "intangibleAssets": 51324000000, "goodwillAndIntangibleAssets": 120425000000, "longTermInvestments": 2137000000, "taxAssets": 11048000000, "otherNonCurrentAssets": 9317000000, "totalNonCurrentAssets": 161807000000, "otherAssets": 0, "totalAssets": 208731000000, "totalPayables": 8823000000, "accountPayables": 5024000000, "otherPayables": 3799000000, "accruedExpenses": 3036000000, "shortTermDebt": 4303000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 3799000000, "deferredRevenue": 924000000, "otherCurrentLiabilities": 19510000000, "totalCurrentLiabilities": 36596000000, "longTermDebt": 57409000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 2467000000, "otherNonCurrentLiabilities": 19163000000, "totalNonCurrentLiabilities": 79039000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 115635000000, "treasuryStock": -115011000000, "preferredStock": 0, "commonStock": 481000000, "retainedEarnings": 121150000000, "additionalPaidInCapital": 94248000000, "accumulatedOtherComprehensiveIncomeLoss": -8067000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 92801000000, "totalEquity": 93096000000, "minorityInterest": 295000000, "totalLiabilitiesAndTotalEquity": 208731000000, "totalInvestments": 15778000000, "totalDebt": 61712000000, "netDebt": 60369000000}}
{"date": "2025-06-29", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2025-06-29", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-08-05", "acceptedDate": "2025-08-05 07:16:27", "fiscalYear": "2025", "period": "Q2", "cashAndCashEquivalents": 1638000000, "shortTermInvestments": 11611000000, "cashAndShortTermInvestments": 13249000000, "netReceivables": 12078000000, "accountsReceivables": 12078000000, "otherReceivables": 0, "inventory": 11669000000, "prepaids": 0, "otherCurrentAssets": 6707000000, "totalCurrentAssets": 43703000000, "propertyPlantEquipmentNet": 18776000000, "goodwill": 68997000000, "intangibleAssets": 52702000000, "goodwillAndIntangibleAssets": 121699000000, "longTermInvestments": 224000000, "taxAssets": 10343000000, "otherNonCurrentAssets": 11350000000, "totalNonCurrentAssets": 162392000000, "otherAssets": 0, "totalAssets": 206095000000, "totalPayables": 8841000000, "accountPayables": 5166000000, "otherPayables": 3675000000, "accruedExpenses": 0, "shortTermDebt": 4295000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 3675000000, "deferredRevenue": 1123000000, "otherCurrentLiabilities": 23467000000, "totalCurrentLiabilities": 37726000000, "longTermDebt": 57502000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 2481000000, "otherNonCurrentLiabilities": 19374000000, "totalNonCurrentLiabilities": 79357000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 117083000000, "treasuryStock": -115010000000, "preferredStock": 0, "commonStock": 481000000, "retainedEarnings": 117609000000, "additionalPaidInCapital": 94053000000, "accumulatedOtherComprehensiveIncomeLoss": -8438000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 88695000000, "totalEquity": 89012000000, "minorityInterest": 317000000, "totalLiabilitiesAndTotalEquity": 206095000000, "totalInvestments": 11835000000, "totalDebt": 61797000000, "netDebt": 60159000000}}
{"date": "2025-03-29", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2025-03-29", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-03-29", "acceptedDate": "2025-03-29 18:00:00", "fiscalYear": "2025", "period": "Q1", "cashAndCashEquivalents": 1430000000, "shortTermInvestments": 15886000000, "cashAndShortTermInvestments": 17316000000, "netReceivables": 14745000000, "accountsReceivables": 11845000000, "otherReceivables": 2900000000, "inventory": 10852000000, "prepaids": 0, "otherCurrentAssets": 2948000000, "totalCurrentAssets": 45861000000, "propertyPlantEquipmentNet": 18347000000, "goodwill": 68444000000, "intangibleAssets": 53974000000, "goodwillAndIntangibleAssets": 122418000000, "longTermInvestments": 2014000000, "taxAssets": 9542000000, "otherNonCurrentAssets": 9845000000, "totalNonCurrentAssets": 162166000000, "otherAssets": 1000000, "totalAssets": 208028000000, "totalPayables": 8345000000, "accountPayables": 5240000000, "otherPayables": 3105000000, "accruedExpenses": 0, "shortTermDebt": 4471000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 0, "deferredRevenue": 1012000000, "otherCurrentLiabilities": 22624000000, "totalCurrentLiabilities": 36452000000, "longTermDebt": 56820000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 2258000000, "otherNonCurrentLiabilities": 21861000000, "totalNonCurrentLiabilities": 80939000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 117391000000, "treasuryStock": -115008000000, "preferredStock": 0, "commonStock": 481000000, "retainedEarnings": 119590000000, "additionalPaidInCapital": 93856000000, "accumulatedOtherComprehensiveIncomeLoss": -8581000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 90338000000, "totalEquity": 90637000000, "minorityInterest": 299000000, "totalLiabilitiesAndTotalEquity": 208028000000, "totalInvestments": 17900000000, "totalDebt": 61291000000, "netDebt": 59861000000}}
{"date": "2024-12-31", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2024-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-02-27", "acceptedDate": "2025-02-27 16:27:18", "fiscalYear": "2024", "period": "Q4", "cashAndCashEquivalents": 1043000000, "shortTermInvestments": 19434000000, "cashAndShortTermInvestments": 20477000000, "netReceivables": 14777000000, "accountsReceivables": 11463000000, "otherReceivables": 3314000000, "inventory": 10851000000, "prepaids": 0, "otherCurrentAssets": 4253000000, "totalCurrentAssets": 50358000000, "propertyPlantEquipmentNet": 18393000000, "goodwill": 68527000000, "intangibleAssets": 55412000000, "goodwillAndIntangibleAssets": 123939000000, "longTermInvestments": 2227000000, "taxAssets": 8662000000, "otherNonCurrentAssets": 9817000000, "totalNonCurrentAssets": 163038000000, "otherAssets": 0, "totalAssets": 213396000000, "totalPayables": 10980000000, "accountPayables": 5633000000, "otherPayables": 5347000000, "accruedExpenses": 0, "shortTermDebt": 6946000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 2910000000, "deferredRevenue": 1511000000, "otherCurrentLiabilities": 23558000000, "totalCurrentLiabilities": 42995000000, "longTermDebt": 56703000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 2122000000, "otherNonCurrentLiabilities": 23079000000, "totalNonCurrentLiabilities": 81904000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 124899000000, "treasuryStock": -114763000000, "preferredStock": 0, "commonStock": 480000000, "retainedEarnings": 116725000000, "additionalPaidInCapital": 93603000000, "accumulatedOtherComprehensiveIncomeLoss": -7842000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 88203000000, "totalEquity": 88497000000, "minorityInterest": 294000000, "totalLiabilitiesAndTotalEquity": 213396000000, "totalInvestments": 21661000000, "totalDebt": 63649000000, "netDebt": 62606000000}}
{"date": "2024-09-29", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2024-09-29", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-11-04", "acceptedDate": "2024-11-04 16:06:08", "fiscalYear": "2024", "period": "Q3", "cashAndCashEquivalents": 1092000000, "shortTermInvestments": 8860000000, "cashAndShortTermInvestments": 9952000000, "netReceivables": 17694000000, "accountsReceivables": 14451000000, "otherReceivables": 3243000000, "inventory": 11721000000, "prepaids": 0, "otherCurrentAssets": 3856000000, "totalCurrentAssets": 43223000000, "propertyPlantEquipmentNet": 18541000000, "goodwill": 68570000000, "intangibleAssets": 59986000000, "goodwillAndIntangibleAssets": 128556000000, "longTermInvestments": 10762000000, "taxAssets": 7909000000, "otherNonCurrentAssets": 10486000000, "totalNonCurrentAssets": 176254000000, "otherAssets": -1000000, "totalAssets": 219476000000, "totalPayables": 8191000000, "accountPayables": 5314000000, "otherPayables": 2877000000, "accruedExpenses": 0, "shortTermDebt": 9699000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 2877000000, "deferredRevenue": 2020000000, "otherCurrentLiabilities": 23301000000, "totalCurrentLiabilities": 43211000000, "longTermDebt": 56918000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 2158000000, "otherNonCurrentLiabilities": 24631000000, "totalNonCurrentLiabilities": 83707000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 126918000000, "treasuryStock": -114760000000, "preferredStock": 0, "commonStock": 480000000, "retainedEarnings": 121059000000, "additionalPaidInCapital": 93477000000, "accumulatedOtherComprehensiveIncomeLoss": -7971000000, "otherTotalStockholdersEquity": 1000000, "totalStockholdersEquity": 92286000000, "totalEquity": 92558000000, "minorityInterest": 272000000, "totalLiabilitiesAndTotalEquity": 219476000000, "totalInvestments": 19622000000, "totalDebt": 66617000000, "netDebt": 65525000000}}
{"date": "2024-06-30", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2024-06-30", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-08-05", "acceptedDate": "2024-08-05 15:54:43", "fiscalYear": "2024", "period": "Q2", "cashAndCashEquivalents": 1052000000, "shortTermInvestments": 6049000000, "cashAndShortTermInvestments": 7101000000, "netReceivables": 15087000000, "accountsReceivables": 11393000000, "otherReceivables": 3694000000, "inventory": 11447000000, "prepaids": 0, "otherCurrentAssets": 4190000000, "totalCurrentAssets": 37825000000, "propertyPlantEquipmentNet": 18957000000, "goodwill": 68445000000, "intangibleAssets": 61240000000, "goodwillAndIntangibleAssets": 129685000000, "longTermInvestments": 11148000000, "taxAssets": 7867000000, "otherNonCurrentAssets": 10710000000, "totalNonCurrentAssets": 178367000000, "otherAssets": 1000000, "totalAssets": 216193000000, "totalPayables": 10370000000, "accountPayables": 5106000000, "otherPayables": 5264000000, "accruedExpenses": 0, "shortTermDebt": 11944000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 2884000000, "deferredRevenue": 2528000000, "otherCurrentLiabilities": 18977000000, "totalCurrentLiabilities": 43819000000, "longTermDebt": 56733000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 2227000000, "otherNonCurrentLiabilities": 25439000000, "totalNonCurrentLiabilities": 84399000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 128218000000, "treasuryStock": -114757000000, "preferredStock": 0, "commonStock": 480000000, "retainedEarnings": 116596000000, "additionalPaidInCapital": 93197000000, "accumulatedOtherComprehensiveIncomeLoss": -7816000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 87700000000, "totalEquity": 87975000000, "minorityInterest": 275000000, "totalLiabilitiesAndTotalEquity": 216193000000, "totalInvestments": 17197000000, "totalDebt": 68677000000, "netDebt": 67625000000}}
{"date": "2024-03-31", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2024-03-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-05-08", "acceptedDate": "2024-05-08 15:56:17", "fiscalYear": "2024", "period": "Q1", "cashAndCashEquivalents": 719000000, "shortTermInvestments": 11210000000, "cashAndShortTermInvestments": 11929000000, "netReceivables": 15222000000, "accountsReceivables": 10989000000, "otherReceivables": 4233000000, "inventory": 10892000000, "prepaids": 0, "otherCurrentAssets": 4372000000, "totalCurrentAssets": 42415000000, "propertyPlantEquipmentNet": 18803000000, "goodwill": 69297000000, "intangibleAssets": 62828000000, "goodwillAndIntangibleAssets": 132125000000, "longTermInvestments": 11613000000, "taxAssets": 4942000000, "otherNonCurrentAssets": 11197000000, "totalNonCurrentAssets": 178680000000, "otherAssets": 0, "totalAssets": 221095000000, "totalPayables": 8783000000, "accountPayables": 5591000000, "otherPayables": 3192000000, "accruedExpenses": 0, "shortTermDebt": 8231000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 3192000000, "deferredRevenue": 2502000000, "otherCurrentLiabilities": 20981000000, "totalCurrentLiabilities": 40497000000, "longTermDebt": 60477000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 931000000, "otherNonCurrentLiabilities": 26632000000, "totalNonCurrentLiabilities": 88040000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 128537000000, "treasuryStock": -114755000000, "preferredStock": 0, "commonStock": 480000000, "retainedEarnings": 121318000000, "additionalPaidInCapital": 92997000000, "accumulatedOtherComprehensiveIncomeLoss": -7758000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 92282000000, "totalEquity": 92558000000, "minorityInterest": 276000000, "totalLiabilitiesAndTotalEquity": 221095000000, "totalInvestments": 22823000000, "totalDebt": 68708000000, "netDebt": 67989000000}}
{"date": "2023-12-31", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2023-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-02-22", "acceptedDate": "2024-02-22 13:17:37", "fiscalYear": "2023", "period": "Q4", "cashAndCashEquivalents": 2853000000, "shortTermInvestments": 9837000000, "cashAndShortTermInvestments": 12690000000, "netReceivables": 15544000000, "accountsReceivables": 11566000000, "otherReceivables": 3978000000, "inventory": 10189000000, "prepaids": 0, "otherCurrentAssets": 4910000000, "totalCurrentAssets": 43333000000, "propertyPlantEquipmentNet": 18940000000, "goodwill": 67783000000, "intangibleAssets": 64900000000, "goodwillAndIntangibleAssets": 132683000000, "longTermInvestments": 15368000000, "taxAssets": 3706000000, "otherNonCurrentAssets": 12471000000, "totalNonCurrentAssets": 183168000000, "otherAssets": 0, "totalAssets": 226501000000, "totalPayables": 11431000000, "accountPayables": 6710000000, "otherPayables": 4721000000, "accruedExpenses": 0, "shortTermDebt": 10346000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 2349000000, "deferredRevenue": 2700000000, "otherCurrentLiabilities": 23317000000, "totalCurrentLiabilities": 47794000000, "longTermDebt": 60499000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 640000000, "otherNonCurrentLiabilities": 28280000000, "totalNonCurrentLiabilities": 89419000000, "otherLiabilities": 0, "capitalLeaseObligations": 2626000000, "totalLiabilities": 137213000000, "treasuryStock": -114487000000, "preferredStock": 0, "commonStock": 478000000, "retainedEarnings": 118353000000, "additionalPaidInCapital": 92631000000, "accumulatedOtherComprehensiveIncomeLoss": -7961000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 89014000000, "totalEquity": 89288000000, "minorityInterest": 274000000, "totalLiabilitiesAndTotalEquity": 226501000000, "totalInvestments": 25205000000, "totalDebt": 70845000000, "netDebt": 67992000000}}
{"date": "2023-10-01", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2023-10-01", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-11-08", "acceptedDate": "2023-11-08 16:00:02", "fiscalYear": "2023", "period": "Q3", "cashAndCashEquivalents": 3148000000, "shortTermInvestments": 41033000000, "cashAndShortTermInvestments": 44181000000, "netReceivables": 15003000000, "accountsReceivables": 11086000000, "otherReceivables": 3917000000, "inventory": 10204000000, "prepaids": 0, "otherCurrentAssets": 4624000000, "totalCurrentAssets": 74012000000, "propertyPlantEquipmentNet": 17862000000, "goodwill": 51527000000, "intangibleAssets": 40224000000, "goodwillAndIntangibleAssets": 91751000000, "longTermInvestments": 14238000000, "taxAssets": 8350000000, "otherNonCurrentAssets": 8393000000, "totalNonCurrentAssets": 141009000000, "otherAssets": 0, "totalAssets": 215021000000, "totalPayables": 7236000000, "accountPayables": 5338000000, "otherPayables": 1898000000, "accruedExpenses": 0, "shortTermDebt": 2548000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 1898000000, "deferredRevenue": 2204000000, "otherCurrentLiabilities": 19148000000, "totalCurrentLiabilities": 31136000000, "longTermDebt": 61048000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 1125000000, "otherNonCurrentLiabilities": 24508000000, "totalNonCurrentLiabilities": 86681000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 117817000000, "treasuryStock": -114485000000, "preferredStock": 0, "commonStock": 478000000, "retainedEarnings": 126411000000, "additionalPaidInCapital": 92496000000, "accumulatedOtherComprehensiveIncomeLoss": -7966000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 96934000000, "totalEquity": 97204000000, "minorityInterest": 270000000, "totalLiabilitiesAndTotalEquity": 215020000000, "totalInvestments": 55271000000, "totalDebt": 63596000000, "netDebt": 60448000000}}
{"date": "2023-07-02", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2023-07-02", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-08-09", "acceptedDate": "2023-08-09 16:11:52", "fiscalYear": "2023", "period": "Q2", "cashAndCashEquivalents": 2632000000, "shortTermInvestments": 42153000000, "cashAndShortTermInvestments": 44785000000, "netReceivables": 13425000000, "accountsReceivables": 10231000000, "otherReceivables": 3194000000, "inventory": 10310000000, "prepaids": 0, "otherCurrentAssets": 4827000000, "totalCurrentAssets": 73347000000, "propertyPlantEquipmentNet": 17488000000, "goodwill": 51572000000, "intangibleAssets": 41407000000, "goodwillAndIntangibleAssets": 92979000000, "longTermInvestments": 15066000000, "taxAssets": 8261000000, "otherNonCurrentAssets": 12735000000, "totalNonCurrentAssets": 146821000000, "otherAssets": 0, "totalAssets": 220168000000, "totalPayables": 11324000000, "accountPayables": 6081000000, "otherPayables": 5243000000, "accruedExpenses": 0, "shortTermDebt": 3985000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 2928000000, "deferredRevenue": 1286000000, "otherCurrentLiabilities": 18052000000, "totalCurrentLiabilities": 34647000000, "longTermDebt": 61356000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 1232000000, "otherNonCurrentLiabilities": 23640000000, "totalNonCurrentLiabilities": 86228000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 120875000000, "treasuryStock": -114482000000, "preferredStock": 0, "commonStock": 478000000, "retainedEarnings": 128796000000, "additionalPaidInCapital": 92329000000, "accumulatedOtherComprehensiveIncomeLoss": -8102000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 99019000000, "totalEquity": 99293000000, "minorityInterest": 274000000, "totalLiabilitiesAndTotalEquity": 220167000000, "totalInvestments": 57219000000, "totalDebt": 65341000000, "netDebt": 62709000000}}
{"date": "2023-04-02", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2023-04-02", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-05-10", "acceptedDate": "2023-05-10 15:53:31", "fiscalYear": "2023", "period": "Q1", "cashAndCashEquivalents": 2166000000, "shortTermInvestments": 17806000000, "cashAndShortTermInvestments": 19972000000, "netReceivables": 15445000000, "accountsReceivables": 12305000000, "otherReceivables": 3140000000, "inventory": 9541000000, "prepaids": 0, "otherCurrentAssets": 5120000000, "totalCurrentAssets": 50078000000, "propertyPlantEquipmentNet": 17052000000, "goodwill": 51476000000, "intangibleAssets": 42001000000, "goodwillAndIntangibleAssets": 93477000000, "longTermInvestments": 14743000000, "taxAssets": 7302000000, "otherNonCurrentAssets": 12670000000, "totalNonCurrentAssets": 145539000000, "otherAssets": 0, "totalAssets": 195617000000, "totalPayables": 8092000000, "accountPayables": 6123000000, "otherPayables": 1969000000, "accruedExpenses": 0, "shortTermDebt": 4189000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 1969000000, "deferredRevenue": 1750000000, "otherCurrentLiabilities": 22531000000, "totalCurrentLiabilities": 36562000000, "longTermDebt": 30738000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 1067000000, "otherNonCurrentLiabilities": 26014000000, "totalNonCurrentLiabilities": 57819000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 94381000000, "treasuryStock": -114473000000, "preferredStock": 0, "commonStock": 478000000, "retainedEarnings": 131102000000, "additionalPaidInCapital": 92153000000, "accumulatedOtherComprehensiveIncomeLoss": -8289000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 100971000000, "totalEquity": 101237000000, "minorityInterest": 266000000, "totalLiabilitiesAndTotalEquity": 195618000000, "totalInvestments": 32549000000, "totalDebt": 34927000000, "netDebt": 32761000000}}
{"date": "2022-12-31", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2022-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-02-23", "acceptedDate": "2023-02-23 14:12:53", "fiscalYear": "2022", "period": "Q4", "cashAndCashEquivalents": 416000000, "shortTermInvestments": 22316000000, "cashAndShortTermInvestments": 22732000000, "netReceivables": 14529000000, "accountsReceivables": 10952000000, "otherReceivables": 3577000000, "inventory": 8981000000, "prepaids": 0, "otherCurrentAssets": 5017000000, "totalCurrentAssets": 51259000000, "propertyPlantEquipmentNet": 16274000000, "goodwill": 51375000000, "intangibleAssets": 43370000000, "goodwillAndIntangibleAssets": 94745000000, "longTermInvestments": 15069000000, "taxAssets": 6693000000, "otherNonCurrentAssets": 13163000000, "totalNonCurrentAssets": 145944000000, "otherAssets": 3000000, "totalAssets": 197206000000, "totalPayables": 10699000000, "accountPayables": 6809000000, "otherPayables": 3890000000, "accruedExpenses": 0, "shortTermDebt": 2934000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 1587000000, "deferredRevenue": 2520000000, "otherCurrentLiabilities": 25985000000, "totalCurrentLiabilities": 42138000000, "longTermDebt": 31925000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 1023000000, "otherNonCurrentLiabilities": 26203000000, "totalNonCurrentLiabilities": 59151000000, "otherLiabilities": 0, "capitalLeaseObligations": 2597000000, "totalLiabilities": 101289000000, "treasuryStock": -113969000000, "preferredStock": 0, "commonStock": 476000000, "retainedEarnings": 125656000000, "additionalPaidInCapital": 91802000000, "accumulatedOtherComprehensiveIncomeLoss": -8304000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 95661000000, "totalEquity": 95917000000, "minorityInterest": 256000000, "totalLiabilitiesAndTotalEquity": 197206000000, "totalInvestments": 37385000000, "totalDebt": 34859000000, "netDebt": 34443000000}}
{"date": "2022-10-02", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2022-10-02", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-11-09", "acceptedDate": "2022-11-09 16:05:15", "fiscalYear": "2022", "period": "Q3", "cashAndCashEquivalents": 1298000000, "shortTermInvestments": 34825000000, "cashAndShortTermInvestments": 36123000000, "netReceivables": 18620000000, "accountsReceivables": 16076000000, "otherReceivables": 2544000000, "inventory": 9513000000, "prepaids": 0, "otherCurrentAssets": 6147000000, "totalCurrentAssets": 70403000000, "propertyPlantEquipmentNet": 15441000000, "goodwill": 49441000000, "intangibleAssets": 28150000000, "goodwillAndIntangibleAssets": 77591000000, "longTermInvestments": 13888000000, "taxAssets": 7136000000, "otherNonCurrentAssets": 10890000000, "totalNonCurrentAssets": 124946000000, "otherAssets": 0, "totalAssets": 195349000000, "totalPayables": 11583000000, "accountPayables": 6267000000, "otherPayables": 5316000000, "accruedExpenses": 0, "shortTermDebt": 4024000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 3071000000, "deferredRevenue": 6191000000, "otherCurrentLiabilities": 22516000000, "totalCurrentLiabilities": 44314000000, "longTermDebt": 31653000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 616000000, "otherNonCurrentLiabilities": 25876000000, "totalNonCurrentLiabilities": 58145000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 102459000000, "treasuryStock": -113945000000, "preferredStock": 0, "commonStock": 476000000, "retainedEarnings": 122967000000, "additionalPaidInCapital": 91359000000, "accumulatedOtherComprehensiveIncomeLoss": -8225000000, "otherTotalStockholdersEquity": -1000000, "totalStockholdersEquity": 92631000000, "totalEquity": 92890000000, "minorityInterest": 259000000, "totalLiabilitiesAndTotalEquity": 195349000000, "totalInvestments": 48713000000, "totalDebt": 35677000000, "netDebt": 34379000000}}
{"date": "2022-07-03", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2022-07-03", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-08-10", "acceptedDate": "2022-08-10 16:26:18", "fiscalYear": "2022", "period": "Q2", "cashAndCashEquivalents": 1780000000, "shortTermInvestments": 31524000000, "cashAndShortTermInvestments": 33304000000, "netReceivables": 17738000000, "accountsReceivables": 15155000000, "otherReceivables": 2583000000, "inventory": 10454000000, "prepaids": 0, "otherCurrentAssets": 5970000000, "totalCurrentAssets": 67466000000, "propertyPlantEquipmentNet": 15244000000, "goodwill": 49891000000, "intangibleAssets": 29065000000, "goodwillAndIntangibleAssets": 78956000000, "longTermInvestments": 18963000000, "taxAssets": 7002000000, "otherNonCurrentAssets": 7098000000, "totalNonCurrentAssets": 127824000000, "otherAssets": 0, "totalAssets": 195290000000, "totalPayables": 11803000000, "accountPayables": 6208000000, "otherPayables": 5595000000, "accruedExpenses": 0, "shortTermDebt": 5965000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 3350000000, "deferredRevenue": 3804000000, "otherCurrentLiabilities": 25838000000, "totalCurrentLiabilities": 47410000000, "longTermDebt": 33169000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 558000000, "otherNonCurrentLiabilities": 26684000000, "totalNonCurrentLiabilities": 60411000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 107821000000, "treasuryStock": -113939000000, "preferredStock": 0, "commonStock": 476000000, "retainedEarnings": 116608000000, "additionalPaidInCapital": 91183000000, "accumulatedOtherComprehensiveIncomeLoss": -7119000000, "otherTotalStockholdersEquity": -1000000, "totalStockholdersEquity": 87209000000, "totalEquity": 87470000000, "minorityInterest": 261000000, "totalLiabilitiesAndTotalEquity": 195290000000, "totalInvestments": 50487000000, "totalDebt": 39134000000, "netDebt": 37354000000}}
{"date": "2022-04-03", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2022-04-03", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-05-11", "acceptedDate": "2022-05-11 16:19:49", "fiscalYear": "2022", "period": "Q1", "cashAndCashEquivalents": 2470000000, "shortTermInvestments": 21427000000, "cashAndShortTermInvestments": 23897000000, "netReceivables": 16342000000, "accountsReceivables": 13225000000, "otherReceivables": 3117000000, "inventory": 9979000000, "prepaids": 0, "otherCurrentAssets": 4202000000, "totalCurrentAssets": 54420000000, "propertyPlantEquipmentNet": 15109000000, "goodwill": 50211000000, "intangibleAssets": 29816000000, "goodwillAndIntangibleAssets": 80027000000, "longTermInvestments": 20737000000, "taxAssets": 5668000000, "otherNonCurrentAssets": 7879000000, "totalNonCurrentAssets": 129420000000, "otherAssets": 1000000, "totalAssets": 183841000000, "totalPayables": 8683000000, "accountPayables": 5506000000, "otherPayables": 3177000000, "accruedExpenses": 0, "shortTermDebt": 636000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 3177000000, "deferredRevenue": 3108000000, "otherCurrentLiabilities": 26841000000, "totalCurrentLiabilities": 39268000000, "longTermDebt": 34416000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 655000000, "otherNonCurrentLiabilities": 26817000000, "totalNonCurrentLiabilities": 61888000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 101156000000, "treasuryStock": -113931000000, "preferredStock": 0, "commonStock": 476000000, "retainedEarnings": 111193000000, "additionalPaidInCapital": 90844000000, "accumulatedOtherComprehensiveIncomeLoss": -6157000000, "otherTotalStockholdersEquity": -1000000, "totalStockholdersEquity": 82424000000, "totalEquity": 82685000000, "minorityInterest": 261000000, "totalLiabilitiesAndTotalEquity": 183841000000, "totalInvestments": 42164000000, "totalDebt": 35052000000, "netDebt": 32582000000}}
{"date": "2021-12-31", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2021-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-02-24", "acceptedDate": "2022-02-24 14:25:01", "fiscalYear": "2021", "period": "Q4", "cashAndCashEquivalents": 1944000000, "shortTermInvestments": 29125000000, "cashAndShortTermInvestments": 31069000000, "netReceivables": 15745000000, "accountsReceivables": 11479000000, "otherReceivables": 4266000000, "inventory": 9059000000, "prepaids": 0, "otherCurrentAssets": 3820000000, "totalCurrentAssets": 59693000000, "propertyPlantEquipmentNet": 14882000000, "goodwill": 49208000000, "intangibleAssets": 25146000000, "goodwillAndIntangibleAssets": 74354000000, "longTermInvestments": 21526000000, "taxAssets": 3341000000, "otherNonCurrentAssets": 7679000000, "totalNonCurrentAssets": 121782000000, "otherAssets": 2000000, "totalAssets": 181477000000, "totalPayables": 9093000000, "accountPayables": 5578000000, "otherPayables": 3515000000, "accruedExpenses": 0, "shortTermDebt": 2241000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 1266000000, "deferredRevenue": 3067000000, "otherCurrentLiabilities": 28270000000, "totalCurrentLiabilities": 42671000000, "longTermDebt": 34757000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 349000000, "otherNonCurrentLiabilities": 26237000000, "totalNonCurrentLiabilities": 61343000000, "otherLiabilities": 0, "capitalLeaseObligations": 2510000000, "totalLiabilities": 104014000000, "treasuryStock": -111361000000, "preferredStock": 0, "commonStock": 473000000, "retainedEarnings": 103394000000, "additionalPaidInCapital": 90591000000, "accumulatedOtherComprehensiveIncomeLoss": -5897000000, "otherTotalStockholdersEquity": 0, "totalStockholdersEquity": 77201000000, "totalEquity": 77463000000, "minorityInterest": 262000000, "totalLiabilitiesAndTotalEquity": 181477000000, "totalInvestments": 50651000000, "totalDebt": 36998000000, "netDebt": 35054000000}}
{"date": "2021-10-03", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2021-10-03", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2021-11-12", "acceptedDate": "2021-11-12 06:06:57", "fiscalYear": "2021", "period": "Q3", "cashAndCashEquivalents": 1966000000, "shortTermInvestments": 27730000000, "cashAndShortTermInvestments": 29696000000, "netReceivables": 15774000000, "accountsReceivables": 11897000000, "otherReceivables": 3877000000, "inventory": 8640000000, "prepaids": 0, "otherCurrentAssets": 3790000000, "totalCurrentAssets": 57900000000, "propertyPlantEquipmentNet": 14436000000, "goodwill": 49489000000, "intangibleAssets": 26306000000, "goodwillAndIntangibleAssets": 75795000000, "longTermInvestments": 21597000000, "taxAssets": 2755000000, "otherNonCurrentAssets": 6705000000, "totalNonCurrentAssets": 121288000000, "otherAssets": 0, "totalAssets": 179188000000, "totalPayables": 11385000000, "accountPayables": 4698000000, "otherPayables": 6687000000, "accruedExpenses": 0, "shortTermDebt": 3629000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 4496000000, "deferredRevenue": 3529000000, "otherCurrentLiabilities": 23260000000, "totalCurrentLiabilities": 41803000000, "longTermDebt": 34779000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 328000000, "otherNonCurrentLiabilities": 26311000000, "totalNonCurrentLiabilities": 61418000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 103221000000, "treasuryStock": -111359000000, "preferredStock": 0, "commonStock": 473000000, "retainedEarnings": 102252000000, "additionalPaidInCapital": 89973000000, "accumulatedOtherComprehensiveIncomeLoss": -5649000000, "otherTotalStockholdersEquity": 1000000, "totalStockholdersEquity": 75691000000, "totalEquity": 75966000000, "minorityInterest": 275000000, "totalLiabilitiesAndTotalEquity": 179187000000, "totalInvestments": 49327000000, "totalDebt": 38408000000, "netDebt": 36442000000}}
{"date": "2021-07-04", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2021-07-04", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2021-08-12", "acceptedDate": "2021-08-12 16:01:31", "fiscalYear": "2021", "period": "Q2", "cashAndCashEquivalents": 2372000000, "shortTermInvestments": 19328000000, "cashAndShortTermInvestments": 21700000000, "netReceivables": 14348000000, "accountsReceivables": 10587000000, "otherReceivables": 3761000000, "inventory": 8948000000, "prepaids": 0, "otherCurrentAssets": 3818000000, "totalCurrentAssets": 48814000000, "propertyPlantEquipmentNet": 14224000000, "goodwill": 49867000000, "intangibleAssets": 27323000000, "goodwillAndIntangibleAssets": 77190000000, "longTermInvestments": 20942000000, "taxAssets": 2694000000, "otherNonCurrentAssets": 6056000000, "totalNonCurrentAssets": 121106000000, "otherAssets": 0, "totalAssets": 169920000000, "totalPayables": 8253000000, "accountPayables": 4327000000, "otherPayables": 3926000000, "accruedExpenses": 0, "shortTermDebt": 3888000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 1742000000, "deferredRevenue": 4291000000, "otherCurrentLiabilities": 19232000000, "totalCurrentLiabilities": 35664000000, "longTermDebt": 33847000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 4161000000, "otherNonCurrentLiabilities": 25933000000, "totalNonCurrentLiabilities": 63941000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 99605000000, "treasuryStock": -111356000000, "preferredStock": 0, "commonStock": 472000000, "retainedEarnings": 96346000000, "additionalPaidInCapital": 89336000000, "accumulatedOtherComprehensiveIncomeLoss": -4758000000, "otherTotalStockholdersEquity": 2000000, "totalStockholdersEquity": 70042000000, "totalEquity": 70315000000, "minorityInterest": 273000000, "totalLiabilitiesAndTotalEquity": 169920000000, "totalInvestments": 40270000000, "totalDebt": 37735000000, "netDebt": 35363000000}}
{"date": "2021-04-04", "symbol": "PFE", "type": "balance_sheet_quarter", "result": {"date": "2021-04-04", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2021-05-13", "acceptedDate": "2021-05-13 11:32:26", "fiscalYear": "2021", "period": "Q1", "cashAndCashEquivalents": 1768000000, "shortTermInvestments": 11899000000, "cashAndShortTermInvestments": 13667000000, "netReceivables": 13283000000, "accountsReceivables": 9864000000, "otherReceivables": 3419000000, "inventory": 8493000000, "prepaids": 0, "otherCurrentAssets": 4090000000, "totalCurrentAssets": 39533000000, "propertyPlantEquipmentNet": 14011000000, "goodwill": 49791000000, "intangibleAssets": 27973000000, "goodwillAndIntangibleAssets": 77764000000, "longTermInvestments": 20228000000, "taxAssets": 2537000000, "otherNonCurrentAssets": 4744000000, "totalNonCurrentAssets": 119284000000, "otherAssets": 1000000, "totalAssets": 158818000000, "totalPayables": 5465000000, "accountPayables": 4064000000, "otherPayables": 1401000000, "accruedExpenses": 0, "shortTermDebt": 4352000000, "capitalLeaseObligationsCurrent": 0, "taxPayables": 1401000000, "deferredRevenue": 2052000000, "otherCurrentLiabilities": 14783000000, "totalCurrentLiabilities": 26652000000, "longTermDebt": 33836000000, "capitalLeaseObligationsNonCurrent": 0, "deferredRevenueNonCurrent": 0, "deferredTaxLiabilitiesNonCurrent": 4355000000, "otherNonCurrentLiabilities": 25110000000, "totalNonCurrentLiabilities": 63301000000, "otherLiabilities": 0, "capitalLeaseObligations": 0, "totalLiabilities": 89953000000, "treasuryStock": -111349000000, "preferredStock": 0, "commonStock": 472000000, "retainedEarnings": 95158000000, "additionalPaidInCapital": 89002000000, "accumulatedOtherComprehensiveIncomeLoss": -4664000000, "otherTotalStockholdersEquity": 1000000, "totalStockholdersEquity": 68620000000, "totalEquity": 68865000000, "minorityInterest": 245000000, "totalLiabilitiesAndTotalEquity": 158818000000, "totalInvestments": 32127000000, "totalDebt": 38188000000, "netDebt": 36420000000}}
{"date": "2024-12-31", "symbol": "PFE", "type": "cash_flow_annual", "result": {"date": "2024-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-02-27", "acceptedDate": "2025-02-27 16:27:18", "fiscalYear": "2024", "period": "FY", "netIncome": 8051000000, "depreciationAndAmortization": 7013000000, "deferredIncomeTax": -2102000000, "stockBasedCompensation": 877000000, "changeInWorkingCapital": -3066000000, "accountsReceivables": -109000000, "inventory": -854000000, "accountsPayables": -1023000000, "otherWorkingCapital": -1080000000, "otherNonCashItems": 1971000000, "netCashProvidedByOperatingActivities": 12744000000, "investmentsInPropertyPlantAndEquipment": -2909000000, "acquisitionsNet": 7040000000, "purchasesOfInvestments": -10313000000, "salesMaturitiesOfInvestments": 8834000000, "otherInvestingActivities": 0, "netCashProvidedByInvestingActivities": 2652000000, "netDebtIssuance": -7159000000, "longTermNetDebtIssuance": -2250000000, "shortTermNetDebtIssuance": -4909000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -9512000000, "commonDividendsPaid": -9512000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -469000000, "netCashProvidedByFinancingActivities": -17140000000, "effectOfForexChangesOnCash": -66000000, "netChangeInCash": -1810000000, "cashAtEndOfPeriod": 1107000000, "cashAtBeginningOfPeriod": 2917000000, "operatingCashFlow": 12744000000, "capitalExpenditure": -2909000000, "freeCashFlow": 9835000000, "incomeTaxesPaid": 3605000000, "interestPaid": 3227000000}}
{"date": "2023-12-31", "symbol": "PFE", "type": "cash_flow_annual", "result": {"date": "2023-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-02-22", "acceptedDate": "2024-02-22 13:17:37", "fiscalYear": "2023", "period": "FY", "netIncome": 2172000000, "depreciationAndAmortization": 6290000000, "deferredIncomeTax": -3442000000, "stockBasedCompensation": 525000000, "changeInWorkingCapital": -2172000000, "accountsReceivables": 347000000, "inventory": 6199000000, "accountsPayables": -300000000, "otherWorkingCapital": -8418000000, "otherNonCashItems": 5327000000, "netCashProvidedByOperatingActivities": 8700000000, "investmentsInPropertyPlantAndEquipment": -3907000000, "acquisitionsNet": -43430000000, "purchasesOfInvestments": -31178000000, "salesMaturitiesOfInvestments": 46417000000, "otherInvestingActivities": -180000000, "netCashProvidedByInvestingActivities": -32278000000, "netDebtIssuance": 35945000000, "longTermNetDebtIssuance": 28262000000, "shortTermNetDebtIssuance": 7683000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -9247000000, "commonDividendsPaid": -9247000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -632000000, "netCashProvidedByFinancingActivities": 26066000000, "effectOfForexChangesOnCash": -40000000, "netChangeInCash": 2449000000, "cashAtEndOfPeriod": 2917000000, "cashAtBeginningOfPeriod": 468000000, "operatingCashFlow": 8700000000, "capitalExpenditure": -3907000000, "freeCashFlow": 4793000000, "incomeTaxesPaid": 3147000000, "interestPaid": 2215000000}}
{"date": "2022-12-31", "symbol": "PFE", "type": "cash_flow_annual", "result": {"date": "2022-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-02-23", "acceptedDate": "2023-02-23 14:12:53", "fiscalYear": "2022", "period": "FY", "netIncome": 31401000000, "depreciationAndAmortization": 5064000000, "deferredIncomeTax": -3764000000, "stockBasedCompensation": 872000000, "changeInWorkingCapital": -4456000000, "accountsReceivables": 261000000, "inventory": 592000000, "accountsPayables": 1191000000, "otherWorkingCapital": -6500000000, "otherNonCashItems": 150000000, "netCashProvidedByOperatingActivities": 29267000000, "investmentsInPropertyPlantAndEquipment": -3236000000, "acquisitionsNet": -22997000000, "purchasesOfInvestments": -38780000000, "salesMaturitiesOfInvestments": 45462000000, "otherInvestingActivities": 3768000000, "netCashProvidedByInvestingActivities": -15783000000, "netDebtIssuance": -3516000000, "longTermNetDebtIssuance": -3298000000, "shortTermNetDebtIssuance": -218000000, "netStockIssuance": -2000000000, "netCommonStockIssuance": -2000000000, "commonStockIssuance": 0, "commonStockRepurchased": -2000000000, "netPreferredStockIssuance": 0, "netDividendsPaid": -8983000000, "commonDividendsPaid": -8983000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -335000000, "netCashProvidedByFinancingActivities": -14834000000, "effectOfForexChangesOnCash": -165000000, "netChangeInCash": -1515000000, "cashAtEndOfPeriod": 468000000, "cashAtBeginningOfPeriod": 1983000000, "operatingCashFlow": 29267000000, "capitalExpenditure": -3236000000, "freeCashFlow": 26031000000, "incomeTaxesPaid": 7867000000, "interestPaid": 1442000000}}
{"date": "2021-12-31", "symbol": "PFE", "type": "cash_flow_annual", "result": {"date": "2021-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-02-24", "acceptedDate": "2022-02-24 14:25:01", "fiscalYear": "2021", "period": "FY", "netIncome": 22459000000, "depreciationAndAmortization": 5191000000, "deferredIncomeTax": -4293000000, "stockBasedCompensation": 1182000000, "changeInWorkingCapital": 12804000000, "accountsReceivables": -3811000000, "inventory": -1125000000, "accountsPayables": 1242000000, "otherWorkingCapital": 16498000000, "otherNonCashItems": -4763000000, "netCashProvidedByOperatingActivities": 32580000000, "investmentsInPropertyPlantAndEquipment": -2711000000, "acquisitionsNet": -12000000, "purchasesOfInvestments": -47613000000, "salesMaturitiesOfInvestments": 28096000000, "otherInvestingActivities": -306000000, "netCashProvidedByInvestingActivities": -22546000000, "netDebtIssuance": -1103000000, "longTermNetDebtIssuance": -1007000000, "shortTermNetDebtIssuance": -96000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -8729000000, "commonDividendsPaid": -8729000000, "preferredDividendsPaid": 0, "otherFinancingActivities": 16000000, "netCashProvidedByFinancingActivities": -9816000000, "effectOfForexChangesOnCash": -60000000, "netChangeInCash": 158000000, "cashAtEndOfPeriod": 1983000000, "cashAtBeginningOfPeriod": 1825000000, "operatingCashFlow": 32580000000, "capitalExpenditure": -2711000000, "freeCashFlow": 29869000000, "incomeTaxesPaid": 7427000000, "interestPaid": 1467000000}}
{"date": "2025-09-28", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2025-09-28", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-11-04", "acceptedDate": "2025-11-04 07:03:48", "fiscalYear": "2025", "period": "Q3", "netIncome": 3551000000, "depreciationAndAmortization": 1662000000, "deferredIncomeTax": -765000000, "stockBasedCompensation": 201000000, "changeInWorkingCapital": -36000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": -36000000, "otherNonCashItems": -10000000, "netCashProvidedByOperatingActivities": 4603000000, "investmentsInPropertyPlantAndEquipment": -602000000, "acquisitionsNet": 0, "purchasesOfInvestments": -4935000000, "salesMaturitiesOfInvestments": 3095000000, "otherInvestingActivities": 12000000, "netCashProvidedByInvestingActivities": -2430000000, "netDebtIssuance": 6000000, "longTermNetDebtIssuance": 0, "shortTermNetDebtIssuance": 6000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2444000000, "commonDividendsPaid": -2444000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -33000000, "netCashProvidedByFinancingActivities": -2476000000, "effectOfForexChangesOnCash": 2000000, "netChangeInCash": -300000000, "cashAtEndOfPeriod": 1394000000, "cashAtBeginningOfPeriod": 1694000000, "operatingCashFlow": 4603000000, "capitalExpenditure": -602000000, "freeCashFlow": 4001000000, "incomeTaxesPaid": 0, "interestPaid": 0}}
{"date": "2025-06-29", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2025-06-29", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-08-05", "acceptedDate": "2025-08-05 07:16:27", "fiscalYear": "2025", "period": "Q2", "netIncome": 2928000000, "depreciationAndAmortization": 1625000000, "deferredIncomeTax": -272000000, "stockBasedCompensation": 203000000, "changeInWorkingCapital": 1919000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": 1919000000, "otherNonCashItems": -6985000000, "netCashProvidedByOperatingActivities": -582000000, "investmentsInPropertyPlantAndEquipment": -618000000, "acquisitionsNet": -6311000000, "purchasesOfInvestments": -2030000000, "salesMaturitiesOfInvestments": 12919000000, "otherInvestingActivities": -9000000, "netCashProvidedByInvestingActivities": 3951000000, "netDebtIssuance": -731000000, "longTermNetDebtIssuance": -63000000, "shortTermNetDebtIssuance": -668000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2445000000, "commonDividendsPaid": -2445000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -20000000, "netCashProvidedByFinancingActivities": -3196000000, "effectOfForexChangesOnCash": 41000000, "netChangeInCash": 213000000, "cashAtEndOfPeriod": 1694000000, "cashAtBeginningOfPeriod": 1481000000, "operatingCashFlow": -582000000, "capitalExpenditure": -618000000, "freeCashFlow": -1200000000, "incomeTaxesPaid": 3341000000, "interestPaid": 1130000000}}
{"date": "2025-03-30", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2025-03-30", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-05-05", "acceptedDate": "2025-05-05 16:00:34", "fiscalYear": "2025", "period": "Q1", "netIncome": 2973000000, "depreciationAndAmortization": 1618000000, "deferredIncomeTax": -663000000, "stockBasedCompensation": 170000000, "changeInWorkingCapital": -1919000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": -1919000000, "otherNonCashItems": 156000000, "netCashProvidedByOperatingActivities": 2335000000, "investmentsInPropertyPlantAndEquipment": -564000000, "acquisitionsNet": 6311000000, "purchasesOfInvestments": -6809000000, "salesMaturitiesOfInvestments": 4037000000, "otherInvestingActivities": 299000000, "netCashProvidedByInvestingActivities": 3274000000, "netDebtIssuance": -2434000000, "longTermNetDebtIssuance": 0, "shortTermNetDebtIssuance": -2434000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2437000000, "commonDividendsPaid": -2437000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -356000000, "netCashProvidedByFinancingActivities": -5227000000, "effectOfForexChangesOnCash": -7000000, "netChangeInCash": 374000000, "cashAtEndOfPeriod": 1481000000, "cashAtBeginningOfPeriod": 1107000000, "operatingCashFlow": 2335000000, "capitalExpenditure": -564000000, "freeCashFlow": 1771000000, "incomeTaxesPaid": 152000000, "interestPaid": 353000000}}
{"date": "2024-12-31", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2024-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2025-02-27", "acceptedDate": "2025-02-27 16:27:18", "fiscalYear": "2024", "period": "Q4", "netIncome": 411000000, "depreciationAndAmortization": 1791000000, "deferredIncomeTax": -396000000, "stockBasedCompensation": 177000000, "changeInWorkingCapital": 2926000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": 2926000000, "otherNonCashItems": 1812000000, "netCashProvidedByOperatingActivities": 6721000000, "investmentsInPropertyPlantAndEquipment": -917000000, "acquisitionsNet": 3549000000, "purchasesOfInvestments": -6281000000, "salesMaturitiesOfInvestments": 2014000000, "otherInvestingActivities": 12000000, "netCashProvidedByInvestingActivities": -1623000000, "netDebtIssuance": -2720000000, "longTermNetDebtIssuance": 0, "shortTermNetDebtIssuance": -2720000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2380000000, "commonDividendsPaid": -2380000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -14000000, "netCashProvidedByFinancingActivities": -5114000000, "effectOfForexChangesOnCash": -29000000, "netChangeInCash": -45000000, "cashAtEndOfPeriod": 1107000000, "cashAtBeginningOfPeriod": 1152000000, "operatingCashFlow": 6721000000, "capitalExpenditure": -917000000, "freeCashFlow": 5804000000, "incomeTaxesPaid": -3172000000, "interestPaid": 1394000000}}
{"date": "2024-09-29", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2024-09-29", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-11-04", "acceptedDate": "2024-11-04 16:06:08", "fiscalYear": "2024", "period": "Q3", "netIncome": 4481000000, "depreciationAndAmortization": 1755000000, "deferredIncomeTax": -482000000, "stockBasedCompensation": 274000000, "changeInWorkingCapital": 879000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": 879000000, "otherNonCashItems": -193000000, "netCashProvidedByOperatingActivities": 6714000000, "investmentsInPropertyPlantAndEquipment": -651000000, "acquisitionsNet": 0, "purchasesOfInvestments": -2670000000, "salesMaturitiesOfInvestments": 1258000000, "otherInvestingActivities": 6000000, "netCashProvidedByInvestingActivities": -2057000000, "netDebtIssuance": -2250000000, "longTermNetDebtIssuance": 0, "shortTermNetDebtIssuance": -2250000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2380000000, "commonDividendsPaid": -2380000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -6000000, "netCashProvidedByFinancingActivities": -4636000000, "effectOfForexChangesOnCash": 19000000, "netChangeInCash": 40000000, "cashAtEndOfPeriod": 1092000000, "cashAtBeginningOfPeriod": 1052000000, "operatingCashFlow": 6714000000, "capitalExpenditure": -651000000, "freeCashFlow": 6063000000, "incomeTaxesPaid": 486000000, "interestPaid": 280000000}}
{"date": "2024-06-30", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2024-06-30", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-08-05", "acceptedDate": "2024-08-05 15:54:43", "fiscalYear": "2024", "period": "Q2", "netIncome": 31000000, "depreciationAndAmortization": 1731000000, "deferredIncomeTax": -783000000, "stockBasedCompensation": 206000000, "changeInWorkingCapital": -3535000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": -3535000000, "otherNonCashItems": 569000000, "netCashProvidedByOperatingActivities": -1781000000, "investmentsInPropertyPlantAndEquipment": -637000000, "acquisitionsNet": 0, "purchasesOfInvestments": 657000000, "salesMaturitiesOfInvestments": 4599000000, "otherInvestingActivities": -19000000, "netCashProvidedByInvestingActivities": 4600000000, "netDebtIssuance": -16000000, "longTermNetDebtIssuance": -1000000000, "shortTermNetDebtIssuance": 984000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2380000000, "commonDividendsPaid": -2380000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -63000000, "netCashProvidedByFinancingActivities": -2459000000, "effectOfForexChangesOnCash": -18000000, "netChangeInCash": 343000000, "cashAtEndOfPeriod": 1123000000, "cashAtBeginningOfPeriod": 780000000, "operatingCashFlow": -1781000000, "capitalExpenditure": -637000000, "freeCashFlow": -2418000000, "incomeTaxesPaid": 2502000000, "interestPaid": 1138000000}}
{"date": "2024-03-31", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2024-03-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-05-08", "acceptedDate": "2024-05-08 15:56:17", "fiscalYear": "2024", "period": "Q1", "netIncome": 3128000000, "depreciationAndAmortization": 1736000000, "deferredIncomeTax": -441000000, "stockBasedCompensation": 220000000, "changeInWorkingCapital": -3336000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": -3336000000, "otherNonCashItems": -217000000, "netCashProvidedByOperatingActivities": 1090000000, "investmentsInPropertyPlantAndEquipment": -704000000, "acquisitionsNet": 3491000000, "purchasesOfInvestments": -2019000000, "salesMaturitiesOfInvestments": 963000000, "otherInvestingActivities": 1000000, "netCashProvidedByInvestingActivities": 1732000000, "netDebtIssuance": -2173000000, "longTermNetDebtIssuance": -1250000000, "shortTermNetDebtIssuance": -923000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2372000000, "commonDividendsPaid": -2372000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -386000000, "netCashProvidedByFinancingActivities": -4931000000, "effectOfForexChangesOnCash": -28000000, "netChangeInCash": -2137000000, "cashAtEndOfPeriod": 780000000, "cashAtBeginningOfPeriod": 2917000000, "operatingCashFlow": 1090000000, "capitalExpenditure": -704000000, "freeCashFlow": 386000000, "incomeTaxesPaid": 184000000, "interestPaid": 415000000}}
{"date": "2023-12-31", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2023-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2024-02-22", "acceptedDate": "2024-02-22 13:17:37", "fiscalYear": "2023", "period": "Q4", "netIncome": -3344000000, "depreciationAndAmortization": 1670000000, "deferredIncomeTax": -1858000000, "stockBasedCompensation": 121000000, "changeInWorkingCapital": 8450000000, "accountsReceivables": 347000000, "inventory": -1169000000, "accountsPayables": 822000000, "otherWorkingCapital": 8450000000, "otherNonCashItems": 201000000, "netCashProvidedByOperatingActivities": 5240000000, "investmentsInPropertyPlantAndEquipment": -1044000000, "acquisitionsNet": -43405000000, "purchasesOfInvestments": -874000000, "salesMaturitiesOfInvestments": 34312000000, "otherInvestingActivities": 15000000, "netCashProvidedByInvestingActivities": -10996000000, "netDebtIssuance": 7775000000, "longTermNetDebtIssuance": 0, "shortTermNetDebtIssuance": 7775000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2315000000, "commonDividendsPaid": -2315000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -18000000, "netCashProvidedByFinancingActivities": 5442000000, "effectOfForexChangesOnCash": 19000000, "netChangeInCash": -295000000, "cashAtEndOfPeriod": 2853000000, "cashAtBeginningOfPeriod": 3148000000, "operatingCashFlow": 5240000000, "capitalExpenditure": -1044000000, "freeCashFlow": 4196000000, "incomeTaxesPaid": 240000000, "interestPaid": 1062000000}}
{"date": "2023-10-01", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2023-10-01", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-11-08", "acceptedDate": "2023-11-08 16:00:02", "fiscalYear": "2023", "period": "Q3", "netIncome": -2394000000, "depreciationAndAmortization": 1560000000, "deferredIncomeTax": -113000000, "stockBasedCompensation": 151000000, "changeInWorkingCapital": -1199000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": -1199000000, "otherNonCashItems": 5451000000, "netCashProvidedByOperatingActivities": 3456000000, "investmentsInPropertyPlantAndEquipment": -810000000, "acquisitionsNet": -2000000, "purchasesOfInvestments": -9206000000, "salesMaturitiesOfInvestments": 10556000000, "otherInvestingActivities": 350000000, "netCashProvidedByInvestingActivities": 888000000, "netDebtIssuance": -1428000000, "longTermNetDebtIssuance": -1300000000, "shortTermNetDebtIssuance": -128000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2314000000, "commonDividendsPaid": -2314000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -37000000, "netCashProvidedByFinancingActivities": -3779000000, "effectOfForexChangesOnCash": -32000000, "netChangeInCash": 535000000, "cashAtEndOfPeriod": 3233000000, "cashAtBeginningOfPeriod": 2698000000, "operatingCashFlow": 3456000000, "capitalExpenditure": -810000000, "freeCashFlow": 2646000000, "incomeTaxesPaid": 882000000, "interestPaid": 332000000}}
{"date": "2023-07-02", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2023-07-02", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-08-09", "acceptedDate": "2023-08-09 16:11:52", "fiscalYear": "2023", "period": "Q2", "netIncome": 2329000000, "depreciationAndAmortization": 1573000000, "deferredIncomeTax": -873000000, "stockBasedCompensation": 148000000, "changeInWorkingCapital": -3916000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": -3916000000, "otherNonCashItems": -470000000, "netCashProvidedByOperatingActivities": -1209000000, "investmentsInPropertyPlantAndEquipment": -914000000, "acquisitionsNet": -25000000, "purchasesOfInvestments": -14382000000, "salesMaturitiesOfInvestments": -9640000000, "otherInvestingActivities": -524000000, "netCashProvidedByInvestingActivities": -25485000000, "netDebtIssuance": 29630000000, "longTermNetDebtIssuance": 29831000000, "shortTermNetDebtIssuance": -201000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2315000000, "commonDividendsPaid": -2315000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -141000000, "netCashProvidedByFinancingActivities": 27174000000, "effectOfForexChangesOnCash": -5000000, "netChangeInCash": 476000000, "cashAtEndOfPeriod": 2632000000, "cashAtBeginningOfPeriod": 2166000000, "operatingCashFlow": -1209000000, "capitalExpenditure": -914000000, "freeCashFlow": -2123000000, "incomeTaxesPaid": 1696000000, "interestPaid": 402000000}}
{"date": "2023-04-02", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2023-04-02", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-05-10", "acceptedDate": "2023-05-10 15:53:31", "fiscalYear": "2023", "period": "Q1", "netIncome": 5542000000, "depreciationAndAmortization": 1487000000, "deferredIncomeTax": -598000000, "stockBasedCompensation": 105000000, "changeInWorkingCapital": -5507000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": -5507000000, "otherNonCashItems": 184000000, "netCashProvidedByOperatingActivities": 1213000000, "investmentsInPropertyPlantAndEquipment": -1139000000, "acquisitionsNet": -1000000, "purchasesOfInvestments": -6716000000, "salesMaturitiesOfInvestments": 11189000000, "otherInvestingActivities": -18000000, "netCashProvidedByInvestingActivities": 3315000000, "netDebtIssuance": -32000000, "longTermNetDebtIssuance": -269000000, "shortTermNetDebtIssuance": 237000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2303000000, "commonDividendsPaid": -2303000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -436000000, "netCashProvidedByFinancingActivities": -2771000000, "effectOfForexChangesOnCash": -2000000, "netChangeInCash": 1750000000, "cashAtEndOfPeriod": 2166000000, "cashAtBeginningOfPeriod": 416000000, "operatingCashFlow": 1213000000, "capitalExpenditure": -1139000000, "freeCashFlow": 74000000, "incomeTaxesPaid": 329000000, "interestPaid": 419000000}}
{"date": "2022-12-31", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2022-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2023-02-23", "acceptedDate": "2023-02-23 14:12:53", "fiscalYear": "2022", "period": "Q4", "netIncome": 5001000000, "depreciationAndAmortization": 1519000000, "deferredIncomeTax": -365000000, "stockBasedCompensation": 364000000, "changeInWorkingCapital": 3149000000, "accountsReceivables": 261000000, "inventory": 592000000, "accountsPayables": 1191000000, "otherWorkingCapital": 1105000000, "otherNonCashItems": -1086000000, "netCashProvidedByOperatingActivities": 8582000000, "investmentsInPropertyPlantAndEquipment": -1001000000, "acquisitionsNet": -16772000000, "purchasesOfInvestments": 3425000000, "salesMaturitiesOfInvestments": 9929000000, "otherInvestingActivities": 9000000, "netCashProvidedByInvestingActivities": -4410000000, "netDebtIssuance": -2777000000, "longTermNetDebtIssuance": -1689000000, "shortTermNetDebtIssuance": -1088000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2245000000, "commonDividendsPaid": -2245000000, "preferredDividendsPaid": 0, "otherFinancingActivities": 7000000, "netCashProvidedByFinancingActivities": -5015000000, "effectOfForexChangesOnCash": -26000000, "netChangeInCash": -870000000, "cashAtEndOfPeriod": 468000000, "cashAtBeginningOfPeriod": 1338000000, "operatingCashFlow": 8582000000, "capitalExpenditure": -1001000000, "freeCashFlow": 7581000000, "incomeTaxesPaid": 2948000000, "interestPaid": 321000000}}
{"date": "2022-10-02", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2022-10-02", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-11-09", "acceptedDate": "2022-11-09 16:05:15", "fiscalYear": "2022", "period": "Q3", "netIncome": 8644000000, "depreciationAndAmortization": 1183000000, "deferredIncomeTax": 62000000, "stockBasedCompensation": 135000000, "changeInWorkingCapital": -4109000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": -4109000000, "otherNonCashItems": 59000000, "netCashProvidedByOperatingActivities": 5974000000, "investmentsInPropertyPlantAndEquipment": -841000000, "acquisitionsNet": 0, "purchasesOfInvestments": -18791000000, "salesMaturitiesOfInvestments": 15156000000, "otherInvestingActivities": 3849000000, "netCashProvidedByInvestingActivities": -627000000, "netDebtIssuance": -3521000000, "longTermNetDebtIssuance": 0, "shortTermNetDebtIssuance": -3521000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2245000000, "commonDividendsPaid": -2245000000, "preferredDividendsPaid": 0, "otherFinancingActivities": 5000000, "netCashProvidedByFinancingActivities": -5761000000, "effectOfForexChangesOnCash": -72000000, "netChangeInCash": -486000000, "cashAtEndOfPeriod": 1338000000, "cashAtBeginningOfPeriod": 1824000000, "operatingCashFlow": 5974000000, "capitalExpenditure": -841000000, "freeCashFlow": 5133000000, "incomeTaxesPaid": 1821000000, "interestPaid": 350000000}}
{"date": "2022-07-03", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2022-07-03", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-08-10", "acceptedDate": "2022-08-10 16:26:18", "fiscalYear": "2022", "period": "Q2", "netIncome": 9871000000, "depreciationAndAmortization": 1175000000, "deferredIncomeTax": -1140000000, "stockBasedCompensation": 287000000, "changeInWorkingCapital": -2766000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": -2766000000, "otherNonCashItems": 742000000, "netCashProvidedByOperatingActivities": 8169000000, "investmentsInPropertyPlantAndEquipment": -751000000, "acquisitionsNet": 0, "purchasesOfInvestments": -17389000000, "salesMaturitiesOfInvestments": 6904000000, "otherInvestingActivities": -77000000, "netCashProvidedByInvestingActivities": -11313000000, "netDebtIssuance": 4611000000, "longTermNetDebtIssuance": 0, "shortTermNetDebtIssuance": 4611000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2244000000, "commonDividendsPaid": -2244000000, "preferredDividendsPaid": 0, "otherFinancingActivities": 153000000, "netCashProvidedByFinancingActivities": 2520000000, "effectOfForexChangesOnCash": -66000000, "netChangeInCash": -690000000, "cashAtEndOfPeriod": 1780000000, "cashAtBeginningOfPeriod": 2470000000, "operatingCashFlow": 8169000000, "capitalExpenditure": -751000000, "freeCashFlow": 7418000000, "incomeTaxesPaid": 2744000000, "interestPaid": 318000000}}
{"date": "2022-04-03", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2022-04-03", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-05-11", "acceptedDate": "2022-05-11 16:19:49", "fiscalYear": "2022", "period": "Q1", "netIncome": 7879000000, "depreciationAndAmortization": 1187000000, "deferredIncomeTax": -2321000000, "stockBasedCompensation": 86000000, "changeInWorkingCapital": -730000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": -730000000, "otherNonCashItems": 440000000, "netCashProvidedByOperatingActivities": 6541000000, "investmentsInPropertyPlantAndEquipment": -643000000, "acquisitionsNet": -6225000000, "purchasesOfInvestments": -9434000000, "salesMaturitiesOfInvestments": 16882000000, "otherInvestingActivities": -13000000, "netCashProvidedByInvestingActivities": 567000000, "netDebtIssuance": -1829000000, "longTermNetDebtIssuance": -1609000000, "shortTermNetDebtIssuance": -220000000, "netStockIssuance": -2000000000, "netCommonStockIssuance": -2000000000, "commonStockIssuance": 0, "commonStockRepurchased": -2000000000, "netPreferredStockIssuance": 0, "netDividendsPaid": -2249000000, "commonDividendsPaid": -2249000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -500000000, "netCashProvidedByFinancingActivities": -6578000000, "effectOfForexChangesOnCash": -1000000, "netChangeInCash": 530000000, "cashAtEndOfPeriod": 2513000000, "cashAtBeginningOfPeriod": 1983000000, "operatingCashFlow": 6541000000, "capitalExpenditure": -643000000, "freeCashFlow": 5898000000, "incomeTaxesPaid": 354000000, "interestPaid": 453000000}}
{"date": "2021-12-31", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2021-12-31", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2022-02-24", "acceptedDate": "2022-02-24 14:25:01", "fiscalYear": "2021", "period": "Q4", "netIncome": 3850000000, "depreciationAndAmortization": 1277000000, "deferredIncomeTax": -591000000, "stockBasedCompensation": 495000000, "changeInWorkingCapital": 1988000000, "accountsReceivables": -3811000000, "inventory": -1125000000, "accountsPayables": 1242000000, "otherWorkingCapital": 5682000000, "otherNonCashItems": -1105000000, "netCashProvidedByOperatingActivities": 5914000000, "investmentsInPropertyPlantAndEquipment": -993000000, "acquisitionsNet": -12000000, "purchasesOfInvestments": -13320000000, "salesMaturitiesOfInvestments": 11675000000, "otherInvestingActivities": 64000000, "netCashProvidedByInvestingActivities": -2586000000, "netDebtIssuance": -1363000000, "longTermNetDebtIssuance": -1003000000, "shortTermNetDebtIssuance": -360000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2189000000, "commonDividendsPaid": -2189000000, "preferredDividendsPaid": 0, "otherFinancingActivities": 201000000, "netCashProvidedByFinancingActivities": -3351000000, "effectOfForexChangesOnCash": 1000000, "netChangeInCash": -22000000, "cashAtEndOfPeriod": 1944000000, "cashAtBeginningOfPeriod": 1966000000, "operatingCashFlow": 5914000000, "capitalExpenditure": -993000000, "freeCashFlow": 4921000000, "incomeTaxesPaid": 4484000000, "interestPaid": 262000000}}
{"date": "2021-10-03", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2021-10-03", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2021-11-12", "acceptedDate": "2021-11-12 06:06:57", "fiscalYear": "2021", "period": "Q3", "netIncome": 8166000000, "depreciationAndAmortization": 1360000000, "deferredIncomeTax": -3749000000, "stockBasedCompensation": 293000000, "changeInWorkingCapital": 6765000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": 6765000000, "otherNonCashItems": -2006000000, "netCashProvidedByOperatingActivities": 10829000000, "investmentsInPropertyPlantAndEquipment": -624000000, "acquisitionsNet": 0, "purchasesOfInvestments": -17706000000, "salesMaturitiesOfInvestments": 8552000000, "otherInvestingActivities": -298000000, "netCashProvidedByInvestingActivities": -10076000000, "netDebtIssuance": 759000000, "longTermNetDebtIssuance": -4000000, "shortTermNetDebtIssuance": 763000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2185000000, "commonDividendsPaid": -2185000000, "preferredDividendsPaid": 0, "otherFinancingActivities": 325000000, "netCashProvidedByFinancingActivities": -1101000000, "effectOfForexChangesOnCash": -37000000, "netChangeInCash": -384000000, "cashAtEndOfPeriod": 2034000000, "cashAtBeginningOfPeriod": 2418000000, "operatingCashFlow": 10829000000, "capitalExpenditure": -624000000, "freeCashFlow": 10205000000, "incomeTaxesPaid": 755000000, "interestPaid": 407000000}}
{"date": "2021-07-04", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2021-07-04", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2021-08-12", "acceptedDate": "2021-08-12 16:01:31", "fiscalYear": "2021", "period": "Q2", "netIncome": 5566000000, "depreciationAndAmortization": 1328000000, "deferredIncomeTax": -152000000, "stockBasedCompensation": 221000000, "changeInWorkingCapital": 5383000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": 5383000000, "otherNonCashItems": -1047000000, "netCashProvidedByOperatingActivities": 11299000000, "investmentsInPropertyPlantAndEquipment": -540000000, "acquisitionsNet": 0, "purchasesOfInvestments": -9510000000, "salesMaturitiesOfInvestments": 2148000000, "otherInvestingActivities": -235000000, "netCashProvidedByInvestingActivities": -8137000000, "netDebtIssuance": -474000000, "longTermNetDebtIssuance": 0, "shortTermNetDebtIssuance": -474000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2183000000, "commonDividendsPaid": -2183000000, "preferredDividendsPaid": 0, "otherFinancingActivities": 100000000, "netCashProvidedByFinancingActivities": -2557000000, "effectOfForexChangesOnCash": 5000000, "netChangeInCash": 609000000, "cashAtEndOfPeriod": 2418000000, "cashAtBeginningOfPeriod": 1809000000, "operatingCashFlow": 11299000000, "capitalExpenditure": -540000000, "freeCashFlow": 10759000000, "incomeTaxesPaid": 1794000000, "interestPaid": 353000000}}
{"date": "2021-04-04", "symbol": "PFE", "type": "cash_flow_quarter", "result": {"date": "2021-04-04", "symbol": "PFE", "reportedCurrency": "USD", "cik": "0000078003", "filingDate": "2021-05-13", "acceptedDate": "2021-05-13 11:32:26", "fiscalYear": "2021", "period": "Q1", "netIncome": 4877000000, "depreciationAndAmortization": 1226000000, "deferredIncomeTax": 199000000, "stockBasedCompensation": 172000000, "changeInWorkingCapital": -1327000000, "accountsReceivables": 0, "inventory": 0, "accountsPayables": 0, "otherWorkingCapital": -1327000000, "otherNonCashItems": -609000000, "netCashProvidedByOperatingActivities": 4538000000, "investmentsInPropertyPlantAndEquipment": -554000000, "acquisitionsNet": 0, "purchasesOfInvestments": -7077000000, "salesMaturitiesOfInvestments": 5721000000, "otherInvestingActivities": 163000000, "netCashProvidedByInvestingActivities": -1747000000, "netDebtIssuance": -25000000, "longTermNetDebtIssuance": 0, "shortTermNetDebtIssuance": -25000000, "netStockIssuance": 0, "netCommonStockIssuance": 0, "commonStockIssuance": 0, "commonStockRepurchased": 0, "netPreferredStockIssuance": 0, "netDividendsPaid": -2172000000, "commonDividendsPaid": -2172000000, "preferredDividendsPaid": 0, "otherFinancingActivities": -610000000, "netCashProvidedByFinancingActivities": -2807000000, "effectOfForexChangesOnCash": 0, "netChangeInCash": -16000000, "cashAtEndOfPeriod": 1809000000, "cashAtBeginningOfPeriod": 1825000000, "operatingCashFlow": 4538000000, "capitalExpenditure": -554000000, "freeCashFlow": 3984000000, "incomeTaxesPaid": 394000000, "interestPaid": 445000000}}
{"date": "2025-09-28", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2025-09-28", "fiscalYear": "2025", "period": "Q3", "reportedCurrency": "USD", "grossProfitMargin": 0.7494896121051999, "ebitMargin": 0.23934189984388135, "ebitdaMargin": 0.3391377446859613, "operatingProfitMargin": 0.21316200312237302, "pretaxProfitMargin": 0.20019214603098354, "continuousOperationsProfitMargin": 0.21316200312237302, "netProfitMargin": 0.21262159241023176, "bottomLineProfitMargin": 0.21262159241023176, "receivablesTurnover": 1.167882187938289, "payablesTurnover": 0.8304140127388535, "inventoryTurnover": 0.3637949075688873, "fixedAssetTurnover": 0.8820974576271187, "assetTurnover": 0.07978690276001169, "currentRatio": 1.2822166356978906, "quickRatio": 0.96884905454148, "solvencyRatio": 0.044995027457084794, "cashRatio": 0.03669799978139687, "priceToEarningsRatio": 9.572666619598984, "priceToEarningsGrowthRatio": 0.44382363418140763, "forwardPriceToEarningsGrowthRatio": 0.44382363418140763, "priceToBookRatio": 1.4610537601965496, "priceToSalesRatio": 8.141422481085627, "priceToFreeCashFlowRatio": 33.88834041489628, "priceToOperatingCashFlowRatio": 29.456278514012602, "debtToAssetsRatio": 0.2956532570629183, "debtToEquityRatio": 0.6649928341289426, "debtToCapitalRatio": 0.3993968145075172, "longTermDebtToCapitalRatio": 0.38219159842886624, "financialLeverageRatio": 2.24923222810099, "workingCapitalTurnoverRatio": 2.0428089543084944, "operatingCashFlowRatio": 0.125778773636463, "operatingCashFlowSalesRatio": 0.2763900564428966, "freeCashFlowOperatingCashFlowRatio": 0.8692157288724744, "debtServiceCoverageRatio": 1.1834510595358223, "interestCoverageRatio": 5.4447852760736195, "shortTermOperatingCashFlowCoverageRatio": 1.0697188008366256, "operatingCashFlowCoverageRatio": 0.0745884106818771, "capitalExpenditureCoverageRatio": 7.646179401993355, "dividendPaidAndCapexCoverageRatio": 1.511162179908076, "dividendPayoutRatio": 0.6902005083309799, "dividendYield": 0.01802529367621218, "dividendYieldPercentage": 1.802529367621218, "revenuePerShare": 2.929463500439754, "netIncomePerShare": 0.6228671943711521, "interestDebtPerShare": 10.969920844327177, "cashPerShare": 2.63570800351803, "bookValuePerShare": 16.375725593667546, "tangibleBookValuePerShare": -4.807211961301671, "shareholdersEquityPerShare": 16.32383465259455, "operatingCashFlowPerShare": 0.809674582233949, "capexPerShare": 0.10589270008795075, "freeCashFlowPerShare": 0.7037818821459982, "netIncomePerEBT": 1.0620875824835032, "ebtPerEbit": 0.9391549295774648, "priceToFairValue": 1.4610537601965496, "debtToMarketCap": 0.4551460406491023, "effectiveTaxRate": -0.0647870425914817, "enterpriseValueMultiple": 34.69480347025496, "dividendPerShare": 0.4299032541776605}}
{"date": "2025-06-29", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2025-06-29", "fiscalYear": "2025", "period": "Q2", "reportedCurrency": "USD", "grossProfitMargin": 0.6428717668736778, "ebitMargin": 0.252371528014741, "ebitdaMargin": 0.3632703200709752, "operatingProfitMargin": 0.24397734252371528, "pretaxProfitMargin": 0.20773902955026274, "continuousOperationsProfitMargin": 0.19811642667030643, "netProfitMargin": 0.19859414454377944, "bottomLineProfitMargin": 0.19688800928137581, "receivablesTurnover": 1.213197549263123, "payablesTurnover": 1.0129694154084399, "inventoryTurnover": 0.44845316650955525, "fixedAssetTurnover": 0.7804111631870473, "assetTurnover": 0.07109827991945462, "currentRatio": 1.158431850713036, "quickRatio": 0.8491226210040821, "solvencyRatio": 0.03873320635788287, "cashRatio": 0.043418332184700204, "priceToEarningsRatio": 11.838865979381442, "priceToEarningsGrowthRatio": -4.835436823453604, "forwardPriceToEarningsGrowthRatio": -4.835436823453604, "priceToBookRatio": 1.5536884830035516, "priceToSalesRatio": 9.404517846174844, "priceToFreeCashFlowRatio": -114.837, "priceToOperatingCashFlowRatio": -236.77731958762885, "debtToAssetsRatio": 0.29984715786409183, "debtToEquityRatio": 0.6967360054118045, "debtToCapitalRatio": 0.4106331233553943, "longTermDebtToCapitalRatio": 0.39331860434892646, "financialLeverageRatio": 2.323637183606742, "workingCapitalTurnoverRatio": 1.9047185753282205, "operatingCashFlowRatio": -0.01542702645390447, "operatingCashFlowSalesRatio": -0.03971882890875589, "freeCashFlowOperatingCashFlowRatio": 2.0618556701030926, "debtServiceCoverageRatio": 1.0470802182259042, "interestCoverageRatio": 5.466360856269113, "shortTermOperatingCashFlowCoverageRatio": -0.13550640279394646, "operatingCashFlowCoverageRatio": -0.009417932909364532, "capitalExpenditureCoverageRatio": -0.941747572815534, "dividendPaidAndCapexCoverageRatio": -0.19000979431929482, "dividendPayoutRatio": 0.8402061855670103, "dividendYield": 0.017742539425446503, "dividendYieldPercentage": 1.7742539425446504, "revenuePerShare": 2.5774846086191734, "netIncomePerShare": 0.5118733509234829, "interestDebtPerShare": 10.985224274406333, "cashPerShare": 2.33051890941073, "bookValuePerShare": 15.657343887423043, "tangibleBookValuePerShare": -5.749692172383465, "shareholdersEquityPerShare": 15.601583113456464, "operatingCashFlowPerShare": -0.10237467018469656, "capexPerShare": 0.10870712401055409, "freeCashFlowPerShare": -0.21108179419525067, "netIncomePerEBT": 0.9559789750328516, "ebtPerEbit": 0.8514685314685315, "priceToFairValue": 1.5536884830035516, "debtToMarketCap": 0.4484399627297822, "effectiveTaxRate": 0.046320630749014456, "enterpriseValueMultiple": 37.190193499906066, "dividendPerShare": 0.43007915567282323}}
{"date": "2025-03-29", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2025-03-29", "fiscalYear": "2025", "period": "Q1", "reportedCurrency": "USD", "grossProfitMargin": 0.7165147648559971, "ebitMargin": 0.25067444403937295, "ebitdaMargin": 0.36864746627779804, "operatingProfitMargin": 0.3371491068173533, "pretaxProfitMargin": 0.2029894276339774, "continuousOperationsProfitMargin": 0.21676995989792197, "netProfitMargin": 0.21633248268319358, "bottomLineProfitMargin": 0.21633248268319358, "receivablesTurnover": 0.9301458121397084, "payablesTurnover": 0.7419847328244275, "inventoryTurnover": 0.3582749723553262, "fixedAssetTurnover": 0.7475336567286205, "assetTurnover": 0.06592862499278944, "currentRatio": 1.258120267749369, "quickRatio": 0.9604136947218259, "solvencyRatio": 0.039057508667615065, "cashRatio": 0.039229671897289584, "priceToEarningsRatio": 12.116995281429054, "priceToEarningsGrowthRatio": 0.019477585665529828, "forwardPriceToEarningsGrowthRatio": 0.019477585665529828, "priceToBookRatio": 1.5918494985498903, "priceToSalesRatio": 10.485198687568356, "priceToFreeCashFlowRatio": 81.199604743083, "priceToOperatingCashFlowRatio": 61.5865096359743, "debtToAssetsRatio": 0.2946286076874267, "debtToEquityRatio": 0.6784631052270362, "debtToCapitalRatio": 0.4042168714427979, "longTermDebtToCapitalRatio": 0.3861156036369073, "financialLeverageRatio": 2.302774026434059, "workingCapitalTurnoverRatio": 1.6354638683520153, "operatingCashFlowRatio": 0.06405684187424558, "operatingCashFlowSalesRatio": 0.17025154939846884, "freeCashFlowOperatingCashFlowRatio": 0.758458244111349, "debtServiceCoverageRatio": 1.0234146341463415, "interestCoverageRatio": 7.0703363914373085, "shortTermOperatingCashFlowCoverageRatio": 0.5222545291881011, "operatingCashFlowCoverageRatio": 0.03809694734952929, "capitalExpenditureCoverageRatio": 4.140070921985815, "dividendPaidAndCapexCoverageRatio": 0.7780739753415529, "dividendPayoutRatio": 0.8213683855746545, "dividendYield": 0.01694661849942109, "dividendYieldPercentage": 1.694661849942109, "revenuePerShare": 2.416740088105727, "netIncomePerShare": 0.5228193832599118, "interestDebtPerShare": 10.915418502202643, "cashPerShare": 3.0512775330396478, "bookValuePerShare": 15.971277533039647, "tangibleBookValuePerShare": -5.600176211453745, "shareholdersEquityPerShare": 15.918590308370044, "operatingCashFlowPerShare": 0.41145374449339206, "capexPerShare": 0.09938325991189427, "freeCashFlowPerShare": 0.3120704845814978, "netIncomePerEBT": 1.0657327586206897, "ebtPerEbit": 0.6020761245674741, "priceToFairValue": 1.5918494985498903, "debtToMarketCap": 0.4262105845088297, "effectiveTaxRate": -0.06788793103448276, "enterpriseValueMultiple": 40.28194224683544, "dividendPerShare": 0.4294273127753304}}
{"date": "2024-12-31", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2024-12-31", "fiscalYear": "2024", "period": "Q4", "reportedCurrency": "USD", "grossProfitMargin": 0.7300568597646794, "ebitMargin": 0.1887068625795192, "ebitdaMargin": 0.2895344254911896, "operatingProfitMargin": 0.322299161177729, "pretaxProfitMargin": -0.0005629679671226707, "continuousOperationsProfitMargin": 0.023137983448741767, "netProfitMargin": 0.02268760907504363, "bottomLineProfitMargin": 0.0230816866520295, "receivablesTurnover": 1.2020707856804493, "payablesTurnover": 0.8512338008166164, "inventoryTurnover": 0.4418947562436642, "fixedAssetTurnover": 0.9657478388517371, "assetTurnover": 0.0832396108643086, "currentRatio": 1.1712524712175834, "quickRatio": 0.918874287707873, "solvencyRatio": 0.017566193484335343, "cashRatio": 0.02425863472496802, "priceToEarningsRatio": 93.2664454094293, "priceToEarningsGrowthRatio": -1.0268545872738533, "forwardPriceToEarningsGrowthRatio": -1.0268545872738533, "priceToBookRatio": 1.7045396415087923, "priceToSalesRatio": 8.463970613072116, "priceToFreeCashFlowRatio": 25.903774982770503, "priceToOperatingCashFlowRatio": 22.369514953131976, "debtToAssetsRatio": 0.29826707154773285, "debtToEquityRatio": 0.7216194460505878, "debtToCapitalRatio": 0.41915154229117824, "longTermDebtToCapitalRatio": 0.39130884849488634, "financialLeverageRatio": 2.419373490697595, "workingCapitalTurnoverRatio": 4.8170847457627115, "operatingCashFlowRatio": 0.15632050238399814, "operatingCashFlowSalesRatio": 0.378370770703147, "freeCashFlowOperatingCashFlowRatio": 0.8635619699449487, "debtServiceCoverageRatio": 0.7240078074170462, "interestCoverageRatio": 7.7469553450608934, "shortTermOperatingCashFlowCoverageRatio": 0.9676072559746617, "operatingCashFlowCoverageRatio": 0.10559474618611447, "capitalExpenditureCoverageRatio": 7.329334787350055, "dividendPaidAndCapexCoverageRatio": 2.0385198665453443, "dividendPayoutRatio": 5.905707196029777, "dividendYield": 0.015830203376209905, "dividendYieldPercentage": 1.5830203376209906, "revenuePerShare": 3.134462678665961, "netIncomePerShare": 0.07111346391388741, "interestDebtPerShare": 11.361919887065467, "cashPerShare": 3.613375683783307, "bookValuePerShare": 15.616199047114875, "tangibleBookValuePerShare": -6.2541026998411855, "shareholdersEquityPerShare": 15.5643197458973, "operatingCashFlowPerShare": 1.18598905946709, "capexPerShare": 0.1618140109405329, "freeCashFlowPerShare": 1.0241750485265573, "netIncomePerEBT": -40.3, "ebtPerEbit": -0.0017467248908296944, "priceToFairValue": 1.7045396415087923, "debtToMarketCap": 0.4233515187783127, "effectiveTaxRate": 42.1, "enterpriseValueMultiple": 41.4060878864476, "dividendPerShare": 0.4199752955708488}}
{"date": "2024-09-29", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2024-09-29", "fiscalYear": "2024", "period": "Q3", "reportedCurrency": "USD", "grossProfitMargin": 0.6084623206417354, "ebitMargin": 0.31058637442096937, "ebitdaMargin": 0.4097277143825556, "operatingProfitMargin": 0.2806462546604903, "pretaxProfitMargin": 0.26635408428426166, "continuousOperationsProfitMargin": 0.25313523895605017, "netProfitMargin": 0.25268331262004295, "bottomLineProfitMargin": 0.25268331262004295, "receivablesTurnover": 1.0004521306657623, "payablesTurnover": 1.3042905532555513, "inventoryTurnover": 0.5913317976281888, "fixedAssetTurnover": 0.9547489347931611, "assetTurnover": 0.08065574368040242, "currentRatio": 1.0002777070653306, "quickRatio": 0.7290273310036797, "solvencyRatio": 0.04907105375124096, "cashRatio": 0.025271342945083427, "priceToEarningsRatio": 9.166274312541919, "priceToEarningsGrowthRatio": 0.0004903624011294874, "forwardPriceToEarningsGrowthRatio": 0.0004903624011294874, "priceToBookRatio": 1.7771165723945128, "priceToSalesRatio": 9.264658230708395, "priceToFreeCashFlowRatio": 27.04980702622464, "priceToOperatingCashFlowRatio": 24.427015192135837, "debtToAssetsRatio": 0.30352749275547214, "debtToEquityRatio": 0.7218538023102096, "debtToCapitalRatio": 0.4192305997998779, "longTermDebtToCapitalRatio": 0.38147770837242967, "financialLeverageRatio": 2.378215547320287, "workingCapitalTurnoverRatio": -5.918421932464059, "operatingCashFlowRatio": 0.1553771030524635, "operatingCashFlowSalesRatio": 0.3792791774940685, "freeCashFlowOperatingCashFlowRatio": 0.9030384271671135, "debtServiceCoverageRatio": 0.6696241175348217, "interestCoverageRatio": 6.344827586206897, "shortTermOperatingCashFlowCoverageRatio": 0.692236313021961, "operatingCashFlowCoverageRatio": 0.10078508488824174, "capitalExpenditureCoverageRatio": 10.31336405529954, "dividendPaidAndCapexCoverageRatio": 2.2151105245793468, "dividendPayoutRatio": 0.5320813771517997, "dividendYield": 0.014511931429538659, "dividendYieldPercentage": 1.4511931429538658, "revenuePerShare": 3.1236986059643552, "netIncomePerShare": 0.7893065113816834, "interestDebtPerShare": 11.89341803423328, "cashPerShare": 1.7561319922357508, "bookValuePerShare": 16.332803952708666, "tangibleBookValuePerShare": -6.352214575613199, "shareholdersEquityPerShare": 16.284806776071996, "operatingCashFlowPerShare": 1.1847538380095288, "capexPerShare": 0.11487559555320276, "freeCashFlowPerShare": 1.069878242456326, "netIncomePerEBT": 0.9486744432661718, "ebtPerEbit": 0.9490740740740741, "priceToFairValue": 1.7771165723945128, "debtToMarketCap": 0.4061938386729314, "effectiveTaxRate": 0.0496288441145281, "enterpriseValueMultiple": 31.645936853715703, "dividendPerShare": 0.4199752955708488}}
{"date": "2024-06-30", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2024-06-30", "fiscalYear": "2024", "period": "Q2", "reportedCurrency": "USD", "grossProfitMargin": 0.6205676428517655, "ebitMargin": 0.05074154934879169, "ebitdaMargin": 0.181058495821727, "operatingProfitMargin": 0.14145900775427236, "pretaxProfitMargin": -0.00775427237822781, "continuousOperationsProfitMargin": 0.00233381013325303, "netProfitMargin": 0.0018068207483249265, "bottomLineProfitMargin": 0.0018068207483249265, "receivablesTurnover": 0.8804268575594884, "payablesTurnover": 0.9870740305522914, "inventoryTurnover": 0.44029003232287933, "fixedAssetTurnover": 0.7006910376114364, "assetTurnover": 0.061440472170699326, "currentRatio": 0.8632100230493621, "quickRatio": 0.6019763116456331, "solvencyRatio": 0.013687625762373458, "cashRatio": 0.02400785047582099, "priceToEarningsRatio": 1665.5679166666666, "priceToEarningsGrowthRatio": -16.78349545115415, "forwardPriceToEarningsGrowthRatio": -16.78349545115415, "priceToBookRatio": 1.8231986316989737, "priceToSalesRatio": 12.037530678310622, "priceToFreeCashFlowRatio": -66.12676592224979, "priceToOperatingCashFlowRatio": -89.77794497473329, "debtToAssetsRatio": 0.3176652343045335, "debtToEquityRatio": 0.7830900798175598, "debtToCapitalRatio": 0.43917583787897196, "longTermDebtToCapitalRatio": 0.3927980447681624, "financialLeverageRatio": 2.4651425313568986, "workingCapitalTurnoverRatio": -6.517664376840039, "operatingCashFlowRatio": -0.04064446929414181, "operatingCashFlowSalesRatio": -0.13408115636527893, "freeCashFlowOperatingCashFlowRatio": 1.3576642335766422, "debtServiceCoverageRatio": 0.19957553843735262, "interestCoverageRatio": 2.4151670951156814, "shortTermOperatingCashFlowCoverageRatio": -0.14911252511721365, "operatingCashFlowCoverageRatio": -0.025932990666453107, "capitalExpenditureCoverageRatio": -2.795918367346939, "dividendPaidAndCapexCoverageRatio": -0.5903215114352005, "dividendPayoutRatio": 99.16666666666667, "dividendYield": 0.01488481281284687, "dividendYieldPercentage": 1.488481281284687, "revenuePerShare": 2.3443346276032475, "netIncomePerShare": 0.004235792446170138, "interestDebtPerShare": 12.258206847864455, "cashPerShare": 1.2532650900105895, "bookValuePerShare": 15.526826685492411, "tangibleBookValuePerShare": -7.361454288739852, "shareholdersEquityPerShare": 15.478291563713379, "operatingCashFlowPerShare": -0.314331097776209, "capexPerShare": 0.1124249911754324, "freeCashFlowPerShare": -0.42675608895164135, "netIncomePerEBT": -0.23300970873786409, "ebtPerEbit": -0.05481639169771155, "priceToFairValue": 1.8231986316989737, "debtToMarketCap": 0.4295144073730607, "effectiveTaxRate": 1.3009708737864079, "enterpriseValueMultiple": 94.60271101871102, "dividendPerShare": 0.42004941757853864}}
{"date": "2024-03-31", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2024-03-31", "fiscalYear": "2024", "period": "Q1", "reportedCurrency": "USD", "grossProfitMargin": 0.7055581692318033, "ebitMargin": 0.28308354056052154, "ebitdaMargin": 0.3997580482559312, "operatingProfitMargin": 0.30640500033604406, "pretaxProfitMargin": 0.22992136568317764, "continuousOperationsProfitMargin": 0.2102291820686874, "netProfitMargin": 0.20969151152631224, "bottomLineProfitMargin": 0.20969151152631224, "receivablesTurnover": 0.977466824333202, "payablesTurnover": 0.7835807547844751, "inventoryTurnover": 0.4022218141755417, "fixedAssetTurnover": 0.7913098973568048, "assetTurnover": 0.06729686333928854, "currentRatio": 1.0473615329530583, "quickRatio": 0.7784033385189026, "solvencyRatio": 0.03777900526696593, "cashRatio": 0.017754401560609426, "priceToEarningsRatio": 12.565067307692308, "priceToEarningsGrowthRatio": -0.06529325978372295, "forwardPriceToEarningsGrowthRatio": -0.06529325978372295, "priceToBookRatio": 1.6992700635010076, "priceToSalesRatio": 10.539151824719402, "priceToFreeCashFlowRatio": 406.24880829015547, "priceToOperatingCashFlowRatio": 143.86425688073393, "debtToAssetsRatio": 0.310762341979692, "debtToEquityRatio": 0.7445438980516244, "debtToCapitalRatio": 0.4267842723150506, "longTermDebtToCapitalRatio": 0.3958981140227417, "financialLeverageRatio": 2.395862681779762, "workingCapitalTurnoverRatio": -11.701926858041682, "operatingCashFlowRatio": 0.026915573993135294, "operatingCashFlowSalesRatio": 0.0732576113986155, "freeCashFlowOperatingCashFlowRatio": 0.3541284403669725, "debtServiceCoverageRatio": 0.6268706351845693, "interestCoverageRatio": 5.770886075949367, "shortTermOperatingCashFlowCoverageRatio": 0.13242619365812172, "operatingCashFlowCoverageRatio": 0.01586423706118647, "capitalExpenditureCoverageRatio": 1.5482954545454546, "dividendPaidAndCapexCoverageRatio": 0.3543563068920676, "dividendPayoutRatio": 0.7602564102564102, "dividendYield": 0.015126389529783556, "dividendYieldPercentage": 1.5126389529783557, "revenuePerShare": 2.6301926816333747, "netIncomePerShare": 0.5515290790171469, "interestDebtPerShare": 12.285310235106946, "cashPerShare": 2.1087148665370337, "bookValuePerShare": 16.361675799893938, "tangibleBookValuePerShare": -6.99434329149726, "shareholdersEquityPerShare": 16.312886689057805, "operatingCashFlowPerShare": 0.19268163337458016, "capexPerShare": 0.1244475870602793, "freeCashFlowPerShare": 0.06823404631430087, "netIncomePerEBT": 0.912014030985092, "ebtPerEbit": 0.7503838561087958, "priceToFairValue": 1.6992700635010076, "debtToMarketCap": 0.4381551314554673, "effectiveTaxRate": 0.08564747149956153, "enterpriseValueMultiple": 37.79439139206456, "dividendPerShare": 0.41930351776560015}}
{"date": "2023-12-31", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2023-12-31", "fiscalYear": "2023", "period": "Q4", "reportedCurrency": "USD", "grossProfitMargin": 0.4104323953328758, "ebitMargin": -0.2361015785861359, "ebitdaMargin": -0.12148249828414551, "operatingProfitMargin": -0.08668496911461908, "pretaxProfitMargin": -0.28339052848318463, "continuousOperationsProfitMargin": -0.22889498970487301, "netProfitMargin": -0.22944406314344543, "bottomLineProfitMargin": -0.23122855181880578, "receivablesTurnover": 0.9373391662377767, "payablesTurnover": 1.2801788375558867, "inventoryTurnover": 0.8430660516243007, "fixedAssetTurnover": 0.7692713833157339, "assetTurnover": 0.06432642681489265, "currentRatio": 0.9066619240908901, "quickRatio": 0.6934761685567226, "solvencyRatio": -0.01219272226392543, "cashRatio": 0.05969368539984098, "priceToEarningsRatio": -12.15802647322764, "priceToEarningsGrowthRatio": -0.29866762599354096, "forwardPriceToEarningsGrowthRatio": -0.29866762599354096, "priceToBookRatio": 1.826422023501921, "priceToSalesRatio": 11.158347975291695, "priceToFreeCashFlowRatio": 38.74574118207817, "priceToOperatingCashFlowRatio": 31.026169847328244, "debtToAssetsRatio": 0.31278007602615443, "debtToEquityRatio": 0.7958860403981396, "debtToCapitalRatio": 0.4431717951444711, "longTermDebtToCapitalRatio": 0.40464039916261463, "financialLeverageRatio": 2.5445547891342937, "workingCapitalTurnoverRatio": 0.7585578550045555, "operatingCashFlowRatio": 0.10963719295309035, "operatingCashFlowSalesRatio": 0.35964310226492796, "freeCashFlowOperatingCashFlowRatio": 0.8007633587786259, "debtServiceCoverageRatio": -0.08844585410058904, "interestCoverageRatio": -1.8330914368650217, "shortTermOperatingCashFlowCoverageRatio": 0.5064759327276243, "operatingCashFlowCoverageRatio": 0.07396428823487897, "capitalExpenditureCoverageRatio": 5.019157088122605, "dividendPaidAndCapexCoverageRatio": 1.5599880916939566, "dividendPayoutRatio": -0.6924917738558182, "dividendYield": 0.014239395172002359, "dividendYieldPercentage": 1.4239395172002358, "revenuePerShare": 2.5801310430316984, "netIncomePerShare": -0.5919957499557287, "interestDebtPerShare": 12.667611120949177, "cashPerShare": 2.247210908446963, "bookValuePerShare": 15.811581370639278, "tangibleBookValuePerShare": -7.684611298034355, "shareholdersEquityPerShare": 15.763060031875332, "operatingCashFlowPerShare": 0.9279263325659642, "capexPerShare": 0.18487692580131043, "freeCashFlowPerShare": 0.7430494067646538, "netIncomePerEBT": 0.8096391378057641, "ebtPerEbit": 3.269200316706255, "priceToFairValue": 1.826422023501921, "debtToMarketCap": 0.43576239782311327, "effectiveTaxRate": 0.1922983773310729, "enterpriseValueMultiple": -130.2650451977401, "dividendPerShare": 0.4099521870019479}}
{"date": "2023-10-01", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2023-10-01", "fiscalYear": "2023", "period": "Q3", "reportedCurrency": "USD", "grossProfitMargin": 0.2140686383514936, "ebitMargin": -0.19694611222296346, "ebitdaMargin": -0.08131346823808465, "operatingProfitMargin": -0.2228152101400934, "pretaxProfitMargin": -0.24846193758802165, "continuousOperationsProfitMargin": -0.17700689348454526, "netProfitMargin": -0.17745163442294865, "bottomLineProfitMargin": -0.17745163442294865, "receivablesTurnover": 0.8992201559688062, "payablesTurnover": 1.9863244660921693, "inventoryTurnover": 1.0391023128185026, "fixedAssetTurnover": 0.7552905609674169, "assetTurnover": 0.06274270885169356, "currentRatio": 2.3770554984583763, "quickRatio": 2.049331963001028, "solvencyRatio": -0.007078774709931504, "cashRatio": 0.10110483042137719, "priceToEarningsRatio": -20.010989974937342, "priceToEarningsGrowthRatio": 0.09867941858531565, "forwardPriceToEarningsGrowthRatio": 0.09867941858531565, "priceToBookRatio": 1.9768630201993105, "priceToSalesRatio": 14.203931509895487, "priceToFreeCashFlowRatio": 72.42072562358277, "priceToOperatingCashFlowRatio": 55.44711805555555, "debtToAssetsRatio": 0.2957664600201841, "debtToEquityRatio": 0.656075267707925, "debtToCapitalRatio": 0.3961627110197471, "longTermDebtToCapitalRatio": 0.3864237697965591, "financialLeverageRatio": 2.2182206449749313, "workingCapitalTurnoverRatio": 0.33075904677846424, "operatingCashFlowRatio": 0.11099691675231244, "operatingCashFlowSalesRatio": 0.2561707805203469, "freeCashFlowOperatingCashFlowRatio": 0.765625, "debtServiceCoverageRatio": -0.04101140918902251, "interestCoverageRatio": -4.325179856115108, "shortTermOperatingCashFlowCoverageRatio": 1.3563579277864992, "operatingCashFlowCoverageRatio": 0.05434304044279514, "capitalExpenditureCoverageRatio": 4.266666666666667, "dividendPaidAndCapexCoverageRatio": 1.1062740076824584, "dividendPayoutRatio": -0.9665831244778613, "dividendYield": 0.012075653499507686, "dividendYieldPercentage": 1.2075653499507686, "revenuePerShare": 2.3894792773645057, "netIncomePerShare": -0.42401700318809776, "interestDebtPerShare": 11.386999645766915, "cashPerShare": 7.82518597236982, "bookValuePerShare": 17.216436415161176, "tangibleBookValuePerShare": 0.9658165072617783, "shareholdersEquityPerShare": 17.168614948636204, "operatingCashFlowPerShare": 0.61211477151966, "capexPerShare": 0.1434643995749203, "freeCashFlowPerShare": 0.46865037194473963, "netIncomePerEBT": 0.714200477326969, "ebtPerEbit": 1.115103127079175, "priceToFairValue": 1.9768630201993105, "debtToMarketCap": 0.33187694898646963, "effectiveTaxRate": 0.28758949880668255, "enterpriseValueMultiple": -229.7841750227894, "dividendPerShare": 0.40984767977329084}}
{"date": "2023-07-02", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2023-07-02", "fiscalYear": "2023", "period": "Q2", "reportedCurrency": "USD", "grossProfitMargin": 0.6467286845544706, "ebitMargin": 0.2135773045283309, "ebitdaMargin": 0.33451218574613667, "operatingProfitMargin": 0.18074882755439378, "pretaxProfitMargin": 0.17444452986853232, "continuousOperationsProfitMargin": 0.1799031290843392, "netProfitMargin": 0.1790574306142846, "bottomLineProfitMargin": 0.1790574306142846, "receivablesTurnover": 0.9688640595903166, "payablesTurnover": 0.7556322973195199, "inventoryTurnover": 0.4456838021338506, "fixedAssetTurnover": 0.7437671546203111, "assetTurnover": 0.05907761345881327, "currentRatio": 2.1169798250930816, "quickRatio": 1.8194071636793951, "solvencyRatio": 0.0322812823164426, "cashRatio": 0.07596617311744162, "priceToEarningsRatio": 22.211882782310003, "priceToEarningsGrowthRatio": -0.3825250191344249, "forwardPriceToEarningsGrowthRatio": -0.3825250191344249, "priceToBookRatio": 2.0897595410981733, "priceToSalesRatio": 15.908810640424386, "priceToFreeCashFlowRatio": -97.46862929816298, "priceToOperatingCashFlowRatio": -171.1545905707196, "debtToAssetsRatio": 0.2967779150466916, "debtToEquityRatio": 0.6598834567103283, "debtToCapitalRatio": 0.39754806522268193, "longTermDebtToCapitalRatio": 0.38257833203429464, "financialLeverageRatio": 2.2234924610428304, "workingCapitalTurnoverRatio": 0.4981997855063582, "operatingCashFlowRatio": -0.034894796086241235, "operatingCashFlowSalesRatio": -0.09294995002690859, "freeCashFlowOperatingCashFlowRatio": 1.7559966914805625, "debtServiceCoverageRatio": 0.9841976407745382, "interestCoverageRatio": 4.627952755905512, "shortTermOperatingCashFlowCoverageRatio": -0.30338770388958597, "operatingCashFlowCoverageRatio": -0.01850293077853109, "capitalExpenditureCoverageRatio": -1.3227571115973742, "dividendPaidAndCapexCoverageRatio": -0.3744193248683803, "dividendPayoutRatio": 0.9939888364104766, "dividendYield": 0.011187579708485018, "dividendYieldPercentage": 1.118757970848502, "revenuePerShare": 2.303754870704924, "netIncomePerShare": 0.4125044279135671, "interestDebtPerShare": 11.66294721927028, "cashPerShare": 7.932164364151612, "bookValuePerShare": 17.586432872830322, "tangibleBookValuePerShare": 1.118313850513638, "shareholdersEquityPerShare": 17.537902940134607, "operatingCashFlowPerShare": -0.21413390010626993, "capexPerShare": 0.16188452001416934, "freeCashFlowPerShare": -0.37601842012043923, "netIncomePerEBT": 1.0264433671220803, "ebtPerEbit": 0.9651212250106338, "priceToFairValue": 2.0897595410981733, "debtToMarketCap": 0.31577004135296743, "effectiveTaxRate": -0.03129131776112825, "enterpriseValueMultiple": 61.9707883245231, "dividendPerShare": 0.41002479631597594}}
{"date": "2023-04-02", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2023-04-02", "fiscalYear": "2023", "period": "Q1", "reportedCurrency": "USD", "grossProfitMargin": 0.6781348047170832, "ebitMargin": 0.35643189440657796, "ebitdaMargin": 0.4368711457319052, "operatingProfitMargin": 0.3616250135237477, "pretaxProfitMargin": 0.3391755923401493, "continuousOperationsProfitMargin": 0.30049767391539545, "netProfitMargin": 0.29979443903494535, "bottomLineProfitMargin": 0.29979443903494535, "receivablesTurnover": 1.1968921981223697, "payablesTurnover": 0.971745876204475, "inventoryTurnover": 0.623624358033749, "fixedAssetTurnover": 1.0840957072484165, "assetTurnover": 0.09450098917783219, "currentRatio": 1.3696734314315409, "quickRatio": 1.1087194354794596, "solvencyRatio": 0.07447473538106186, "cashRatio": 0.059241835785788524, "priceToEarningsRatio": 10.509107722843739, "priceToEarningsGrowthRatio": 0.9865466489554463, "forwardPriceToEarningsGrowthRatio": 0.9865466489554463, "priceToBookRatio": 2.307255548622872, "priceToSalesRatio": 12.602288218111003, "priceToFreeCashFlowRatio": 3148.187837837838, "priceToOperatingCashFlowRatio": 192.05762572135203, "debtToAssetsRatio": 0.17854787671828112, "debtToEquityRatio": 0.34591120222638183, "debtToCapitalRatio": 0.2570089331704661, "longTermDebtToCapitalRatio": 0.2333781290572398, "financialLeverageRatio": 1.9373582513791088, "workingCapitalTurnoverRatio": 1.6332552900119275, "operatingCashFlowRatio": 0.03317652207209671, "operatingCashFlowSalesRatio": 0.06561722384507195, "freeCashFlowOperatingCashFlowRatio": 0.06100577081615829, "debtServiceCoverageRatio": 1.6332371865986244, "interestCoverageRatio": 21.02201257861635, "shortTermOperatingCashFlowCoverageRatio": 0.28956791597039866, "operatingCashFlowCoverageRatio": 0.034729578835857644, "capitalExpenditureCoverageRatio": 1.0649692712906058, "dividendPaidAndCapexCoverageRatio": 0.352411388727484, "dividendPayoutRatio": 0.4155539516420065, "dividendYield": 0.009885566943488295, "dividendYieldPercentage": 0.9885566943488296, "revenuePerShare": 3.281150159744409, "netIncomePerShare": 0.9836705715299965, "interestDebtPerShare": 6.255768548100816, "cashPerShare": 3.54490592829251, "bookValuePerShare": 17.96876109336173, "tangibleBookValuePerShare": 1.3771742988995386, "shareholdersEquityPerShare": 17.921725239616613, "operatingCashFlowPerShare": 0.21529996450124245, "capexPerShare": 0.20216542421015266, "freeCashFlowPerShare": 0.013134540291089812, "netIncomePerEBT": 0.8838915470494418, "ebtPerEbit": 0.9379207180254301, "priceToFairValue": 2.307255548622872, "debtToMarketCap": 0.1499232291077793, "effectiveTaxRate": 0.11403508771929824, "enterpriseValueMultiple": 32.9032813273898, "dividendPerShare": 0.40876819311324103}}
{"date": "2022-12-31", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2022-12-31", "fiscalYear": "2022", "period": "Q4", "reportedCurrency": "USD", "grossProfitMargin": 0.5512556607657472, "ebitMargin": 0.2282832441333882, "ebitdaMargin": 0.29081926718814327, "operatingProfitMargin": 0.2201729106628242, "pretaxProfitMargin": 0.215356113627007, "continuousOperationsProfitMargin": 0.20588719637710992, "netProfitMargin": 0.20555784273363525, "bottomLineProfitMargin": 0.20547550432276657, "receivablesTurnover": 1.6718287562805423, "payablesTurnover": 1.6008224408870613, "inventoryTurnover": 1.2136733103217905, "fixedAssetTurnover": 1.4925648273319405, "assetTurnover": 0.12317069460361246, "currentRatio": 1.216455455883051, "quickRatio": 1.0033224168209218, "solvencyRatio": 0.06429128533206963, "cashRatio": 0.009872324267881722, "priceToEarningsRatio": 14.405798117364311, "priceToEarningsGrowthRatio": -0.3410849738865181, "forwardPriceToEarningsGrowthRatio": -0.3410849738865181, "priceToBookRatio": 3.0076269326057643, "priceToSalesRatio": 11.844899135446687, "priceToFreeCashFlowRatio": 37.95180055401662, "priceToOperatingCashFlowRatio": 33.52512234910277, "debtToAssetsRatio": 0.17676439864912832, "debtToEquityRatio": 0.36440137569124303, "debtToCapitalRatio": 0.26707784247624883, "longTermDebtToCapitalRatio": 0.2502233787406142, "financialLeverageRatio": 2.061508869863372, "workingCapitalTurnoverRatio": 1.3797216699801194, "operatingCashFlowRatio": 0.20366415112250225, "operatingCashFlowSalesRatio": 0.35331412103746396, "freeCashFlowOperatingCashFlowRatio": 0.8833605220228385, "debtServiceCoverageRatio": 2.1047120418848166, "interestCoverageRatio": 17.08626198083067, "shortTermOperatingCashFlowCoverageRatio": 2.9250170415814587, "operatingCashFlowCoverageRatio": 0.24619180125649043, "capitalExpenditureCoverageRatio": 8.573426573426573, "dividendPaidAndCapexCoverageRatio": 2.6438693776956255, "dividendPayoutRatio": 0.44962948127378327, "dividendYield": 0.0078029255583523275, "dividendYieldPercentage": 0.7802925558352327, "revenuePerShare": 4.325912733748887, "netIncomePerShare": 0.8892252894033837, "interestDebtPerShare": 6.26393588601959, "cashPerShare": 4.048441674087266, "bookValuePerShare": 17.08227960819234, "tangibleBookValuePerShare": 0.208726625111309, "shareholdersEquityPerShare": 17.036687444345503, "operatingCashFlowPerShare": 1.5284060552092609, "capexPerShare": 0.17827248441674087, "freeCashFlowPerShare": 1.35013357079252, "netIncomePerEBT": 0.9545020072643854, "ebtPerEbit": 0.9781226626776365, "priceToFairValue": 3.0076269326057643, "debtToMarketCap": 0.1211591011307812, "effectiveTaxRate": 0.0439686484419805, "enterpriseValueMultiple": 45.60526613816535, "dividendPerShare": 0.39982190560997327}}
{"date": "2022-10-02", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2022-10-02", "fiscalYear": "2022", "period": "Q3", "reportedCurrency": "USD", "grossProfitMargin": 0.6912713137202933, "ebitMargin": 0.4113437582825338, "ebitdaMargin": 0.46360102482551463, "operatingProfitMargin": 0.42843890803074475, "pretaxProfitMargin": 0.3976057955649792, "continuousOperationsProfitMargin": 0.3818800247371676, "netProfitMargin": 0.3812174220337486, "bottomLineProfitMargin": 0.3811732485201873, "receivablesTurnover": 1.2157894736842105, "payablesTurnover": 1.1152066379447902, "inventoryTurnover": 0.7346788605066751, "fixedAssetTurnover": 1.46609675539149, "assetTurnover": 0.11588490342924715, "currentRatio": 1.588730423793835, "quickRatio": 1.3740578598185675, "solvencyRatio": 0.09577489532398326, "cashRatio": 0.02929096899399738, "priceToEarningsRatio": 7.169553302433372, "priceToEarningsGrowthRatio": -0.559707144366437, "forwardPriceToEarningsGrowthRatio": -0.559707144366437, "priceToBookRatio": 2.6718159147585583, "priceToSalesRatio": 10.932634508348794, "priceToFreeCashFlowRatio": 48.216049094097016, "priceToOperatingCashFlowRatio": 41.42835286240375, "debtToAssetsRatio": 0.18263210971133714, "debtToEquityRatio": 0.3851518390171757, "debtToCapitalRatio": 0.2780574866726938, "longTermDebtToCapitalRatio": 0.25468282321135466, "financialLeverageRatio": 2.1088944305901913, "workingCapitalTurnoverRatio": 0.9811680572109654, "operatingCashFlowRatio": 0.1348106693144379, "operatingCashFlowSalesRatio": 0.263892570015019, "freeCashFlowOperatingCashFlowRatio": 0.8592233009708737, "debtServiceCoverageRatio": 2.338869665513264, "interestCoverageRatio": 31.186495176848876, "shortTermOperatingCashFlowCoverageRatio": 1.484592445328032, "operatingCashFlowCoverageRatio": 0.16744681447431117, "capitalExpenditureCoverageRatio": 7.103448275862069, "dividendPaidAndCapexCoverageRatio": 1.9358392741412833, "dividendPayoutRatio": 0.26013904982618774, "dividendYield": 0.009070964356241539, "dividendYieldPercentage": 0.9070964356241539, "revenuePerShare": 4.037453183520599, "netIncomePerShare": 1.539147494203674, "interestDebtPerShare": 6.41840556447298, "cashPerShare": 6.442482611021937, "bookValuePerShare": 16.566791510611736, "tangibleBookValuePerShare": 2.728553593722133, "shareholdersEquityPerShare": 16.52059925093633, "operatingCashFlowPerShare": 1.065453896914571, "capexPerShare": 0.14999108257535224, "freeCashFlowPerShare": 0.9154628143392188, "netIncomePerEBT": 0.9587823575158316, "ebtPerEbit": 0.9280338179193731, "priceToFairValue": 2.6718159147585583, "debtToMarketCap": 0.14415358366932265, "effectiveTaxRate": 0.0395511609821131, "enterpriseValueMultiple": 26.85773987613149, "dividendPerShare": 0.4003923666845015}}
{"date": "2022-07-03", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2022-07-03", "fiscalYear": "2022", "period": "Q2", "reportedCurrency": "USD", "grossProfitMargin": 0.6732030855742196, "ebitMargin": 0.4231490159325211, "ebitdaMargin": 0.4655035685963521, "operatingProfitMargin": 0.4666931007137193, "pretaxProfitMargin": 0.4126234590152116, "continuousOperationsProfitMargin": 0.35603056737077354, "netProfitMargin": 0.35581428880397953, "bottomLineProfitMargin": 0.35585033523177856, "receivablesTurnover": 1.563986920735145, "payablesTurnover": 1.4603737113402062, "inventoryTurnover": 0.8672278553663669, "fixedAssetTurnover": 1.8198635528732616, "assetTurnover": 0.14205540478263096, "currentRatio": 1.4230331153765028, "quickRatio": 1.2025311115798354, "solvencyRatio": 0.1024475751476985, "cashRatio": 0.037544821767559584, "priceToEarningsRatio": 7.4098325904163715, "priceToEarningsGrowthRatio": 0.28571172926348254, "forwardPriceToEarningsGrowthRatio": 0.28571172926348254, "priceToBookRatio": 3.354812347349471, "priceToSalesRatio": 10.546097253262202, "priceToFreeCashFlowRatio": 39.44052709625236, "priceToOperatingCashFlowRatio": 35.81464438731791, "debtToAssetsRatio": 0.20038916483178862, "debtToEquityRatio": 0.44873808895870837, "debtToCapitalRatio": 0.3097441092897905, "longTermDebtToCapitalRatio": 0.27554038113276513, "financialLeverageRatio": 2.239333096354734, "workingCapitalTurnoverRatio": 1.5758918427630084, "operatingCashFlowRatio": 0.17230542079730016, "operatingCashFlowSalesRatio": 0.29446326869007283, "freeCashFlowOperatingCashFlowRatio": 0.9080670828742808, "debtServiceCoverageRatio": 1.8127197187599873, "interestCoverageRatio": 44.18771331058021, "shortTermOperatingCashFlowCoverageRatio": 1.3694886839899414, "operatingCashFlowCoverageRatio": 0.2087443144069096, "capitalExpenditureCoverageRatio": 10.877496671105193, "dividendPaidAndCapexCoverageRatio": 2.7275459098497494, "dividendPayoutRatio": 0.2273325904163712, "dividendYield": 0.007669963782663441, "dividendYieldPercentage": 0.7669963782663441, "revenuePerShare": 4.9601287323440015, "netIncomePerShare": 1.7648846772751654, "interestDebtPerShare": 7.0493473985338815, "cashPerShare": 5.954586089755051, "bookValuePerShare": 15.639013052029322, "tangibleBookValuePerShare": 1.5220811728946897, "shareholdersEquityPerShare": 15.592526372251028, "operatingCashFlowPerShare": 1.460575719649562, "capexPerShare": 0.13427498659038084, "freeCashFlowPerShare": 1.3263007330591812, "netIncomePerEBT": 0.8623220057657028, "ebtPerEbit": 0.8841430447207848, "priceToFairValue": 3.354812347349471, "debtToMarketCap": 0.13375951990675183, "effectiveTaxRate": 0.13715383943391282, "enterpriseValueMultiple": 25.54776444169119, "dividendPerShare": 0.4012158054711246}}
{"date": "2022-04-03", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2022-04-03", "fiscalYear": "2022", "period": "Q1", "reportedCurrency": "USD", "grossProfitMargin": 0.5792057986828261, "ebitMargin": 0.3652624605432368, "ebitdaMargin": 0.41151942636686023, "operatingProfitMargin": 0.39137212111764935, "pretaxProfitMargin": 0.35267526596781107, "continuousOperationsProfitMargin": 0.3070028447839133, "netProfitMargin": 0.3068079965706714, "bottomLineProfitMargin": 0.3068079965706714, "receivablesTurnover": 1.5702484396034757, "payablesTurnover": 1.9611333091173266, "inventoryTurnover": 1.082072351939072, "fixedAssetTurnover": 1.6983916870739295, "assetTurnover": 0.13958257407216018, "currentRatio": 1.3858612610777223, "quickRatio": 1.1317357644901702, "solvencyRatio": 0.08956463284431966, "cashRatio": 0.06290108994601203, "priceToEarningsRatio": 9.085798933062364, "priceToEarningsGrowthRatio": 0.0688442402226772, "forwardPriceToEarningsGrowthRatio": 0.0688442402226772, "priceToBookRatio": 3.4714401145297487, "priceToSalesRatio": 11.150383071587234, "priceToFreeCashFlowRatio": 48.513051881993896, "priceToOperatingCashFlowRatio": 43.74407277174743, "debtToAssetsRatio": 0.19066475922128362, "debtToEquityRatio": 0.42526448607201783, "debtToCapitalRatio": 0.2983758384691341, "longTermDebtToCapitalRatio": 0.29455665867853476, "financialLeverageRatio": 2.2304304571484033, "workingCapitalTurnoverRatio": 1.5951389320569405, "operatingCashFlowRatio": 0.16657329122949985, "operatingCashFlowSalesRatio": 0.2549004325630334, "freeCashFlowOperatingCashFlowRatio": 0.9016969882280996, "debtServiceCoverageRatio": 9.799582463465553, "interestCoverageRatio": 31.18944099378882, "shortTermOperatingCashFlowCoverageRatio": 10.284591194968554, "operatingCashFlowCoverageRatio": 0.1866084674198334, "capitalExpenditureCoverageRatio": 10.172628304821151, "dividendPaidAndCapexCoverageRatio": 2.261756569847856, "dividendPayoutRatio": 0.2856598501206656, "dividendYield": 0.007860064156856266, "dividendYieldPercentage": 0.7860064156856265, "revenuePerShare": 4.568452910806481, "netIncomePerShare": 1.4016378849919886, "interestDebtPerShare": 6.29766779419619, "cashPerShare": 4.254406266690404, "bookValuePerShare": 14.720491365497596, "tangibleBookValuePerShare": 0.4732063379027951, "shareholdersEquityPerShare": 14.674025280398789, "operatingCashFlowPerShare": 1.164500623108421, "capexPerShare": 0.11447391846181236, "freeCashFlowPerShare": 1.0500267046466085, "netIncomePerEBT": 0.8699447513812155, "ebtPerEbit": 0.9011251618042417, "priceToFairValue": 3.4714401145297487, "debtToMarketCap": 0.12250376559632095, "effectiveTaxRate": 0.12950276243093922, "enterpriseValueMultiple": 30.181058712121214, "dividendPerShare": 0.4003916681502581}}
{"date": "2021-12-31", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2021-12-31", "fiscalYear": "2021", "period": "Q4", "reportedCurrency": "USD", "grossProfitMargin": 0.5520597365550801, "ebitMargin": 0.17371423777162515, "ebitdaMargin": 0.22728416813491065, "operatingProfitMargin": 0.13759543585871298, "pretaxProfitMargin": 0.1605419917778337, "continuousOperationsProfitMargin": 0.15009648460441313, "netProfitMargin": 0.14233576642335766, "bottomLineProfitMargin": 0.14233576642335766, "receivablesTurnover": 1.5140044458558273, "payablesTurnover": 1.9143062029401219, "inventoryTurnover": 1.1787172977149796, "fixedAssetTurnover": 1.6018008332213411, "assetTurnover": 0.1313554885743097, "currentRatio": 1.3989126104380023, "quickRatio": 1.1866138595298914, "solvencyRatio": 0.04489780221893207, "cashRatio": 0.04555787302852054, "priceToEarningsRatio": 24.43448275862069, "priceToEarningsGrowthRatio": -0.4179491841567457, "forwardPriceToEarningsGrowthRatio": -0.4179491841567457, "priceToBookRatio": 4.295602388570096, "priceToSalesRatio": 13.911603322426378, "priceToFreeCashFlowRatio": 67.38971753708596, "priceToOperatingCashFlowRatio": 56.0745350016909, "debtToAssetsRatio": 0.20387156499170694, "debtToEquityRatio": 0.47924249685884895, "debtToCapitalRatio": 0.32397831854919923, "longTermDebtToCapitalRatio": 0.3104467746833634, "financialLeverageRatio": 2.3507078923848135, "workingCapitalTurnoverRatio": 1.4395362178809747, "operatingCashFlowRatio": 0.13859529891495395, "operatingCashFlowSalesRatio": 0.24809128282574042, "freeCashFlowOperatingCashFlowRatio": 0.8320933378424078, "debtServiceCoverageRatio": 2.022300469483568, "interestCoverageRatio": 10.412698412698413, "shortTermOperatingCashFlowCoverageRatio": 2.6390004462293617, "operatingCashFlowCoverageRatio": 0.15984647818801015, "capitalExpenditureCoverageRatio": 5.955689828801611, "dividendPaidAndCapexCoverageRatio": 1.8585795097423004, "dividendPayoutRatio": 0.6451517830828176, "dividendYield": 0.006600833230807829, "dividendYieldPercentage": 0.6600833230807829, "revenuePerShare": 4.244658119658119, "netIncomePerShare": 0.6041666666666666, "interestDebtPerShare": 6.644052706552706, "cashPerShare": 5.532229344729345, "bookValuePerShare": 13.79326923076923, "tangibleBookValuePerShare": 0.5535968660968661, "shareholdersEquityPerShare": 13.746616809116809, "operatingCashFlowPerShare": 1.0530626780626782, "capexPerShare": 0.17681623931623933, "freeCashFlowPerShare": 0.8762464387464387, "netIncomePerEBT": 0.8865952443166971, "ebtPerEbit": 1.1667682926829268, "priceToFairValue": 4.295602388570096, "debtToMarketCap": 0.1115658418791357, "effectiveTaxRate": 0.06506401881369218, "enterpriseValueMultiple": 67.67788851974899, "dividendPerShare": 0.38977920227920226}}
{"date": "2021-10-03", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2021-10-03", "fiscalYear": "2021", "period": "Q3", "reportedCurrency": "USD", "grossProfitMargin": 0.5483669648429373, "ebitMargin": 0.3398377366340753, "ebitdaMargin": 0.39563137091741213, "operatingProfitMargin": 0.3224464322862492, "pretaxProfitMargin": 0.3263157894736842, "continuousOperationsProfitMargin": 0.3399625546078635, "netProfitMargin": 0.33946328271271065, "bottomLineProfitMargin": 0.338922404826295, "receivablesTurnover": 1.5237099023709901, "payablesTurnover": 2.3105576841209023, "inventoryTurnover": 1.2563657407407407, "fixedAssetTurnover": 1.6649348850096979, "assetTurnover": 0.1341328660401366, "currentRatio": 1.3850680573164604, "quickRatio": 1.1783843264837452, "solvencyRatio": 0.09203553540461727, "cashRatio": 0.047030117455685, "priceToEarningsRatio": 7.290531315112147, "priceToEarningsGrowthRatio": 0.18037404798960294, "forwardPriceToEarningsGrowthRatio": 0.18037404798960294, "priceToBookRatio": 3.143488393600296, "priceToSalesRatio": 9.899470771791139, "priceToFreeCashFlowRatio": 23.31541205291524, "priceToOperatingCashFlowRatio": 21.971906916612802, "debtToAssetsRatio": 0.214344710583298, "debtToEquityRatio": 0.5074315308292928, "debtToCapitalRatio": 0.33661995284796536, "longTermDebtToCapitalRatio": 0.3148275549923056, "financialLeverageRatio": 2.3673620377587823, "workingCapitalTurnoverRatio": 1.6435873764830582, "operatingCashFlowRatio": 0.2590483936559577, "operatingCashFlowSalesRatio": 0.45055127938423134, "freeCashFlowOperatingCashFlowRatio": 0.9423769507803121, "debtServiceCoverageRatio": 2.4878603945371776, "interestCoverageRatio": 23.846153846153847, "shortTermOperatingCashFlowCoverageRatio": 2.9840176357123176, "operatingCashFlowCoverageRatio": 0.2819464694855239, "capitalExpenditureCoverageRatio": 17.354166666666668, "dividendPaidAndCapexCoverageRatio": 3.8551085795656816, "dividendPayoutRatio": 0.26780242676798627, "dividendYield": 0.009183227366874934, "dividendYieldPercentage": 0.9183227366874933, "revenuePerShare": 4.285077553931182, "netIncomePerShare": 1.4546264931360313, "interestDebtPerShare": 6.905509003387413, "cashPerShare": 5.294348368693171, "bookValuePerShare": 13.543768942770548, "tangibleBookValuePerShare": 0.030665002674273488, "shareholdersEquityPerShare": 13.494562310572295, "operatingCashFlowPerShare": 1.9306471741843465, "capexPerShare": 0.11124977714387592, "freeCashFlowPerShare": 1.8193973970404707, "netIncomePerEBT": 1.0402907050873391, "ebtPerEbit": 1.012, "priceToFairValue": 3.143488393600296, "debtToMarketCap": 0.16142306485443134, "effectiveTaxRate": -0.041820731862807596, "enterpriseValueMultiple": 28.85432537595962, "dividendPerShare": 0.3895525049028347}}
{"date": "2021-07-04", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2021-07-04", "fiscalYear": "2021", "period": "Q2", "reportedCurrency": "USD", "grossProfitMargin": 0.5848986718874014, "ebitMargin": 0.3843589607915763, "ebitdaMargin": 0.45356897190327533, "operatingProfitMargin": 0.3168421609608974, "pretaxProfitMargin": 0.36769141224403407, "continuousOperationsProfitMargin": 0.3082702788507328, "netProfitMargin": 0.30684163183237206, "bottomLineProfitMargin": 0.30684163183237206, "receivablesTurnover": 1.3171870643992194, "payablesTurnover": 1.8130344349433787, "inventoryTurnover": 0.8767322306660706, "fixedAssetTurnover": 1.328669853768279, "assetTurnover": 0.11122292843691149, "currentRatio": 1.368719156572454, "quickRatio": 1.1178218932256618, "solvencyRatio": 0.07135183976707997, "cashRatio": 0.06650964558097802, "priceToEarningsRatio": 9.588228142783239, "priceToEarningsGrowthRatio": 0.5153451359942696, "forwardPriceToEarningsGrowthRatio": 0.5153451359942696, "priceToBookRatio": 3.175359641358042, "priceToSalesRatio": 11.768270278850732, "priceToFreeCashFlowRatio": 20.67185983827493, "priceToOperatingCashFlowRatio": 19.683913620674392, "debtToAssetsRatio": 0.22207509416195856, "debtToEquityRatio": 0.5387481796636304, "debtToCapitalRatio": 0.35012108334802416, "longTermDebtToCapitalRatio": 0.3257996515511748, "financialLeverageRatio": 2.4259729876359897, "workingCapitalTurnoverRatio": 1.452037954746264, "operatingCashFlowRatio": 0.31681807985643784, "operatingCashFlowSalesRatio": 0.5978623207577121, "freeCashFlowOperatingCashFlowRatio": 0.9522081600141605, "debtServiceCoverageRatio": 1.771883920076118, "interestCoverageRatio": 18.949367088607595, "shortTermOperatingCashFlowCoverageRatio": 2.906121399176955, "operatingCashFlowCoverageRatio": 0.29943023718033657, "capitalExpenditureCoverageRatio": 20.924074074074074, "dividendPaidAndCapexCoverageRatio": 4.149467499081895, "dividendPayoutRatio": 0.3764442145197448, "dividendYield": 0.009815270582685361, "dividendYieldPercentage": 0.981527058268536, "revenuePerShare": 3.376027152554484, "netIncomePerShare": 1.0359056806002143, "interestDebtPerShare": 6.797249017506252, "cashPerShare": 3.876384423008217, "bookValuePerShare": 12.56073597713469, "tangibleBookValuePerShare": -1.2281171847088246, "shareholdersEquityPerShare": 12.51196856020007, "operatingCashFlowPerShare": 2.018399428367274, "capexPerShare": 0.09646302250803858, "freeCashFlowPerShare": 1.9219364058592354, "netIncomePerEBT": 0.8345085623830767, "ebtPerEbit": 1.1604876419505679, "priceToFairValue": 3.175359641358042, "debtToMarketCap": 0.16966524756648285, "effectiveTaxRate": 0.1616059864728738, "enterpriseValueMultiple": 30.071341577228182, "dividendPerShare": 0.38996070025008933}}
{"date": "2021-04-04", "symbol": "PFE", "type": "ratios_quarter", "result": {"symbol": "PFE", "date": "2021-04-04", "fiscalYear": "2021", "period": "Q1", "reportedCurrency": "USD", "grossProfitMargin": 0.6556902728024249, "ebitMargin": 0.41533480297602643, "ebitdaMargin": 0.49848443097271977, "operatingProfitMargin": 0.33142739046569303, "pretaxProfitMargin": 0.3921190410581427, "continuousOperationsProfitMargin": 0.33645632405621384, "netProfitMargin": 0.33597409754753377, "bottomLineProfitMargin": 0.33597409754753377, "receivablesTurnover": 1.0928254159451931, "payablesTurnover": 1.2298228346456692, "inventoryTurnover": 0.5884846344048039, "fixedAssetTurnover": 1.0360431089857969, "assetTurnover": 0.09140021911873969, "currentRatio": 1.4833033168242533, "quickRatio": 1.164640552303767, "solvencyRatio": 0.06763532066745967, "cashRatio": 0.06633648506678673, "priceToEarningsRatio": 10.384843141275374, "priceToEarningsGrowthRatio": 0.021933318685567044, "forwardPriceToEarningsGrowthRatio": 0.021933318685567044, "priceToBookRatio": 2.9523101136694843, "priceToSalesRatio": 13.956153210250758, "priceToFreeCashFlowRatio": 50.85028112449799, "priceToOperatingCashFlowRatio": 44.642468047598065, "debtToAssetsRatio": 0.2404513342316362, "debtToEquityRatio": 0.5565141358204605, "debtToCapitalRatio": 0.3575387611414875, "longTermDebtToCapitalRatio": 0.3302490825329898, "financialLeverageRatio": 2.3144564266977556, "workingCapitalTurnoverRatio": 1.3179589613219538, "operatingCashFlowRatio": 0.17026864775626593, "operatingCashFlowSalesRatio": 0.31262055662717003, "freeCashFlowOperatingCashFlowRatio": 0.8779197884530631, "debtServiceCoverageRatio": 1.371160409556314, "interestCoverageRatio": 14.318452380952381, "shortTermOperatingCashFlowCoverageRatio": 1.0427389705882353, "operatingCashFlowCoverageRatio": 0.11883314130093223, "capitalExpenditureCoverageRatio": 8.191335740072201, "dividendPaidAndCapexCoverageRatio": 1.6647101980924432, "dividendPayoutRatio": 0.44535575148656964, "dividendYield": 0.010721292209905132, "dividendYieldPercentage": 1.072129220990513, "revenuePerShare": 2.599570200573066, "netIncomePerShare": 0.8733882521489972, "interestDebtPerShare": 6.898997134670487, "cashPerShare": 2.447528653295129, "bookValuePerShare": 12.332557306590259, "tangibleBookValuePerShare": -1.593660458452722, "shareholdersEquityPerShare": 12.288681948424069, "operatingCashFlowPerShare": 0.8126790830945558, "capexPerShare": 0.09921203438395415, "freeCashFlowPerShare": 0.7134670487106017, "netIncomePerEBT": 0.856816584680253, "ebtPerEbit": 1.1831220120557058, "priceToFairValue": 2.9523101136694843, "debtToMarketCap": 0.18850124627617731, "effectiveTaxRate": 0.14195361911454674, "enterpriseValueMultiple": 33.03033720287451, "dividendPerShare": 0.38896848137535817}}
{"date": "2024-12-31", "symbol": "PFE", "type": "ratios_annual", "result": {"symbol": "PFE", "date": "2024-12-31", "fiscalYear": "2024", "period": "FY", "reportedCurrency": "USD", "grossProfitMargin": 0.6576767724393732, "ebitMargin": 0.17467427350024362, "ebitdaMargin": 0.28489477737438507, "operatingProfitMargin": 0.2590566897700662, "pretaxProfitMargin": 0.1260942681566002, "continuousOperationsProfitMargin": 0.1265343329089852, "netProfitMargin": 0.1260471183617018, "bottomLineProfitMargin": 0.1262200009429959, "receivablesTurnover": 4.305813087906882, "payablesTurnover": 3.8666785016864904, "inventoryTurnover": 2.0072804349829507, "fixedAssetTurnover": 3.459305170445278, "assetTurnover": 0.2981639768318057, "currentRatio": 1.1712524712175834, "quickRatio": 0.918874287707873, "solvencyRatio": 0.12036125189152835, "cashRatio": 0.02425863472496802, "priceToEarningsRatio": 18.736399002493766, "priceToEarningsGrowthRatio": 0.06735775802236868, "forwardPriceToEarningsGrowthRatio": 0.06735775802236868, "priceToBookRatio": 1.703637291248597, "priceToSalesRatio": 2.3616691027394032, "priceToFreeCashFlowRatio": 15.278690391459074, "priceToOperatingCashFlowRatio": 11.791111111111112, "debtToAssetsRatio": 0.3139374683686667, "debtToEquityRatio": 0.7595319887078671, "debtToCapitalRatio": 0.43166705327456895, "longTermDebtToCapitalRatio": 0.39424344816218887, "financialLeverageRatio": 2.419373490697595, "workingCapitalTurnoverRatio": 43.85044796691937, "operatingCashFlowRatio": 0.2964065589021979, "operatingCashFlowSalesRatio": 0.20029232872837002, "freeCashFlowOperatingCashFlowRatio": 0.7717357187696171, "debtServiceCoverageRatio": 1.808807412573478, "interestCoverageRatio": 5.332578453574895, "shortTermOperatingCashFlowCoverageRatio": 1.8347250215951627, "operatingCashFlowCoverageRatio": 0.19022882987774842, "capitalExpenditureCoverageRatio": 4.38088690271571, "dividendPaidAndCapexCoverageRatio": 1.0260043474760485, "dividendPayoutRatio": 1.1860349127182044, "dividendYield": 0.0633011131199942, "dividendYieldPercentage": 6.330111311999421, "revenuePerShare": 11.233580508474576, "netIncomePerShare": 1.4159604519774012, "interestDebtPerShare": 12.373587570621469, "cashPerShare": 3.615289548022599, "bookValuePerShare": 15.62447033898305, "tangibleBookValuePerShare": -6.257415254237288, "shareholdersEquityPerShare": 15.572563559322035, "operatingCashFlowPerShare": 2.25, "capexPerShare": 0.5135946327683616, "freeCashFlowPerShare": 1.7364053672316384, "netIncomePerEBT": 0.9996260750342765, "ebtPerEbit": 0.48674391797609656, "priceToFairValue": 1.703637291248597, "debtToMarketCap": 0.42824746955264376, "effectiveTaxRate": -0.0034899663467530847, "enterpriseValueMultiple": 11.927838031665472, "dividendPerShare": 1.6793785310734464}}
{"date": "2023-12-31", "symbol": "PFE", "type": "ratios_annual", "result": {"symbol": "PFE", "date": "2023-12-31", "fiscalYear": "2023", "period": "FY", "reportedCurrency": "USD", "grossProfitMargin": 0.5094621597568553, "ebitMargin": 0.05485869729484661, "ebitdaMargin": 0.16047890114687757, "operatingProfitMargin": 0.08886202206437963, "pretaxProfitMargin": 0.01776568770674861, "continuousOperationsProfitMargin": 0.03647171427132134, "netProfitMargin": 0.035816835423908115, "bottomLineProfitMargin": 0.03558175070945208, "receivablesTurnover": 3.8312532166752447, "payablesTurnover": 4.353651266766021, "inventoryTurnover": 2.8671115909313967, "fixedAssetTurnover": 3.144297782470961, "assetTurnover": 0.2629259914967263, "currentRatio": 0.9066619240908901, "quickRatio": 0.6934761685567226, "solvencyRatio": 0.061386311792614404, "cashRatio": 0.05969368539984098, "priceToEarningsRatio": 76.16594936708861, "priceToEarningsGrowthRatio": -0.8164766707846627, "forwardPriceToEarningsGrowthRatio": -0.8164766707846627, "priceToBookRatio": 1.8251282944255958, "priceToSalesRatio": 2.7280232733867313, "priceToFreeCashFlowRatio": 33.89567494262466, "priceToOperatingCashFlowRatio": 18.673789655172413, "debtToAssetsRatio": 0.31278007602615443, "debtToEquityRatio": 0.7958860403981396, "debtToCapitalRatio": 0.4431717951444711, "longTermDebtToCapitalRatio": 0.40464039916261463, "financialLeverageRatio": 2.5445547891342937, "workingCapitalTurnoverRatio": 25.55922746781116, "operatingCashFlowRatio": 0.18203121730761185, "operatingCashFlowSalesRatio": 0.14608835826910482, "freeCashFlowOperatingCashFlowRatio": 0.5509195402298851, "debtServiceCoverageRatio": 0.8499402628434887, "interestCoverageRatio": 2.395654142145767, "shortTermOperatingCashFlowCoverageRatio": 0.8409046974676203, "operatingCashFlowCoverageRatio": 0.12280330298539065, "capitalExpenditureCoverageRatio": 2.22677245968774, "dividendPaidAndCapexCoverageRatio": 0.661395773148852, "dividendPayoutRatio": 4.335208626347867, "dividendYield": 0.0569179359329448, "dividendYieldPercentage": 5.69179359329448, "revenuePerShare": 10.553429027113237, "netIncomePerShare": 0.37799043062200954, "interestDebtPerShare": 12.94595073542442, "cashPerShare": 2.248803827751196, "bookValuePerShare": 15.822789296473507, "tangibleBookValuePerShare": -7.690058479532164, "shareholdersEquityPerShare": 15.774233563707249, "operatingCashFlowPerShare": 1.5417331206804892, "capexPerShare": 0.6923622186780082, "freeCashFlowPerShare": 0.849370902002481, "netIncomePerEBT": 2.0160680529300565, "ebtPerEbit": 0.1999244142101285, "priceToFairValue": 1.8251282944255958, "debtToMarketCap": 0.43607128486746777, "effectiveTaxRate": -1.052930056710775, "enterpriseValueMultiple": 24.113630846499948, "dividendPerShare": 1.6386673755094807}}
{"date": "2022-12-31", "symbol": "PFE", "type": "ratios_annual", "result": {"symbol": "PFE", "date": "2022-12-31", "fiscalYear": "2022", "period": "FY", "reportedCurrency": "USD", "grossProfitMargin": 0.6188577693611084, "ebitMargin": 0.35848699292335295, "ebitdaMargin": 0.408960430579089, "operatingProfitMargin": 0.37425495863649955, "pretaxProfitMargin": 0.34614771254858967, "continuousOperationsProfitMargin": 0.31297717532143926, "netProfitMargin": 0.312618359413934, "bottomLineProfitMargin": 0.312618359413934, "receivablesTurnover": 6.905499346135316, "payablesTurnover": 5.616096343075341, "inventoryTurnover": 4.2578777418995655, "fixedAssetTurnover": 6.165048543689321, "assetTurnover": 0.5087573400403639, "currentRatio": 1.216455455883051, "quickRatio": 1.0033224168209218, "solvencyRatio": 0.35965405917720583, "cashRatio": 0.009872324267881722, "priceToEarningsRatio": 9.161610712577716, "priceToEarningsGrowthRatio": 0.22101337764771822, "forwardPriceToEarningsGrowthRatio": 0.22101337764771822, "priceToBookRatio": 3.003877442217832, "priceToSalesRatio": 2.864087710555168, "priceToFreeCashFlowRatio": 11.038912066382391, "priceToOperatingCashFlowRatio": 9.818359244199954, "debtToAssetsRatio": 0.17676439864912832, "debtToEquityRatio": 0.36440137569124303, "debtToCapitalRatio": 0.26707784247624883, "longTermDebtToCapitalRatio": 0.2502233787406142, "financialLeverageRatio": 2.061508869863372, "workingCapitalTurnoverRatio": 7.675477183184792, "operatingCashFlowRatio": 0.6945512364136883, "operatingCashFlowSalesRatio": 0.2917073656932124, "freeCashFlowOperatingCashFlowRatio": 0.8894317832370929, "debtServiceCoverageRatio": 9.037152444870566, "interestCoverageRatio": 30.33037156704362, "shortTermOperatingCashFlowCoverageRatio": 9.975119291070211, "operatingCashFlowCoverageRatio": 0.8395823173355518, "capitalExpenditureCoverageRatio": 9.044190358467244, "dividendPaidAndCapexCoverageRatio": 2.395204190195597, "dividendPayoutRatio": 0.28640204049099316, "dividendYield": 0.03126110129278904, "dividendYieldPercentage": 3.1261101292789046, "revenuePerShare": 17.890513552068473, "netIncomePerShare": 5.592902995720399, "interestDebtPerShare": 6.43669757489301, "cashPerShare": 4.053495007132668, "bookValuePerShare": 17.10360199714693, "tangibleBookValuePerShare": 0.20898716119828817, "shareholdersEquityPerShare": 17.057952924393724, "operatingCashFlowPerShare": 5.21879457917261, "capexPerShare": 0.5770328102710414, "freeCashFlowPerShare": 4.641761768901569, "netIncomePerEBT": 0.903135707909816, "ebtPerEbit": 0.9248981331060747, "priceToFairValue": 3.003877442217832, "debtToMarketCap": 0.12131033396029538, "effectiveTaxRate": 0.09582769443404647, "enterpriseValueMultiple": 7.842775462455217, "dividendPerShare": 1.6018188302425107}}
{"date": "2021-12-31", "symbol": "PFE", "type": "ratios_annual", "result": {"symbol": "PFE", "date": "2021-12-31", "fiscalYear": "2021", "period": "FY", "reportedCurrency": "USD", "grossProfitMargin": 0.5766533805727783, "ebitMargin": 0.3149542367877177, "ebitdaMargin": 0.3788136010235213, "operatingProfitMargin": 0.2557942131679953, "pretaxProfitMargin": 0.29907243381556936, "continuousOperationsProfitMargin": 0.2762892431847259, "netProfitMargin": 0.2724510382836335, "bottomLineProfitMargin": 0.27243873634484794, "receivablesTurnover": 5.162781835503335, "payablesTurnover": 6.169415561133023, "inventoryTurnover": 3.798763660448173, "fixedAssetTurnover": 5.462169063297944, "assetTurnover": 0.44792453038126046, "currentRatio": 1.3989126104380023, "quickRatio": 1.1866138595298914, "solvencyRatio": 0.26283000365335435, "cashRatio": 0.04555787302852054, "priceToEarningsRatio": 14.933808190725605, "priceToEarningsGrowthRatio": 0.10681906617877049, "forwardPriceToEarningsGrowthRatio": 0.10681906617877049, "priceToBookRatio": 4.284129091592078, "priceToSalesRatio": 4.068731547091821, "priceToFreeCashFlowRatio": 11.072987043422946, "priceToOperatingCashFlowRatio": 10.151597605893185, "debtToAssetsRatio": 0.20387156499170694, "debtToEquityRatio": 0.47924249685884895, "debtToCapitalRatio": 0.32397831854919923, "longTermDebtToCapitalRatio": 0.3104467746833634, "financialLeverageRatio": 2.3507078923848135, "workingCapitalTurnoverRatio": 6.212541556803852, "operatingCashFlowRatio": 0.7635162053853906, "operatingCashFlowSalesRatio": 0.4007971656333038, "freeCashFlowOperatingCashFlowRatio": 0.9167894413750768, "debtServiceCoverageRatio": 8.193941109852775, "interestCoverageRatio": 16.106119287374128, "shortTermOperatingCashFlowCoverageRatio": 14.538152610441767, "operatingCashFlowCoverageRatio": 0.8805881398994541, "capitalExpenditureCoverageRatio": 12.01770564367392, "dividendPaidAndCapexCoverageRatio": 2.847902097902098, "dividendPayoutRatio": 0.39413916106018876, "dividendYield": 0.026392408153799802, "dividendYieldPercentage": 2.6392408153799805, "revenuePerShare": 14.513122656668452, "netIncomePerShare": 3.954115336547045, "interestDebtPerShare": 6.836100696304231, "cashPerShare": 5.547045170505267, "bookValuePerShare": 13.830208891269416, "tangibleBookValuePerShare": 0.5550794500981967, "shareholdersEquityPerShare": 13.783431530083913, "operatingCashFlowPerShare": 5.8168184252812, "capexPerShare": 0.4840207105873951, "freeCashFlowPerShare": 5.332797714693805, "netIncomePerEBT": 0.9109867961005306, "ebtPerEbit": 1.1691915548501899, "priceToFairValue": 4.284129091592078, "debtToMarketCap": 0.11186462560136155, "effectiveTaxRate": 0.07617950721895438, "enterpriseValueMultiple": 11.879097522164129, "dividendPerShare": 1.5584717014818783}}
{"date": "2025-09-28", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2025-09-28", "fiscalYear": "2025", "period": "Q3", "reportedCurrency": "USD", "marketCap": 135587250000.00002, "enterpriseValue": 195956250000, "evToSales": 11.766317401224931, "evToOperatingCashFlow": 42.57142081251358, "evToFreeCashFlow": 48.97681829542614, "evToEBITDA": 34.69480347025496, "netDebtToEBITDA": 10.688562322946176, "currentRatio": 1.2822166356978906, "incomeQuality": 1.2962545761757251, "grahamNumber": 15.125163620847331, "grahamNetNet": -14.814775725593668, "taxBurden": 1.0620875824835032, "interestBurden": 0.8364274962368289, "workingCapital": 10328000000, "investedCapital": 149633000000, "returnOnAssets": 0.016964418318314002, "operatingReturnOnAssets": 0.017115609918375414, "returnOnTangibleAssets": 0.04009920050732679, "returnOnEquity": 0.038156916412538655, "returnOnInvestedCapital": 0.021423922291115064, "returnOnCapitalEmployed": 0.020623347953641038, "earningsYield": 0.02611602492122231, "freeCashFlowYield": 0.029508674303815437, "capexToOperatingCashFlow": 0.13078427112752553, "capexToDepreciation": 0.3622141997593261, "capexToRevenue": 0.03614747207877987, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.23633961810976342, "stockBasedCompensationToRevenue": 0.012069172571154077, "intangiblesToTotalAssets": 0.5769387393343586, "averageReceivables": 13169000000, "averagePayables": 5095000000, "averageInventory": 11568500000, "daysOfSalesOutstanding": 77.06256755133901, "daysOfPayablesOutstanding": 108.37967401725791, "daysOfInventoryOutstanding": 247.39213806327902, "operatingCycle": 324.45470561461804, "cashConversionCycle": 216.07503159736012, "freeCashFlowToEquity": -56368000000, "freeCashFlowToFirm": 953241151.7696457, "tangibleAssetValue": -27329000000, "netCurrentAssetValue": -68711000000}}
{"date": "2025-06-29", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2025-06-29", "fiscalYear": "2025", "period": "Q2", "reportedCurrency": "USD", "marketCap": 137804400000, "enterpriseValue": 197963400000, "evToSales": 13.510093496212379, "evToOperatingCashFlow": -340.1432989690722, "evToFreeCashFlow": -164.9695, "evToEBITDA": 37.190193499906066, "netDebtToEBITDA": 11.301709562276912, "currentRatio": 1.158431850713036, "incomeQuality": -0.1987704918032787, "grahamNumber": 13.404692429515649, "grahamNetNet": -15.644854881266491, "taxBurden": 0.9559789750328516, "interestBurden": 0.8231476473769606, "workingCapital": 5977000000, "investedCapital": 146452000000, "returnOnAssets": 0.014119702079138262, "operatingReturnOnAssets": 0.017265401825061637, "returnOnTangibleAssets": 0.03448030712356036, "returnOnEquity": 0.03280906477253509, "returnOnInvestedCapital": 0.019745886490943526, "returnOnCapitalEmployed": 0.021233124862652865, "earningsYield": 0.021116887414335102, "freeCashFlowYield": -0.008707994810035093, "capexToOperatingCashFlow": -1.0618556701030928, "capexToDepreciation": 0.3803076923076923, "capexToRevenue": 0.04217566368661708, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.16672353784208013, "stockBasedCompensationToRevenue": 0.01385381833071726, "intangiblesToTotalAssets": 0.5904995269171984, "averageReceivables": 13411500000, "averagePayables": 5203000000, "averageInventory": 11260500000, "daysOfSalesOutstanding": 74.1841261175186, "daysOfPayablesOutstanding": 88.84769730556086, "daysOfInventoryOutstanding": 200.68985285686986, "operatingCycle": 274.8739789743885, "cashConversionCycle": 186.0262816688276, "freeCashFlowToEquity": -61359000000, "freeCashFlowToFirm": 7965706307.490145, "tangibleAssetValue": -32687000000, "netCurrentAssetValue": -73380000000}}
{"date": "2025-03-29", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2025-03-29", "fiscalYear": "2025", "period": "Q1", "reportedCurrency": "USD", "marketCap": 143804500000, "enterpriseValue": 203665500000, "evToSales": 14.849835946044477, "evToOperatingCashFlow": 87.22291220556745, "evToFreeCashFlow": 115.00028232636929, "evToEBITDA": 40.28194224683544, "netDebtToEBITDA": 11.839596518987342, "currentRatio": 1.258120267749369, "incomeQuality": 0.7854019508913556, "grahamNumber": 13.684199657497615, "grahamNetNet": -14.729559471365638, "taxBurden": 1.0657327586206897, "interestBurden": 0.8097731239092496, "workingCapital": 9409000000, "investedCapital": 150174000000, "returnOnAssets": 0.014262503124579384, "operatingReturnOnAssets": 0.02194464482326588, "returnOnTangibleAssets": 0.03465716621889966, "returnOnEquity": 0.03284332174721601, "returnOnInvestedCapital": 0.028048997381953853, "returnOnCapitalEmployed": 0.026950156199002193, "earningsYield": 0.020632177713492968, "freeCashFlowYield": 0.012315330883247743, "capexToOperatingCashFlow": 0.24154175588865096, "capexToDepreciation": 0.34857849196538937, "capexToRevenue": 0.041122858184469556, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.15887714181553045, "stockBasedCompensationToRevenue": 0.012395187750637988, "intangiblesToTotalAssets": 0.588468859961159, "averageReceivables": 14761000000, "averagePayables": 5436500000, "averageInventory": 10851500000, "daysOfSalesOutstanding": 96.75902296755378, "daysOfPayablesOutstanding": 121.29629629629629, "daysOfInventoryOutstanding": 251.2037037037037, "operatingCycle": 347.9627266712575, "cashConversionCycle": 226.66643037496118, "freeCashFlowToEquity": -58090000000, "freeCashFlowToFirm": 2679398706.896551, "tangibleAssetValue": -31781000000, "netCurrentAssetValue": -71530000000}}
{"date": "2024-12-31", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2024-12-31", "fiscalYear": "2024", "period": "Q4", "reportedCurrency": "USD", "marketCap": 150345510000, "enterpriseValue": 212951510000, "evToSales": 11.988487868040309, "evToOperatingCashFlow": 31.68449784258295, "evToFreeCashFlow": 36.690473811164715, "evToEBITDA": 41.4060878864476, "netDebtToEBITDA": 12.173050748590317, "currentRatio": 1.1712524712175834, "incomeQuality": 16.35279805352798, "grahamNumber": 4.990364269105678, "grahamNetNet": -15.513278630668784, "taxBurden": -40.3, "interestBurden": -0.0029832935560859188, "workingCapital": 7363000000, "investedCapital": 149695000000, "returnOnAssets": 0.0018885077508481883, "operatingReturnOnAssets": 0.026451237317266996, "returnOnTangibleAssets": 0.004504957689169098, "returnOnEquity": 0.004569005589379046, "returnOnInvestedCapital": -1.326763350944758, "returnOnCapitalEmployed": 0.0335972206735876, "earningsYield": 0.0026804924204254584, "freeCashFlowYield": 0.038604411930891716, "capexToOperatingCashFlow": 0.13643803005505134, "capexToDepreciation": 0.5120044667783361, "capexToRevenue": 0.0516241625851489, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.16984743568090976, "stockBasedCompensationToRevenue": 0.009964533018071271, "intangiblesToTotalAssets": 0.5807934544227633, "averageReceivables": 16235500000, "averagePayables": 5473500000, "averageInventory": 11286000000, "daysOfSalesOutstanding": 74.87079885154535, "daysOfPayablesOutstanding": 105.7288842544317, "daysOfInventoryOutstanding": 203.66840458811262, "operatingCycle": 278.53920343965797, "cashConversionCycle": 172.81031918522626, "freeCashFlowToEquity": -56802000000, "freeCashFlowToFirm": -144244200000, "tangibleAssetValue": -35442000000, "netCurrentAssetValue": -74541000000}}
{"date": "2024-09-29", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2024-09-29", "fiscalYear": "2024", "period": "Q3", "reportedCurrency": "USD", "marketCap": 164002980000, "enterpriseValue": 229527980000, "evToSales": 12.96621737656762, "evToOperatingCashFlow": 34.18647304140602, "evToFreeCashFlow": 37.85716312056738, "evToEBITDA": 31.645936853715703, "netDebtToEBITDA": 9.034192747828484, "currentRatio": 1.0002777070653306, "incomeQuality": 1.4983262664583799, "grahamNumber": 17.006126559604606, "grahamNetNet": -17.263984471501676, "taxBurden": 0.9486744432661718, "interestBurden": 0.8575845762095308, "workingCapital": 12000000, "investedCapital": 147109000000, "returnOnAssets": 0.020380360494997175, "operatingReturnOnAssets": 0.0228063047864319, "returnOnTangibleAssets": 0.04919709634843819, "returnOnEquity": 0.04846889018919446, "returnOnInvestedCapital": 0.02538888448062283, "returnOnCapitalEmployed": 0.028184835333163134, "earningsYield": 0.027273894657280005, "freeCashFlowYield": 0.03696884044424071, "capexToOperatingCashFlow": 0.0969615728328865, "capexToDepreciation": 0.37094017094017095, "capexToRevenue": 0.03677550559258841, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.1448988814823184, "stockBasedCompensationToRevenue": 0.015478477008247655, "intangiblesToTotalAssets": 0.5857405821137619, "averageReceivables": 16390500000, "averagePayables": 5210000000, "averageInventory": 11584000000, "daysOfSalesOutstanding": 89.95932662975935, "daysOfPayablesOutstanding": 69.00302986582024, "daysOfInventoryOutstanding": 152.19881690953687, "operatingCycle": 242.15814353929622, "cashConversionCycle": 173.15511367347597, "freeCashFlowToEquity": -59462000000, "freeCashFlowToFirm": 323140615.0583248, "tangibleAssetValue": -35998000000, "netCurrentAssetValue": -83695000000}}
{"date": "2024-06-30", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2024-06-30", "fiscalYear": "2024", "period": "Q2", "reportedCurrency": "USD", "marketCap": 159894520000, "enterpriseValue": 227519520000, "evToSales": 17.128624557705336, "evToOperatingCashFlow": -127.74818641212802, "evToFreeCashFlow": -94.09409429280397, "evToEBITDA": 94.60271101871102, "netDebtToEBITDA": 28.118503118503117, "currentRatio": 0.8632100230493621, "incomeQuality": -57.45161290322581, "grahamNumber": 1.2145631667051788, "grahamNetNet": -18.36891104835863, "taxBurden": -0.23300970873786409, "interestBurden": -0.15281899109792285, "workingCapital": -5994000000, "investedCapital": 142648000000, "returnOnAssets": 0.00011101191990489978, "operatingReturnOnAssets": 0.008593878633760817, "returnOnTangibleAssets": 0.00027743098904147595, "returnOnEquity": 0.00027366020524515394, "returnOnInvestedCapital": -0.003068215475754599, "returnOnCapitalEmployed": 0.01090071588522631, "earningsYield": 0.0001500989527345903, "freeCashFlowYield": -0.01512246948800997, "capexToOperatingCashFlow": -0.35766423357664234, "capexToDepreciation": 0.36799537839399193, "capexToRevenue": 0.047956034028457425, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.20146051343822932, "stockBasedCompensationToRevenue": 0.01550854475645562, "intangiblesToTotalAssets": 0.5998575347027887, "averageReceivables": 15154500000, "averagePayables": 5348500000, "averageInventory": 11169500000, "daysOfSalesOutstanding": 102.22314236241813, "daysOfPayablesOutstanding": 91.17857142857143, "daysOfInventoryOutstanding": 204.41071428571428, "operatingCycle": 306.6338566481324, "cashConversionCycle": 215.45528521956095, "freeCashFlowToEquity": -70043000000, "freeCashFlowToFirm": 8803145631.06796, "tangibleAssetValue": -41710000000, "netCurrentAssetValue": -90393000000}}
{"date": "2024-03-31", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2024-03-31", "fiscalYear": "2024", "period": "Q1", "reportedCurrency": "USD", "marketCap": 156812040000, "enterpriseValue": 224801040000, "evToSales": 15.108612137912495, "evToOperatingCashFlow": 206.23948623853212, "evToFreeCashFlow": 582.3861139896374, "evToEBITDA": 37.79439139206456, "netDebtToEBITDA": 11.430564895763283, "currentRatio": 1.0473615329530583, "incomeQuality": 0.34846547314578, "grahamNumber": 14.22790237047824, "grahamNetNet": -17.63222556125155, "taxBurden": 0.912014030985092, "interestBurden": 0.8122032288698955, "workingCapital": 1918000000, "investedCapital": 152846000000, "returnOnAssets": 0.014111580994595084, "operatingReturnOnAssets": 0.020371048892304667, "returnOnTangibleAssets": 0.03506800044958975, "returnOnEquity": 0.0338094102858629, "returnOnInvestedCapital": 0.02207570435385189, "returnOnCapitalEmployed": 0.02524391189271199, "earningsYield": 0.019896431421974996, "freeCashFlowYield": 0.0024615456823340862, "capexToOperatingCashFlow": 0.6458715596330276, "capexToDepreciation": 0.4055299539170507, "capexToRevenue": 0.04731500772901405, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.16667786813629948, "stockBasedCompensationToRevenue": 0.01478593991531689, "intangiblesToTotalAssets": 0.5975937945227164, "averageReceivables": 15383000000, "averagePayables": 6150500000, "averageInventory": 10540500000, "daysOfSalesOutstanding": 92.07473620539015, "daysOfPayablesOutstanding": 114.85733850719015, "daysOfInventoryOutstanding": 223.7571330746405, "operatingCycle": 315.8318692800307, "cashConversionCycle": 200.97453077284052, "freeCashFlowToEquity": -67603000000, "freeCashFlowToFirm": -1495747149.9561539, "tangibleAssetValue": -39567000000, "netCurrentAssetValue": -86122000000}}
{"date": "2023-12-31", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2023-12-31", "fiscalYear": "2023", "period": "Q4", "reportedCurrency": "USD", "marketCap": 162577130000, "enterpriseValue": 230569130000, "evToSales": 15.8249231297186, "evToOperatingCashFlow": 44.001742366412216, "evToFreeCashFlow": 54.94974499523356, "evToEBITDA": -130.2650451977401, "netDebtToEBITDA": -38.4135593220339, "currentRatio": 0.9066619240908901, "incomeQuality": -1.5669856459330143, "grahamNumber": null, "grahamNetNet": -19.084558172480964, "taxBurden": 0.8096391378057641, "interestBurden": 1.2002906976744185, "workingCapital": -4461000000, "investedCapital": 147162000000, "returnOnAssets": -0.01475931673590845, "operatingReturnOnAssets": -0.0057211192194273446, "returnOnTangibleAssets": -0.03563282099383914, "returnOnEquity": -0.03755589008470578, "returnOnInvestedCapital": -0.005395984985326099, "returnOnCapitalEmployed": -0.0070674344038006345, "earningsYield": -0.02056254775810103, "freeCashFlowYield": 0.025809288182169286, "capexToOperatingCashFlow": 0.19923664122137405, "capexToDepreciation": 0.6251497005988024, "capexToRevenue": 0.07165408373369939, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.19032258064516128, "stockBasedCompensationToRevenue": 0.008304735758407686, "intangiblesToTotalAssets": 0.585794323203871, "averageReceivables": 15273500000, "averagePayables": 6024000000, "averageInventory": 10196500000, "daysOfSalesOutstanding": 96.01647220315716, "daysOfPayablesOutstanding": 70.30267753201397, "daysOfInventoryOutstanding": 106.75320139697322, "operatingCycle": 202.76967360013037, "cashConversionCycle": 132.4669960681164, "freeCashFlowToEquity": -63796000000, "freeCashFlowToFirm": 45184506418.01889, "tangibleAssetValue": -43395000000, "netCurrentAssetValue": -93880000000}}
{"date": "2023-10-01", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2023-10-01", "fiscalYear": "2023", "period": "Q3", "reportedCurrency": "USD", "marketCap": 191625240000, "enterpriseValue": 252073240000, "evToSales": 18.68454821733007, "evToOperatingCashFlow": 72.9378587962963, "evToFreeCashFlow": 95.26577475434618, "evToEBITDA": -229.7841750227894, "netDebtToEBITDA": -55.10300820419325, "currentRatio": 2.3770554984583763, "incomeQuality": -1.443609022556391, "grahamNumber": null, "grahamNetNet": -10.14554551895147, "taxBurden": 0.714200477326969, "interestBurden": 1.2615732028603688, "workingCapital": 42876000000, "investedCapital": 152489000000, "returnOnAssets": -0.011133796233856227, "operatingReturnOnAssets": -0.013814687411676307, "returnOnTangibleAssets": -0.019420783645655876, "returnOnEquity": -0.024697216662884023, "returnOnInvestedCapital": -0.011486732319852776, "returnOnCapitalEmployed": -0.016347173505179866, "earningsYield": -0.012493135037952203, "freeCashFlowYield": 0.013808201884052435, "capexToOperatingCashFlow": 0.234375, "capexToDepreciation": 0.5192307692307693, "capexToRevenue": 0.06004002668445631, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.19879919946631086, "stockBasedCompensationToRevenue": 0.011192646949818398, "intangiblesToTotalAssets": 0.42670715883564864, "averageReceivables": 14214000000, "averagePayables": 5709500000, "averageInventory": 10257000000, "daysOfSalesOutstanding": 100.08672448298866, "daysOfPayablesOutstanding": 45.30981797604452, "daysOfInventoryOutstanding": 86.61322267282846, "operatingCycle": 186.6999471558171, "cashConversionCycle": 141.3901291797726, "freeCashFlowToEquity": -57802000000, "freeCashFlowToFirm": -5318874701.670645, "tangibleAssetValue": 5453000000, "netCurrentAssetValue": -43805000000}}
{"date": "2023-07-02", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2023-07-02", "fiscalYear": "2023", "period": "Q2", "reportedCurrency": "USD", "marketCap": 206925900000, "enterpriseValue": 269634900000, "evToSales": 20.72998385484739, "evToOperatingCashFlow": -223.02307692307693, "evToFreeCashFlow": -127.0065473386717, "evToEBITDA": 61.9707883245231, "netDebtToEBITDA": 14.412548839347277, "currentRatio": 2.1169798250930816, "incomeQuality": -0.5191069128381279, "grahamNumber": 12.758346637800981, "grahamNetNet": -10.780419766206164, "taxBurden": 1.0264433671220803, "interestBurden": 0.8167746580273578, "workingCapital": 38700000000, "investedCapital": 149167000000, "returnOnAssets": 0.010578285672758984, "operatingReturnOnAssets": 0.011308729271137727, "returnOnTangibleAssets": 0.018311331954807414, "returnOnEquity": 0.023520738444136984, "returnOnInvestedCapital": 0.012794137853452727, "returnOnCapitalEmployed": 0.012672419833873254, "earningsYield": 0.011255236777996374, "freeCashFlowYield": -0.010259711326614986, "capexToOperatingCashFlow": -0.7559966914805625, "capexToDepreciation": 0.5810553083280356, "capexToRevenue": 0.07026985469362651, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.20212193434304604, "stockBasedCompensationToRevenue": 0.011378488506188975, "intangiblesToTotalAssets": 0.4223093274226954, "averageReceivables": 14435000000, "averagePayables": 6102000000, "averageInventory": 9925500000, "daysOfSalesOutstanding": 92.89228876758669, "daysOfPayablesOutstanding": 119.10554951033733, "daysOfInventoryOutstanding": 201.93688792165398, "operatingCycle": 294.8291766892407, "cashConversionCycle": 175.72362717890337, "freeCashFlowToEquity": -64832000000, "freeCashFlowToFirm": -21660072719.259586, "tangibleAssetValue": 6314000000, "netCurrentAssetValue": -47528000000}}
{"date": "2023-04-02", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2023-04-02", "fiscalYear": "2023", "period": "Q1", "reportedCurrency": "USD", "marketCap": 232965900000, "enterpriseValue": 265726900000, "evToSales": 14.374494211835984, "evToOperatingCashFlow": 219.06586974443528, "evToFreeCashFlow": 3590.904054054054, "evToEBITDA": 32.9032813273898, "netDebtToEBITDA": 4.056587419514611, "currentRatio": 1.3696734314315409, "incomeQuality": 0.21887405268856008, "grahamNumber": 19.9161783095625, "grahamNetNet": -10.304357472488462, "taxBurden": 0.8838915470494418, "interestBurden": 0.9515859766277128, "workingCapital": 13516000000, "investedCapital": 124045000000, "returnOnAssets": 0.028330871038815646, "operatingReturnOnAssets": 0.0340356852831937, "returnOnTangibleAssets": 0.05425886038770315, "returnOnEquity": 0.054887046775806914, "returnOnInvestedCapital": 0.03628112174779159, "returnOnCapitalEmployed": 0.042029486655559396, "earningsYield": 0.02378888927521152, "freeCashFlowYield": 0.00031764305419806075, "capexToOperatingCashFlow": 0.9389942291838417, "capexToDepreciation": 0.7659717552118359, "capexToRevenue": 0.06161419452558693, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.1349129070648058, "stockBasedCompensationToRevenue": 0.005679974034404414, "intangiblesToTotalAssets": 0.47785724144629554, "averageReceivables": 14987000000, "averagePayables": 6466000000, "averageInventory": 9261000000, "daysOfSalesOutstanding": 75.19474196689387, "daysOfPayablesOutstanding": 92.61680672268908, "daysOfInventoryOutstanding": 144.31764705882352, "operatingCycle": 219.5123890257174, "cashConversionCycle": 126.89558230302832, "freeCashFlowToEquity": -32687000000, "freeCashFlowToFirm": 1790622807.0175438, "tangibleAssetValue": 7759000000, "netCurrentAssetValue": -44303000000}}
{"date": "2022-12-31", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2022-12-31", "fiscalYear": "2022", "period": "Q4", "reportedCurrency": "USD", "marketCap": 287712600000, "enterpriseValue": 322155600000, "evToSales": 13.26289007822149, "evToOperatingCashFlow": 37.53852248893032, "evToFreeCashFlow": 42.49513256826276, "evToEBITDA": 45.60526613816535, "netDebtToEBITDA": 4.875849377123443, "currentRatio": 1.216455455883051, "incomeQuality": 1.7160567886422715, "grahamNumber": 18.462467326210636, "grahamNetNet": -11.250178094390026, "taxBurden": 0.9545020072643854, "interestBurden": 0.9433724075743913, "workingCapital": 9121000000, "investedCapital": 120140000000, "returnOnAssets": 0.025318702270721985, "operatingReturnOnAssets": 0.027247137343811696, "returnOnTangibleAssets": 0.04873073657293995, "returnOnEquity": 0.05219472930452326, "returnOnInvestedCapital": 0.03236005081128544, "returnOnCapitalEmployed": 0.03448809554518018, "earningsYield": 0.0173541235246562, "freeCashFlowYield": 0.026349210983460578, "capexToOperatingCashFlow": 0.1166394779771615, "capexToDepreciation": 0.6589861751152074, "capexToRevenue": 0.041210374639769454, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.14882667764512145, "stockBasedCompensationToRevenue": 0.014985590778097982, "intangiblesToTotalAssets": 0.4804367007089034, "averageReceivables": 16574500000, "averagePayables": 6538000000, "averageInventory": 9247000000, "daysOfSalesOutstanding": 53.83326471799094, "daysOfPayablesOutstanding": 56.221100917431194, "daysOfInventoryOutstanding": 74.15504587155964, "operatingCycle": 127.98831058955058, "cashConversionCycle": 71.76720967211938, "freeCashFlowToEquity": -26862000000, "freeCashFlowToFirm": 22787193844.389217, "tangibleAssetValue": 1172000000, "netCurrentAssetValue": -50030000000}}
{"date": "2022-10-02", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2022-10-02", "fiscalYear": "2022", "period": "Q3", "reportedCurrency": "USD", "marketCap": 247492980000, "enterpriseValue": 281871980000, "evToSales": 12.45127573107165, "evToOperatingCashFlow": 47.183123535319716, "evToFreeCashFlow": 54.91369179816871, "evToEBITDA": 26.85773987613149, "netDebtToEBITDA": 3.2757503573130062, "currentRatio": 1.588730423793835, "incomeQuality": 0.6911152244331328, "grahamNumber": 23.91906929932662, "grahamNetNet": -8.491974317817014, "taxBurden": 0.9587823575158316, "interestBurden": 0.966602233676976, "workingCapital": 26089000000, "investedCapital": 119121000000, "returnOnAssets": 0.0441773441379275, "operatingReturnOnAssets": 0.04965710028952562, "returnOnTangibleAssets": 0.07328589140440564, "returnOnEquity": 0.09316535501074154, "returnOnInvestedCapital": 0.06007644373841238, "returnOnCapitalEmployed": 0.06421690336676929, "earningsYield": 0.0348696758994942, "freeCashFlowYield": 0.020739982200707267, "capexToOperatingCashFlow": 0.1407766990291262, "capexToDepreciation": 0.7109044801352493, "capexToRevenue": 0.03714992490502694, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.11909179256118031, "stockBasedCompensationToRevenue": 0.00596342433077127, "intangiblesToTotalAssets": 0.39719169281644645, "averageReceivables": 18179000000, "averagePayables": 6237500000, "averageInventory": 9983500000, "daysOfSalesOutstanding": 74.02597402597402, "daysOfPayablesOutstanding": 80.70253255115182, "daysOfInventoryOutstanding": 122.50250393475461, "operatingCycle": 196.52847796072865, "cashConversionCycle": 115.82594540957683, "freeCashFlowToEquity": -29246000000, "freeCashFlowToFirm": 3252699588.9345627, "tangibleAssetValue": 15299000000, "netCurrentAssetValue": -32056000000}}
{"date": "2022-07-03", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2022-07-03", "fiscalYear": "2022", "period": "Q2", "reportedCurrency": "USD", "marketCap": 292569830000, "enterpriseValue": 329923830000, "evToSales": 11.89257551726624, "evToOperatingCashFlow": 40.3872970987881, "evToFreeCashFlow": 44.476116203828525, "evToEBITDA": 25.54776444169119, "netDebtToEBITDA": 2.8925197460120797, "currentRatio": 1.4230331153765028, "incomeQuality": 0.8275757268767095, "grahamNumber": 24.88328243367185, "grahamNetNet": -10.010101913105668, "taxBurden": 0.8623220057657028, "interestBurden": 0.9751256495442542, "workingCapital": 20056000000, "investedCapital": 114256000000, "returnOnAssets": 0.05054534282349327, "operatingReturnOnAssets": 0.06829829267456368, "returnOnTangibleAssets": 0.08485051661595062, "returnOnEquity": 0.1131878590512447, "returnOnInvestedCapital": 0.07261379466897937, "returnOnCapitalEmployed": 0.0875507167974033, "earningsYield": 0.03373895387641303, "freeCashFlowYield": 0.025354630721834852, "capexToOperatingCashFlow": 0.09193291712571919, "capexToDepreciation": 0.6391489361702127, "capexToRevenue": 0.027070867277052844, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.10147069425419941, "stockBasedCompensationToRevenue": 0.01034532477831447, "intangiblesToTotalAssets": 0.40430129550924265, "averageReceivables": 17040000000, "averagePayables": 5857000000, "averageInventory": 10216500000, "daysOfSalesOutstanding": 57.54523826688776, "daysOfPayablesOutstanding": 61.628060886829914, "daysOfInventoryOutstanding": 103.77895433487757, "operatingCycle": 161.32419260176533, "cashConversionCycle": 99.69613171493542, "freeCashFlowToEquity": -29936000000, "freeCashFlowToFirm": 5648951078.885298, "tangibleAssetValue": 8513000000, "netCurrentAssetValue": -40355000000}}
{"date": "2022-04-03", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2022-04-03", "fiscalYear": "2022", "period": "Q1", "reportedCurrency": "USD", "marketCap": 286129980000, "enterpriseValue": 318711980000, "evToSales": 12.42009196835665, "evToOperatingCashFlow": 48.72526830759823, "evToFreeCashFlow": 54.037297388945404, "evToEBITDA": 30.181058712121214, "netDebtToEBITDA": 3.0854166666666667, "currentRatio": 1.3858612610777223, "incomeQuality": 0.8301814951135931, "grahamNumber": 21.5121493478124, "grahamNetNet": -10.684173046110024, "taxBurden": 0.8699447513812155, "interestBurden": 0.9655393150538781, "workingCapital": 15152000000, "investedCapital": 110288000000, "returnOnAssets": 0.042825049907256815, "operatingReturnOnAssets": 0.05498223465583409, "returnOnTangibleAssets": 0.07583755562833529, "returnOnEquity": 0.095518295642046, "returnOnInvestedCapital": 0.06020607512606796, "returnOnCapitalEmployed": 0.06946663623221487, "earningsYield": 0.027515466921711595, "freeCashFlowYield": 0.020613009514067696, "capexToOperatingCashFlow": 0.09830301177190032, "capexToDepreciation": 0.5417017691659646, "capexToRevenue": 0.025057480222906357, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.08966914773391528, "stockBasedCompensationToRevenue": 0.0033513892677604147, "intangiblesToTotalAssets": 0.43530550856446604, "averageReceivables": 16043500000, "averagePayables": 5542000000, "averageInventory": 9519000000, "daysOfSalesOutstanding": 57.3157710143798, "daysOfPayablesOutstanding": 45.89183182070754, "daysOfInventoryOutstanding": 83.17373587701427, "operatingCycle": 140.48950689139406, "cashConversionCycle": 94.59767507068652, "freeCashFlowToEquity": -26684000000, "freeCashFlowToFirm": 10573170607.734806, "tangibleAssetValue": 2658000000, "netCurrentAssetValue": -46736000000}}
{"date": "2021-12-31", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2021-12-31", "fiscalYear": "2021", "period": "Q4", "reportedCurrency": "USD", "marketCap": 331624800000, "enterpriseValue": 366678800000, "evToSales": 15.382112593338368, "evToOperatingCashFlow": 62.00182617517755, "evToFreeCashFlow": 74.51306644990855, "evToEBITDA": 67.67788851974899, "netDebtToEBITDA": 6.469915097822074, "currentRatio": 1.3989126104380023, "incomeQuality": 1.5361038961038962, "grahamNumber": 13.669969723775237, "grahamNetNet": -10.079549501424502, "taxBurden": 0.8865952443166971, "interestBurden": 0.9241729050953876, "workingCapital": 17022000000, "investedCapital": 106258000000, "returnOnAssets": 0.018696584140138972, "operatingReturnOnAssets": 0.018188623792161702, "returnOnTangibleAssets": 0.03167387022394817, "returnOnEquity": 0.043950207898861414, "returnOnInvestedCapital": 0.021741926465249313, "returnOnCapitalEmployed": 0.02363010244513926, "earningsYield": 0.010231442280553203, "freeCashFlowYield": 0.014839059081226735, "capexToOperatingCashFlow": 0.16790666215759215, "capexToDepreciation": 0.7776037588097102, "capexToRevenue": 0.04165617920966524, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.24813323265374612, "stockBasedCompensationToRevenue": 0.02076516486282406, "intangiblesToTotalAssets": 0.40971583175829446, "averageReceivables": 15759500000, "averagePayables": 5138000000, "averageInventory": 8849500000, "daysOfSalesOutstanding": 59.44500377548452, "daysOfPayablesOutstanding": 47.014422176437535, "daysOfInventoryOutstanding": 76.35418617718673, "operatingCycle": 135.79918995267127, "cashConversionCycle": 88.78476777623374, "freeCashFlowToEquity": -30133000000, "freeCashFlowToFirm": 3230569898.0925007, "tangibleAssetValue": 3109000000, "netCurrentAssetValue": -44321000000}}
{"date": "2021-10-03", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2021-10-03", "fiscalYear": "2021", "period": "Q3", "reportedCurrency": "USD", "marketCap": 237933780000, "enterpriseValue": 274375780000, "evToSales": 11.415676305387976, "evToOperatingCashFlow": 25.337129928894633, "evToFreeCashFlow": 26.886406663400294, "evToEBITDA": 28.85432537595962, "netDebtToEBITDA": 3.8323693343148597, "currentRatio": 1.3850680573164604, "incomeQuality": 1.3261082537349989, "grahamNumber": 21.01582324417134, "grahamNetNet": -10.229006953111071, "taxBurden": 1.0402907050873391, "interestBurden": 0.9602105778648384, "workingCapital": 16097000000, "investedCapital": 106328000000, "returnOnAssets": 0.045533183025649036, "operatingReturnOnAssets": 0.04439886797208887, "returnOnTangibleAssets": 0.07891249891191861, "returnOnEquity": 0.10779352895324411, "returnOnInvestedCapital": 0.05725751111192335, "returnOnCapitalEmployed": 0.05641081631910325, "earningsYield": 0.03429105358642224, "freeCashFlowYield": 0.04289008479586211, "capexToOperatingCashFlow": 0.057623049219687875, "capexToDepreciation": 0.4588235294117647, "capexToRevenue": 0.025962138547950906, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.11154566257541086, "stockBasedCompensationToRevenue": 0.012190555439983358, "intangiblesToTotalAssets": 0.42299149496618077, "averageReceivables": 15061000000, "averagePayables": 4512500000, "averageInventory": 8794000000, "daysOfSalesOutstanding": 59.066361556064074, "daysOfPayablesOutstanding": 38.95163519115615, "daysOfInventoryOutstanding": 71.63519115614925, "operatingCycle": 130.70155271221333, "cashConversionCycle": 91.74991752105717, "freeCashFlowToEquity": -26237000000, "freeCashFlowToFirm": 6279591737.855412, "tangibleAssetValue": 172000000, "netCurrentAssetValue": -45321000000}}
{"date": "2021-07-04", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2021-07-04", "fiscalYear": "2021", "period": "Q2", "reportedCurrency": "USD", "marketCap": 222408539999.99997, "enterpriseValue": 257771539999.99997, "evToSales": 13.639427482935604, "evToOperatingCashFlow": 22.813659615895208, "evToFreeCashFlow": 23.95868946928153, "evToEBITDA": 30.071341577228182, "netDebtToEBITDA": 4.125408306112925, "currentRatio": 1.368719156572454, "incomeQuality": 2.0300035932447, "grahamNumber": 17.077102635036105, "grahamNetNet": -11.195069667738478, "taxBurden": 0.8345085623830767, "interestBurden": 0.956635462555066, "workingCapital": 13150000000, "investedCapital": 104564000000, "returnOnAssets": 0.03412782485875706, "operatingReturnOnAssets": 0.03643022711095158, "returnOnTangibleAssets": 0.06253639598835328, "returnOnEquity": 0.08279318123411668, "returnOnInvestedCapital": 0.036341088668349196, "returnOnCapitalEmployed": 0.04460135859849839, "earningsYield": 0.02607363907878717, "freeCashFlowYield": 0.04837494099821887, "capexToOperatingCashFlow": 0.047791839985839454, "capexToDepreciation": 0.4066265060240964, "capexToRevenue": 0.028572940367215197, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.1184718768188793, "stockBasedCompensationToRevenue": 0.011693740409545478, "intangiblesToTotalAssets": 0.4542725988700565, "averageReceivables": 13815500000, "averagePayables": 4195500000, "averageInventory": 8720500000, "daysOfSalesOutstanding": 68.32742473146727, "daysOfPayablesOutstanding": 49.640535372848944, "daysOfInventoryOutstanding": 102.65391969407266, "operatingCycle": 170.98134442553993, "cashConversionCycle": 121.34080905269099, "freeCashFlowToEquity": -24604000000, "freeCashFlowToFirm": 6589094114.2610445, "tangibleAssetValue": -6875000000, "netCurrentAssetValue": -50791000000}}
{"date": "2021-04-04", "symbol": "PFE", "type": "key_metrics_quarter", "result": {"symbol": "PFE", "date": "2021-04-04", "fiscalYear": "2021", "period": "Q1", "reportedCurrency": "USD", "marketCap": 202587520000, "enterpriseValue": 239007520000, "evToSales": 16.465108845411958, "evToOperatingCashFlow": 52.66802996914941, "evToFreeCashFlow": 59.99184738955823, "evToEBITDA": 33.03033720287451, "netDebtToEBITDA": 5.033167495854063, "currentRatio": 1.4833033168242533, "incomeQuality": 0.9304900553619028, "grahamNumber": 15.53987725444938, "grahamNetNet": -11.116986031518625, "taxBurden": 0.856816584680253, "interestBurden": 0.9441034997512026, "workingCapital": 12881000000, "investedCapital": 104656000000, "returnOnAssets": 0.030708106134065407, "operatingReturnOnAssets": 0.030736598657709547, "returnOnTangibleAssets": 0.060169763367631454, "returnOnEquity": 0.07107257359370446, "returnOnInvestedCapital": 0.030238440182833753, "returnOnCapitalEmployed": 0.03640119243981054, "earningsYield": 0.02407354609010466, "freeCashFlowYield": 0.01966557466126245, "capexToOperatingCashFlow": 0.12208021154693698, "capexToDepreciation": 0.45187601957585644, "capexToRevenue": 0.03816478368696611, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.13736566547258197, "stockBasedCompensationToRevenue": 0.011848994213281895, "intangiblesToTotalAssets": 0.4896422319888174, "averageReceivables": 12230000000, "averagePayables": 4186500000, "averageInventory": 8269500000, "daysOfSalesOutstanding": 82.35533204739598, "daysOfPayablesOutstanding": 73.18127250900359, "daysOfInventoryOutstanding": 152.93517406962783, "operatingCycle": 235.29050611702382, "cashConversionCycle": 162.10923360802025, "freeCashFlowToEquity": -32436000000, "freeCashFlowToFirm": 2092161630.3583975, "tangibleAssetValue": -8899000000, "netCurrentAssetValue": -50420000000}}
{"date": "2024-12-31", "symbol": "PFE", "type": "key_metrics_annual", "result": {"symbol": "PFE", "date": "2024-12-31", "fiscalYear": "2024", "period": "FY", "reportedCurrency": "USD", "marketCap": 150265920000, "enterpriseValue": 216215920000, "evToSales": 3.398178760589058, "evToOperatingCashFlow": 16.96609541745135, "evToFreeCashFlow": 21.984333502796137, "evToEBITDA": 11.927838031665472, "netDebtToEBITDA": 3.638219230981409, "currentRatio": 1.1712524712175834, "incomeQuality": 1.582908955409266, "grahamNumber": 22.273931356135805, "grahamNetNet": -15.521495409604519, "taxBurden": 0.9996260750342765, "interestBurden": 0.7218823105992442, "workingCapital": 7363000000, "investedCapital": 149695000000, "returnOnAssets": 0.03758271007891432, "operatingReturnOnAssets": 0.07494027010868454, "returnOnTangibleAssets": 0.08965201158098304, "returnOnEquity": 0.09092661247349863, "returnOnInvestedCapital": 0.09307960538254015, "returnOnCapitalEmployed": 0.09673065298912566, "earningsYield": 0.05337204869873355, "freeCashFlowYield": 0.06545063577955666, "capexToOperatingCashFlow": 0.22826428123038292, "capexToDepreciation": 0.4148010837016968, "capexToRevenue": 0.04571958445314096, "salesGeneralAndAdministrativeToRevenue": 0.18028509909315227, "researchAndDevelopementToRevenue": 0.1687648325396451, "stockBasedCompensationToRevenue": 0.013783456708629984, "intangiblesToTotalAssets": 0.5807934544227633, "averageReceivables": 15160500000, "averagePayables": 6171500000, "averageInventory": 10520000000, "daysOfSalesOutstanding": 84.76912317098088, "daysOfPayablesOutstanding": 94.39626279785134, "daysOfInventoryOutstanding": 181.83806987741607, "operatingCycle": 266.60719304839694, "cashConversionCycle": 172.2109302505456, "freeCashFlowToEquity": -52771000000, "freeCashFlowToFirm": 3432787485.9778137, "tangibleAssetValue": -35442000000, "netCurrentAssetValue": -74541000000}}
{"date": "2023-12-31", "symbol": "PFE", "type": "key_metrics_annual", "result": {"symbol": "PFE", "date": "2023-12-31", "fiscalYear": "2023", "period": "FY", "reportedCurrency": "USD", "marketCap": 162461970000, "enterpriseValue": 230453970000, "evToSales": 3.869728980907763, "evToOperatingCashFlow": 26.488962068965517, "evToFreeCashFlow": 48.08136240350511, "evToEBITDA": 24.113630846499948, "netDebtToEBITDA": 7.114366432981061, "currentRatio": 0.9066619240908901, "incomeQuality": 4.005524861878453, "grahamNumber": 11.58259297796706, "grahamNetNet": -19.098086124401913, "taxBurden": 2.0160680529300565, "interestBurden": 0.32384450566268747, "workingCapital": -4461000000, "investedCapital": 147162000000, "returnOnAssets": 0.00941717696610611, "operatingReturnOnAssets": 0.0249795259459957, "returnOnTangibleAssets": 0.022735509177343367, "returnOnEquity": 0.02396252274923046, "returnOnInvestedCapital": 0.05746592680419471, "returnOnCapitalEmployed": 0.029612718024475817, "earningsYield": 0.0131292264891285, "freeCashFlowYield": 0.02950228905878711, "capexToOperatingCashFlow": 0.44908045977011496, "capexToDepreciation": 0.6211446740858505, "capexToRevenue": 0.06560542709855087, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.17762329353684952, "stockBasedCompensationToRevenue": 0.008815676792101153, "intangiblesToTotalAssets": 0.585794323203871, "averageReceivables": 15036500000, "averagePayables": 6759500000, "averageInventory": 9585000000, "daysOfSalesOutstanding": 95.26908803922557, "daysOfPayablesOutstanding": 83.83767500770206, "daysOfInventoryOutstanding": 127.3058227501455, "operatingCycle": 222.57491078937107, "cashConversionCycle": 138.73723578166903, "freeCashFlowToEquity": -63199000000, "freeCashFlowToFirm": 22671922495.2741, "tangibleAssetValue": -43395000000, "netCurrentAssetValue": -93880000000}}
{"date": "2022-12-31", "symbol": "PFE", "type": "key_metrics_annual", "result": {"symbol": "PFE", "date": "2022-12-31", "fiscalYear": "2022", "period": "FY", "reportedCurrency": "USD", "marketCap": 287353920000, "enterpriseValue": 321796920000, "evToSales": 3.2073848300607994, "evToOperatingCashFlow": 10.995213721939386, "evToFreeCashFlow": 12.362065229918175, "evToEBITDA": 7.842775462455217, "netDebtToEBITDA": 0.8394384733494187, "currentRatio": 1.216455455883051, "incomeQuality": 0.9320403808795898, "grahamNumber": 46.33117967700836, "grahamNetNet": -11.264220756062768, "taxBurden": 0.903135707909816, "interestBurden": 0.9655795590402313, "workingCapital": 9121000000, "investedCapital": 120140000000, "returnOnAssets": 0.1590468849832155, "operatingReturnOnAssets": 0.198313629077619, "returnOnTangibleAssets": 0.3061164735850714, "returnOnEquity": 0.3278765641170383, "returnOnInvestedCapital": 0.21487962519823536, "returnOnCapitalEmployed": 0.24214538138107153, "earningsYield": 0.10915111232865728, "freeCashFlowYield": 0.09058863717606497, "capexToOperatingCashFlow": 0.11056821676290703, "capexToDepreciation": 0.6390205371248026, "capexToRevenue": 0.0322535632413037, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.11388418219874415, "stockBasedCompensationToRevenue": 0.008691318648460082, "intangiblesToTotalAssets": 0.4804367007089034, "averageReceivables": 15137000000, "averagePayables": 6193500000, "averageInventory": 9020000000, "daysOfSalesOutstanding": 52.8564238014552, "daysOfPayablesOutstanding": 64.99176255230125, "daysOfInventoryOutstanding": 85.7234571129707, "operatingCycle": 138.5798809144259, "cashConversionCycle": 73.58811836212465, "freeCashFlowToEquity": -8412000000, "freeCashFlowToFirm": 42249365314.29065, "tangibleAssetValue": 1172000000, "netCurrentAssetValue": -50030000000}}
{"date": "2021-12-31", "symbol": "PFE", "type": "key_metrics_annual", "result": {"symbol": "PFE", "date": "2021-12-31", "fiscalYear": "2021", "period": "FY", "reportedCurrency": "USD", "marketCap": 330739050000, "enterpriseValue": 365793050000, "evToSales": 4.499963709280583, "evToOperatingCashFlow": 11.227533763044812, "evToFreeCashFlow": 12.2465783923131, "evToEBITDA": 11.879097522164129, "netDebtToEBITDA": 1.1383756048452571, "currentRatio": 1.3989126104380023, "incomeQuality": 1.450643394630215, "grahamNumber": 35.01826316474584, "grahamNetNet": -10.106543474379576, "taxBurden": 0.9109867961005306, "interestBurden": 0.9495742520115616, "workingCapital": 17022000000, "investedCapital": 106258000000, "returnOnAssets": 0.12203750337508334, "operatingReturnOnAssets": 0.12387624886061017, "returnOnTangibleAssets": 0.20674364982310056, "returnOnEquity": 0.28687452235074673, "returnOnInvestedCapital": 0.13619057397565515, "returnOnCapitalEmployed": 0.1497990000432258, "earningsYield": 0.06696215641908629, "freeCashFlowYield": 0.09030986815738873, "capexToOperatingCashFlow": 0.08321055862492327, "capexToDepreciation": 0.5222500481602774, "capexToRevenue": 0.03335055604763311, "salesGeneralAndAdministrativeToRevenue": 0, "researchAndDevelopementToRevenue": 0.1701112095266214, "stockBasedCompensationToRevenue": 0.014540891644523176, "intangiblesToTotalAssets": 0.40971583175829446, "averageReceivables": 13461000000, "averagePayables": 4930500000, "averageInventory": 8552500000, "daysOfSalesOutstanding": 70.6983195551619, "daysOfPayablesOutstanding": 59.16281637753175, "daysOfInventoryOutstanding": 96.08389271496237, "operatingCycle": 166.78221227012426, "cashConversionCycle": 107.61939589259251, "freeCashFlowToEquity": -5185000000, "freeCashFlowToFirm": 18256652256.18033, "tangibleAssetValue": 3109000000, "netCurrentAssetValue": -44321000000}}
{"date": "2025-12-23", "symbol": "PFE", "type": "ratios_ttm", "result": [{"symbol": "PFE", "grossProfitMarginTTM": 0.7119057099625706, "ebitMarginTTM": 0.23053277056621804, "ebitdaMarginTTM": 0.3371824480369515, "operatingProfitMarginTTM": 0.27831488412837463, "pretaxProfitMarginTTM": 0.1457673011069523, "continuousOperationsProfitMarginTTM": 0.1566775503703114, "netProfitMarginTTM": 0.1564227124313132, "bottomLineProfitMarginTTM": 0.15613601974994026, "receivablesTurnoverTTM": 4.402875175315568, "payablesTurnoverTTM": 3.6003184713375798, "inventoryTurnoverTTM": 1.5772584583188, "fixedAssetTurnoverTTM": 3.3254766949152543, "assetTurnoverTTM": 0.30079384470921905, "currentRatioTTM": 1.2822166356978906, "quickRatioTTM": 0.96884905454148, "solvencyRatioTTM": 0.14283737622692091, "cashRatioTTM": 0.03669799978139687, "priceToEarningsRatioTTM": 14.630727522655533, "priceToEarningsGrowthRatioTTM": -1.7282546886136856, "forwardPriceToEarningsGrowthRatioTTM": -4.200119572957941, "priceToBookRatioTTM": 1.5483494251139533, "priceToSalesRatioTTM": 2.288862919120809, "priceToFreeCashFlowRatioTTM": 13.849870699402468, "priceToOperatingCashFlowRatioTTM": 10.987869924294563, "debtToAssetsRatioTTM": 0.2956532570629183, "debtToEquityRatioTTM": 0.6649928341289426, "debtToCapitalRatioTTM": 0.3993968145075172, "longTermDebtToCapitalRatioTTM": 0.38219159842886624, "financialLeverageRatioTTM": 2.24923222810099, "workingCapitalTurnoverRatioTTM": 7.70131861392211, "operatingCashFlowRatioTTM": 0.35733413487812876, "operatingCashFlowSalesRatioTTM": 0.20828223301744048, "freeCashFlowOperatingCashFlowRatioTTM": 0.7934541561520226, "debtServiceCoverageRatioTTM": 3.1212510711225363, "interestCoverageRatioTTM": 6.474249722119303, "shortTermOperatingCashFlowCoverageRatioTTM": 3.0390425284685105, "operatingCashFlowCoverageRatioTTM": 0.2119036816178377, "capitalExpenditureCoverageRatioTTM": 4.841540170307294, "dividendPaidAndCapexCoverageRatioTTM": 1.0540017731925526, "dividendPayoutRatioTTM": 0.9882903981264637, "dividendYieldTTM": 0.06805143, "enterpriseValueTTM": 204075258377, "revenuePerShareTTM": 11.043975373790678, "netIncomePerShareTTM": 1.727528583992964, "interestDebtPerShareTTM": 11.329991204925243, "cashPerShareTTM": 2.63570800351803, "bookValuePerShareTTM": 16.375725593667546, "tangibleBookValuePerShareTTM": -4.807211961301671, "shareholdersEquityPerShareTTM": 16.32383465259455, "operatingCashFlowPerShareTTM": 2.300263852242744, "capexPerShareTTM": 0.4751099384344767, "freeCashFlowPerShareTTM": 1.8251539138082673, "netIncomePerEBTTTM": 1.0730987762237763, "ebtPerEbitTTM": 0.5237495707908894, "priceToFairValueTTM": 1.5483494251139533, "debtToMarketCapTTM": 0.4294315410961735, "effectiveTaxRateTTM": -0.07484702797202797, "enterpriseValueMultipleTTM": 9.639832705573927, "dividendPerShareTTM": 1.72}]}
{"date": "2025-12-23", "symbol": "PFE", "type": "key_metrics_ttm", "result": [{"symbol": "PFE", "marketCap": 143706258377, "enterpriseValueTTM": 204075258377, "evToSalesTTM": 3.250382390332086, "evToOperatingCashFlowTTM": 15.60566325433968, "evToFreeCashFlowTTM": 19.66800871019661, "evToEBITDATTM": 9.639832705573927, "netDebtToEBITDATTM": 2.851629664619745, "currentRatioTTM": 1.2822166356978906, "incomeQualityTTM": 1.325864341478252, "grahamNumberTTM": 25.18923473751175, "grahamNetNetTTM": -14.814775725593668, "taxBurdenTTM": 1.0730987762237763, "interestBurdenTTM": 0.6323062042282713, "workingCapitalTTM": 10328000000, "investedCapitalTTM": 149633000000, "returnOnAssetsTTM": 0.047050989072059256, "operatingReturnOnAssetsTTM": 0.0842473711869555, "returnOnTangibleAssetsTTM": 0.11121554594251806, "returnOnEquityTTM": 0.10911100803528526, "returnOnInvestedCapitalTTM": 0.10645029396605728, "returnOnCapitalEmployedTTM": 0.10151334708223198, "earningsYieldTTM": 0.06834930104818848, "freeCashFlowYieldTTM": 0.07220284013504498, "capexToOperatingCashFlowTTM": 0.20654584384797736, "capexToDepreciationTTM": 0.40337514934289126, "capexToRevenueTTM": 0.04301982957712829, "salesGeneralAndAdministrativeToRevenueTTM": 0, "researchAndDevelopementToRevenueTTM": 0.18435932149398743, "stockBasedCompensationToRevenueTTM": 0.011961455761726527, "intangiblesToTotalAssetsTTM": 0.5769387393343586, "averageReceivablesTTM": 13169000000, "averagePayablesTTM": 5095000000, "averageInventoryTTM": 11568500000, "daysOfSalesOutstandingTTM": 82.9003742932229, "daysOfPayablesOutstandingTTM": 101.37992038920832, "daysOfInventoryOutstandingTTM": 231.41419725785053, "operatingCycleTTM": 314.3145715510734, "cashConversionCycleTTM": 212.93465116186508, "freeCashFlowToEquityTTM": -49993000000, "freeCashFlowToFirmTTM": 15201335882.867134, "tangibleAssetValueTTM": -27329000000, "netCurrentAssetValueTTM": -68711000000}]}
{"date": "2025-09-28", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2025-09-28", "stockPrice": 23.85, "numberOfShares": 5685000000, "marketCapitalization": 135587250000, "minusCashAndCashEquivalents": 1343000000, "addTotalDebt": 61712000000, "enterpriseValue": 195956250000}}
{"date": "2025-06-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2025-06-29", "stockPrice": 24.24, "numberOfShares": 5685000000, "marketCapitalization": 137804400000, "minusCashAndCashEquivalents": 1638000000, "addTotalDebt": 61797000000, "enterpriseValue": 197963400000}}
{"date": "2025-03-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2025-03-29", "stockPrice": 25.34, "numberOfShares": 5675000000, "marketCapitalization": 143804500000, "minusCashAndCashEquivalents": 1430000000, "addTotalDebt": 61291000000, "enterpriseValue": 203665500000}}
{"date": "2024-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2024-12-31", "stockPrice": 26.53, "numberOfShares": 5667000000, "marketCapitalization": 150345510000, "minusCashAndCashEquivalents": 1043000000, "addTotalDebt": 63649000000, "enterpriseValue": 212951510000}}
{"date": "2024-09-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2024-09-29", "stockPrice": 28.94, "numberOfShares": 5667000000, "marketCapitalization": 164002980000, "minusCashAndCashEquivalents": 1092000000, "addTotalDebt": 66617000000, "enterpriseValue": 229527980000}}
{"date": "2024-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2024-06-30", "stockPrice": 28.22, "numberOfShares": 5666000000, "marketCapitalization": 159894520000, "minusCashAndCashEquivalents": 1052000000, "addTotalDebt": 68677000000, "enterpriseValue": 227519520000}}
{"date": "2024-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2024-03-31", "stockPrice": 27.72, "numberOfShares": 5657000000, "marketCapitalization": 156812040000, "minusCashAndCashEquivalents": 719000000, "addTotalDebt": 68708000000, "enterpriseValue": 224801040000}}
{"date": "2023-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2023-12-31", "stockPrice": 28.79, "numberOfShares": 5647000000, "marketCapitalization": 162577130000, "minusCashAndCashEquivalents": 2853000000, "addTotalDebt": 70845000000, "enterpriseValue": 230569130000}}
{"date": "2023-10-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2023-10-01", "stockPrice": 33.94, "numberOfShares": 5646000000, "marketCapitalization": 191625240000, "minusCashAndCashEquivalents": 3148000000, "addTotalDebt": 63596000000, "enterpriseValue": 252073240000}}
{"date": "2023-07-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2023-07-02", "stockPrice": 36.65, "numberOfShares": 5646000000, "marketCapitalization": 206925900000, "minusCashAndCashEquivalents": 2632000000, "addTotalDebt": 65341000000, "enterpriseValue": 269634900000}}
{"date": "2023-04-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2023-04-02", "stockPrice": 41.35, "numberOfShares": 5634000000, "marketCapitalization": 232965900000, "minusCashAndCashEquivalents": 2166000000, "addTotalDebt": 34927000000, "enterpriseValue": 265726900000}}
{"date": "2022-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2022-12-31", "stockPrice": 51.24, "numberOfShares": 5615000000, "marketCapitalization": 287712600000, "minusCashAndCashEquivalents": 416000000, "addTotalDebt": 34859000000, "enterpriseValue": 322155600000}}
{"date": "2022-10-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2022-10-02", "stockPrice": 44.14, "numberOfShares": 5607000000, "marketCapitalization": 247492980000, "minusCashAndCashEquivalents": 1298000000, "addTotalDebt": 35677000000, "enterpriseValue": 281871980000}}
{"date": "2022-07-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2022-07-03", "stockPrice": 52.31, "numberOfShares": 5593000000, "marketCapitalization": 292569830000, "minusCashAndCashEquivalents": 1780000000, "addTotalDebt": 39134000000, "enterpriseValue": 329923830000}}
{"date": "2022-04-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2022-04-03", "stockPrice": 50.94, "numberOfShares": 5617000000, "marketCapitalization": 286129980000, "minusCashAndCashEquivalents": 2470000000, "addTotalDebt": 35052000000, "enterpriseValue": 318711980000}}
{"date": "2021-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2021-12-31", "stockPrice": 59.05, "numberOfShares": 5616000000, "marketCapitalization": 331624800000, "minusCashAndCashEquivalents": 1944000000, "addTotalDebt": 36998000000, "enterpriseValue": 366678800000}}
{"date": "2021-10-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2021-10-03", "stockPrice": 42.42, "numberOfShares": 5609000000, "marketCapitalization": 237933780000, "minusCashAndCashEquivalents": 1966000000, "addTotalDebt": 38408000000, "enterpriseValue": 274375780000}}
{"date": "2021-07-04", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2021-07-04", "stockPrice": 39.73, "numberOfShares": 5598000000, "marketCapitalization": 222408539999, "minusCashAndCashEquivalents": 2372000000, "addTotalDebt": 37735000000, "enterpriseValue": 257771539999}}
{"date": "2021-04-04", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2021-04-04", "stockPrice": 36.28, "numberOfShares": 5584000000, "marketCapitalization": 202587520000, "minusCashAndCashEquivalents": 1768000000, "addTotalDebt": 38188000000, "enterpriseValue": 239007520000}}
{"date": "2020-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2020-12-31", "stockPrice": 36.81, "numberOfShares": 5562000000, "marketCapitalization": 204737220000, "minusCashAndCashEquivalents": 1786000000, "addTotalDebt": 38274000000, "enterpriseValue": 241225220000}}
{"date": "2020-09-27", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2020-09-27", "stockPrice": 34.5, "numberOfShares": 5557000000, "marketCapitalization": 191716500000, "minusCashAndCashEquivalents": 1587000000, "addTotalDebt": 61528000000, "enterpriseValue": 251657500000}}
{"date": "2020-06-28", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2020-06-28", "stockPrice": 30.94, "numberOfShares": 5554000000, "marketCapitalization": 171840760000, "minusCashAndCashEquivalents": 1801000000, "addTotalDebt": 63612000000, "enterpriseValue": 233651760000}}
{"date": "2020-03-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2020-03-29", "stockPrice": 30.97, "numberOfShares": 5545000000, "marketCapitalization": 171728650000, "minusCashAndCashEquivalents": 2151000000, "addTotalDebt": 52285000000, "enterpriseValue": 221862650000}}
{"date": "2019-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2019-12-31", "stockPrice": 37.14, "numberOfShares": 5535000000, "marketCapitalization": 205569900000, "minusCashAndCashEquivalents": 1121000000, "addTotalDebt": 50840000000, "enterpriseValue": 255288900000}}
{"date": "2019-09-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2019-09-29", "stockPrice": 34.06, "numberOfShares": 5545000000, "marketCapitalization": 188862700000, "minusCashAndCashEquivalents": 2785000000, "addTotalDebt": 52654000000, "enterpriseValue": 238731700000}}
{"date": "2019-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2019-06-30", "stockPrice": 41.49, "numberOfShares": 5562000000, "marketCapitalization": 230767380000, "minusCashAndCashEquivalents": 1784000000, "addTotalDebt": 46674000000, "enterpriseValue": 275657380000}}
{"date": "2019-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2019-03-31", "stockPrice": 40.61, "numberOfShares": 5635000000, "marketCapitalization": 228837350000, "minusCashAndCashEquivalents": 1937000000, "addTotalDebt": 45144000000, "enterpriseValue": 272044350000}}
{"date": "2018-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2018-12-31", "stockPrice": 41.38, "numberOfShares": 5788000000, "marketCapitalization": 239507440000, "minusCashAndCashEquivalents": 1139000000, "addTotalDebt": 41745000000, "enterpriseValue": 280113440000}}
{"date": "2018-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2018-09-30", "stockPrice": 41.97, "numberOfShares": 5875000000, "marketCapitalization": 246573750000, "minusCashAndCashEquivalents": 3559000000, "addTotalDebt": 48432000000, "enterpriseValue": 291446750000}}
{"date": "2018-07-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2018-07-01", "stockPrice": 34.44, "numberOfShares": 5866000000, "marketCapitalization": 202025040000, "minusCashAndCashEquivalents": 2704000000, "addTotalDebt": 40522000000, "enterpriseValue": 239843040000}}
{"date": "2018-04-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2018-04-01", "stockPrice": 33.23, "numberOfShares": 5957000000, "marketCapitalization": 197951109999, "minusCashAndCashEquivalents": 2302000000, "addTotalDebt": 40832000000, "enterpriseValue": 236481109999}}
{"date": "2017-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2017-12-31", "stockPrice": 34.33, "numberOfShares": 5963000000, "marketCapitalization": 204709790000, "minusCashAndCashEquivalents": 1342000000, "addTotalDebt": 42606000000, "enterpriseValue": 245973790000}}
{"date": "2017-10-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2017-10-01", "stockPrice": 34.19, "numberOfShares": 5951000000, "marketCapitalization": 203464690000, "minusCashAndCashEquivalents": 2779000000, "addTotalDebt": 43951000000, "enterpriseValue": 244636690000}}
{"date": "2017-07-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2017-07-02", "stockPrice": 32.06, "numberOfShares": 5958000000, "marketCapitalization": 191013480000, "minusCashAndCashEquivalents": 2585000000, "addTotalDebt": 43705000000, "enterpriseValue": 232133480000}}
{"date": "2017-04-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2017-04-02", "stockPrice": 32.46, "numberOfShares": 6006000000, "marketCapitalization": 194954760000, "minusCashAndCashEquivalents": 4057000000, "addTotalDebt": 44010000000, "enterpriseValue": 234907760000}}
{"date": "2016-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2016-12-31", "stockPrice": 30.79, "numberOfShares": 6070000000, "marketCapitalization": 186895300000, "minusCashAndCashEquivalents": 2595000000, "addTotalDebt": 41062000000, "enterpriseValue": 225362300000}}
{"date": "2016-10-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2016-10-02", "stockPrice": 31.93, "numberOfShares": 6066000000, "marketCapitalization": 193687380000, "minusCashAndCashEquivalents": 2094000000, "addTotalDebt": 44070000000, "enterpriseValue": 235663380000}}
{"date": "2016-07-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2016-07-03", "stockPrice": 33.72, "numberOfShares": 6068000000, "marketCapitalization": 204612960000, "minusCashAndCashEquivalents": 3411000000, "addTotalDebt": 44181000000, "enterpriseValue": 245382960000}}
{"date": "2016-04-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2016-04-03", "stockPrice": 29.12, "numberOfShares": 6150000000, "marketCapitalization": 179088000000, "minusCashAndCashEquivalents": 2561000000, "addTotalDebt": 39370000000, "enterpriseValue": 215897000000}}
{"date": "2015-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2015-12-31", "stockPrice": 30.6, "numberOfShares": 6174000000, "marketCapitalization": 188924400000, "minusCashAndCashEquivalents": 3641000000, "addTotalDebt": 38899000000, "enterpriseValue": 224182400000}}
{"date": "2015-09-27", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2015-09-27", "stockPrice": 29.22, "numberOfShares": 6168000000, "marketCapitalization": 180228960000, "minusCashAndCashEquivalents": 3099000000, "addTotalDebt": 38897000000, "enterpriseValue": 216026960000}}
{"date": "2015-06-28", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2015-06-28", "stockPrice": 31.84, "numberOfShares": 6159000000, "marketCapitalization": 196102560000, "minusCashAndCashEquivalents": 3670000000, "addTotalDebt": 35123000000, "enterpriseValue": 227555560000}}
{"date": "2015-03-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2015-03-29", "stockPrice": 33.18, "numberOfShares": 6203000000, "marketCapitalization": 205815540000, "minusCashAndCashEquivalents": 3563000000, "addTotalDebt": 35925000000, "enterpriseValue": 238177540000}}
{"date": "2014-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2014-12-31", "stockPrice": 29.53, "numberOfShares": 6296000000, "marketCapitalization": 185920880000, "minusCashAndCashEquivalents": 3343000000, "addTotalDebt": 36682000000, "enterpriseValue": 219259880000}}
{"date": "2014-09-28", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2014-09-28", "stockPrice": 28.22, "numberOfShares": 6330000000, "marketCapitalization": 178632600000, "minusCashAndCashEquivalents": 2437000000, "addTotalDebt": 37055000000, "enterpriseValue": 213250600000}}
{"date": "2014-06-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2014-06-29", "stockPrice": 28.14, "numberOfShares": 6368000000, "marketCapitalization": 179195520000, "minusCashAndCashEquivalents": 3406000000, "addTotalDebt": 37828000000, "enterpriseValue": 213617520000}}
{"date": "2014-03-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2014-03-30", "stockPrice": 30.45, "numberOfShares": 6389000000, "marketCapitalization": 194545050000, "minusCashAndCashEquivalents": 2862000000, "addTotalDebt": 36968000000, "enterpriseValue": 228651050000}}
{"date": "2013-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2013-12-31", "stockPrice": 29.04, "numberOfShares": 6443000000, "marketCapitalization": 187104720000, "minusCashAndCashEquivalents": 2183000000, "addTotalDebt": 36489000000, "enterpriseValue": 221410720000}}
{"date": "2013-09-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2013-09-29", "stockPrice": 27.23, "numberOfShares": 6581000000, "marketCapitalization": 179200630000, "minusCashAndCashEquivalents": 2052000000, "addTotalDebt": 36550000000, "enterpriseValue": 213698630000}}
{"date": "2013-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2013-06-30", "stockPrice": 26.33, "numberOfShares": 7042000000, "marketCapitalization": 185415860000, "minusCashAndCashEquivalents": 2436000000, "addTotalDebt": 36746000000, "enterpriseValue": 219725860000}}
{"date": "2013-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2013-03-31", "stockPrice": 27.34, "numberOfShares": 7187000000, "marketCapitalization": 196492580000, "minusCashAndCashEquivalents": 2134000000, "addTotalDebt": 40377000000, "enterpriseValue": 234735580000}}
{"date": "2012-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2012-12-31", "stockPrice": 23.77, "numberOfShares": 7319000000, "marketCapitalization": 173972630000, "minusCashAndCashEquivalents": 10081000000, "addTotalDebt": 37460000000, "enterpriseValue": 201351630000}}
{"date": "2012-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2012-09-30", "stockPrice": 23.73, "numberOfShares": 7436000000, "marketCapitalization": 176456280000, "minusCashAndCashEquivalents": 4506000000, "addTotalDebt": 38857000000, "enterpriseValue": 210807280000}}
{"date": "2012-07-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2012-07-01", "stockPrice": 21.8, "numberOfShares": 7476000000, "marketCapitalization": 162976800000, "minusCashAndCashEquivalents": 3031000000, "addTotalDebt": 38571000000, "enterpriseValue": 198516800000}}
{"date": "2012-04-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2012-04-01", "stockPrice": 21.41, "numberOfShares": 7537000000, "marketCapitalization": 161367170000, "minusCashAndCashEquivalents": 2934000000, "addTotalDebt": 39069000000, "enterpriseValue": 197502170000}}
{"date": "2011-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2011-12-31", "stockPrice": 20.51, "numberOfShares": 7635000000, "marketCapitalization": 156593850000, "minusCashAndCashEquivalents": 3182000000, "addTotalDebt": 38942000000, "enterpriseValue": 192353850000}}
{"date": "2011-10-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2011-10-02", "stockPrice": 16.43, "numberOfShares": 7770000000, "marketCapitalization": 127661100000, "minusCashAndCashEquivalents": 3706000000, "addTotalDebt": 41036000000, "enterpriseValue": 164991100000}}
{"date": "2011-07-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2011-07-03", "stockPrice": 19.67, "numberOfShares": 7875000000, "marketCapitalization": 154901250000, "minusCashAndCashEquivalents": 3096000000, "addTotalDebt": 41711000000, "enterpriseValue": 193516250000}}
{"date": "2011-04-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2011-04-03", "stockPrice": 19.47, "numberOfShares": 7982000000, "marketCapitalization": 155409540000, "minusCashAndCashEquivalents": 730000000, "addTotalDebt": 41401000000, "enterpriseValue": 196080540000}}
{"date": "2010-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2010-12-31", "stockPrice": 16.6, "numberOfShares": 8009000000, "marketCapitalization": 132949400000, "minusCashAndCashEquivalents": 1735000000, "addTotalDebt": 44033000000, "enterpriseValue": 175247400000}}
{"date": "2010-10-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2010-10-03", "stockPrice": 16.02, "numberOfShares": 8027000000, "marketCapitalization": 128592540000, "minusCashAndCashEquivalents": 2176000000, "addTotalDebt": 44168000000, "enterpriseValue": 170584540000}}
{"date": "2010-07-04", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2010-07-04", "stockPrice": 13.4, "numberOfShares": 8046000000, "marketCapitalization": 107816400000, "minusCashAndCashEquivalents": 1877000000, "addTotalDebt": 43274000000, "enterpriseValue": 149213400000}}
{"date": "2010-04-04", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2010-04-04", "stockPrice": 16.02, "numberOfShares": 8061000000, "marketCapitalization": 129137220000, "minusCashAndCashEquivalents": 1759000000, "addTotalDebt": 46050000000, "enterpriseValue": 173428220000}}
{"date": "2009-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2009-12-31", "stockPrice": 17.24, "numberOfShares": 6762000000, "marketCapitalization": 116576879999, "minusCashAndCashEquivalents": 1978000000, "addTotalDebt": 48662000000, "enterpriseValue": 163260879999}}
{"date": "2009-09-27", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2009-09-27", "stockPrice": 15.71, "numberOfShares": 6730000000, "marketCapitalization": 105728300000, "minusCashAndCashEquivalents": 4234000000, "addTotalDebt": 46199000000, "enterpriseValue": 147693300000}}
{"date": "2009-06-28", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2009-06-28", "stockPrice": 14.47, "numberOfShares": 6728000000, "marketCapitalization": 97354160000, "minusCashAndCashEquivalents": 2244000000, "addTotalDebt": 46538000000, "enterpriseValue": 141648160000}}
{"date": "2009-03-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2009-03-29", "stockPrice": 12.99, "numberOfShares": 6723000000, "marketCapitalization": 87331770000, "minusCashAndCashEquivalents": 1247000000, "addTotalDebt": 35447000000, "enterpriseValue": 121531770000}}
{"date": "2008-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2008-12-31", "stockPrice": 16.79, "numberOfShares": 6718000000, "marketCapitalization": 112795220000, "minusCashAndCashEquivalents": 2122000000, "addTotalDebt": 17283000000, "enterpriseValue": 127956220000}}
{"date": "2008-09-28", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2008-09-28", "stockPrice": 16.73, "numberOfShares": 6718000000, "marketCapitalization": 112392140000, "minusCashAndCashEquivalents": 1265000000, "addTotalDebt": 16345000000, "enterpriseValue": 127472140000}}
{"date": "2008-06-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2008-06-29", "stockPrice": 16.56, "numberOfShares": 6732000000, "marketCapitalization": 111481919999, "minusCashAndCashEquivalents": 820000000, "addTotalDebt": 16694000000, "enterpriseValue": 127355919999}}
{"date": "2008-03-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2008-03-30", "stockPrice": 19.84, "numberOfShares": 6739000000, "marketCapitalization": 133701760000, "minusCashAndCashEquivalents": 2013000000, "addTotalDebt": 17052000000, "enterpriseValue": 148740760000}}
{"date": "2007-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2007-12-31", "stockPrice": 21.55, "numberOfShares": 6776000000, "marketCapitalization": 146022800000, "minusCashAndCashEquivalents": 3406000000, "addTotalDebt": 13139000000, "enterpriseValue": 155755800000}}
{"date": "2007-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2007-09-30", "stockPrice": 23.56, "numberOfShares": 6875000000, "marketCapitalization": 161975000000, "minusCashAndCashEquivalents": 2611000000, "addTotalDebt": 8686000000, "enterpriseValue": 168050000000}}
{"date": "2007-07-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2007-07-01", "stockPrice": 24.39, "numberOfShares": 6966000000, "marketCapitalization": 169900740000, "minusCashAndCashEquivalents": 2138000000, "addTotalDebt": 8209000000, "enterpriseValue": 175971740000}}
{"date": "2007-04-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2007-04-01", "stockPrice": 24.02, "numberOfShares": 7051000000, "marketCapitalization": 169365020000, "minusCashAndCashEquivalents": 2492000000, "addTotalDebt": 7409000000, "enterpriseValue": 174282020000}}
{"date": "2006-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2006-12-31", "stockPrice": 24.55, "numberOfShares": 7143000000, "marketCapitalization": 175360650000, "minusCashAndCashEquivalents": 1827000000, "addTotalDebt": 7980000000, "enterpriseValue": 181513650000}}
{"date": "2006-10-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2006-10-01", "stockPrice": 26.84, "numberOfShares": 7228000000, "marketCapitalization": 193999520000, "minusCashAndCashEquivalents": 1177000000, "addTotalDebt": 8069000000, "enterpriseValue": 200891520000}}
{"date": "2006-07-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2006-07-02", "stockPrice": 22.35, "numberOfShares": 7282000000, "marketCapitalization": 162752700000, "minusCashAndCashEquivalents": 1921000000, "addTotalDebt": 9229000000, "enterpriseValue": 170060700000}}
{"date": "2006-04-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2006-04-02", "stockPrice": 23.81, "numberOfShares": 7314000000, "marketCapitalization": 174146340000, "minusCashAndCashEquivalents": 2869000000, "addTotalDebt": 11567000000, "enterpriseValue": 182844340000}}
{"date": "2005-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2005-12-31", "stockPrice": 22.11, "numberOfShares": 7328000000, "marketCapitalization": 162022080000, "minusCashAndCashEquivalents": 2247000000, "addTotalDebt": 17936000000, "enterpriseValue": 177711080000}}
{"date": "2005-10-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2005-10-02", "stockPrice": 23.97, "numberOfShares": 7333000000, "marketCapitalization": 175772010000, "minusCashAndCashEquivalents": 959000000, "addTotalDebt": 12143000000, "enterpriseValue": 186956010000}}
{"date": "2005-07-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2005-07-03", "stockPrice": 25.69, "numberOfShares": 7366000000, "marketCapitalization": 189232540000, "minusCashAndCashEquivalents": 1276000000, "addTotalDebt": 12778000000, "enterpriseValue": 200734540000}}
{"date": "2005-04-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2005-04-03", "stockPrice": 24.58, "numberOfShares": 7416000000, "marketCapitalization": 182285280000, "minusCashAndCashEquivalents": 1476000000, "addTotalDebt": 19831000000, "enterpriseValue": 200640280000}}
{"date": "2004-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2004-12-31", "stockPrice": 25.49, "numberOfShares": 7462000000, "marketCapitalization": 190206380000, "minusCashAndCashEquivalents": 1808000000, "addTotalDebt": 18545000000, "enterpriseValue": 206943380000}}
{"date": "2004-09-26", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2004-09-26", "stockPrice": 28.08, "numberOfShares": 7501000000, "marketCapitalization": 210628080000, "minusCashAndCashEquivalents": 1864000000, "addTotalDebt": 18814000000, "enterpriseValue": 227578080000}}
{"date": "2004-06-27", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2004-06-27", "stockPrice": 32.29, "numberOfShares": 7574100000, "marketCapitalization": 244567689000, "minusCashAndCashEquivalents": 652000000, "addTotalDebt": 18969000000, "enterpriseValue": 262884689000}}
{"date": "2004-03-28", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2004-03-28", "stockPrice": 33.2, "numberOfShares": 7586000000, "marketCapitalization": 251855200000, "minusCashAndCashEquivalents": 965000000, "addTotalDebt": 17836000000, "enterpriseValue": 268726200000}}
{"date": "2003-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2003-12-31", "stockPrice": 33.49, "numberOfShares": 7586500000, "marketCapitalization": 254071885000, "minusCashAndCashEquivalents": 1520000000, "addTotalDebt": 14573000000, "enterpriseValue": 267124885000}}
{"date": "2003-09-28", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2003-09-28", "stockPrice": 29.28, "numberOfShares": 7710700000, "marketCapitalization": 225769296000, "minusCashAndCashEquivalents": 1610000000, "addTotalDebt": 15835000000, "enterpriseValue": 239994296000}}
{"date": "2003-06-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2003-06-29", "stockPrice": 32.37, "numberOfShares": 7453400000, "marketCapitalization": 241266557999, "minusCashAndCashEquivalents": 2190000000, "addTotalDebt": 14924000000, "enterpriseValue": 254000557999}}
{"date": "2003-03-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2003-03-30", "stockPrice": 29.54, "numberOfShares": 6101400000, "marketCapitalization": 180235356000, "minusCashAndCashEquivalents": 2068000000, "addTotalDebt": 12978000000, "enterpriseValue": 191145356000}}
{"date": "2002-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2002-12-31", "stockPrice": 28.98, "numberOfShares": 6107100000, "marketCapitalization": 176983758000, "minusCashAndCashEquivalents": 1878000000, "addTotalDebt": 11809000000, "enterpriseValue": 186914758000}}
{"date": "2002-09-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2002-09-29", "stockPrice": 27.51, "numberOfShares": 6126300000, "marketCapitalization": 168534513000, "minusCashAndCashEquivalents": 1774000000, "addTotalDebt": 13808000000, "enterpriseValue": 180568513000}}
{"date": "2002-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2002-06-30", "stockPrice": 32.14, "numberOfShares": 6185100000, "marketCapitalization": 198789114000, "minusCashAndCashEquivalents": 1196000000, "addTotalDebt": 11438000000, "enterpriseValue": 209031114000}}
{"date": "2002-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2002-03-31", "stockPrice": 38.02, "numberOfShares": 6205500000, "marketCapitalization": 235933110000, "minusCashAndCashEquivalents": 1332000000, "addTotalDebt": 10326000000, "enterpriseValue": 244927110000}}
{"date": "2001-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2001-12-31", "stockPrice": 37.78, "numberOfShares": 6217700000, "marketCapitalization": 234904706000, "minusCashAndCashEquivalents": 1036000000, "addTotalDebt": 8872000000, "enterpriseValue": 242740706000}}
{"date": "2001-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2001-09-30", "stockPrice": 38.96, "numberOfShares": 6241200000, "marketCapitalization": 243157152000, "minusCashAndCashEquivalents": 1898000000, "addTotalDebt": 8449000000, "enterpriseValue": 249708152000}}
{"date": "2001-07-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2001-07-01", "stockPrice": 38.77, "numberOfShares": 6250000000, "marketCapitalization": 242312500000, "minusCashAndCashEquivalents": 1295000000, "addTotalDebt": 7005000000, "enterpriseValue": 248022500000}}
{"date": "2001-04-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2001-04-01", "stockPrice": 36.92, "numberOfShares": 6247000000, "marketCapitalization": 230639240000, "minusCashAndCashEquivalents": 1176000000, "addTotalDebt": 5851000000, "enterpriseValue": 235314240000}}
{"date": "2000-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2000-12-31", "stockPrice": 43.61, "numberOfShares": 6237000000, "marketCapitalization": 271995570000, "minusCashAndCashEquivalents": 1099000000, "addTotalDebt": 5412000000, "enterpriseValue": 276308570000}}
{"date": "2000-10-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2000-10-01", "stockPrice": 41.95, "numberOfShares": 6228000000, "marketCapitalization": 261264600000, "minusCashAndCashEquivalents": 1341000000, "addTotalDebt": 7191000000, "enterpriseValue": 267114600000}}
{"date": "2000-07-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2000-07-02", "stockPrice": 45.21, "numberOfShares": 6217000000, "marketCapitalization": 281070570000, "minusCashAndCashEquivalents": 1590000000, "addTotalDebt": 6810000000, "enterpriseValue": 286290570000}}
{"date": "2000-04-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "2000-04-02", "stockPrice": 36.38, "numberOfShares": 6152000000, "marketCapitalization": 223809760000, "minusCashAndCashEquivalents": 191000000, "addTotalDebt": 4241000000, "enterpriseValue": 227859760000}}
{"date": "1999-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1999-12-31", "stockPrice": 30.75, "numberOfShares": 6135000000, "marketCapitalization": 188651250000, "minusCashAndCashEquivalents": 2358000000, "addTotalDebt": 7073000000, "enterpriseValue": 193366250000}}
{"date": "1999-10-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1999-10-03", "stockPrice": 35.67, "numberOfShares": 6122000000, "marketCapitalization": 218371740000, "minusCashAndCashEquivalents": 942000000, "addTotalDebt": 6011000000, "enterpriseValue": 223440740000}}
{"date": "1999-07-04", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1999-07-04", "stockPrice": 36.61, "numberOfShares": 6125000000, "marketCapitalization": 224236250000, "minusCashAndCashEquivalents": 1223000000, "addTotalDebt": 5468000000, "enterpriseValue": 228481250000}}
{"date": "1999-04-04", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1999-04-04", "stockPrice": 44.99, "numberOfShares": 3783000000, "marketCapitalization": 170197170000, "minusCashAndCashEquivalents": 1166000000, "addTotalDebt": 4821000000, "enterpriseValue": 173852170000}}
{"date": "1998-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1998-12-31", "stockPrice": 39.5, "numberOfShares": 3789000000, "marketCapitalization": 149665500000, "minusCashAndCashEquivalents": 1552000000, "addTotalDebt": 3256000000, "enterpriseValue": 151369500000}}
{"date": "1998-09-27", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1998-09-27", "stockPrice": 33.51, "numberOfShares": 3880555556, "marketCapitalization": 130037416681, "minusCashAndCashEquivalents": 2723000000, "addTotalDebt": 3878000000, "enterpriseValue": 131192416681}}
{"date": "1998-06-28", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1998-06-28", "stockPrice": 34.74, "numberOfShares": 3694117647, "marketCapitalization": 128333647056, "minusCashAndCashEquivalents": 1089000000, "addTotalDebt": 3307000000, "enterpriseValue": 130551647056}}
{"date": "1998-03-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1998-03-29", "stockPrice": 30.91, "numberOfShares": 3844444444, "marketCapitalization": 118831777764, "minusCashAndCashEquivalents": 1053000000, "addTotalDebt": 3244000000, "enterpriseValue": 121022777764}}
{"date": "1997-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1997-12-31", "stockPrice": 23.56, "numberOfShares": 3771000000, "marketCapitalization": 88844760000, "minusCashAndCashEquivalents": 877000000, "addTotalDebt": 2976000000, "enterpriseValue": 90943760000}}
{"date": "1997-09-28", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1997-09-28", "stockPrice": 19.29, "numberOfShares": 3725000000, "marketCapitalization": 71855250000, "minusCashAndCashEquivalents": 1190000000, "addTotalDebt": 3580000000, "enterpriseValue": 74245250000}}
{"date": "1997-06-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1997-06-29", "stockPrice": 18.88, "numberOfShares": 3808333333, "marketCapitalization": 71901333327, "minusCashAndCashEquivalents": 1514000000, "addTotalDebt": 3709000000, "enterpriseValue": 74096333327}}
{"date": "1997-03-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1997-03-30", "stockPrice": 13.29, "numberOfShares": 3762500000, "marketCapitalization": 50003625000, "minusCashAndCashEquivalents": 1230000000, "addTotalDebt": 3314000000, "enterpriseValue": 52087625000}}
{"date": "1996-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1996-12-31", "stockPrice": 13.11, "numberOfShares": 3864000000, "marketCapitalization": 50657040000, "minusCashAndCashEquivalents": 1150000000, "addTotalDebt": 2922000000, "enterpriseValue": 52429040000}}
{"date": "1996-09-29", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1996-09-29", "stockPrice": 12.5, "numberOfShares": 3671428571, "marketCapitalization": 45892857137, "minusCashAndCashEquivalents": 1046000000, "addTotalDebt": 3710000000, "enterpriseValue": 48556857137}}
{"date": "1996-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1996-06-30", "stockPrice": 11.3, "numberOfShares": 3940000000, "marketCapitalization": 44522000000, "minusCashAndCashEquivalents": 870000000, "addTotalDebt": 3128000000, "enterpriseValue": 46780000000}}
{"date": "1996-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1996-03-31", "stockPrice": 11.06, "numberOfShares": 3692857143, "marketCapitalization": 40843000001, "minusCashAndCashEquivalents": 818000000, "addTotalDebt": 2923000000, "enterpriseValue": 42948000001}}
{"date": "1995-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1995-12-31", "stockPrice": 9.95, "numberOfShares": 3774960000, "marketCapitalization": 37560852000, "minusCashAndCashEquivalents": 403300000, "addTotalDebt": 2868500000, "enterpriseValue": 40026052000}}
{"date": "1995-10-01", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1995-10-01", "stockPrice": 8.41, "numberOfShares": 3866363636, "marketCapitalization": 32516118178, "minusCashAndCashEquivalents": 733600000, "addTotalDebt": 3404600000, "enterpriseValue": 35187118178}}
{"date": "1995-07-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1995-07-02", "stockPrice": 7.39, "numberOfShares": 3953750000, "marketCapitalization": 29218212500, "minusCashAndCashEquivalents": 623600000, "addTotalDebt": 3670700000, "enterpriseValue": 32265312500}}
{"date": "1995-04-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1995-04-02", "stockPrice": 6.87, "numberOfShares": 3821818182, "marketCapitalization": 26255890910, "minusCashAndCashEquivalents": 967000000, "addTotalDebt": 3725000000, "enterpriseValue": 29013890910}}
{"date": "1994-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1994-12-31", "stockPrice": 6.1, "numberOfShares": 3718568019, "marketCapitalization": 22683264915, "minusCashAndCashEquivalents": 1458500000, "addTotalDebt": 2824200000, "enterpriseValue": 24048964915}}
{"date": "1994-10-02", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1994-10-02", "stockPrice": 5.53, "numberOfShares": 3738888889, "marketCapitalization": 20676055556, "minusCashAndCashEquivalents": 894200000, "addTotalDebt": 2383100000, "enterpriseValue": 22164955556}}
{"date": "1994-07-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1994-07-03", "stockPrice": 4.96, "numberOfShares": 3674285714, "marketCapitalization": 18224457141, "minusCashAndCashEquivalents": 804100000, "addTotalDebt": 2406400000, "enterpriseValue": 19826757141}}
{"date": "1994-04-03", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1994-04-03", "stockPrice": 4.24, "numberOfShares": 3707000000, "marketCapitalization": 15717680000, "minusCashAndCashEquivalents": 796800000, "addTotalDebt": 2087900000, "enterpriseValue": 17008780000}}
{"date": "1993-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1993-12-31", "stockPrice": 5.45, "numberOfShares": 3570000000, "marketCapitalization": 19456500000, "minusCashAndCashEquivalents": 729400000, "addTotalDebt": 1749300000, "enterpriseValue": 20476400000}}
{"date": "1993-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1993-09-30", "stockPrice": 4.7, "numberOfShares": 3570000000, "marketCapitalization": 16779000000, "minusCashAndCashEquivalents": 1227900000, "addTotalDebt": 2793000000, "enterpriseValue": 18344100000}}
{"date": "1993-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1993-06-30", "stockPrice": 5.29, "numberOfShares": 3625714286, "marketCapitalization": 19180028572, "minusCashAndCashEquivalents": 1159900000, "addTotalDebt": 2735000000, "enterpriseValue": 20755128572}}
{"date": "1993-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1993-03-31", "stockPrice": 4.92, "numberOfShares": 3655555556, "marketCapitalization": 17985333335, "minusCashAndCashEquivalents": 1019000000, "addTotalDebt": 2413700000, "enterpriseValue": 19380033335}}
{"date": "1992-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1992-12-31", "stockPrice": 5.73, "numberOfShares": 4250000000, "marketCapitalization": 24352500000, "minusCashAndCashEquivalents": 1257100000, "addTotalDebt": 1823600000, "enterpriseValue": 24919000000}}
{"date": "1992-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1992-09-30", "stockPrice": 5.9, "numberOfShares": 4250000000, "marketCapitalization": 25075000000, "minusCashAndCashEquivalents": 1079800000, "addTotalDebt": 1864100000, "enterpriseValue": 25859300000}}
{"date": "1992-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1992-06-30", "stockPrice": 5.77, "numberOfShares": 4076000000, "marketCapitalization": 23518520000, "minusCashAndCashEquivalents": 941900000, "addTotalDebt": 1636600000, "enterpriseValue": 24213220000}}
{"date": "1992-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1992-03-31", "stockPrice": 5.49, "numberOfShares": 4215714286, "marketCapitalization": 23144271430, "minusCashAndCashEquivalents": 1065600000, "addTotalDebt": 1871900000, "enterpriseValue": 23950571430}}
{"date": "1991-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1991-12-31", "stockPrice": 6.64, "numberOfShares": 3924285714, "marketCapitalization": 26057257140, "minusCashAndCashEquivalents": 1317600000, "addTotalDebt": 2087700000, "enterpriseValue": 26827357140}}
{"date": "1991-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1991-09-30", "stockPrice": 5.14, "numberOfShares": 3924285714, "marketCapitalization": 20170828569, "minusCashAndCashEquivalents": 673500000, "addTotalDebt": 1817000000, "enterpriseValue": 21314328569}}
{"date": "1991-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1991-06-30", "stockPrice": 4.44, "numberOfShares": 3582000000, "marketCapitalization": 15904080000, "minusCashAndCashEquivalents": 675800000, "addTotalDebt": 1715600000, "enterpriseValue": 16943880000}}
{"date": "1991-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1991-03-31", "stockPrice": 4.27, "numberOfShares": 3820000000, "marketCapitalization": 16311399999, "minusCashAndCashEquivalents": 608900000, "addTotalDebt": 1438600000, "enterpriseValue": 17141099999}}
{"date": "1990-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1990-12-31", "stockPrice": 3.19, "numberOfShares": 4055000000, "marketCapitalization": 12935450000, "minusCashAndCashEquivalents": 870300000, "addTotalDebt": 1692600000, "enterpriseValue": 13757750000}}
{"date": "1990-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1990-09-30", "stockPrice": 2.9, "numberOfShares": 4055000000, "marketCapitalization": 11759500000, "minusCashAndCashEquivalents": 307900000, "addTotalDebt": 1448200000, "enterpriseValue": 12899800000}}
{"date": "1990-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1990-06-30", "stockPrice": 2.53, "numberOfShares": 3780000000, "marketCapitalization": 9563400000, "minusCashAndCashEquivalents": 399100000, "addTotalDebt": 1270800000, "enterpriseValue": 10435100000}}
{"date": "1990-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1990-03-31", "stockPrice": 2.39, "numberOfShares": 4198333333, "marketCapitalization": 10034016665, "minusCashAndCashEquivalents": 388900000, "addTotalDebt": 1179800000, "enterpriseValue": 10824916665}}
{"date": "1989-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1989-12-31", "stockPrice": 2.8, "numberOfShares": 3971477000, "marketCapitalization": 11120135600, "minusCashAndCashEquivalents": 825400000, "addTotalDebt": 1716900000, "enterpriseValue": 12011635600}}
{"date": "1989-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1989-09-30", "stockPrice": 2.71, "numberOfShares": 3971489000, "marketCapitalization": 10762735190, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 10762735190}}
{"date": "1989-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1989-06-30", "stockPrice": 2.27, "numberOfShares": 3971489000, "marketCapitalization": 9015280030, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 9015280030}}
{"date": "1989-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1989-03-31", "stockPrice": 2.27, "numberOfShares": 3971489000, "marketCapitalization": 9015280030, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 9015280030}}
{"date": "1988-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1988-12-31", "stockPrice": 2.29, "numberOfShares": 3951694000, "marketCapitalization": 9049379260, "minusCashAndCashEquivalents": 807500000, "addTotalDebt": 1194600000, "enterpriseValue": 9436479260}}
{"date": "1988-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1988-09-30", "stockPrice": 2.15, "numberOfShares": 3951694000, "marketCapitalization": 8496142100, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 8496142100}}
{"date": "1988-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1988-06-30", "stockPrice": 2.04, "numberOfShares": 3951694000, "marketCapitalization": 8061455760, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 8061455760}}
{"date": "1988-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1988-03-31", "stockPrice": 2.18, "numberOfShares": 3951694000, "marketCapitalization": 8614692920, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 8614692920}}
{"date": "1987-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1987-12-31", "stockPrice": 1.84, "numberOfShares": 3951694000, "marketCapitalization": 7271116960, "minusCashAndCashEquivalents": 1031100000, "addTotalDebt": 963800000, "enterpriseValue": 7203816960}}
{"date": "1987-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1987-09-30", "stockPrice": 2.74, "numberOfShares": 3964138000, "marketCapitalization": 10861738120, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 10861738120}}
{"date": "1987-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1987-06-30", "stockPrice": 2.84, "numberOfShares": 3964138000, "marketCapitalization": 11258151920, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 11258151920}}
{"date": "1987-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1987-03-31", "stockPrice": 2.86, "numberOfShares": 3964138000, "marketCapitalization": 11337434680, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 11337434680}}
{"date": "1986-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1986-12-31", "stockPrice": 2.41, "numberOfShares": 3946985000, "marketCapitalization": 9512233850, "minusCashAndCashEquivalents": 398600000, "addTotalDebt": 556700000, "enterpriseValue": 9670333850}}
{"date": "1986-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1986-09-30", "stockPrice": 2.29, "numberOfShares": 3946985000, "marketCapitalization": 9038595650, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 9038595650}}
{"date": "1986-06-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1986-06-30", "stockPrice": 2.82, "numberOfShares": 3936414000, "marketCapitalization": 11100687480, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 11100687480}}
{"date": "1986-03-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1986-03-31", "stockPrice": 2.37, "numberOfShares": 3936414000, "marketCapitalization": 9329301180, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 9329301180}}
{"date": "1985-12-31", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1985-12-31", "stockPrice": 2, "numberOfShares": 3929712000, "marketCapitalization": 7859424000, "minusCashAndCashEquivalents": 412600000, "addTotalDebt": 509400000, "enterpriseValue": 7956224000}}
{"date": "1985-09-30", "symbol": "PFE", "type": "enterprise_values", "result": {"symbol": "PFE", "date": "1985-09-30", "stockPrice": 1.87, "numberOfShares": 3929712000, "marketCapitalization": 7348561440, "minusCashAndCashEquivalents": 0, "addTotalDebt": 0, "enterpriseValue": 7348561440}}
{"date": "2029-12-31", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2029-12-31", "revenueLow": 53068957630, "revenueHigh": 54618168304, "revenueAvg": 53817454545, "ebitdaLow": 16443932169, "ebitdaHigh": 16923970150, "ebitdaAvg": 16675861211, "ebitLow": 11746695066, "ebitHigh": 12089609384, "ebitAvg": 11912373184, "netIncomeLow": 13037553002, "netIncomeHigh": 13534479002, "netIncomeAvg": 13277637002, "sgaExpenseLow": 10928509929, "sgaExpenseHigh": 11247539452, "sgaExpenseAvg": 11082648174, "epsAvg": 2.32941, "epsHigh": 2.37447, "epsLow": 2.28729, "numAnalystsRevenue": 11, "numAnalystsEps": 3}}
{"date": "2028-12-31", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2028-12-31", "revenueLow": 55055935496, "revenueHigh": 56663150839, "revenueAvg": 55832457209, "ebitdaLow": 17059616568, "ebitdaHigh": 17557627858, "ebitdaAvg": 17300229366, "ebitLow": 12186508172, "ebitHigh": 12542261694, "ebitAvg": 12358389517, "netIncomeLow": 14257695002, "netIncomeHigh": 14801076002, "netIncomeAvg": 14520237002, "sgaExpenseLow": 11337689011, "sgaExpenseHigh": 11668663456, "sgaExpenseAvg": 11497598412, "epsAvg": 2.54741, "epsHigh": 2.59668, "epsLow": 2.50135, "numAnalystsRevenue": 10, "numAnalystsEps": 4}}
{"date": "2027-12-31", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2027-12-31", "revenueLow": 59056123902, "revenueHigh": 59321072707, "revenueAvg": 59188598305, "ebitdaLow": 18299113814, "ebitdaHigh": 18381210775, "ebitdaAvg": 18340162294, "ebitLow": 13071940928, "ebitHigh": 13130586754, "ebitAvg": 13101263841, "netIncomeLow": 13811955002, "netIncomeHigh": 20764416003, "netIncomeAvg": 17288185502.5, "sgaExpenseLow": 12161449278, "sgaExpenseHigh": 12216010282, "sgaExpenseAvg": 12188729780, "epsAvg": 2.88228, "epsHigh": 3.64288, "epsLow": 2.42315, "numAnalystsRevenue": 20, "numAnalystsEps": 9}}
{"date": "2026-12-31", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2026-12-31", "revenueLow": 60797040380, "revenueHigh": 61615481509, "revenueAvg": 61150687782, "ebitdaLow": 18838553700, "ebitdaHigh": 19092155636, "ebitdaAvg": 18948134784, "ebitLow": 13457288897, "ebitHigh": 13638449010, "ebitAvg": 13535567958, "netIncomeLow": 16585803002, "netIncomeHigh": 18334620003, "netIncomeAvg": 17460211502.5, "sgaExpenseLow": 12519956847, "sgaExpenseHigh": 12688498729, "sgaExpenseAvg": 12592783587, "epsAvg": 3.00876, "epsHigh": 3.2166, "epsLow": 2.90979, "numAnalystsRevenue": 15, "numAnalystsEps": 14}}
{"date": "2025-12-31", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2025-12-31", "revenueLow": 61929488999, "revenueHigh": 62402463647, "revenueAvg": 62201197840, "ebitdaLow": 19189453908, "ebitdaHigh": 19336009698, "ebitdaAvg": 19273645533, "ebitLow": 13707953866, "ebitHigh": 13812645746, "ebitAvg": 13768096010, "netIncomeLow": 16622511002, "netIncomeHigh": 18571341003, "netIncomeAvg": 17596926002.5, "sgaExpenseLow": 12753162407, "sgaExpenseHigh": 12850562250, "sgaExpenseAvg": 12809115509, "epsAvg": 3.11735, "epsHigh": 3.25813, "epsLow": 2.91623, "numAnalystsRevenue": 13, "numAnalystsEps": 13}}
{"date": "2024-12-31", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2024-12-31", "revenueLow": 62674971861, "revenueHigh": 63640733937, "revenueAvg": 63083180574, "ebitdaLow": 19420449016, "ebitdaHigh": 19719699780, "ebitdaAvg": 19546936453, "ebitLow": 13872964830, "ebitHigh": 14086734105, "ebitAvg": 13963320915, "netIncomeLow": 16060206002, "netIncomeHigh": 17694396003, "netIncomeAvg": 16877301002.5, "sgaExpenseLow": 12906679967, "sgaExpenseHigh": 13105559706, "sgaExpenseAvg": 12990742537, "epsAvg": 2.92633, "epsHigh": 3.10428, "epsLow": 2.81758, "numAnalystsRevenue": 14, "numAnalystsEps": 15}}
{"date": "2023-12-31", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2023-12-31", "revenueLow": 57879808021, "revenueHigh": 60095877062, "revenueAvg": 58777743824, "ebitdaLow": 21295292978, "ebitdaHigh": 31942939471, "ebitdaAvg": 26619116225, "ebitLow": 15885315815, "ebitHigh": 23827973726, "ebitAvg": 19856644771, "netIncomeLow": -3111600000, "netIncomeHigh": -2074399999, "netIncomeAvg": -2593000000, "sgaExpenseLow": 8517103508, "sgaExpenseHigh": 12775655265, "sgaExpenseAvg": 10646379387, "epsAvg": 1.54708, "epsHigh": 1.577, "epsLow": 1.51911, "numAnalystsRevenue": 14, "numAnalystsEps": 14}}
{"date": "2022-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2022-12-30", "revenueLow": 98174995305, "revenueHigh": 101963234680, "revenueAvg": 100342363631, "ebitdaLow": 20196437189, "ebitdaHigh": 30294655787, "ebitdaAvg": 25245546488, "ebitLow": 15300245670, "ebitHigh": 22950368508, "ebitAvg": 19125307090, "netIncomeLow": 14749527810, "netIncomeHigh": 22124291717, "netIncomeAvg": 18436909764, "sgaExpenseLow": 7997167118, "sgaExpenseHigh": 11995750680, "sgaExpenseAvg": 9996458899, "epsAvg": 6.50281, "epsHigh": 6.63937, "epsLow": 6.32021, "numAnalystsRevenue": 4, "numAnalystsEps": 7}}
{"date": "2021-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2021-12-30", "revenueLow": 79998434039, "revenueHigh": 83085301696, "revenueAvg": 81764526021, "ebitdaLow": 24788292097, "ebitdaHigh": 25744788034, "ebitdaAvg": 25335532858, "ebitLow": 17707474434, "ebitHigh": 18390745685, "ebitAvg": 18098394943, "netIncomeLow": 23313285004, "netIncomeHigh": 24490563004, "netIncomeAvg": 23986854004, "sgaExpenseLow": 16474106893, "sgaExpenseHigh": 17109786683, "sgaExpenseAvg": 16837798864, "epsAvg": 4.20822, "epsHigh": 4.29659, "epsLow": 4.09005, "numAnalystsRevenue": 5, "numAnalystsEps": 5}}
{"date": "2020-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2020-12-30", "revenueLow": 47160936711, "revenueHigh": 48980716960, "revenueAvg": 48202088994, "ebitdaLow": 11922483467, "ebitdaHigh": 17883725202, "ebitdaAvg": 14903104335, "ebitLow": 4943209875, "ebitHigh": 9878564813, "ebitAvg": 7410887344, "netIncomeLow": 6967452969, "netIncomeHigh": 10451179453, "netIncomeAvg": 8709316211, "sgaExpenseLow": 8628536451, "sgaExpenseHigh": 12942804678, "sgaExpenseAvg": 10785670565, "epsAvg": 2.83075, "epsHigh": 2.89019, "epsLow": 2.75126, "numAnalystsRevenue": 5, "numAnalystsEps": 10}}
{"date": "2019-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2019-12-30", "revenueLow": 50563662976, "revenueHigh": 52514742866, "revenueAvg": 51679935824, "ebitdaLow": 17086691701, "ebitdaHigh": 25630037552, "ebitdaAvg": 21358364627, "ebitLow": 9936392845, "ebitHigh": 14904589268, "ebitAvg": 12420491057, "netIncomeLow": 10898981232, "netIncomeHigh": 16696261323, "netIncomeAvg": 13797621278, "sgaExpenseLow": 10508765499, "sgaExpenseHigh": 15763148249, "sgaExpenseAvg": 13135956874, "epsAvg": 2.96916, "epsHigh": 3.03151, "epsLow": 2.88579, "numAnalystsRevenue": 4, "numAnalystsEps": 7}}
{"date": "2018-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2018-12-30", "revenueLow": 52373692879, "revenueHigh": 54394615670, "revenueAvg": 53529925000, "ebitdaLow": 16228497631, "ebitdaHigh": 16854700194, "ebitdaAvg": 16586767388, "ebitLow": 11592799769, "ebitHigh": 12040126508, "ebitAvg": 11848729163, "netIncomeLow": 16604898002, "netIncomeHigh": 17443368003, "netIncomeAvg": 17084610002, "sgaExpenseLow": 10785333804, "sgaExpenseHigh": 11201503176, "sgaExpenseAvg": 11023437109, "epsAvg": 2.9973, "epsHigh": 3.06024, "epsLow": 2.91314, "numAnalystsRevenue": 4, "numAnalystsEps": 3}}
{"date": "2017-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2017-12-30", "revenueLow": 51389732466, "revenueHigh": 53372687570, "revenueAvg": 52524242105, "ebitdaLow": 15923607936, "ebitdaHigh": 16538045843, "ebitdaAvg": 16275146771, "ebitLow": 11375002332, "ebitHigh": 11813925009, "ebitAvg": 11626123503, "netIncomeLow": 14384349002, "netIncomeHigh": 15110700002, "netIncomeAvg": 14799936002, "sgaExpenseLow": 10582706475, "sgaExpenseHigh": 10991057147, "sgaExpenseAvg": 10816336461, "epsAvg": 2.59648, "epsHigh": 2.651, "epsLow": 2.52357, "numAnalystsRevenue": 8, "numAnalystsEps": 7}}
{"date": "2016-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2016-12-30", "revenueLow": 51776329309, "revenueHigh": 53774201870, "revenueAvg": 52919373684, "ebitdaLow": 11368085395, "ebitdaHigh": 17052128093, "ebitdaAvg": 14210106744, "ebitLow": 10341125114, "ebitHigh": 15511687670, "ebitAvg": 12926406392, "netIncomeLow": 5317068620, "netIncomeHigh": 7975602931, "netIncomeAvg": 6646335776, "sgaExpenseLow": 11448216022, "sgaExpenseHigh": 17172324033, "sgaExpenseAvg": 14310270028, "epsAvg": 2.41672, "epsHigh": 2.46747, "epsLow": 2.34886, "numAnalystsRevenue": 6, "numAnalystsEps": 7}}
{"date": "2015-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2015-12-30", "revenueLow": 47347252156, "revenueHigh": 49174221685, "revenueAvg": 48392517647, "ebitdaLow": 11164374123, "ebitdaHigh": 16746561185, "ebitdaAvg": 13955467654, "ebitLow": 9463871658, "ebitHigh": 14195807487, "ebitAvg": 11829839573, "netIncomeLow": 4963330427, "netIncomeHigh": 7613687948, "netIncomeAvg": 6288509188, "sgaExpenseLow": 10997367068, "sgaExpenseHigh": 16496050602, "sgaExpenseAvg": 13746708835, "epsAvg": 2.18889, "epsHigh": 2.23486, "epsLow": 2.12743, "numAnalystsRevenue": 6, "numAnalystsEps": 5}}
{"date": "2014-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2014-12-30", "revenueLow": 38647823807, "revenueHigh": 57971735711, "revenueAvg": 48309779759, "ebitdaLow": 14898787669, "ebitdaHigh": 22348181506, "ebitdaAvg": 18623484588, "ebitLow": 10499062021, "ebitHigh": 15748593034, "ebitAvg": 13123827528, "netIncomeLow": 7102498917, "netIncomeHigh": 10653748378, "netIncomeAvg": 8878123648, "sgaExpenseLow": 10976222287, "sgaExpenseHigh": 16464333430, "sgaExpenseAvg": 13720277859, "epsAvg": 2.14, "epsHigh": 2.57, "epsLow": 1.71, "numAnalystsRevenue": 9, "numAnalystsEps": 9}}
{"date": "2013-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2013-12-30", "revenueLow": 40142208007, "revenueHigh": 60213312012, "revenueAvg": 50177760010, "ebitdaLow": 26736479160, "ebitdaHigh": 40104718740, "ebitdaAvg": 33420598950, "ebitLow": 12924870368, "ebitHigh": 19387305552, "ebitAvg": 16156087960, "netIncomeLow": 17207665333, "netIncomeHigh": 25811498001, "netIncomeAvg": 21509581667, "sgaExpenseLow": 11425805033, "sgaExpenseHigh": 17138707551, "sgaExpenseAvg": 14282256292, "epsAvg": 2.12, "epsHigh": 2.55, "epsLow": 1.69, "numAnalystsRevenue": 12, "numAnalystsEps": 12}}
{"date": "2011-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2011-12-30", "revenueLow": 49713120601, "revenueHigh": 74569680902, "revenueAvg": 62141400752, "ebitdaLow": 18673895747, "ebitdaHigh": 28010843622, "ebitdaAvg": 23342369685, "ebitLow": 13766313851, "ebitHigh": 20649470777, "ebitAvg": 17207892314, "netIncomeLow": 7547800503, "netIncomeHigh": 11321700756, "netIncomeAvg": 9434750630, "sgaExpenseLow": 14364824789, "sgaExpenseHigh": 21547237183, "sgaExpenseAvg": 17956030986, "epsAvg": 2.1, "epsHigh": 2.53, "epsLow": 1.67, "numAnalystsRevenue": 18, "numAnalystsEps": 18}}
{"date": "2010-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2010-12-30", "revenueLow": 47400254152, "revenueHigh": 71100381228, "revenueAvg": 59250317690, "ebitdaLow": 13231089180, "ebitdaHigh": 19846633770, "ebitdaAvg": 16538861475, "ebitLow": 9616614901, "ebitHigh": 14424922351, "ebitAvg": 12020768626, "netIncomeLow": 5919749032, "netIncomeHigh": 8879623549, "netIncomeAvg": 7399686291, "sgaExpenseLow": 13975803503, "sgaExpenseHigh": 20963705255, "sgaExpenseAvg": 17469754379, "epsAvg": 1.81, "epsHigh": 2.17, "epsLow": 1.45, "numAnalystsRevenue": 17, "numAnalystsEps": 17}}
{"date": "2009-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2009-12-30", "revenueLow": 38742291617, "revenueHigh": 58113437427, "revenueAvg": 48427864522, "ebitdaLow": 11791104071, "ebitdaHigh": 17686656107, "ebitdaAvg": 14738880089, "ebitLow": 11931475420, "ebitHigh": 17897213131, "ebitAvg": 14914344276, "netIncomeLow": 6515111382, "netIncomeHigh": 9772667074, "netIncomeAvg": 8143889228, "sgaExpenseLow": 11400116701, "sgaExpenseHigh": 17100175052, "sgaExpenseAvg": 14250145877, "epsAvg": 1.86, "epsHigh": 2.23, "epsLow": 1.49, "numAnalystsRevenue": 20, "numAnalystsEps": 20}}
{"date": "2008-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2008-12-30", "revenueLow": 38016610951, "revenueHigh": 57024916428, "revenueAvg": 47520763690, "ebitdaLow": 11862068334, "ebitdaHigh": 17793102501, "ebitdaAvg": 14827585418, "ebitLow": 11775352521, "ebitHigh": 17663028782, "ebitAvg": 14719190652, "netIncomeLow": 6528414001, "netIncomeHigh": 9792621002, "netIncomeAvg": 8160517502, "sgaExpenseLow": 11175480664, "sgaExpenseHigh": 16763220995, "sgaExpenseAvg": 13969350830, "epsAvg": 2.35, "epsHigh": 2.83, "epsLow": 1.87, "numAnalystsRevenue": 17, "numAnalystsEps": 17}}
{"date": "2004-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2004-12-30", "revenueLow": 41839907854, "revenueHigh": 62759861782, "revenueAvg": 52299884819, "ebitdaLow": 15212853969, "ebitdaHigh": 22819280956, "ebitdaAvg": 19016067463, "ebitLow": 14193947725, "ebitHigh": 21290921589, "ebitAvg": 17742434657, "netIncomeLow": 9040244081, "netIncomeHigh": 13560366123, "netIncomeAvg": 11300305102, "sgaExpenseLow": 13464316678, "sgaExpenseHigh": 20196475018, "sgaExpenseAvg": 16830395848, "epsAvg": 2.1, "epsHigh": 2.52, "epsLow": 1.68, "numAnalystsRevenue": 9, "numAnalystsEps": 9}}
{"date": "2003-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2003-12-30", "revenueLow": 34445822521, "revenueHigh": 51668733782, "revenueAvg": 43057278152, "ebitdaLow": 6449934538, "ebitdaHigh": 11962212152, "ebitdaAvg": 9206073345, "ebitLow": 8281738224, "ebitHigh": 12422607337, "ebitAvg": 10352172781, "netIncomeLow": 1615379556, "netIncomeHigh": 5890241747, "netIncomeAvg": 3752810652, "sgaExpenseLow": 11610158238, "sgaExpenseHigh": 17415237358, "sgaExpenseAvg": 14512697798, "epsAvg": 1.61, "epsHigh": 1.94, "epsLow": 1.28, "numAnalystsRevenue": 9, "numAnalystsEps": 9}}
{"date": "2002-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "2002-12-30", "revenueLow": 23888642165, "revenueHigh": 35832963249, "revenueAvg": 29860802707, "ebitdaLow": 10360343085, "ebitdaHigh": 15540514627, "ebitdaAvg": 12950428856, "ebitLow": 9699780319, "ebitHigh": 14549670478, "ebitAvg": 12124725399, "netIncomeLow": 7517662234, "netIncomeHigh": 11276493351, "netIncomeAvg": 9397077793, "sgaExpenseLow": 8335484573, "sgaExpenseHigh": 12503226861, "sgaExpenseAvg": 10419355718, "epsAvg": 1.55, "epsHigh": 1.86, "epsLow": 1.24, "numAnalystsRevenue": 15, "numAnalystsEps": 15}}
{"date": "1998-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "1998-12-30", "revenueLow": 16365929411, "revenueHigh": 24548894117, "revenueAvg": 20457411764, "ebitdaLow": 4621218244, "ebitdaHigh": 6931827367, "ebitdaAvg": 5776522806, "ebitLow": 2908733456, "ebitHigh": 4363100184, "ebitAvg": 3635916820, "netIncomeLow": 3431158388, "netIncomeHigh": 5146737583, "netIncomeAvg": 4288947986, "sgaExpenseLow": 4539598760, "sgaExpenseHigh": 6809398140, "sgaExpenseAvg": 5674498450, "epsAvg": 0.68, "epsHigh": 0.82, "epsLow": 0.54, "numAnalystsRevenue": 9, "numAnalystsEps": 9}}
{"date": "1997-12-30", "symbol": "PFE", "type": "analyst_estimates_annual", "result": {"symbol": "PFE", "date": "1997-12-30", "revenueLow": 13742400000, "revenueHigh": 20613600000, "revenueAvg": 17178000000, "ebitdaLow": 3538400000, "ebitdaHigh": 5307600000, "ebitdaAvg": 4423000000, "ebitLow": 2677600000, "ebitHigh": 4016400000, "ebitAvg": 3347000000, "netIncomeLow": 2275200000, "netIncomeHigh": 3412800000, "netIncomeAvg": 2844000000, "sgaExpenseLow": 3859200000, "sgaExpenseHigh": 5788800000, "sgaExpenseAvg": 4824000000, "epsAvg": 0.57, "epsHigh": 0.68, "epsLow": 0.46, "numAnalystsRevenue": 8, "numAnalystsEps": 8}}
{"date": "2025-12-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-12-17 00:00:00", "acceptedDate": "2025-12-17 14:36:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825010078/0001225208-25-010078-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825010078/xslF345X05/doc4.xml"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-12-16 00:00:00", "acceptedDate": "2025-12-16 07:01:53", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000167/0000078003-25-000167-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000167/pfe-20251216.htm"}}
{"date": "2025-12-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-12-02 00:00:00", "acceptedDate": "2025-12-02 17:32:33", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825009599/0001225208-25-009599-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825009599/xslF345X05/doc4.xml"}}
{"date": "2025-11-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-11-21 00:00:00", "acceptedDate": "2025-11-21 16:16:49", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312525291406/0001193125-25-291406-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312525291406/d80089d8k.htm"}}
{"date": "2025-11-20", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-11-20 00:00:00", "acceptedDate": "2025-11-20 16:14:36", "formType": "424B5", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312525289779/0001193125-25-289779-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312525289779/d95338d424b5.htm"}}
{"date": "2025-11-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-11-19 00:00:00", "acceptedDate": "2025-11-18 17:51:41", "formType": "FWP", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312525286519/0001193125-25-286519-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312525286519/d72904dfwp.htm"}}
{"date": "2025-11-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-11-18 00:00:00", "acceptedDate": "2025-11-18 08:15:34", "formType": "424B3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312525285360/0001193125-25-285360-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312525285360/d55952d424b3.htm"}}
{"date": "2025-11-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-11-17 00:00:00", "acceptedDate": "2025-11-17 21:02:04", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825009261/0001225208-25-009261-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825009261/xslF345X05/doc4.xml"}}
{"date": "2025-11-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-11-13 00:00:00", "acceptedDate": "2025-11-13 17:01:29", "formType": "13F-HR", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000161/0000078003-25-000161-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000161/information_table.xml"}}
{"date": "2025-11-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-11-13 00:00:00", "acceptedDate": "2025-11-13 15:33:11", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000159/0000078003-25-000159-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000159/pfe-20251113.htm"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-11-04 00:00:00", "acceptedDate": "2025-11-04 07:03:48", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/pfe-20250928.htm"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-11-04 00:00:00", "acceptedDate": "2025-11-04 07:00:28", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000149/0000078003-25-000149-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000149/pfe-09282025xex99.htm"}}
{"date": "2025-11-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-11-03 00:00:00", "acceptedDate": "2025-11-03 17:19:10", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008875/0001225208-25-008875-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008875/xslF345X05/doc4.xml"}}
{"date": "2025-10-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-10-17 00:00:00", "acceptedDate": "2025-10-17 17:19:03", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008651/0001225208-25-008651-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008651/xslF345X05/doc4.xml"}}
{"date": "2025-10-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-10-16 00:00:00", "acceptedDate": "2025-10-16 19:52:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008635/0001225208-25-008635-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008635/xslF345X05/doc4.xml"}}
{"date": "2025-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-10-02 00:00:00", "acceptedDate": "2025-10-02 16:56:13", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008327/0001225208-25-008327-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008327/xslF345X05/doc4.xml"}}
{"date": "2025-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-10-02 00:00:00", "acceptedDate": "2025-10-02 16:56:12", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008326/0001225208-25-008326-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008326/xslF345X05/doc4.xml"}}
{"date": "2025-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-10-02 00:00:00", "acceptedDate": "2025-10-02 16:55:10", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008325/0001225208-25-008325-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008325/xslF345X05/doc4.xml"}}
{"date": "2025-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-10-02 00:00:00", "acceptedDate": "2025-10-02 16:54:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008321/0001225208-25-008321-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008321/xslF345X05/doc4.xml"}}
{"date": "2025-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-10-02 00:00:00", "acceptedDate": "2025-10-02 16:53:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008317/0001225208-25-008317-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008317/xslF345X05/doc4.xml"}}
{"date": "2025-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-10-02 00:00:00", "acceptedDate": "2025-10-02 16:18:50", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008294/0001225208-25-008294-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008294/xslF345X05/doc4.xml"}}
{"date": "2025-09-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-09-17 00:00:00", "acceptedDate": "2025-09-17 18:09:28", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008034/0001225208-25-008034-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825008034/xslF345X05/doc4.xml"}}
{"date": "2025-09-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-09-03 00:00:00", "acceptedDate": "2025-09-03 11:31:49", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825007661/0001225208-25-007661-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825007661/xslF345X05/doc4.xml"}}
{"date": "2025-08-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-08-19 00:00:00", "acceptedDate": "2025-08-19 15:03:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825007330/0001225208-25-007330-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825007330/xslF345X05/doc4.xml"}}
{"date": "2025-08-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-08-11 00:00:00", "acceptedDate": "2025-08-11 17:08:12", "formType": "13F-HR", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000142/0000078003-25-000142-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000142/information_table.xml"}}
{"date": "2025-08-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-08-05 00:00:00", "acceptedDate": "2025-08-05 07:16:27", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000138/0000078003-25-000138-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000138/pfe-20250629.htm"}}
{"date": "2025-08-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-08-05 00:00:00", "acceptedDate": "2025-08-05 07:08:22", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000136/0000078003-25-000136-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000136/pfe-06292025xex99.htm"}}
{"date": "2025-08-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-08-04 00:00:00", "acceptedDate": "2025-08-04 10:23:16", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006961/0001225208-25-006961-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006961/xslF345X05/doc4.xml"}}
{"date": "2025-07-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-07-16 00:00:00", "acceptedDate": "2025-07-16 18:20:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006701/0001225208-25-006701-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006701/xslF345X05/doc4.xml"}}
{"date": "2025-07-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-07-02 00:00:00", "acceptedDate": "2025-07-02 16:39:02", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006382/0001225208-25-006382-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006382/xslF345X05/doc4.xml"}}
{"date": "2025-07-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-07-02 00:00:00", "acceptedDate": "2025-07-02 16:38:59", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006381/0001225208-25-006381-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006381/xslF345X05/doc4.xml"}}
{"date": "2025-07-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-07-02 00:00:00", "acceptedDate": "2025-07-02 16:38:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006380/0001225208-25-006380-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006380/xslF345X05/doc4.xml"}}
{"date": "2025-07-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-07-02 00:00:00", "acceptedDate": "2025-07-02 16:38:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006379/0001225208-25-006379-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006379/xslF345X05/doc4.xml"}}
{"date": "2025-07-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-07-02 00:00:00", "acceptedDate": "2025-07-02 16:36:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006378/0001225208-25-006378-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006378/xslF345X05/doc4.xml"}}
{"date": "2025-07-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-07-02 00:00:00", "acceptedDate": "2025-07-02 13:07:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006305/0001225208-25-006305-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006305/xslF345X05/doc4.xml"}}
{"date": "2025-06-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-06-17 00:00:00", "acceptedDate": "2025-06-17 11:59:58", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006007/0001225208-25-006007-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825006007/xslF345X05/doc4.xml"}}
{"date": "2025-06-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-06-16 00:00:00", "acceptedDate": "2025-06-16 16:12:32", "formType": "11-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000132/0000078003-25-000132-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000132/pfizersavingsplanforemploy.htm"}}
{"date": "2025-06-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-06-16 00:00:00", "acceptedDate": "2025-06-16 16:07:31", "formType": "11-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000130/0000078003-25-000130-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000130/pfizersavingsplan2024.htm"}}
{"date": "2025-06-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-06-03 00:00:00", "acceptedDate": "2025-06-03 11:44:01", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825005665/0001225208-25-005665-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825005665/xslF345X05/doc4.xml"}}
{"date": "2025-05-30", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-05-30 00:00:00", "acceptedDate": "2025-05-30 13:07:24", "formType": "SD", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000124/0000078003-25-000124-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000124/formsdye2024.htm"}}
{"date": "2025-05-20", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-05-20 00:00:00", "acceptedDate": "2025-05-20 11:20:57", "formType": "CERT", "link": "https://www.sec.gov/Archives/edgar/data/78003/000087666125000361/0000876661-25-000361-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000087666125000361/PFENotes052025.pdf"}}
{"date": "2025-05-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-05-19 00:00:00", "acceptedDate": "2025-05-19 17:08:27", "formType": "8-A12B", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312525122529/0001193125-25-122529-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312525122529/d61751d8a12b.htm"}}
{"date": "2025-05-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-05-19 00:00:00", "acceptedDate": "2025-05-19 16:29:15", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312525122480/0001193125-25-122480-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312525122480/d60311d8k.htm"}}
{"date": "2025-05-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-05-19 00:00:00", "acceptedDate": "2025-05-19 15:32:13", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825005263/0001225208-25-005263-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825005263/xslF345X05/doc4.xml"}}
{"date": "2025-05-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-05-15 00:00:00", "acceptedDate": "2025-05-15 16:31:42", "formType": "424B5", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312525120844/0001193125-25-120844-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312525120844/d910320d424b5.htm"}}
{"date": "2025-05-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-05-14 00:00:00", "acceptedDate": "2025-05-14 16:48:00", "formType": "FWP", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312525119917/0001193125-25-119917-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312525119917/d945917dfwp.htm"}}
{"date": "2025-05-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-05-13 00:00:00", "acceptedDate": "2025-05-13 16:42:09", "formType": "13F-HR", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000118/0000078003-25-000118-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000118/information_table.xml"}}
{"date": "2025-05-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-05-13 00:00:00", "acceptedDate": "2025-05-13 07:34:53", "formType": "424B3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312525118319/0001193125-25-118319-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312525118319/d910320d424b3.htm"}}
{"date": "2025-05-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-05-13 00:00:00", "acceptedDate": "2025-05-13 07:16:47", "formType": "POSASR", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312525118300/0001193125-25-118300-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312525118300/d915273dposasr.htm"}}
{"date": "2025-05-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-05-05 00:00:00", "acceptedDate": "2025-05-05 16:00:34", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000114/0000078003-25-000114-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000114/pfe-20250330.htm"}}
{"date": "2025-05-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-05-02 00:00:00", "acceptedDate": "2025-05-02 13:35:56", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004556/0001225208-25-004556-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004556/xslF345X05/doc4.xml"}}
{"date": "2025-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-29 00:00:00", "acceptedDate": "2025-04-29 08:02:49", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000111/0000078003-25-000111-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000111/pfe-03302025xex99.htm"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 16:24:01", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000109/0000078003-25-000109-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000109/pfe-20250424.htm"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 11:55:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004464/0001225208-25-004464-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004464/xslF345X05/doc4.xml"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 11:55:18", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004463/0001225208-25-004463-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004463/xslF345X05/doc4.xml"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 11:54:13", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004462/0001225208-25-004462-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004462/xslF345X05/doc4.xml"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 11:54:12", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004461/0001225208-25-004461-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004461/xslF345X05/doc4.xml"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 11:53:07", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004460/0001225208-25-004460-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004460/xslF345X05/doc4.xml"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 11:53:06", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004459/0001225208-25-004459-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004459/xslF345X05/doc4.xml"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 11:53:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004458/0001225208-25-004458-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004458/xslF345X05/doc4.xml"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 11:53:03", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004457/0001225208-25-004457-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004457/xslF345X05/doc4.xml"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 11:46:36", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004455/0001225208-25-004455-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004455/xslF345X05/doc4.xml"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 11:45:32", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004454/0001225208-25-004454-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004454/xslF345X05/doc4.xml"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 11:45:30", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004453/0001225208-25-004453-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004453/xslF345X05/doc4.xml"}}
{"date": "2025-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-28 00:00:00", "acceptedDate": "2025-04-28 11:45:29", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004452/0001225208-25-004452-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004452/xslF345X05/doc4.xml"}}
{"date": "2025-04-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-17 00:00:00", "acceptedDate": "2025-04-17 15:15:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004260/0001225208-25-004260-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004260/xslF345X05/doc4.xml"}}
{"date": "2025-04-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-14 00:00:00", "acceptedDate": "2025-04-14 15:52:02", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004225/0001225208-25-004225-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825004225/xslF345X05/doc4.xml"}}
{"date": "2025-04-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-11 00:00:00", "acceptedDate": "2025-04-11 10:09:54", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000102/0000078003-25-000102-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000102/supplemental041125.htm"}}
{"date": "2025-04-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-10 00:00:00", "acceptedDate": "2025-04-10 08:36:11", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000098/0000078003-25-000098-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000098/supplementalc041025.htm"}}
{"date": "2025-04-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-10 00:00:00", "acceptedDate": "2025-04-10 08:31:26", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000095/0000078003-25-000095-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000095/supplementalb041025.htm"}}
{"date": "2025-04-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-10 00:00:00", "acceptedDate": "2025-04-10 08:22:24", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000092/0000078003-25-000092-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000092/supplementala041025.htm"}}
{"date": "2025-04-07", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-07 00:00:00", "acceptedDate": "2025-04-07 16:56:39", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000083/0000078003-25-000083-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000083/supplemental040725.htm"}}
{"date": "2025-04-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-02 00:00:00", "acceptedDate": "2025-04-02 17:10:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003919/0001225208-25-003919-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003919/xslF345X05/doc4.xml"}}
{"date": "2025-04-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-02 00:00:00", "acceptedDate": "2025-04-02 17:09:45", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003918/0001225208-25-003918-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003918/xslF345X05/doc4.xml"}}
{"date": "2025-04-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-02 00:00:00", "acceptedDate": "2025-04-02 17:09:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003917/0001225208-25-003917-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003917/xslF345X05/doc4.xml"}}
{"date": "2025-04-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-02 00:00:00", "acceptedDate": "2025-04-02 17:09:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003916/0001225208-25-003916-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003916/xslF345X05/doc4.xml"}}
{"date": "2025-04-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-02 00:00:00", "acceptedDate": "2025-04-02 17:09:41", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003915/0001225208-25-003915-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003915/xslF345X05/doc4.xml"}}
{"date": "2025-04-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-04-02 00:00:00", "acceptedDate": "2025-04-02 17:09:40", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003914/0001225208-25-003914-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003914/xslF345X05/doc4.xml"}}
{"date": "2025-03-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-25 00:00:00", "acceptedDate": "2025-03-25 17:30:37", "formType": "PX14A6G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000121465925004772/0001214659-25-004772-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000121465925004772/b325252px14a6g.htm"}}
{"date": "2025-03-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-24 00:00:00", "acceptedDate": "2025-03-24 18:55:30", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000079/0000078003-25-000079-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000079/xslSCHEDULE_13D_X01/primary_doc.xml"}}
{"date": "2025-03-20", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-20 00:00:00", "acceptedDate": "2025-03-20 12:20:36", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000074/0000078003-25-000074-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000074/xslSCHEDULE_13D_X01/primary_doc.xml"}}
{"date": "2025-03-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-18 00:00:00", "acceptedDate": "2025-03-18 15:04:53", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003451/0001225208-25-003451-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003451/xslF345X05/doc4.xml"}}
{"date": "2025-03-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-13 00:00:00", "acceptedDate": "2025-03-13 13:28:25", "formType": "ARS", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000066/0000078003-25-000066-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000066/pfe-ars2025.pdf"}}
{"date": "2025-03-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-13 00:00:00", "acceptedDate": "2025-03-13 13:21:29", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000064/0000078003-25-000064-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000064/pfizer2025noticeandaccess.htm"}}
{"date": "2025-03-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-13 00:00:00", "acceptedDate": "2025-03-13 13:11:58", "formType": "DEF 14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000062/0000078003-25-000062-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000062/pfe-20250313.htm"}}
{"date": "2025-03-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-06 00:00:00", "acceptedDate": "2025-03-06 13:59:09", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003077/0001225208-25-003077-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003077/xslF345X05/doc4.xml"}}
{"date": "2025-03-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-06 00:00:00", "acceptedDate": "2025-03-06 13:58:02", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003076/0001225208-25-003076-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003076/xslF345X05/doc4.xml"}}
{"date": "2025-03-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-06 00:00:00", "acceptedDate": "2025-03-06 13:58:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003075/0001225208-25-003075-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003075/xslF345X05/doc4.xml"}}
{"date": "2025-03-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-06 00:00:00", "acceptedDate": "2025-03-06 13:57:58", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003074/0001225208-25-003074-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003074/xslF345X05/doc4.xml"}}
{"date": "2025-03-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-06 00:00:00", "acceptedDate": "2025-03-06 13:57:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003073/0001225208-25-003073-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003073/xslF345X05/doc4.xml"}}
{"date": "2025-03-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-06 00:00:00", "acceptedDate": "2025-03-06 13:56:51", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003072/0001225208-25-003072-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003072/xslF345X05/doc4.xml"}}
{"date": "2025-03-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-06 00:00:00", "acceptedDate": "2025-03-06 13:54:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003071/0001225208-25-003071-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003071/xslF345X05/doc4.xml"}}
{"date": "2025-03-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-06 00:00:00", "acceptedDate": "2025-03-06 13:49:22", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003070/0001225208-25-003070-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003070/xslF345X05/doc4.xml"}}
{"date": "2025-03-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-06 00:00:00", "acceptedDate": "2025-03-06 13:48:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003068/0001225208-25-003068-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003068/xslF345X05/doc4.xml"}}
{"date": "2025-03-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-06 00:00:00", "acceptedDate": "2025-03-06 13:48:18", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003067/0001225208-25-003067-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003067/xslF345X05/doc4.xml"}}
{"date": "2025-03-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-06 00:00:00", "acceptedDate": "2025-03-06 13:47:15", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003064/0001225208-25-003064-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003064/xslF345X05/doc4.xml"}}
{"date": "2025-03-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-06 00:00:00", "acceptedDate": "2025-03-06 13:47:13", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003063/0001225208-25-003063-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825003063/xslF345X05/doc4.xml"}}
{"date": "2025-03-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-03 00:00:00", "acceptedDate": "2025-03-03 17:39:55", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002710/0001225208-25-002710-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002710/xslF345X05/doc4.xml"}}
{"date": "2025-03-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-03 00:00:00", "acceptedDate": "2025-03-03 17:39:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002709/0001225208-25-002709-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002709/xslF345X05/doc4.xml"}}
{"date": "2025-03-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-03 00:00:00", "acceptedDate": "2025-03-03 17:38:46", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002708/0001225208-25-002708-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002708/xslF345X05/doc4.xml"}}
{"date": "2025-03-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-03 00:00:00", "acceptedDate": "2025-03-03 17:38:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002707/0001225208-25-002707-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002707/xslF345X05/doc4.xml"}}
{"date": "2025-03-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-03 00:00:00", "acceptedDate": "2025-03-03 17:37:40", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002706/0001225208-25-002706-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002706/xslF345X05/doc4.xml"}}
{"date": "2025-03-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-03 00:00:00", "acceptedDate": "2025-03-03 17:37:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002705/0001225208-25-002705-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002705/xslF345X05/doc4.xml"}}
{"date": "2025-03-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-03 00:00:00", "acceptedDate": "2025-03-03 17:36:36", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002704/0001225208-25-002704-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002704/xslF345X05/doc4.xml"}}
{"date": "2025-03-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-03 00:00:00", "acceptedDate": "2025-03-03 17:36:32", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002703/0001225208-25-002703-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002703/xslF345X05/doc4.xml"}}
{"date": "2025-03-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-03 00:00:00", "acceptedDate": "2025-03-03 17:33:20", "formType": "4/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002702/0001225208-25-002702-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002702/xslF345X05/doc4a.xml"}}
{"date": "2025-03-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-03-03 00:00:00", "acceptedDate": "2025-03-03 17:31:12", "formType": "4/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002701/0001225208-25-002701-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002701/xslF345X05/doc4a.xml"}}
{"date": "2025-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-28 00:00:00", "acceptedDate": "2025-02-28 12:46:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002613/0001225208-25-002613-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002613/xslF345X05/doc4.xml"}}
{"date": "2025-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-28 00:00:00", "acceptedDate": "2025-02-28 12:41:14", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002612/0001225208-25-002612-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002612/xslF345X05/doc4.xml"}}
{"date": "2025-02-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-27 00:00:00", "acceptedDate": "2025-02-27 16:27:18", "formType": "10-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/0000078003-25-000054-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm"}}
{"date": "2025-02-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-27 00:00:00", "acceptedDate": "2025-02-27 10:39:33", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000052/0000078003-25-000052-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000052/xslSCHEDULE_13D_X01/primary_doc.xml"}}
{"date": "2025-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-25 00:00:00", "acceptedDate": "2025-02-25 19:38:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002413/0001225208-25-002413-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002413/xslF345X05/doc4.xml"}}
{"date": "2025-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-25 00:00:00", "acceptedDate": "2025-02-25 19:38:18", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002412/0001225208-25-002412-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002412/xslF345X05/doc4.xml"}}
{"date": "2025-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-25 00:00:00", "acceptedDate": "2025-02-25 19:06:33", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002402/0001225208-25-002402-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002402/xslF345X05/doc4.xml"}}
{"date": "2025-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-25 00:00:00", "acceptedDate": "2025-02-25 19:05:31", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002401/0001225208-25-002401-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002401/xslF345X05/doc4.xml"}}
{"date": "2025-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-25 00:00:00", "acceptedDate": "2025-02-25 19:04:28", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002400/0001225208-25-002400-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002400/xslF345X05/doc4.xml"}}
{"date": "2025-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-25 00:00:00", "acceptedDate": "2025-02-25 19:02:25", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002399/0001225208-25-002399-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002399/xslF345X05/doc4.xml"}}
{"date": "2025-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-25 00:00:00", "acceptedDate": "2025-02-25 18:58:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002397/0001225208-25-002397-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825002397/xslF345X05/doc4.xml"}}
{"date": "2025-02-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-18 00:00:00", "acceptedDate": "2025-02-18 11:23:37", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825001805/0001225208-25-001805-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825001805/xslF345X05/doc4.xml"}}
{"date": "2025-02-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-14 00:00:00", "acceptedDate": "2025-02-14 17:16:36", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825001778/0001225208-25-001778-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825001778/xslF345X05/doc4.xml"}}
{"date": "2025-02-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-14 00:00:00", "acceptedDate": "2025-02-14 14:08:16", "formType": "13F-HR", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000048/0000078003-25-000048-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000048/information_table.xml"}}
{"date": "2025-02-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-12 00:00:00", "acceptedDate": "2025-02-12 14:51:21", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000042/0000078003-25-000042-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000042/xslSCHEDULE_13G_X01/primary_doc.xml"}}
{"date": "2025-02-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-12 00:00:00", "acceptedDate": "2025-02-12 14:48:08", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000040/0000078003-25-000040-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000040/xslSCHEDULE_13G_X01/primary_doc.xml"}}
{"date": "2025-02-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-04 00:00:00", "acceptedDate": "2025-02-04 13:04:16", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825001142/0001225208-25-001142-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825001142/xslF345X05/doc4.xml"}}
{"date": "2025-02-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-02-04 00:00:00", "acceptedDate": "2025-02-04 08:11:20", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000017/0000078003-25-000017-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000017/pfe-12312024xex99.htm"}}
{"date": "2025-01-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-01-21 00:00:00", "acceptedDate": "2025-01-21 18:26:15", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000013/0000078003-25-000013-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000013/xslSCHEDULE_13D_X01/primary_doc.xml"}}
{"date": "2025-01-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-01-16 00:00:00", "acceptedDate": "2025-01-16 16:34:29", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000005/0000078003-25-000005-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800325000005/xslSCHEDULE_13D_X01/primary_doc.xml"}}
{"date": "2025-01-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-01-15 00:00:00", "acceptedDate": "2025-01-15 14:48:31", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000644/0001225208-25-000644-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000644/xslF345X05/doc4.xml"}}
{"date": "2025-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-01-03 00:00:00", "acceptedDate": "2025-01-03 13:27:09", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000134/0001225208-25-000134-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000134/xslF345X05/doc4.xml"}}
{"date": "2025-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-01-03 00:00:00", "acceptedDate": "2025-01-03 13:25:06", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000133/0001225208-25-000133-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000133/xslF345X05/doc4.xml"}}
{"date": "2025-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-01-03 00:00:00", "acceptedDate": "2025-01-03 13:24:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000132/0001225208-25-000132-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000132/xslF345X05/doc4.xml"}}
{"date": "2025-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-01-03 00:00:00", "acceptedDate": "2025-01-03 11:50:07", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000121/0001225208-25-000121-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000121/xslF345X05/doc4.xml"}}
{"date": "2025-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-01-03 00:00:00", "acceptedDate": "2025-01-03 11:47:55", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000120/0001225208-25-000120-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000120/xslF345X05/doc4.xml"}}
{"date": "2025-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-01-03 00:00:00", "acceptedDate": "2025-01-03 11:47:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000119/0001225208-25-000119-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000119/xslF345X05/doc4.xml"}}
{"date": "2025-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2025-01-03 00:00:00", "acceptedDate": "2025-01-03 09:49:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000085/0001225208-25-000085-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520825000085/xslF345X05/doc4.xml"}}
{"date": "2024-12-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-12-17 00:00:00", "acceptedDate": "2024-12-17 17:20:01", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824010893/0001225208-24-010893-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824010893/xslF345X05/doc4.xml"}}
{"date": "2024-12-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-12-17 00:00:00", "acceptedDate": "2024-12-17 08:05:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824010859/0001225208-24-010859-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824010859/xslF345X05/doc4.xml"}}
{"date": "2024-12-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-12-17 00:00:00", "acceptedDate": "2024-12-17 07:47:10", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000195/0000078003-24-000195-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000195/pfe-12172024xexh99.htm"}}
{"date": "2024-12-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-12-02 00:00:00", "acceptedDate": "2024-12-02 16:18:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824010308/0001225208-24-010308-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824010308/xslF345X05/doc4.xml"}}
{"date": "2024-12-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-12-02 00:00:00", "acceptedDate": "2024-12-02 16:18:17", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824010307/0001225208-24-010307-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824010307/xslF345X05/doc4.xml"}}
{"date": "2024-11-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-11-18 00:00:00", "acceptedDate": "2024-11-18 16:30:12", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824010030/0001225208-24-010030-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824010030/xslF345X05/doc4.xml"}}
{"date": "2024-11-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-11-18 00:00:00", "acceptedDate": "2024-11-18 16:30:10", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824010029/0001225208-24-010029-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824010029/xslF345X05/doc4.xml"}}
{"date": "2024-11-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-11-04 00:00:00", "acceptedDate": "2024-11-04 16:06:08", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000191/0000078003-24-000191-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000191/pfe-20240929.htm"}}
{"date": "2024-11-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-11-01 00:00:00", "acceptedDate": "2024-11-01 15:23:51", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009558/0001225208-24-009558-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009558/xslF345X05/doc4.xml"}}
{"date": "2024-11-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-11-01 00:00:00", "acceptedDate": "2024-11-01 15:23:49", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009557/0001225208-24-009557-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009557/xslF345X05/doc4.xml"}}
{"date": "2024-10-31", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-31 00:00:00", "acceptedDate": "2024-10-31 16:06:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009545/0001225208-24-009545-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009545/xslF345X05/doc4.xml"}}
{"date": "2024-10-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-29 00:00:00", "acceptedDate": "2024-10-29 08:06:28", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000188/0000078003-24-000188-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000188/pfe-9292024xex99.htm"}}
{"date": "2024-10-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-16 00:00:00", "acceptedDate": "2024-10-16 16:51:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009329/0001225208-24-009329-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009329/xslF345X05/doc4.xml"}}
{"date": "2024-10-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-16 00:00:00", "acceptedDate": "2024-10-16 16:50:58", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009328/0001225208-24-009328-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009328/xslF345X05/doc4.xml"}}
{"date": "2024-10-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-15 00:00:00", "acceptedDate": "2024-10-15 17:44:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009305/0001225208-24-009305-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009305/xslF345X05/doc4.xml"}}
{"date": "2024-10-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-15 00:00:00", "acceptedDate": "2024-10-15 17:31:05", "formType": "3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009303/0001225208-24-009303-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009303/xslF345X02/doc3.xml"}}
{"date": "2024-10-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-15 00:00:00", "acceptedDate": "2024-10-15 07:18:26", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000185/0000078003-24-000185-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000185/ex99_pressreleasex1024v2.htm"}}
{"date": "2024-10-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-11 00:00:00", "acceptedDate": "2024-10-11 14:01:59", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009264/0001225208-24-009264-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009264/xslF345X05/doc4.xml"}}
{"date": "2024-10-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-11 00:00:00", "acceptedDate": "2024-10-11 14:01:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009263/0001225208-24-009263-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824009263/xslF345X05/doc4.xml"}}
{"date": "2024-10-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-03 00:00:00", "acceptedDate": "2024-10-03 18:59:16", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000183/0000078003-24-000183-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000183/a13d-a10_10324.htm"}}
{"date": "2024-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-02 00:00:00", "acceptedDate": "2024-10-02 15:43:50", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008996/0001225208-24-008996-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008996/xslF345X05/doc4.xml"}}
{"date": "2024-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-02 00:00:00", "acceptedDate": "2024-10-02 15:43:49", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008995/0001225208-24-008995-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008995/xslF345X05/doc4.xml"}}
{"date": "2024-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-02 00:00:00", "acceptedDate": "2024-10-02 15:43:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008994/0001225208-24-008994-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008994/xslF345X05/doc4.xml"}}
{"date": "2024-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-02 00:00:00", "acceptedDate": "2024-10-02 15:43:46", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008993/0001225208-24-008993-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008993/xslF345X05/doc4.xml"}}
{"date": "2024-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-02 00:00:00", "acceptedDate": "2024-10-02 15:43:45", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008992/0001225208-24-008992-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008992/xslF345X05/doc4.xml"}}
{"date": "2024-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-02 00:00:00", "acceptedDate": "2024-10-02 11:25:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008955/0001225208-24-008955-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008955/xslF345X05/doc4.xml"}}
{"date": "2024-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-02 00:00:00", "acceptedDate": "2024-10-02 11:25:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008954/0001225208-24-008954-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008954/xslF345X05/doc4.xml"}}
{"date": "2024-10-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-10-01 00:00:00", "acceptedDate": "2024-10-01 19:38:46", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000179/0000078003-24-000179-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000179/sch13a_9-930.htm"}}
{"date": "2024-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-16 00:00:00", "acceptedDate": "2024-09-16 13:12:31", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008709/0001225208-24-008709-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008709/xslF345X05/doc4.xml"}}
{"date": "2024-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-16 00:00:00", "acceptedDate": "2024-09-16 13:11:27", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008708/0001225208-24-008708-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008708/xslF345X05/doc4.xml"}}
{"date": "2024-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-16 00:00:00", "acceptedDate": "2024-09-16 13:06:10", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008707/0001225208-24-008707-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008707/xslF345X05/doc4.xml"}}
{"date": "2024-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-16 00:00:00", "acceptedDate": "2024-09-16 13:04:04", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008706/0001225208-24-008706-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008706/xslF345X05/doc4.xml"}}
{"date": "2024-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-16 00:00:00", "acceptedDate": "2024-09-16 12:57:45", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008705/0001225208-24-008705-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008705/xslF345X05/doc4.xml"}}
{"date": "2024-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-16 00:00:00", "acceptedDate": "2024-09-16 12:56:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008704/0001225208-24-008704-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008704/xslF345X05/doc4.xml"}}
{"date": "2024-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-16 00:00:00", "acceptedDate": "2024-09-16 12:54:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008703/0001225208-24-008703-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008703/xslF345X05/doc4.xml"}}
{"date": "2024-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-16 00:00:00", "acceptedDate": "2024-09-16 12:53:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008702/0001225208-24-008702-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008702/xslF345X05/doc4.xml"}}
{"date": "2024-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-16 00:00:00", "acceptedDate": "2024-09-16 12:52:32", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008701/0001225208-24-008701-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008701/xslF345X05/doc4.xml"}}
{"date": "2024-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-16 00:00:00", "acceptedDate": "2024-09-16 12:47:25", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008700/0001225208-24-008700-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008700/xslF345X05/doc4.xml"}}
{"date": "2024-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-16 00:00:00", "acceptedDate": "2024-09-16 12:45:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008699/0001225208-24-008699-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008699/xslF345X05/doc4.xml"}}
{"date": "2024-09-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-13 00:00:00", "acceptedDate": "2024-09-13 16:49:43", "formType": "SC TO-I/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000175/0000078003-24-000175-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000175/pfe_toa2.htm"}}
{"date": "2024-09-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-03 00:00:00", "acceptedDate": "2024-09-03 18:10:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008338/0001225208-24-008338-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008338/xslF345X05/doc4.xml"}}
{"date": "2024-09-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-03 00:00:00", "acceptedDate": "2024-09-03 18:05:31", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008337/0001225208-24-008337-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008337/xslF345X05/doc4.xml"}}
{"date": "2024-09-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-09-03 00:00:00", "acceptedDate": "2024-09-03 18:05:28", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008336/0001225208-24-008336-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008336/xslF345X05/doc4.xml"}}
{"date": "2024-08-22", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-22 00:00:00", "acceptedDate": "2024-08-22 11:17:10", "formType": "SC TO-I/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000093041324002369/0000930413-24-002369-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000093041324002369/c109722_sctoia.htm"}}
{"date": "2024-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-16 00:00:00", "acceptedDate": "2024-08-16 15:19:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008042/0001225208-24-008042-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008042/xslF345X05/doc4.xml"}}
{"date": "2024-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-16 00:00:00", "acceptedDate": "2024-08-16 15:19:56", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008041/0001225208-24-008041-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008041/xslF345X05/doc4.xml"}}
{"date": "2024-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-16 00:00:00", "acceptedDate": "2024-08-16 15:19:55", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008040/0001225208-24-008040-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008040/xslF345X05/doc4.xml"}}
{"date": "2024-08-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-14 00:00:00", "acceptedDate": "2024-08-14 15:47:13", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008006/0001225208-24-008006-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824008006/xslF345X05/doc4.xml"}}
{"date": "2024-08-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-12 00:00:00", "acceptedDate": "2024-08-12 11:42:23", "formType": "SC TO-I", "link": "https://www.sec.gov/Archives/edgar/data/78003/000093041324002290/0000930413-24-002290-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000093041324002290/c109722_sctoi.htm"}}
{"date": "2024-08-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-05 00:00:00", "acceptedDate": "2024-08-05 18:25:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000169/0000078003-24-000169-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000169/xslF345X05/primary_doc.xml"}}
{"date": "2024-08-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-05 00:00:00", "acceptedDate": "2024-08-05 18:12:07", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000168/0000078003-24-000168-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000168/sch13acere8124.htm"}}
{"date": "2024-08-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-05 00:00:00", "acceptedDate": "2024-08-05 15:54:43", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000166/0000078003-24-000166-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000166/pfe-20240630.htm"}}
{"date": "2024-08-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-02 00:00:00", "acceptedDate": "2024-08-02 11:37:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007794/0001225208-24-007794-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007794/xslF345X05/doc4.xml"}}
{"date": "2024-08-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-02 00:00:00", "acceptedDate": "2024-08-02 11:37:21", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007793/0001225208-24-007793-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007793/xslF345X05/doc4.xml"}}
{"date": "2024-08-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-02 00:00:00", "acceptedDate": "2024-08-02 11:37:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007792/0001225208-24-007792-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007792/xslF345X05/doc4.xml"}}
{"date": "2024-08-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-02 00:00:00", "acceptedDate": "2024-08-02 09:49:36", "formType": "3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007789/0001225208-24-007789-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007789/xslF345X02/doc3.xml"}}
{"date": "2024-08-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-08-01 00:00:00", "acceptedDate": "2024-07-31 19:30:26", "formType": "SC TO-C", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000162/0000078003-24-000162-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000162/scto-c_pre731.htm"}}
{"date": "2024-07-30", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-30 00:00:00", "acceptedDate": "2024-07-30 17:17:25", "formType": "SC TO-C", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000159/0000078003-24-000159-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000159/scto-c_pre730.htm"}}
{"date": "2024-07-30", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-30 00:00:00", "acceptedDate": "2024-07-30 08:04:27", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000155/0000078003-24-000155-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000155/pfe-6302024xex99.htm"}}
{"date": "2024-07-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-29 00:00:00", "acceptedDate": "2024-07-29 16:33:42", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000153/0000078003-24-000153-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000153/sch13da-july2024.htm"}}
{"date": "2024-07-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-26 00:00:00", "acceptedDate": "2024-07-26 11:13:42", "formType": "SC TO-C", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000146/0000078003-24-000146-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000146/pfe8k72424.htm"}}
{"date": "2024-07-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-26 00:00:00", "acceptedDate": "2024-07-26 11:09:20", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000144/0000078003-24-000144-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000144/tsruex991.htm"}}
{"date": "2024-07-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-16 00:00:00", "acceptedDate": "2024-07-16 17:28:06", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007464/0001225208-24-007464-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007464/xslF345X05/doc4.xml"}}
{"date": "2024-07-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-16 00:00:00", "acceptedDate": "2024-07-16 17:28:04", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007463/0001225208-24-007463-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007463/xslF345X05/doc4.xml"}}
{"date": "2024-07-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-16 00:00:00", "acceptedDate": "2024-07-16 17:28:03", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007462/0001225208-24-007462-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007462/xslF345X05/doc4.xml"}}
{"date": "2024-07-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-12 00:00:00", "acceptedDate": "2024-07-12 13:24:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007406/0001225208-24-007406-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007406/xslF345X05/doc4.xml"}}
{"date": "2024-07-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-12 00:00:00", "acceptedDate": "2024-07-12 13:24:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007405/0001225208-24-007405-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007405/xslF345X05/doc4.xml"}}
{"date": "2024-07-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-12 00:00:00", "acceptedDate": "2024-07-12 13:24:17", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007404/0001225208-24-007404-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007404/xslF345X05/doc4.xml"}}
{"date": "2024-07-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-10 00:00:00", "acceptedDate": "2024-07-10 16:11:00", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000130/0000078003-24-000130-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000130/0000078003-24-000130.txt"}}
{"date": "2024-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-01 00:00:00", "acceptedDate": "2024-07-01 20:44:01", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007124/0001225208-24-007124-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007124/xslF345X05/doc4.xml"}}
{"date": "2024-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-01 00:00:00", "acceptedDate": "2024-07-01 20:43:59", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007123/0001225208-24-007123-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007123/xslF345X05/doc4.xml"}}
{"date": "2024-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-01 00:00:00", "acceptedDate": "2024-07-01 20:43:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007122/0001225208-24-007122-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007122/xslF345X05/doc4.xml"}}
{"date": "2024-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-01 00:00:00", "acceptedDate": "2024-07-01 20:43:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007121/0001225208-24-007121-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007121/xslF345X05/doc4.xml"}}
{"date": "2024-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-01 00:00:00", "acceptedDate": "2024-07-01 19:28:51", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007120/0001225208-24-007120-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007120/xslF345X05/doc4.xml"}}
{"date": "2024-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-01 00:00:00", "acceptedDate": "2024-07-01 19:20:39", "formType": "3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007119/0001225208-24-007119-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007119/xslF345X02/doc3.xml"}}
{"date": "2024-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-01 00:00:00", "acceptedDate": "2024-07-01 13:15:21", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007065/0001225208-24-007065-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007065/xslF345X05/doc4.xml"}}
{"date": "2024-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-01 00:00:00", "acceptedDate": "2024-07-01 13:15:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007064/0001225208-24-007064-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007064/xslF345X05/doc4.xml"}}
{"date": "2024-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-01 00:00:00", "acceptedDate": "2024-07-01 13:15:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007063/0001225208-24-007063-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824007063/xslF345X05/doc4.xml"}}
{"date": "2024-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-07-01 00:00:00", "acceptedDate": "2024-07-01 08:07:18", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000127/0000078003-24-000127-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000127/exh99_pressrelease7124.htm"}}
{"date": "2024-06-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-06-17 00:00:00", "acceptedDate": "2024-06-17 21:41:51", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006887/0001225208-24-006887-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006887/xslF345X05/doc4.xml"}}
{"date": "2024-06-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-06-17 00:00:00", "acceptedDate": "2024-06-17 21:41:49", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006886/0001225208-24-006886-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006886/xslF345X05/doc4.xml"}}
{"date": "2024-06-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-06-11 00:00:00", "acceptedDate": "2024-06-11 14:43:52", "formType": "11-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000124/0000078003-24-000124-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000124/pfizersavingsplanforemploy.htm"}}
{"date": "2024-06-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-06-11 00:00:00", "acceptedDate": "2024-06-11 14:39:34", "formType": "11-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000122/0000078003-24-000122-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000122/pfizersavingsplan2023.htm"}}
{"date": "2024-06-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-06-04 00:00:00", "acceptedDate": "2024-06-04 17:02:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006587/0001225208-24-006587-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006587/xslF345X05/doc4.xml"}}
{"date": "2024-06-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-06-04 00:00:00", "acceptedDate": "2024-06-04 17:02:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006586/0001225208-24-006586-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006586/xslF345X05/doc4.xml"}}
{"date": "2024-06-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-06-03 00:00:00", "acceptedDate": "2024-06-03 18:34:09", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006527/0001225208-24-006527-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006527/xslF345X05/doc4.xml"}}
{"date": "2024-05-31", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-05-31 00:00:00", "acceptedDate": "2024-05-31 12:15:11", "formType": "SD", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000116/0000078003-24-000116-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000116/pfizerformsdfye2023wd.htm"}}
{"date": "2024-05-22", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-05-22 00:00:00", "acceptedDate": "2024-05-22 12:39:37", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000113/0000078003-24-000113-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000113/0000078003-24-000113.txt"}}
{"date": "2024-05-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-05-16 00:00:00", "acceptedDate": "2024-05-16 11:55:06", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006071/0001225208-24-006071-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006071/xslF345X05/doc4.xml"}}
{"date": "2024-05-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-05-16 00:00:00", "acceptedDate": "2024-05-16 11:55:03", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006070/0001225208-24-006070-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824006070/xslF345X05/doc4.xml"}}
{"date": "2024-05-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-05-09 00:00:00", "acceptedDate": "2024-05-09 09:01:36", "formType": "S-8", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000110/0000078003-24-000110-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000110/forms-8ar2019plan_52024.htm"}}
{"date": "2024-05-08", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-05-08 00:00:00", "acceptedDate": "2024-05-08 15:56:17", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000107/0000078003-24-000107-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000107/pfe-20240331.htm"}}
{"date": "2024-05-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-05-01 00:00:00", "acceptedDate": "2024-05-01 15:37:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005424/0001225208-24-005424-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005424/xslF345X05/doc4.xml"}}
{"date": "2024-05-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-05-01 00:00:00", "acceptedDate": "2024-05-01 15:37:55", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005423/0001225208-24-005423-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005423/xslF345X05/doc4.xml"}}
{"date": "2024-05-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-05-01 00:00:00", "acceptedDate": "2024-05-01 08:11:26", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000103/0000078003-24-000103-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000103/pfe-3312024xex99.htm"}}
{"date": "2024-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-29 00:00:00", "acceptedDate": "2024-04-29 10:19:15", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000101/0000078003-24-000101-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000101/0000078003-24-000101.txt"}}
{"date": "2024-04-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-26 00:00:00", "acceptedDate": "2024-04-26 13:23:31", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005276/0001225208-24-005276-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005276/xslF345X05/doc4.xml"}}
{"date": "2024-04-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-26 00:00:00", "acceptedDate": "2024-04-26 13:23:29", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005277/0001225208-24-005277-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005277/xslF345X05/doc4.xml"}}
{"date": "2024-04-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-26 00:00:00", "acceptedDate": "2024-04-26 13:23:26", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005275/0001225208-24-005275-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005275/xslF345X05/doc4.xml"}}
{"date": "2024-04-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-26 00:00:00", "acceptedDate": "2024-04-26 13:23:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005274/0001225208-24-005274-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005274/xslF345X05/doc4.xml"}}
{"date": "2024-04-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-26 00:00:00", "acceptedDate": "2024-04-26 13:23:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005272/0001225208-24-005272-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005272/xslF345X05/doc4.xml"}}
{"date": "2024-04-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-26 00:00:00", "acceptedDate": "2024-04-26 13:23:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005273/0001225208-24-005273-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005273/xslF345X05/doc4.xml"}}
{"date": "2024-04-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-26 00:00:00", "acceptedDate": "2024-04-26 13:23:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005271/0001225208-24-005271-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005271/xslF345X05/doc4.xml"}}
{"date": "2024-04-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-26 00:00:00", "acceptedDate": "2024-04-26 13:23:16", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005270/0001225208-24-005270-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005270/xslF345X05/doc4.xml"}}
{"date": "2024-04-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-26 00:00:00", "acceptedDate": "2024-04-26 13:23:13", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005269/0001225208-24-005269-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005269/xslF345X05/doc4.xml"}}
{"date": "2024-04-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-26 00:00:00", "acceptedDate": "2024-04-26 13:23:10", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005268/0001225208-24-005268-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005268/xslF345X05/doc4.xml"}}
{"date": "2024-04-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-26 00:00:00", "acceptedDate": "2024-04-26 13:21:04", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005267/0001225208-24-005267-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005267/xslF345X05/doc4.xml"}}
{"date": "2024-04-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-16 00:00:00", "acceptedDate": "2024-04-16 13:49:59", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005065/0001225208-24-005065-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005065/xslF345X05/doc4.xml"}}
{"date": "2024-04-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-16 00:00:00", "acceptedDate": "2024-04-16 13:49:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005064/0001225208-24-005064-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005064/xslF345X05/doc4.xml"}}
{"date": "2024-04-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-16 00:00:00", "acceptedDate": "2024-04-16 10:19:48", "formType": "PX14A6G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000121465924006888/0001214659-24-006888-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000121465924006888/o415249px14a6g.htm"}}
{"date": "2024-04-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-11 00:00:00", "acceptedDate": "2024-04-11 14:51:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005034/0001225208-24-005034-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005034/xslF345X05/doc4.xml"}}
{"date": "2024-04-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-11 00:00:00", "acceptedDate": "2024-04-11 14:51:50", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005033/0001225208-24-005033-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824005033/xslF345X05/doc4.xml"}}
{"date": "2024-04-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-11 00:00:00", "acceptedDate": "2024-04-11 11:00:39", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000097/0000078003-24-000097-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000097/pfe3inv.htm"}}
{"date": "2024-04-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-11 00:00:00", "acceptedDate": "2024-04-11 10:59:03", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000096/0000078003-24-000096-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000096/pfe2inv.htm"}}
{"date": "2024-04-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-11 00:00:00", "acceptedDate": "2024-04-11 10:57:34", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000095/0000078003-24-000095-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000095/pfe1inv.htm"}}
{"date": "2024-04-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-09 00:00:00", "acceptedDate": "2024-04-09 10:29:32", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000094/0000078003-24-000094-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000094/votereminder24_defax14a.htm"}}
{"date": "2024-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-01 00:00:00", "acceptedDate": "2024-04-01 19:44:59", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004695/0001225208-24-004695-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004695/xslF345X05/doc4.xml"}}
{"date": "2024-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-01 00:00:00", "acceptedDate": "2024-04-01 19:33:39", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004693/0001225208-24-004693-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004693/xslF345X05/doc4.xml"}}
{"date": "2024-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-01 00:00:00", "acceptedDate": "2024-04-01 13:32:36", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004643/0001225208-24-004643-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004643/xslF345X05/doc4.xml"}}
{"date": "2024-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-01 00:00:00", "acceptedDate": "2024-04-01 13:32:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004641/0001225208-24-004641-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004641/xslF345X05/doc4.xml"}}
{"date": "2024-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-01 00:00:00", "acceptedDate": "2024-04-01 13:32:31", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004642/0001225208-24-004642-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004642/xslF345X05/doc4.xml"}}
{"date": "2024-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-04-01 00:00:00", "acceptedDate": "2024-04-01 13:32:28", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004640/0001225208-24-004640-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004640/xslF345X05/doc4.xml"}}
{"date": "2024-03-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-03-28 00:00:00", "acceptedDate": "2024-03-28 16:19:36", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000088/0000078003-24-000088-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000088/pfizer-supplementalfiling3.htm"}}
{"date": "2024-03-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-03-28 00:00:00", "acceptedDate": "2024-03-28 16:10:07", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000086/0000078003-24-000086-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000086/pfe_-xproxyxsupplement1224.htm"}}
{"date": "2024-03-22", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-03-22 00:00:00", "acceptedDate": "2024-03-22 09:05:38", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000082/0000078003-24-000082-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000082/hln13d-a7.htm"}}
{"date": "2024-03-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-03-19 00:00:00", "acceptedDate": "2024-03-19 20:48:01", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000080/0000078003-24-000080-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000080/hln13d-a31924.htm"}}
{"date": "2024-03-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-03-18 00:00:00", "acceptedDate": "2024-03-18 18:39:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004294/0001225208-24-004294-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004294/xslF345X05/doc4.xml"}}
{"date": "2024-03-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-03-18 00:00:00", "acceptedDate": "2024-03-18 18:39:41", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004293/0001225208-24-004293-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824004293/xslF345X05/doc4.xml"}}
{"date": "2024-03-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-03-15 00:00:00", "acceptedDate": "2024-03-15 07:45:13", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000075/0000078003-24-000075-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000075/tourmalinebioschedule13ga3.htm"}}
{"date": "2024-03-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-03-14 00:00:00", "acceptedDate": "2024-03-14 09:12:34", "formType": "ARS", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000072/0000078003-24-000072-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000072/arsatt24.pdf"}}
{"date": "2024-03-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-03-14 00:00:00", "acceptedDate": "2024-03-14 09:07:17", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000070/0000078003-24-000070-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000070/noticeaccess2024.htm"}}
{"date": "2024-03-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-03-14 00:00:00", "acceptedDate": "2024-03-14 09:03:08", "formType": "DEF 14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000068/0000078003-24-000068-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000068/pfe-20240313.htm"}}
{"date": "2024-03-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-03-05 00:00:00", "acceptedDate": "2024-03-05 15:55:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003584/0001225208-24-003584-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003584/xslF345X05/doc4.xml"}}
{"date": "2024-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-03-01 00:00:00", "acceptedDate": "2024-03-01 13:28:14", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003340/0001225208-24-003340-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003340/xslF345X05/doc4.xml"}}
{"date": "2024-02-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-29 00:00:00", "acceptedDate": "2024-02-29 06:53:32", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003244/0001225208-24-003244-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003244/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 17:00:17", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003208/0001225208-24-003208-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003208/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 17:00:10", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003207/0001225208-24-003207-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003207/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 17:00:08", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003205/0001225208-24-003205-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003205/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 17:00:06", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003206/0001225208-24-003206-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003206/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 17:00:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003204/0001225208-24-003204-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003204/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 17:00:03", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003203/0001225208-24-003203-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003203/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 17:00:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003202/0001225208-24-003202-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003202/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 16:59:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003201/0001225208-24-003201-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003201/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 16:59:56", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003200/0001225208-24-003200-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003200/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 16:59:51", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003199/0001225208-24-003199-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003199/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 16:59:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003198/0001225208-24-003198-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003198/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 16:58:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003197/0001225208-24-003197-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003197/xslF345X05/doc4.xml"}}
{"date": "2024-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-28 00:00:00", "acceptedDate": "2024-02-28 16:58:40", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003196/0001225208-24-003196-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003196/xslF345X05/doc4.xml"}}
{"date": "2024-02-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-27 00:00:00", "acceptedDate": "2024-02-27 13:47:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003056/0001225208-24-003056-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003056/xslF345X05/doc4.xml"}}
{"date": "2024-02-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-27 00:00:00", "acceptedDate": "2024-02-27 13:46:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003055/0001225208-24-003055-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003055/xslF345X05/doc4.xml"}}
{"date": "2024-02-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-27 00:00:00", "acceptedDate": "2024-02-27 13:46:41", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003054/0001225208-24-003054-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003054/xslF345X05/doc4.xml"}}
{"date": "2024-02-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-27 00:00:00", "acceptedDate": "2024-02-27 13:46:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003053/0001225208-24-003053-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003053/xslF345X05/doc4.xml"}}
{"date": "2024-02-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-27 00:00:00", "acceptedDate": "2024-02-27 13:46:32", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003052/0001225208-24-003052-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003052/xslF345X05/doc4.xml"}}
{"date": "2024-02-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-27 00:00:00", "acceptedDate": "2024-02-27 13:46:28", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003051/0001225208-24-003051-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003051/xslF345X05/doc4.xml"}}
{"date": "2024-02-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-27 00:00:00", "acceptedDate": "2024-02-27 13:46:17", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003050/0001225208-24-003050-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003050/xslF345X05/doc4.xml"}}
{"date": "2024-02-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-27 00:00:00", "acceptedDate": "2024-02-27 13:46:16", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003049/0001225208-24-003049-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003049/xslF345X05/doc4.xml"}}
{"date": "2024-02-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-27 00:00:00", "acceptedDate": "2024-02-27 13:44:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003047/0001225208-24-003047-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824003047/xslF345X05/doc4.xml"}}
{"date": "2024-02-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-23 00:00:00", "acceptedDate": "2024-02-23 16:34:33", "formType": "S-3ASR", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312524044552/0001193125-24-044552-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312524044552/d718279ds3asr.htm"}}
{"date": "2024-02-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-23 00:00:00", "acceptedDate": "2024-02-23 16:33:25", "formType": "S-8", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000052/0000078003-24-000052-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000052/pfizers822324wd.htm"}}
{"date": "2024-02-22", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-22 00:00:00", "acceptedDate": "2024-02-22 13:17:37", "formType": "10-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000039/0000078003-24-000039-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000039/pfe-20231231.htm"}}
{"date": "2024-02-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-16 00:00:00", "acceptedDate": "2024-02-16 12:55:10", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824002267/0001225208-24-002267-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824002267/xslF345X05/doc4.xml"}}
{"date": "2024-02-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-16 00:00:00", "acceptedDate": "2024-02-16 12:53:06", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824002266/0001225208-24-002266-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824002266/xslF345X05/doc4.xml"}}
{"date": "2024-02-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-16 00:00:00", "acceptedDate": "2024-02-16 12:52:03", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824002265/0001225208-24-002265-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824002265/xslF345X05/doc4.xml"}}
{"date": "2024-02-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-14 00:00:00", "acceptedDate": "2024-02-14 15:48:31", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000035/0000078003-24-000035-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000035/effectorschedule13gaexitfi.htm"}}
{"date": "2024-02-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-14 00:00:00", "acceptedDate": "2024-02-14 15:31:31", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000033/0000078003-24-000033-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000033/enlivenschedule13gaexitfil.htm"}}
{"date": "2024-02-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-14 00:00:00", "acceptedDate": "2024-02-14 14:29:58", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000031/0000078003-24-000031-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000031/an2schedule13gaexitfiling2.htm"}}
{"date": "2024-02-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-14 00:00:00", "acceptedDate": "2024-02-14 14:24:22", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000029/0000078003-24-000029-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000029/cellectisschedule13gaexitf.htm"}}
{"date": "2024-02-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-02-14 00:00:00", "acceptedDate": "2024-02-14 14:19:47", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000027/0000078003-24-000027-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000027/akerotherapeuticsschedule1.htm"}}
{"date": "2024-01-30", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-30 00:00:00", "acceptedDate": "2024-01-30 08:04:28", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/0000078003-24-000017-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000017/pfe-12312023xex99.htm"}}
{"date": "2024-01-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-29 00:00:00", "acceptedDate": "2024-01-29 17:01:05", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000015/0000078003-24-000015-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000015/sch13dalongboard124x.htm"}}
{"date": "2024-01-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-29 00:00:00", "acceptedDate": "2024-01-29 13:04:48", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000009375124000352/0000093751-24-000352-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000009375124000352/Pfizer_Inc.txt"}}
{"date": "2024-01-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-26 00:00:00", "acceptedDate": "2024-01-26 11:49:44", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000108636424004377/0001086364-24-004377-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000108636424004377/us7170811035_012624.txt"}}
{"date": "2024-01-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-19 00:00:00", "acceptedDate": "2024-01-19 16:20:19", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000010/0000078003-24-000010-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000010/a13d-a_12024hln.htm"}}
{"date": "2024-01-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-12 00:00:00", "acceptedDate": "2024-01-12 16:16:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000903/0001225208-24-000903-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000903/xslF345X05/doc4.xml"}}
{"date": "2024-01-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-12 00:00:00", "acceptedDate": "2024-01-12 16:16:40", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000902/0001225208-24-000902-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000902/xslF345X05/doc4.xml"}}
{"date": "2024-01-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-12 00:00:00", "acceptedDate": "2024-01-12 16:16:26", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000901/0001225208-24-000901-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000901/xslF345X05/doc4.xml"}}
{"date": "2024-01-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-10 00:00:00", "acceptedDate": "2024-01-10 16:38:30", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000006/0000078003-24-000006-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000006/exh99_11024.htm"}}
{"date": "2024-01-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-10 00:00:00", "acceptedDate": "2024-01-10 16:12:34", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000004/0000078003-24-000004-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800324000004/sc13d_alongboard24.htm"}}
{"date": "2024-01-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-02 00:00:00", "acceptedDate": "2024-01-02 17:49:53", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000078/0001225208-24-000078-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000078/xslF345X05/doc4.xml"}}
{"date": "2024-01-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-02 00:00:00", "acceptedDate": "2024-01-02 17:49:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000077/0001225208-24-000077-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000077/xslF345X05/doc4.xml"}}
{"date": "2024-01-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-02 00:00:00", "acceptedDate": "2024-01-02 17:49:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000076/0001225208-24-000076-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000076/xslF345X05/doc4.xml"}}
{"date": "2024-01-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-02 00:00:00", "acceptedDate": "2024-01-02 17:49:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000075/0001225208-24-000075-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000075/xslF345X05/doc4.xml"}}
{"date": "2024-01-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-02 00:00:00", "acceptedDate": "2024-01-02 17:42:12", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000072/0001225208-24-000072-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000072/xslF345X05/doc4.xml"}}
{"date": "2024-01-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-02 00:00:00", "acceptedDate": "2024-01-02 17:42:03", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000071/0001225208-24-000071-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000071/xslF345X05/doc4.xml"}}
{"date": "2024-01-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2024-01-02 00:00:00", "acceptedDate": "2024-01-02 17:42:02", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000070/0001225208-24-000070-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520824000070/xslF345X05/doc4.xml"}}
{"date": "2023-12-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-29 00:00:00", "acceptedDate": "2023-12-29 18:05:11", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011363/0001225208-23-011363-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011363/xslF345X05/doc4.xml"}}
{"date": "2023-12-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-21 00:00:00", "acceptedDate": "2023-12-21 16:20:34", "formType": "3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011312/0001225208-23-011312-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011312/xslF345X02/doc3.xml"}}
{"date": "2023-12-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-19 00:00:00", "acceptedDate": "2023-12-19 16:37:40", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011271/0001225208-23-011271-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011271/xslF345X05/doc4.xml"}}
{"date": "2023-12-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-19 00:00:00", "acceptedDate": "2023-12-19 12:35:45", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011256/0001225208-23-011256-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011256/xslF345X05/doc4.xml"}}
{"date": "2023-12-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-19 00:00:00", "acceptedDate": "2023-12-19 12:34:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011255/0001225208-23-011255-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011255/xslF345X05/doc4.xml"}}
{"date": "2023-12-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-19 00:00:00", "acceptedDate": "2023-12-19 09:31:01", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011250/0001225208-23-011250-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011250/xslF345X05/doc4.xml"}}
{"date": "2023-12-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-19 00:00:00", "acceptedDate": "2023-12-19 09:30:58", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011249/0001225208-23-011249-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011249/xslF345X05/doc4.xml"}}
{"date": "2023-12-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-19 00:00:00", "acceptedDate": "2023-12-19 09:30:56", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011248/0001225208-23-011248-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823011248/xslF345X05/doc4.xml"}}
{"date": "2023-12-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-14 00:00:00", "acceptedDate": "2023-12-14 17:04:35", "formType": "8-K/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312523295562/0001193125-23-295562-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312523295562/d612444d8ka.htm"}}
{"date": "2023-12-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-14 00:00:00", "acceptedDate": "2023-12-14 07:51:03", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312523294930/0001193125-23-294930-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312523294930/d553734dex991.htm"}}
{"date": "2023-12-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-13 00:00:00", "acceptedDate": "2023-12-13 07:44:52", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000120/0000078003-23-000120-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000120/exh99pr121323.htm"}}
{"date": "2023-12-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-12 00:00:00", "acceptedDate": "2023-12-12 16:35:24", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000118/0000078003-23-000118-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000118/pr121223ex991.htm"}}
{"date": "2023-12-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-04 00:00:00", "acceptedDate": "2023-12-04 09:23:58", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823010632/0001225208-23-010632-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823010632/xslF345X05/doc4.xml"}}
{"date": "2023-12-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-04 00:00:00", "acceptedDate": "2023-12-04 09:23:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823010631/0001225208-23-010631-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823010631/xslF345X05/doc4.xml"}}
{"date": "2023-12-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-12-04 00:00:00", "acceptedDate": "2023-12-04 09:23:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823010630/0001225208-23-010630-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823010630/xslF345X05/doc4.xml"}}
{"date": "2023-11-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-11-16 00:00:00", "acceptedDate": "2023-11-16 18:23:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823010273/0001225208-23-010273-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823010273/xslF345X05/doc4.xml"}}
{"date": "2023-11-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-11-16 00:00:00", "acceptedDate": "2023-11-16 18:22:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823010272/0001225208-23-010272-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823010272/xslF345X05/doc4.xml"}}
{"date": "2023-11-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-11-16 00:00:00", "acceptedDate": "2023-11-16 18:22:39", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823010271/0001225208-23-010271-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823010271/xslF345X05/doc4.xml"}}
{"date": "2023-11-08", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-11-08 00:00:00", "acceptedDate": "2023-11-08 16:00:02", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000115/0000078003-23-000115-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000115/pfe-20231001.htm"}}
{"date": "2023-11-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-11-01 00:00:00", "acceptedDate": "2023-11-01 18:19:03", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009877/0001225208-23-009877-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009877/xslF345X05/doc4.xml"}}
{"date": "2023-11-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-11-01 00:00:00", "acceptedDate": "2023-11-01 18:19:01", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009876/0001225208-23-009876-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009876/xslF345X05/doc4.xml"}}
{"date": "2023-11-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-11-01 00:00:00", "acceptedDate": "2023-11-01 18:18:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009875/0001225208-23-009875-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009875/xslF345X05/doc4.xml"}}
{"date": "2023-10-31", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-31 00:00:00", "acceptedDate": "2023-10-31 08:04:50", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000111/0000078003-23-000111-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000111/pfe-10012023xex99.htm"}}
{"date": "2023-10-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-27 00:00:00", "acceptedDate": "2023-10-27 16:01:23", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000109/0000078003-23-000109-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000109/a13gtourmalinebio.htm"}}
{"date": "2023-10-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-25 00:00:00", "acceptedDate": "2023-10-25 17:29:38", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000104/0000078003-23-000104-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000104/sch13d_allox1023.htm"}}
{"date": "2023-10-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-18 00:00:00", "acceptedDate": "2023-10-18 16:27:42", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000102/0000078003-23-000102-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000102/schedule13d_acere1023.htm"}}
{"date": "2023-10-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-16 00:00:00", "acceptedDate": "2023-10-16 16:08:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009518/0001225208-23-009518-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009518/xslF345X05/doc4.xml"}}
{"date": "2023-10-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-16 00:00:00", "acceptedDate": "2023-10-16 16:08:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009517/0001225208-23-009517-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009517/xslF345X05/doc4.xml"}}
{"date": "2023-10-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-16 00:00:00", "acceptedDate": "2023-10-16 16:08:36", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009516/0001225208-23-009516-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009516/xslF345X05/doc4.xml"}}
{"date": "2023-10-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-13 00:00:00", "acceptedDate": "2023-10-13 17:30:20", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000099/0000078003-23-000099-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000099/ex99_pressrelease1013.htm"}}
{"date": "2023-10-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-12 00:00:00", "acceptedDate": "2023-10-12 15:32:49", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009472/0001225208-23-009472-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009472/xslF345X05/doc4.xml"}}
{"date": "2023-10-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-12 00:00:00", "acceptedDate": "2023-10-12 15:32:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009470/0001225208-23-009470-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009470/xslF345X05/doc4.xml"}}
{"date": "2023-10-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-12 00:00:00", "acceptedDate": "2023-10-12 15:32:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009471/0001225208-23-009471-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009471/xslF345X05/doc4.xml"}}
{"date": "2023-10-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-10 00:00:00", "acceptedDate": "2023-10-10 16:11:45", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000096/0000078003-23-000096-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000096/pfizer13da_hln1023.htm"}}
{"date": "2023-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-02 00:00:00", "acceptedDate": "2023-10-02 19:25:40", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009140/0001225208-23-009140-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009140/xslF345X05/doc4.xml"}}
{"date": "2023-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-02 00:00:00", "acceptedDate": "2023-10-02 19:25:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009139/0001225208-23-009139-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009139/xslF345X05/doc4.xml"}}
{"date": "2023-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-02 00:00:00", "acceptedDate": "2023-10-02 19:25:36", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009138/0001225208-23-009138-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009138/xslF345X05/doc4.xml"}}
{"date": "2023-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-02 00:00:00", "acceptedDate": "2023-10-02 19:25:33", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009137/0001225208-23-009137-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009137/xslF345X05/doc4.xml"}}
{"date": "2023-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-02 00:00:00", "acceptedDate": "2023-10-02 18:11:53", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009135/0001225208-23-009135-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009135/xslF345X05/doc4.xml"}}
{"date": "2023-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-02 00:00:00", "acceptedDate": "2023-10-02 18:11:50", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009134/0001225208-23-009134-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009134/xslF345X05/doc4.xml"}}
{"date": "2023-10-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-10-02 00:00:00", "acceptedDate": "2023-10-02 18:11:49", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009133/0001225208-23-009133-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823009133/xslF345X05/doc4.xml"}}
{"date": "2023-09-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-09-18 00:00:00", "acceptedDate": "2023-09-18 14:30:04", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008985/0001225208-23-008985-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008985/xslF345X05/doc4.xml"}}
{"date": "2023-09-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-09-18 00:00:00", "acceptedDate": "2023-09-18 14:30:04", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008984/0001225208-23-008984-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008984/xslF345X05/doc4.xml"}}
{"date": "2023-09-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-09-18 00:00:00", "acceptedDate": "2023-09-18 14:30:02", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008983/0001225208-23-008983-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008983/xslF345X05/doc4.xml"}}
{"date": "2023-09-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-09-11 00:00:00", "acceptedDate": "2023-09-11 16:08:29", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000093/0000078003-23-000093-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000093/pfizer13d-a3_hln.htm"}}
{"date": "2023-09-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-09-01 00:00:00", "acceptedDate": "2023-09-01 13:36:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008608/0001225208-23-008608-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008608/xslF345X05/doc4.xml"}}
{"date": "2023-09-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-09-01 00:00:00", "acceptedDate": "2023-09-01 13:36:55", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008607/0001225208-23-008607-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008607/xslF345X05/doc4.xml"}}
{"date": "2023-09-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-09-01 00:00:00", "acceptedDate": "2023-09-01 13:36:53", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008606/0001225208-23-008606-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008606/xslF345X05/doc4.xml"}}
{"date": "2023-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-08-16 00:00:00", "acceptedDate": "2023-08-16 13:21:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008253/0001225208-23-008253-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008253/xslF345X05/doc4.xml"}}
{"date": "2023-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-08-16 00:00:00", "acceptedDate": "2023-08-16 13:21:46", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008252/0001225208-23-008252-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008252/xslF345X05/doc4.xml"}}
{"date": "2023-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-08-16 00:00:00", "acceptedDate": "2023-08-16 13:21:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008251/0001225208-23-008251-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008251/xslF345X05/doc4.xml"}}
{"date": "2023-08-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-08-09 00:00:00", "acceptedDate": "2023-08-09 16:11:52", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000088/0000078003-23-000088-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000088/pfe-20230702.htm"}}
{"date": "2023-08-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-08-04 00:00:00", "acceptedDate": "2023-08-04 17:13:57", "formType": "3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008002/0001225208-23-008002-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823008002/xslF345X02/doc3.xml"}}
{"date": "2023-08-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-08-01 00:00:00", "acceptedDate": "2023-08-01 19:23:25", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007855/0001225208-23-007855-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007855/xslF345X05/doc4.xml"}}
{"date": "2023-08-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-08-01 00:00:00", "acceptedDate": "2023-08-01 19:22:24", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007854/0001225208-23-007854-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007854/xslF345X05/doc4.xml"}}
{"date": "2023-08-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-08-01 00:00:00", "acceptedDate": "2023-08-01 19:13:13", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007853/0001225208-23-007853-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007853/xslF345X05/doc4.xml"}}
{"date": "2023-08-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-08-01 00:00:00", "acceptedDate": "2023-08-01 08:09:25", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000085/0000078003-23-000085-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000085/pfe-07022023xex99.htm"}}
{"date": "2023-07-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-07-27 00:00:00", "acceptedDate": "2023-07-27 16:11:19", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000081/0000078003-23-000081-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000081/0000078003-23-000081.txt"}}
{"date": "2023-07-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-07-17 00:00:00", "acceptedDate": "2023-07-17 15:03:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007520/0001225208-23-007520-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007520/xslF345X05/doc4.xml"}}
{"date": "2023-07-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-07-17 00:00:00", "acceptedDate": "2023-07-17 15:03:22", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007519/0001225208-23-007519-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007519/xslF345X05/doc4.xml"}}
{"date": "2023-07-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-07-17 00:00:00", "acceptedDate": "2023-07-17 15:03:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007518/0001225208-23-007518-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007518/xslF345X05/doc4.xml"}}
{"date": "2023-07-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-07-10 00:00:00", "acceptedDate": "2023-07-10 09:10:42", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000079/0000078003-23-000079-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000079/caribou-13g_fv.htm"}}
{"date": "2023-07-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-07-05 00:00:00", "acceptedDate": "2023-07-05 10:14:46", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007154/0001225208-23-007154-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007154/xslF345X04/doc4.xml"}}
{"date": "2023-07-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-07-05 00:00:00", "acceptedDate": "2023-07-05 10:14:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007153/0001225208-23-007153-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007153/xslF345X04/doc4.xml"}}
{"date": "2023-07-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-07-05 00:00:00", "acceptedDate": "2023-07-05 10:14:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007152/0001225208-23-007152-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007152/xslF345X04/doc4.xml"}}
{"date": "2023-07-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-07-05 00:00:00", "acceptedDate": "2023-07-05 10:14:40", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007151/0001225208-23-007151-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007151/xslF345X04/doc4.xml"}}
{"date": "2023-07-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-07-03 00:00:00", "acceptedDate": "2023-07-03 14:16:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007056/0001225208-23-007056-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007056/xslF345X04/doc4.xml"}}
{"date": "2023-07-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-07-03 00:00:00", "acceptedDate": "2023-07-03 14:16:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007055/0001225208-23-007055-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007055/xslF345X04/doc4.xml"}}
{"date": "2023-07-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-07-03 00:00:00", "acceptedDate": "2023-07-03 14:16:39", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007054/0001225208-23-007054-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823007054/xslF345X04/doc4.xml"}}
{"date": "2023-06-20", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-06-20 00:00:00", "acceptedDate": "2023-06-20 14:51:00", "formType": "11-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000077/0000078003-23-000077-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000077/pfizersavingsplanforemploy.htm"}}
{"date": "2023-06-20", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-06-20 00:00:00", "acceptedDate": "2023-06-20 14:45:43", "formType": "11-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000075/0000078003-23-000075-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000075/pfizersavingsplan2022.htm"}}
{"date": "2023-06-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-06-16 00:00:00", "acceptedDate": "2023-06-16 16:04:28", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006900/0001225208-23-006900-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006900/xslF345X04/doc4.xml"}}
{"date": "2023-06-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-06-16 00:00:00", "acceptedDate": "2023-06-16 16:04:26", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006899/0001225208-23-006899-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006899/xslF345X04/doc4.xml"}}
{"date": "2023-06-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-06-16 00:00:00", "acceptedDate": "2023-06-16 16:04:24", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006898/0001225208-23-006898-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006898/xslF345X04/doc4.xml"}}
{"date": "2023-06-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-06-01 00:00:00", "acceptedDate": "2023-06-01 16:07:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006422/0001225208-23-006422-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006422/xslF345X04/doc4.xml"}}
{"date": "2023-06-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-06-01 00:00:00", "acceptedDate": "2023-06-01 16:06:58", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006421/0001225208-23-006421-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006421/xslF345X04/doc4.xml"}}
{"date": "2023-06-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-06-01 00:00:00", "acceptedDate": "2023-06-01 16:06:55", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006420/0001225208-23-006420-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006420/xslF345X04/doc4.xml"}}
{"date": "2023-06-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-06-01 00:00:00", "acceptedDate": "2023-06-01 16:06:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006419/0001225208-23-006419-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823006419/xslF345X04/doc4.xml"}}
{"date": "2023-05-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-19 00:00:00", "acceptedDate": "2023-05-19 16:26:03", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312523149364/0001193125-23-149364-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312523149364/d414076dex11.htm"}}
{"date": "2023-05-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-18 00:00:00", "acceptedDate": "2023-05-18 16:37:34", "formType": "424B5", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312523148218/0001193125-23-148218-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312523148218/d502458d424b5.htm"}}
{"date": "2023-05-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-17 00:00:00", "acceptedDate": "2023-05-16 21:31:58", "formType": "FWP", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312523146344/0001193125-23-146344-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312523146344/d510144dfwp.htm"}}
{"date": "2023-05-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-16 00:00:00", "acceptedDate": "2023-05-16 15:48:33", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005948/0001225208-23-005948-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005948/xslF345X04/doc4.xml"}}
{"date": "2023-05-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-16 00:00:00", "acceptedDate": "2023-05-16 15:48:31", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005947/0001225208-23-005947-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005947/xslF345X04/doc4.xml"}}
{"date": "2023-05-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-16 00:00:00", "acceptedDate": "2023-05-16 15:48:27", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005946/0001225208-23-005946-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005946/xslF345X04/doc4.xml"}}
{"date": "2023-05-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-15 00:00:00", "acceptedDate": "2023-05-15 16:45:51", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000162828023018229/0001628280-23-018229-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000162828023018229/sch13d-a2_hal.htm"}}
{"date": "2023-05-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-15 00:00:00", "acceptedDate": "2023-05-15 07:50:08", "formType": "424B3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312523144205/0001193125-23-144205-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312523144205/d502458d424b3.htm"}}
{"date": "2023-05-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-15 00:00:00", "acceptedDate": "2023-05-15 07:40:20", "formType": "POSASR", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312523144191/0001193125-23-144191-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312523144191/d381947dposasr.htm"}}
{"date": "2023-05-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-15 00:00:00", "acceptedDate": "2023-05-15 06:25:59", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312523144089/0001193125-23-144089-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312523144089/0001193125-23-144089.txt"}}
{"date": "2023-05-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-11 00:00:00", "acceptedDate": "2023-05-11 18:46:49", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005759/0001225208-23-005759-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005759/xslF345X04/doc4.xml"}}
{"date": "2023-05-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-10 00:00:00", "acceptedDate": "2023-05-10 15:53:31", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000162828023017196/0001628280-23-017196-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000162828023017196/pfe-20230402.htm"}}
{"date": "2023-05-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-09 00:00:00", "acceptedDate": "2023-05-09 16:17:58", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005604/0001225208-23-005604-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005604/xslF345X04/doc4.xml"}}
{"date": "2023-05-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-02 00:00:00", "acceptedDate": "2023-05-02 08:05:53", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000162828023014759/0001628280-23-014759-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000162828023014759/pfe-04022023xex99.htm"}}
{"date": "2023-05-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-01 00:00:00", "acceptedDate": "2023-05-01 13:30:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005189/0001225208-23-005189-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005189/xslF345X04/doc4.xml"}}
{"date": "2023-05-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-01 00:00:00", "acceptedDate": "2023-05-01 13:29:59", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005188/0001225208-23-005188-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005188/xslF345X04/doc4.xml"}}
{"date": "2023-05-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-01 00:00:00", "acceptedDate": "2023-05-01 13:29:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005187/0001225208-23-005187-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005187/xslF345X04/doc4.xml"}}
{"date": "2023-05-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-05-01 00:00:00", "acceptedDate": "2023-05-01 09:39:02", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000162828023014368/0001628280-23-014368-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000162828023014368/0001628280-23-014368.txt"}}
{"date": "2023-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-28 00:00:00", "acceptedDate": "2023-04-28 16:34:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005156/0001225208-23-005156-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005156/xslF345X04/doc4.xml"}}
{"date": "2023-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-28 00:00:00", "acceptedDate": "2023-04-28 16:34:21", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005155/0001225208-23-005155-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005155/xslF345X04/doc4.xml"}}
{"date": "2023-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-28 00:00:00", "acceptedDate": "2023-04-28 16:34:13", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005154/0001225208-23-005154-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005154/xslF345X04/doc4.xml"}}
{"date": "2023-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-28 00:00:00", "acceptedDate": "2023-04-28 16:34:06", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005153/0001225208-23-005153-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005153/xslF345X04/doc4.xml"}}
{"date": "2023-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-28 00:00:00", "acceptedDate": "2023-04-28 16:34:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005152/0001225208-23-005152-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005152/xslF345X04/doc4.xml"}}
{"date": "2023-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-28 00:00:00", "acceptedDate": "2023-04-28 16:33:59", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005150/0001225208-23-005150-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005150/xslF345X04/doc4.xml"}}
{"date": "2023-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-28 00:00:00", "acceptedDate": "2023-04-28 16:33:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005151/0001225208-23-005151-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005151/xslF345X04/doc4.xml"}}
{"date": "2023-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-28 00:00:00", "acceptedDate": "2023-04-28 16:33:46", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005149/0001225208-23-005149-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005149/xslF345X04/doc4.xml"}}
{"date": "2023-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-28 00:00:00", "acceptedDate": "2023-04-28 16:33:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005147/0001225208-23-005147-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005147/xslF345X04/doc4.xml"}}
{"date": "2023-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-28 00:00:00", "acceptedDate": "2023-04-28 16:33:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005148/0001225208-23-005148-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005148/xslF345X04/doc4.xml"}}
{"date": "2023-04-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-28 00:00:00", "acceptedDate": "2023-04-28 16:31:15", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005146/0001225208-23-005146-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823005146/xslF345X04/doc4.xml"}}
{"date": "2023-04-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-17 00:00:00", "acceptedDate": "2023-04-17 19:35:13", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004851/0001225208-23-004851-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004851/xslF345X04/doc4.xml"}}
{"date": "2023-04-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-17 00:00:00", "acceptedDate": "2023-04-17 19:33:10", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004850/0001225208-23-004850-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004850/xslF345X04/doc4.xml"}}
{"date": "2023-04-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-17 00:00:00", "acceptedDate": "2023-04-17 19:33:08", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004849/0001225208-23-004849-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004849/xslF345X04/doc4.xml"}}
{"date": "2023-04-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-14 00:00:00", "acceptedDate": "2023-04-14 06:42:15", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004839/0001225208-23-004839-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004839/xslF345X04/doc4.xml"}}
{"date": "2023-04-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-14 00:00:00", "acceptedDate": "2023-04-14 06:42:13", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004838/0001225208-23-004838-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004838/xslF345X04/doc4.xml"}}
{"date": "2023-04-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-14 00:00:00", "acceptedDate": "2023-04-14 06:42:12", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004837/0001225208-23-004837-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004837/xslF345X04/doc4.xml"}}
{"date": "2023-04-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-12 00:00:00", "acceptedDate": "2023-04-12 09:04:11", "formType": "PX14A6G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000121465923005238/0001214659-23-005238-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000121465923005238/d412231px14a6g.htm"}}
{"date": "2023-04-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-10 00:00:00", "acceptedDate": "2023-04-10 10:43:38", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000068/0000078003-23-000068-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000068/pfe_media.htm"}}
{"date": "2023-04-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-10 00:00:00", "acceptedDate": "2023-04-10 10:40:44", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000067/0000078003-23-000067-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000067/pfe_eml.htm"}}
{"date": "2023-04-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-04 00:00:00", "acceptedDate": "2023-04-04 11:46:39", "formType": "PX14A6G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000121465923004777/0001214659-23-004777-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000121465923004777/b44231px14a6g.htm"}}
{"date": "2023-04-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-04 00:00:00", "acceptedDate": "2023-04-04 08:03:29", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004409/0001225208-23-004409-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004409/xslF345X04/doc4.xml"}}
{"date": "2023-04-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-04 00:00:00", "acceptedDate": "2023-04-04 08:03:27", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004408/0001225208-23-004408-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004408/xslF345X04/doc4.xml"}}
{"date": "2023-04-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-04 00:00:00", "acceptedDate": "2023-04-04 08:03:25", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004407/0001225208-23-004407-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004407/xslF345X04/doc4.xml"}}
{"date": "2023-04-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-04 00:00:00", "acceptedDate": "2023-04-04 08:03:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004406/0001225208-23-004406-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004406/xslF345X04/doc4.xml"}}
{"date": "2023-04-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-03 00:00:00", "acceptedDate": "2023-04-03 18:23:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004400/0001225208-23-004400-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004400/xslF345X04/doc4.xml"}}
{"date": "2023-04-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-03 00:00:00", "acceptedDate": "2023-04-03 18:23:33", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004399/0001225208-23-004399-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004399/xslF345X04/doc4.xml"}}
{"date": "2023-04-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-03 00:00:00", "acceptedDate": "2023-04-03 18:23:27", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004398/0001225208-23-004398-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004398/xslF345X04/doc4.xml"}}
{"date": "2023-04-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-04-03 00:00:00", "acceptedDate": "2023-04-03 18:23:22", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004397/0001225208-23-004397-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004397/xslF345X04/doc4.xml"}}
{"date": "2023-03-30", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-30 00:00:00", "acceptedDate": "2023-03-30 18:10:14", "formType": "3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000062/0000078003-23-000062-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000062/xslF345X02/primary_doc.xml"}}
{"date": "2023-03-30", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-30 00:00:00", "acceptedDate": "2023-03-30 17:28:15", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000061/0000078003-23-000061-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000061/pfevote23.htm"}}
{"date": "2023-03-30", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-30 00:00:00", "acceptedDate": "2023-03-30 17:02:30", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000060/0000078003-23-000060-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000060/zurabio_13gxpfizer032023.htm"}}
{"date": "2023-03-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-27 00:00:00", "acceptedDate": "2023-03-27 16:27:15", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000056/0000078003-23-000056-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000056/schedule13d_a-longboard.htm"}}
{"date": "2023-03-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-23 00:00:00", "acceptedDate": "2023-03-23 16:20:29", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000053/0000078003-23-000053-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000053/pyxis_13gx2x31723.htm"}}
{"date": "2023-03-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-23 00:00:00", "acceptedDate": "2023-03-23 16:14:26", "formType": "4/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000052/0000078003-23-000052-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000052/xslF345X04/primary_doc.xml"}}
{"date": "2023-03-22", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-22 00:00:00", "acceptedDate": "2023-03-22 12:34:50", "formType": "PX14A6G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000121465923004087/0001214659-23-004087-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000121465923004087/x322230px14a6g.htm"}}
{"date": "2023-03-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-21 00:00:00", "acceptedDate": "2023-03-21 18:07:27", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000050/0000078003-23-000050-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000050/xslF345X04/primary_doc.xml"}}
{"date": "2023-03-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-21 00:00:00", "acceptedDate": "2023-03-21 09:28:59", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004144/0001225208-23-004144-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004144/xslF345X04/doc4.xml"}}
{"date": "2023-03-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-17 00:00:00", "acceptedDate": "2023-03-17 19:19:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004110/0001225208-23-004110-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004110/xslF345X03/doc4.xml"}}
{"date": "2023-03-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-17 00:00:00", "acceptedDate": "2023-03-17 16:53:37", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004095/0001225208-23-004095-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004095/xslF345X03/doc4.xml"}}
{"date": "2023-03-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-17 00:00:00", "acceptedDate": "2023-03-17 16:53:29", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004094/0001225208-23-004094-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823004094/xslF345X03/doc4.xml"}}
{"date": "2023-03-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-17 00:00:00", "acceptedDate": "2023-03-16 18:43:21", "formType": "ARS", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000049/0000078003-23-000049-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000049/pfe_arsfl.pdf"}}
{"date": "2023-03-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-16 00:00:00", "acceptedDate": "2023-03-16 09:25:56", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000042/0000078003-23-000042-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000042/pficenotice2023.htm"}}
{"date": "2023-03-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-16 00:00:00", "acceptedDate": "2023-03-16 09:20:12", "formType": "DEF 14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000040/0000078003-23-000040-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000040/pfe-20230315.htm"}}
{"date": "2023-03-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-03-13 00:00:00", "acceptedDate": "2023-03-13 08:29:10", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312523068538/0001193125-23-068538-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312523068538/d408093dex21.htm"}}
{"date": "2023-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-28 00:00:00", "acceptedDate": "2023-02-28 17:53:09", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002988/0001225208-23-002988-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002988/xslF345X03/doc4.xml"}}
{"date": "2023-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-28 00:00:00", "acceptedDate": "2023-02-28 17:52:58", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002987/0001225208-23-002987-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002987/xslF345X03/doc4.xml"}}
{"date": "2023-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-28 00:00:00", "acceptedDate": "2023-02-28 17:52:56", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002986/0001225208-23-002986-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002986/xslF345X03/doc4.xml"}}
{"date": "2023-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-28 00:00:00", "acceptedDate": "2023-02-28 17:52:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002985/0001225208-23-002985-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002985/xslF345X03/doc4.xml"}}
{"date": "2023-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-28 00:00:00", "acceptedDate": "2023-02-28 17:52:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002984/0001225208-23-002984-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002984/xslF345X03/doc4.xml"}}
{"date": "2023-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-28 00:00:00", "acceptedDate": "2023-02-28 17:52:28", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002983/0001225208-23-002983-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002983/xslF345X03/doc4.xml"}}
{"date": "2023-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-28 00:00:00", "acceptedDate": "2023-02-28 08:24:51", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002919/0001225208-23-002919-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002919/xslF345X03/doc4.xml"}}
{"date": "2023-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-28 00:00:00", "acceptedDate": "2023-02-28 08:24:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002918/0001225208-23-002918-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002918/xslF345X03/doc4.xml"}}
{"date": "2023-02-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-28 00:00:00", "acceptedDate": "2023-02-28 08:24:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002917/0001225208-23-002917-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002917/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 21:34:04", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002832/0001225208-23-002832-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002832/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 21:17:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002831/0001225208-23-002831-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002831/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 21:03:09", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002818/0001225208-23-002818-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002818/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 20:58:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002817/0001225208-23-002817-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002817/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 20:52:26", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002816/0001225208-23-002816-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002816/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 20:45:09", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002815/0001225208-23-002815-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002815/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 20:35:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002814/0001225208-23-002814-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002814/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 20:27:02", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002813/0001225208-23-002813-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002813/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 20:22:50", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002812/0001225208-23-002812-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002812/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 20:18:31", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002811/0001225208-23-002811-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002811/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 20:17:25", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002810/0001225208-23-002810-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002810/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 20:14:17", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002809/0001225208-23-002809-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002809/xslF345X03/doc4.xml"}}
{"date": "2023-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-24 00:00:00", "acceptedDate": "2023-02-24 20:11:11", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002808/0001225208-23-002808-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002808/xslF345X03/doc4.xml"}}
{"date": "2023-02-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-27 00:00:00", "acceptedDate": "2023-02-24 20:02:57", "formType": "S-8", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000030/0000078003-23-000030-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000030/pfizerforms-8febx22x23_wd.htm"}}
{"date": "2023-02-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-23 00:00:00", "acceptedDate": "2023-02-23 14:12:53", "formType": "10-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/0000078003-23-000024-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/pfe-20221231.htm"}}
{"date": "2023-02-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-21 00:00:00", "acceptedDate": "2023-02-21 17:32:36", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002431/0001225208-23-002431-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002431/xslF345X03/doc4.xml"}}
{"date": "2023-02-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-21 00:00:00", "acceptedDate": "2023-02-21 17:19:30", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002424/0001225208-23-002424-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002424/xslF345X03/doc4.xml"}}
{"date": "2023-02-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-21 00:00:00", "acceptedDate": "2023-02-21 17:14:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002421/0001225208-23-002421-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823002421/xslF345X03/doc4.xml"}}
{"date": "2023-02-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-21 00:00:00", "acceptedDate": "2023-02-21 16:17:02", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000019/0000078003-23-000019-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000019/0000078003-23-000019.txt"}}
{"date": "2023-02-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-13 00:00:00", "acceptedDate": "2023-02-13 17:14:07", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000013/0000078003-23-000013-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000013/pyxis_13gx2x22fv.htm"}}
{"date": "2023-02-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-13 00:00:00", "acceptedDate": "2023-02-13 17:06:33", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000011/0000078003-23-000011-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000011/an2therapeuticsinc_13gx2x2.htm"}}
{"date": "2023-02-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-09 00:00:00", "acceptedDate": "2023-02-09 11:30:22", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000110465923016719/0001104659-23-016719-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000110465923016719/tv01663-pfizerinc.htm"}}
{"date": "2023-02-07", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-07 00:00:00", "acceptedDate": "2023-02-07 13:11:32", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000009375123000307/0000093751-23-000307-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000009375123000307/Pfizer_Inc.txt"}}
{"date": "2023-02-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-03 00:00:00", "acceptedDate": "2023-02-03 16:27:54", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000130655023007780/0001306550-23-007780-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000130655023007780/us7170811035_020323.txt"}}
{"date": "2023-02-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-02-01 00:00:00", "acceptedDate": "2023-02-01 17:06:10", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000007/0000078003-23-000007-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000007/haleon13da_23.htm"}}
{"date": "2023-01-31", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-01-31 00:00:00", "acceptedDate": "2023-01-31 08:11:36", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/0000078003-23-000004-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800323000004/pfe-12312022xex99.htm"}}
{"date": "2023-01-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-01-13 00:00:00", "acceptedDate": "2023-01-13 18:40:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000629/0001225208-23-000629-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000629/xslF345X03/doc4.xml"}}
{"date": "2023-01-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-01-13 00:00:00", "acceptedDate": "2023-01-13 18:39:53", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000628/0001225208-23-000628-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000628/xslF345X03/doc4.xml"}}
{"date": "2023-01-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-01-13 00:00:00", "acceptedDate": "2023-01-13 18:39:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000627/0001225208-23-000627-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000627/xslF345X03/doc4.xml"}}
{"date": "2023-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-01-03 00:00:00", "acceptedDate": "2023-01-03 18:52:39", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000090/0001225208-23-000090-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000090/xslF345X03/doc4.xml"}}
{"date": "2023-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-01-03 00:00:00", "acceptedDate": "2023-01-03 18:52:34", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000089/0001225208-23-000089-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000089/xslF345X03/doc4.xml"}}
{"date": "2023-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-01-03 00:00:00", "acceptedDate": "2023-01-03 18:52:24", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000088/0001225208-23-000088-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000088/xslF345X03/doc4.xml"}}
{"date": "2023-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-01-03 00:00:00", "acceptedDate": "2023-01-03 18:52:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000087/0001225208-23-000087-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000087/xslF345X03/doc4.xml"}}
{"date": "2023-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-01-03 00:00:00", "acceptedDate": "2023-01-03 17:50:33", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000075/0001225208-23-000075-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000075/xslF345X03/doc4.xml"}}
{"date": "2023-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-01-03 00:00:00", "acceptedDate": "2023-01-03 17:50:27", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000074/0001225208-23-000074-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000074/xslF345X03/doc4.xml"}}
{"date": "2023-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2023-01-03 00:00:00", "acceptedDate": "2023-01-03 17:50:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000073/0001225208-23-000073-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520823000073/xslF345X03/doc4.xml"}}
{"date": "2022-12-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-12-29 00:00:00", "acceptedDate": "2022-12-29 16:41:08", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000112/0000078003-22-000112-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000112/sc13goric1222.htm"}}
{"date": "2022-12-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-12-29 00:00:00", "acceptedDate": "2022-12-29 16:30:39", "formType": "3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000110/0000078003-22-000110-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000110/xslF345X02/primary_doc.xml"}}
{"date": "2022-12-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-12-16 00:00:00", "acceptedDate": "2022-12-16 18:14:50", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012888/0001225208-22-012888-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012888/xslF345X03/doc4.xml"}}
{"date": "2022-12-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-12-16 00:00:00", "acceptedDate": "2022-12-16 18:14:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012887/0001225208-22-012887-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012887/xslF345X03/doc4.xml"}}
{"date": "2022-12-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-12-16 00:00:00", "acceptedDate": "2022-12-16 18:14:39", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012886/0001225208-22-012886-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012886/xslF345X03/doc4.xml"}}
{"date": "2022-12-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-12-16 00:00:00", "acceptedDate": "2022-12-16 18:14:34", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012885/0001225208-22-012885-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012885/xslF345X03/doc4.xml"}}
{"date": "2022-12-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-12-13 00:00:00", "acceptedDate": "2022-12-13 16:19:14", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000107/0000078003-22-000107-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000107/bylaws_exh31.htm"}}
{"date": "2022-12-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-12-01 00:00:00", "acceptedDate": "2022-12-01 16:01:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012050/0001225208-22-012050-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012050/xslF345X03/doc4.xml"}}
{"date": "2022-12-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-12-01 00:00:00", "acceptedDate": "2022-12-01 16:01:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012048/0001225208-22-012048-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012048/xslF345X03/doc4.xml"}}
{"date": "2022-12-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-12-01 00:00:00", "acceptedDate": "2022-12-01 16:01:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012049/0001225208-22-012049-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822012049/xslF345X03/doc4.xml"}}
{"date": "2022-11-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-11-16 00:00:00", "acceptedDate": "2022-11-16 17:30:14", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011748/0001225208-22-011748-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011748/xslF345X03/doc4.xml"}}
{"date": "2022-11-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-11-16 00:00:00", "acceptedDate": "2022-11-16 17:30:09", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011747/0001225208-22-011747-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011747/xslF345X03/doc4.xml"}}
{"date": "2022-11-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-11-16 00:00:00", "acceptedDate": "2022-11-16 17:29:58", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011746/0001225208-22-011746-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011746/xslF345X03/doc4.xml"}}
{"date": "2022-11-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-11-09 00:00:00", "acceptedDate": "2022-11-09 16:08:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011483/0001225208-22-011483-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011483/xslF345X03/doc4.xml"}}
{"date": "2022-11-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-11-09 00:00:00", "acceptedDate": "2022-11-09 16:05:15", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000101/0000078003-22-000101-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000101/pfe-20221002.htm"}}
{"date": "2022-11-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-11-01 00:00:00", "acceptedDate": "2022-11-01 18:21:53", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011267/0001225208-22-011267-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011267/xslF345X03/doc4.xml"}}
{"date": "2022-11-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-11-01 00:00:00", "acceptedDate": "2022-11-01 18:21:45", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011266/0001225208-22-011266-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011266/xslF345X03/doc4.xml"}}
{"date": "2022-11-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-11-01 00:00:00", "acceptedDate": "2022-11-01 18:21:39", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011265/0001225208-22-011265-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011265/xslF345X03/doc4.xml"}}
{"date": "2022-11-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-11-01 00:00:00", "acceptedDate": "2022-11-01 08:11:28", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000098/0000078003-22-000098-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000098/pfe-10022022xex99.htm"}}
{"date": "2022-10-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-18 00:00:00", "acceptedDate": "2022-10-18 19:11:34", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011025/0001225208-22-011025-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011025/xslF345X03/doc4.xml"}}
{"date": "2022-10-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-18 00:00:00", "acceptedDate": "2022-10-18 19:11:27", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011024/0001225208-22-011024-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011024/xslF345X03/doc4.xml"}}
{"date": "2022-10-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-18 00:00:00", "acceptedDate": "2022-10-18 19:11:22", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011023/0001225208-22-011023-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822011023/xslF345X03/doc4.xml"}}
{"date": "2022-10-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-13 00:00:00", "acceptedDate": "2022-10-13 18:14:33", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010964/0001225208-22-010964-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010964/xslF345X03/doc4.xml"}}
{"date": "2022-10-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-13 00:00:00", "acceptedDate": "2022-10-13 18:14:29", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010963/0001225208-22-010963-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010963/xslF345X03/doc4.xml"}}
{"date": "2022-10-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-13 00:00:00", "acceptedDate": "2022-10-13 18:14:27", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010962/0001225208-22-010962-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010962/xslF345X03/doc4.xml"}}
{"date": "2022-10-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-13 00:00:00", "acceptedDate": "2022-10-13 08:34:29", "formType": "3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000095/0000078003-22-000095-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000095/xslF345X02/primary_doc.xml"}}
{"date": "2022-10-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-03 00:00:00", "acceptedDate": "2022-10-03 19:08:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010620/0001225208-22-010620-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010620/xslF345X03/doc4.xml"}}
{"date": "2022-10-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-03 00:00:00", "acceptedDate": "2022-10-03 19:08:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010619/0001225208-22-010619-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010619/xslF345X03/doc4.xml"}}
{"date": "2022-10-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-03 00:00:00", "acceptedDate": "2022-10-03 19:08:18", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010618/0001225208-22-010618-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010618/xslF345X03/doc4.xml"}}
{"date": "2022-10-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-03 00:00:00", "acceptedDate": "2022-10-03 19:08:14", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010617/0001225208-22-010617-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010617/xslF345X03/doc4.xml"}}
{"date": "2022-10-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-03 00:00:00", "acceptedDate": "2022-10-03 16:53:46", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010598/0001225208-22-010598-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010598/xslF345X03/doc4.xml"}}
{"date": "2022-10-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-03 00:00:00", "acceptedDate": "2022-10-03 16:53:17", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010597/0001225208-22-010597-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010597/xslF345X03/doc4.xml"}}
{"date": "2022-10-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-10-03 00:00:00", "acceptedDate": "2022-10-03 16:53:02", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010596/0001225208-22-010596-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822010596/xslF345X03/doc4.xml"}}
{"date": "2022-09-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-09-01 00:00:00", "acceptedDate": "2022-09-01 16:02:16", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009898/0001225208-22-009898-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009898/xslF345X03/doc4.xml"}}
{"date": "2022-09-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-09-01 00:00:00", "acceptedDate": "2022-09-01 16:02:10", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009897/0001225208-22-009897-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009897/xslF345X03/doc4.xml"}}
{"date": "2022-09-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-09-01 00:00:00", "acceptedDate": "2022-09-01 16:02:08", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009896/0001225208-22-009896-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009896/xslF345X03/doc4.xml"}}
{"date": "2022-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-08-16 00:00:00", "acceptedDate": "2022-08-16 15:43:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009600/0001225208-22-009600-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009600/xslF345X03/doc4.xml"}}
{"date": "2022-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-08-16 00:00:00", "acceptedDate": "2022-08-16 15:43:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009599/0001225208-22-009599-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009599/xslF345X03/doc4.xml"}}
{"date": "2022-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-08-16 00:00:00", "acceptedDate": "2022-08-16 15:43:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009598/0001225208-22-009598-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009598/xslF345X03/doc4.xml"}}
{"date": "2022-08-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-08-10 00:00:00", "acceptedDate": "2022-08-10 16:26:18", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000094/0000078003-22-000094-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000094/pfe-20220703.htm"}}
{"date": "2022-08-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-08-01 00:00:00", "acceptedDate": "2022-08-01 15:42:09", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009087/0001225208-22-009087-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009087/xslF345X03/doc4.xml"}}
{"date": "2022-08-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-08-01 00:00:00", "acceptedDate": "2022-08-01 15:42:02", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009086/0001225208-22-009086-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009086/xslF345X03/doc4.xml"}}
{"date": "2022-08-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-08-01 00:00:00", "acceptedDate": "2022-08-01 15:41:55", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009085/0001225208-22-009085-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822009085/xslF345X03/doc4.xml"}}
{"date": "2022-07-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-28 00:00:00", "acceptedDate": "2022-07-28 08:09:00", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000091/0000078003-22-000091-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000091/pfe-07032022xex99.htm"}}
{"date": "2022-07-27", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-27 00:00:00", "acceptedDate": "2022-07-27 16:42:06", "formType": "SC 13D", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000089/0000078003-22-000089-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000089/haleon13dv1.htm"}}
{"date": "2022-07-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-18 00:00:00", "acceptedDate": "2022-07-18 12:40:03", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008815/0001225208-22-008815-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008815/xslF345X03/doc4.xml"}}
{"date": "2022-07-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-18 00:00:00", "acceptedDate": "2022-07-18 12:39:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008814/0001225208-22-008814-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008814/xslF345X03/doc4.xml"}}
{"date": "2022-07-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-18 00:00:00", "acceptedDate": "2022-07-18 12:39:53", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008813/0001225208-22-008813-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008813/xslF345X03/doc4.xml"}}
{"date": "2022-07-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-14 00:00:00", "acceptedDate": "2022-07-14 18:17:55", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008782/0001225208-22-008782-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008782/xslF345X03/doc4.xml"}}
{"date": "2022-07-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-14 00:00:00", "acceptedDate": "2022-07-14 18:17:51", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008781/0001225208-22-008781-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008781/xslF345X03/doc4.xml"}}
{"date": "2022-07-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-14 00:00:00", "acceptedDate": "2022-07-14 18:17:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008780/0001225208-22-008780-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008780/xslF345X03/doc4.xml"}}
{"date": "2022-07-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-05 00:00:00", "acceptedDate": "2022-07-05 16:53:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008511/0001225208-22-008511-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008511/xslF345X03/doc4.xml"}}
{"date": "2022-07-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-05 00:00:00", "acceptedDate": "2022-07-05 16:53:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008510/0001225208-22-008510-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008510/xslF345X03/doc4.xml"}}
{"date": "2022-07-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-05 00:00:00", "acceptedDate": "2022-07-05 16:53:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008509/0001225208-22-008509-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008509/xslF345X03/doc4.xml"}}
{"date": "2022-07-05", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-05 00:00:00", "acceptedDate": "2022-07-05 16:53:27", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008508/0001225208-22-008508-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008508/xslF345X03/doc4.xml"}}
{"date": "2022-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-01 00:00:00", "acceptedDate": "2022-07-01 17:07:55", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008399/0001225208-22-008399-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008399/xslF345X03/doc4.xml"}}
{"date": "2022-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-01 00:00:00", "acceptedDate": "2022-07-01 17:07:29", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008398/0001225208-22-008398-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008398/xslF345X03/doc4.xml"}}
{"date": "2022-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-07-01 00:00:00", "acceptedDate": "2022-07-01 17:07:14", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008397/0001225208-22-008397-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008397/xslF345X03/doc4.xml"}}
{"date": "2022-06-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-06-29 00:00:00", "acceptedDate": "2022-06-29 17:09:13", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000085/0000078003-22-000085-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000085/sch13g_valneva1x.htm"}}
{"date": "2022-06-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-06-28 00:00:00", "acceptedDate": "2022-06-28 16:19:32", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000082/0000078003-22-000082-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000082/akero13g.htm"}}
{"date": "2022-06-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-06-16 00:00:00", "acceptedDate": "2022-06-16 14:07:11", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008145/0001225208-22-008145-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008145/xslF345X03/doc4.xml"}}
{"date": "2022-06-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-06-16 00:00:00", "acceptedDate": "2022-06-16 14:07:04", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008144/0001225208-22-008144-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008144/xslF345X03/doc4.xml"}}
{"date": "2022-06-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-06-16 00:00:00", "acceptedDate": "2022-06-16 14:06:58", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008143/0001225208-22-008143-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822008143/xslF345X03/doc4.xml"}}
{"date": "2022-06-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-06-09 00:00:00", "acceptedDate": "2022-06-09 14:13:30", "formType": "11-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000079/0000078003-22-000079-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000079/pfizersavingsplanforemploy.htm"}}
{"date": "2022-06-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-06-09 00:00:00", "acceptedDate": "2022-06-09 14:09:33", "formType": "11-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000077/0000078003-22-000077-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000077/pfizersavingsplan2021.htm"}}
{"date": "2022-06-08", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-06-08 00:00:00", "acceptedDate": "2022-06-08 16:43:10", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007875/0001225208-22-007875-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007875/xslF345X03/doc4.xml"}}
{"date": "2022-06-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-06-01 00:00:00", "acceptedDate": "2022-06-01 17:51:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007556/0001225208-22-007556-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007556/xslF345X03/doc4.xml"}}
{"date": "2022-06-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-06-01 00:00:00", "acceptedDate": "2022-06-01 17:50:56", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007555/0001225208-22-007555-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007555/xslF345X03/doc4.xml"}}
{"date": "2022-06-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-06-01 00:00:00", "acceptedDate": "2022-06-01 17:50:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007554/0001225208-22-007554-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007554/xslF345X03/doc4.xml"}}
{"date": "2022-06-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-06-01 00:00:00", "acceptedDate": "2022-06-01 17:50:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007553/0001225208-22-007553-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007553/xslF345X03/doc4.xml"}}
{"date": "2022-05-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-17 00:00:00", "acceptedDate": "2022-05-17 07:48:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007104/0001225208-22-007104-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007104/xslF345X03/doc4.xml"}}
{"date": "2022-05-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-16 00:00:00", "acceptedDate": "2022-05-16 21:23:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007095/0001225208-22-007095-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007095/xslF345X03/doc4.xml"}}
{"date": "2022-05-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-16 00:00:00", "acceptedDate": "2022-05-16 21:22:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007094/0001225208-22-007094-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007094/xslF345X03/doc4.xml"}}
{"date": "2022-05-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-16 00:00:00", "acceptedDate": "2022-05-16 21:22:29", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007093/0001225208-22-007093-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007093/xslF345X03/doc4.xml"}}
{"date": "2022-05-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-13 00:00:00", "acceptedDate": "2022-05-13 17:38:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007019/0001225208-22-007019-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007019/xslF345X03/doc4.xml"}}
{"date": "2022-05-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-13 00:00:00", "acceptedDate": "2022-05-13 17:19:30", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007018/0001225208-22-007018-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822007018/xslF345X03/doc4.xml"}}
{"date": "2022-05-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-12 00:00:00", "acceptedDate": "2022-05-12 16:34:07", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006909/0001225208-22-006909-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006909/xslF345X03/doc4.xml"}}
{"date": "2022-05-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-12 00:00:00", "acceptedDate": "2022-05-12 16:34:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006908/0001225208-22-006908-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006908/xslF345X03/doc4.xml"}}
{"date": "2022-05-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-11 00:00:00", "acceptedDate": "2022-05-11 16:19:49", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000071/0000078003-22-000071-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000071/pfe-20220403.htm"}}
{"date": "2022-05-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-10 00:00:00", "acceptedDate": "2022-05-10 07:08:06", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312522145661/0001193125-22-145661-index.htm", "finalLink": ""}}
{"date": "2022-05-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-09 00:00:00", "acceptedDate": "2022-05-09 13:19:25", "formType": "3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006691/0001225208-22-006691-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006691/xslF345X02/doc3.xml"}}
{"date": "2022-05-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-03 00:00:00", "acceptedDate": "2022-05-03 08:08:57", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000068/0000078003-22-000068-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000068/pfe-20220503.htm"}}
{"date": "2022-05-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-02 00:00:00", "acceptedDate": "2022-05-02 16:36:20", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000066/0000078003-22-000066-index.htm", "finalLink": ""}}
{"date": "2022-05-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-02 00:00:00", "acceptedDate": "2022-05-02 16:20:51", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006322/0001225208-22-006322-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006322/xslF345X03/doc4.xml"}}
{"date": "2022-05-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-02 00:00:00", "acceptedDate": "2022-05-02 16:19:50", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006324/0001225208-22-006324-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006324/xslF345X03/doc4.xml"}}
{"date": "2022-05-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-05-02 00:00:00", "acceptedDate": "2022-05-02 16:19:39", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006323/0001225208-22-006323-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006323/xslF345X03/doc4.xml"}}
{"date": "2022-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-29 00:00:00", "acceptedDate": "2022-04-29 16:23:45", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006296/0001225208-22-006296-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006296/xslF345X03/doc4.xml"}}
{"date": "2022-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-29 00:00:00", "acceptedDate": "2022-04-29 16:22:26", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006295/0001225208-22-006295-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006295/xslF345X03/doc4.xml"}}
{"date": "2022-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-29 00:00:00", "acceptedDate": "2022-04-29 16:21:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006294/0001225208-22-006294-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006294/xslF345X03/doc4.xml"}}
{"date": "2022-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-29 00:00:00", "acceptedDate": "2022-04-29 16:21:17", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006293/0001225208-22-006293-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006293/xslF345X03/doc4.xml"}}
{"date": "2022-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-29 00:00:00", "acceptedDate": "2022-04-29 16:20:15", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006292/0001225208-22-006292-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006292/xslF345X03/doc4.xml"}}
{"date": "2022-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-29 00:00:00", "acceptedDate": "2022-04-29 16:18:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006290/0001225208-22-006290-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006290/xslF345X03/doc4.xml"}}
{"date": "2022-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-29 00:00:00", "acceptedDate": "2022-04-29 16:18:16", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006289/0001225208-22-006289-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006289/xslF345X03/doc4.xml"}}
{"date": "2022-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-29 00:00:00", "acceptedDate": "2022-04-29 16:17:26", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006288/0001225208-22-006288-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006288/xslF345X03/doc4.xml"}}
{"date": "2022-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-29 00:00:00", "acceptedDate": "2022-04-29 16:15:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006287/0001225208-22-006287-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006287/xslF345X03/doc4.xml"}}
{"date": "2022-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-29 00:00:00", "acceptedDate": "2022-04-29 16:15:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006286/0001225208-22-006286-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006286/xslF345X03/doc4.xml"}}
{"date": "2022-04-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-29 00:00:00", "acceptedDate": "2022-04-29 16:14:24", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006285/0001225208-22-006285-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822006285/xslF345X03/doc4.xml"}}
{"date": "2022-04-22", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-22 00:00:00", "acceptedDate": "2022-04-22 17:30:44", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000093041322000814/0000930413-22-000814-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000093041322000814/c103600_defa14a.htm"}}
{"date": "2022-04-20", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-20 00:00:00", "acceptedDate": "2022-04-20 16:41:43", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000062/0000078003-22-000062-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000062/pfe-20220420.htm"}}
{"date": "2022-04-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-15 00:00:00", "acceptedDate": "2022-04-15 13:49:56", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005859/0001225208-22-005859-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005859/xslF345X03/doc4.xml"}}
{"date": "2022-04-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-15 00:00:00", "acceptedDate": "2022-04-15 13:49:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005858/0001225208-22-005858-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005858/xslF345X03/doc4.xml"}}
{"date": "2022-04-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-15 00:00:00", "acceptedDate": "2022-04-15 13:49:37", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005857/0001225208-22-005857-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005857/xslF345X03/doc4.xml"}}
{"date": "2022-04-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-14 00:00:00", "acceptedDate": "2022-04-14 16:30:04", "formType": "UPLOAD", "link": "https://www.sec.gov/Archives/edgar/data/78003/000000000022004060/0000000000-22-004060-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000000000022004060/filename1.pdf"}}
{"date": "2022-04-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-14 00:00:00", "acceptedDate": "2022-04-14 15:00:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005836/0001225208-22-005836-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005836/xslF345X03/doc4.xml"}}
{"date": "2022-04-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-14 00:00:00", "acceptedDate": "2022-04-14 15:00:37", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005835/0001225208-22-005835-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005835/xslF345X03/doc4.xml"}}
{"date": "2022-04-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-14 00:00:00", "acceptedDate": "2022-04-14 15:00:30", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005834/0001225208-22-005834-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005834/xslF345X03/doc4.xml"}}
{"date": "2022-04-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-14 00:00:00", "acceptedDate": "2022-04-14 14:38:52", "formType": "PX14A6G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000121465922005234/0001214659-22-005234-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000121465922005234/o414220px14a6g.htm"}}
{"date": "2022-04-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-12 00:00:00", "acceptedDate": "2022-04-12 16:24:44", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000057/0000078003-22-000057-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000057/pfe-20220411.htm"}}
{"date": "2022-04-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-12 00:00:00", "acceptedDate": "2022-04-12 16:07:47", "formType": "CORRESP", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000055/0000078003-22-000055-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000055/filename1.htm"}}
{"date": "2022-04-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-11 00:00:00", "acceptedDate": "2022-04-11 11:10:37", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000093041322000699/0000930413-22-000699-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000093041322000699/c103510_defa14a.htm"}}
{"date": "2022-04-07", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-07 00:00:00", "acceptedDate": "2022-04-07 16:51:40", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000051/0000078003-22-000051-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000051/sch13da_cere.htm"}}
{"date": "2022-04-07", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-07 00:00:00", "acceptedDate": "2022-04-07 16:11:49", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000049/0000078003-22-000049-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000049/sch13da2_allo.htm"}}
{"date": "2022-04-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-06 00:00:00", "acceptedDate": "2022-04-06 17:07:55", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000093041322000655/0000930413-22-000655-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000093041322000655/c103509_defa14a.htm"}}
{"date": "2022-04-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-04 00:00:00", "acceptedDate": "2022-04-04 17:56:41", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005440/0001225208-22-005440-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005440/xslF345X03/doc4.xml"}}
{"date": "2022-04-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-04 00:00:00", "acceptedDate": "2022-04-04 17:56:36", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005439/0001225208-22-005439-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005439/xslF345X03/doc4.xml"}}
{"date": "2022-04-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-04 00:00:00", "acceptedDate": "2022-04-04 17:56:29", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005438/0001225208-22-005438-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005438/xslF345X03/doc4.xml"}}
{"date": "2022-04-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-04 00:00:00", "acceptedDate": "2022-04-04 17:56:24", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005437/0001225208-22-005437-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005437/xslF345X03/doc4.xml"}}
{"date": "2022-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-01 00:00:00", "acceptedDate": "2022-04-01 15:44:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005297/0001225208-22-005297-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005297/xslF345X03/doc4.xml"}}
{"date": "2022-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-01 00:00:00", "acceptedDate": "2022-04-01 15:44:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005296/0001225208-22-005296-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005296/xslF345X03/doc4.xml"}}
{"date": "2022-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-01 00:00:00", "acceptedDate": "2022-04-01 15:43:50", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005295/0001225208-22-005295-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005295/xslF345X03/doc4.xml"}}
{"date": "2022-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-04-01 00:00:00", "acceptedDate": "2022-04-01 15:43:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005294/0001225208-22-005294-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005294/xslF345X03/doc4.xml"}}
{"date": "2022-03-30", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-30 00:00:00", "acceptedDate": "2022-03-30 11:47:46", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000093041322000621/0000930413-22-000621-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000093041322000621/c103328_defa14a.htm"}}
{"date": "2022-03-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-29 00:00:00", "acceptedDate": "2022-03-29 16:31:14", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312522088144/0001193125-22-088144-index.htm", "finalLink": ""}}
{"date": "2022-03-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-28 00:00:00", "acceptedDate": "2022-03-28 12:31:08", "formType": "3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005094/0001225208-22-005094-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822005094/xslF345X02/doc3.xml"}}
{"date": "2022-03-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-21 00:00:00", "acceptedDate": "2022-03-21 16:25:51", "formType": "SC 13D", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000045/0000078003-22-000045-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000045/sch13dlongboardv1.htm"}}
{"date": "2022-03-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-21 00:00:00", "acceptedDate": "2022-03-21 13:54:16", "formType": "PX14A6G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000121465922004156/0001214659-22-004156-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000121465922004156/b32122px14a6g.htm"}}
{"date": "2022-03-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-21 00:00:00", "acceptedDate": "2022-03-21 13:50:50", "formType": "PX14A6G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000121465922004151/0001214659-22-004151-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000121465922004151/b321221px14a6g.htm"}}
{"date": "2022-03-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-17 00:00:00", "acceptedDate": "2022-03-17 11:35:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822004809/0001225208-22-004809-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822004809/xslF345X03/doc4.xml"}}
{"date": "2022-03-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-17 00:00:00", "acceptedDate": "2022-03-17 11:35:13", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822004808/0001225208-22-004808-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822004808/xslF345X03/doc4.xml"}}
{"date": "2022-03-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-17 00:00:00", "acceptedDate": "2022-03-17 11:35:07", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822004807/0001225208-22-004807-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822004807/xslF345X03/doc4.xml"}}
{"date": "2022-03-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-17 00:00:00", "acceptedDate": "2022-03-17 09:59:16", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000039/0000078003-22-000039-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000039/pfizer_notice22.htm"}}
{"date": "2022-03-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-17 00:00:00", "acceptedDate": "2022-03-17 09:53:34", "formType": "DEF 14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000038/0000078003-22-000038-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000038/proxywc22.htm"}}
{"date": "2022-03-07", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-07 00:00:00", "acceptedDate": "2022-03-07 09:40:01", "formType": "25-NSE", "link": "https://www.sec.gov/Archives/edgar/data/78003/000087666122000258/0000876661-22-000258-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000087666122000258/xslF25X02/primary_doc.xml"}}
{"date": "2022-03-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-04 00:00:00", "acceptedDate": "2022-03-04 16:13:12", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822004229/0001225208-22-004229-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822004229/xslF345X03/doc4.xml"}}
{"date": "2022-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-01 00:00:00", "acceptedDate": "2022-03-01 17:55:34", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003725/0001225208-22-003725-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003725/xslF345X03/doc4.xml"}}
{"date": "2022-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-01 00:00:00", "acceptedDate": "2022-03-01 17:55:32", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003724/0001225208-22-003724-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003724/xslF345X03/doc4.xml"}}
{"date": "2022-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-01 00:00:00", "acceptedDate": "2022-03-01 17:55:21", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003723/0001225208-22-003723-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003723/xslF345X03/doc4.xml"}}
{"date": "2022-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-01 00:00:00", "acceptedDate": "2022-03-01 16:03:11", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003667/0001225208-22-003667-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003667/xslF345X03/doc4.xml"}}
{"date": "2022-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-01 00:00:00", "acceptedDate": "2022-03-01 16:03:08", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003668/0001225208-22-003668-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003668/xslF345X03/doc4.xml"}}
{"date": "2022-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-01 00:00:00", "acceptedDate": "2022-03-01 16:03:02", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003666/0001225208-22-003666-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003666/xslF345X03/doc4.xml"}}
{"date": "2022-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-01 00:00:00", "acceptedDate": "2022-03-01 16:02:50", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003665/0001225208-22-003665-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003665/xslF345X03/doc4.xml"}}
{"date": "2022-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-01 00:00:00", "acceptedDate": "2022-03-01 16:02:40", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003664/0001225208-22-003664-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003664/xslF345X03/doc4.xml"}}
{"date": "2022-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-01 00:00:00", "acceptedDate": "2022-03-01 16:02:33", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003663/0001225208-22-003663-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003663/xslF345X03/doc4.xml"}}
{"date": "2022-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-01 00:00:00", "acceptedDate": "2022-03-01 16:01:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003662/0001225208-22-003662-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003662/xslF345X03/doc4.xml"}}
{"date": "2022-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-03-01 00:00:00", "acceptedDate": "2022-03-01 16:01:10", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003661/0001225208-22-003661-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003661/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 18:40:18", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003473/0001225208-22-003473-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003473/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 18:29:37", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003472/0001225208-22-003472-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003472/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 18:27:06", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003471/0001225208-22-003471-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003471/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 18:23:02", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003470/0001225208-22-003470-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003470/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 18:20:39", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003469/0001225208-22-003469-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003469/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 18:17:31", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003468/0001225208-22-003468-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003468/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 18:10:12", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003467/0001225208-22-003467-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003467/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 18:04:49", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003466/0001225208-22-003466-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003466/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 17:46:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003465/0001225208-22-003465-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003465/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 17:43:22", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003464/0001225208-22-003464-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003464/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 17:43:11", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003463/0001225208-22-003463-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003463/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 17:06:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003460/0001225208-22-003460-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003460/xslF345X03/doc4.xml"}}
{"date": "2022-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-25 00:00:00", "acceptedDate": "2022-02-25 17:06:24", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003459/0001225208-22-003459-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822003459/xslF345X03/doc4.xml"}}
{"date": "2022-02-24", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-24 00:00:00", "acceptedDate": "2022-02-24 14:25:01", "formType": "10-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000027/0000078003-22-000027-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000027/pfe-20211231.htm"}}
{"date": "2022-02-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-17 00:00:00", "acceptedDate": "2022-02-17 18:51:51", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822002646/0001225208-22-002646-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822002646/xslF345X03/doc4.xml"}}
{"date": "2022-02-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-17 00:00:00", "acceptedDate": "2022-02-17 18:50:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822002645/0001225208-22-002645-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822002645/xslF345X03/doc4.xml"}}
{"date": "2022-02-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-17 00:00:00", "acceptedDate": "2022-02-17 18:50:34", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822002644/0001225208-22-002644-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822002644/xslF345X03/doc4.xml"}}
{"date": "2022-02-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-14 00:00:00", "acceptedDate": "2022-02-14 16:04:09", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000024/0000078003-22-000024-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000024/effector13g_2x2022vf.htm"}}
{"date": "2022-02-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-14 00:00:00", "acceptedDate": "2022-02-14 12:06:28", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000009375122000393/0000093751-22-000393-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000009375122000393/PFIZER_INC.txt"}}
{"date": "2022-02-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-14 00:00:00", "acceptedDate": "2022-02-11 19:01:39", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000020/0000078003-22-000020-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000020/springworks_13gax2xvf.htm"}}
{"date": "2022-02-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-14 00:00:00", "acceptedDate": "2022-02-11 18:06:57", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000018/0000078003-22-000018-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000018/cortexyme_13gax3x2x22f.htm"}}
{"date": "2022-02-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-14 00:00:00", "acceptedDate": "2022-02-11 17:32:26", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000016/0000078003-22-000016-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000016/contrafect_13ga2x2x22f.htm"}}
{"date": "2022-02-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-11 00:00:00", "acceptedDate": "2022-02-11 17:10:06", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000014/0000078003-22-000014-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000014/essa_sc13ga1222f.htm"}}
{"date": "2022-02-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-11 00:00:00", "acceptedDate": "2022-02-11 16:55:43", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000012/0000078003-22-000012-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000012/bioatla_13gax2x22f.htm"}}
{"date": "2022-02-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-11 00:00:00", "acceptedDate": "2022-02-11 16:26:42", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000010/0000078003-22-000010-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000010/pyxis_13gx2x22vf.htm"}}
{"date": "2022-02-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-11 00:00:00", "acceptedDate": "2022-02-11 16:06:55", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000008/0000078003-22-000008-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000008/wave_13gax2x22xvf.htm"}}
{"date": "2022-02-11", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-11 00:00:00", "acceptedDate": "2022-02-11 15:54:39", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000006/0000078003-22-000006-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000006/a4dm_13gax2x22f.htm"}}
{"date": "2022-02-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-10 00:00:00", "acceptedDate": "2022-02-10 08:32:46", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000110465922018324/0001104659-22-018324-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000110465922018324/tv01654-pfizerinc.htm"}}
{"date": "2022-02-08", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-08 00:00:00", "acceptedDate": "2022-02-08 08:53:53", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000003/0000078003-22-000003-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800322000003/pfe-20220208.htm"}}
{"date": "2022-02-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-02 00:00:00", "acceptedDate": "2022-02-02 08:44:39", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822001256/0001225208-22-001256-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822001256/xslF345X03/doc4.xml"}}
{"date": "2022-02-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-02-01 00:00:00", "acceptedDate": "2022-01-31 17:59:24", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000083423722004011/0000834237-22-004011-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000083423722004011/us7170811035_012822.txt"}}
{"date": "2022-01-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-01-14 00:00:00", "acceptedDate": "2022-01-14 14:50:41", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000743/0001225208-22-000743-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000743/xslF345X03/doc4.xml"}}
{"date": "2022-01-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-01-14 00:00:00", "acceptedDate": "2022-01-14 14:50:33", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000742/0001225208-22-000742-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000742/xslF345X03/doc4.xml"}}
{"date": "2022-01-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-01-14 00:00:00", "acceptedDate": "2022-01-14 14:50:26", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000741/0001225208-22-000741-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000741/xslF345X03/doc4.xml"}}
{"date": "2022-01-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-01-10 00:00:00", "acceptedDate": "2022-01-10 09:15:20", "formType": "3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000620/0001225208-22-000620-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000620/xslF345X02/doc3.xml"}}
{"date": "2022-01-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-01-04 00:00:00", "acceptedDate": "2022-01-04 14:16:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000150/0001225208-22-000150-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000150/xslF345X03/doc4.xml"}}
{"date": "2022-01-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-01-04 00:00:00", "acceptedDate": "2022-01-04 14:16:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000149/0001225208-22-000149-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000149/xslF345X03/doc4.xml"}}
{"date": "2022-01-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-01-04 00:00:00", "acceptedDate": "2022-01-04 14:16:34", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000148/0001225208-22-000148-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000148/xslF345X03/doc4.xml"}}
{"date": "2022-01-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-01-04 00:00:00", "acceptedDate": "2022-01-04 14:16:29", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000147/0001225208-22-000147-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000147/xslF345X03/doc4.xml"}}
{"date": "2022-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-01-03 00:00:00", "acceptedDate": "2022-01-03 10:27:29", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000022/0001225208-22-000022-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000022/xslF345X03/doc4.xml"}}
{"date": "2022-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-01-03 00:00:00", "acceptedDate": "2022-01-03 10:27:25", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000021/0001225208-22-000021-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000021/xslF345X03/doc4.xml"}}
{"date": "2022-01-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2022-01-03 00:00:00", "acceptedDate": "2022-01-03 10:27:21", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000020/0001225208-22-000020-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520822000020/xslF345X03/doc4.xml"}}
{"date": "2021-12-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-23 00:00:00", "acceptedDate": "2021-12-23 15:07:32", "formType": "CORRESP", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000122/0000078003-21-000122-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000122/filename1.htm"}}
{"date": "2021-12-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-21 00:00:00", "acceptedDate": "2021-12-21 18:31:55", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821015184/0001225208-21-015184-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821015184/xslF345X03/doc4.xml"}}
{"date": "2021-12-21", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-21 00:00:00", "acceptedDate": "2021-12-21 18:03:55", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821015181/0001225208-21-015181-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821015181/xslF345X03/doc4.xml"}}
{"date": "2021-12-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-16 00:00:00", "acceptedDate": "2021-12-16 18:05:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821015081/0001225208-21-015081-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821015081/xslF345X03/doc4.xml"}}
{"date": "2021-12-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-16 00:00:00", "acceptedDate": "2021-12-16 18:05:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821015080/0001225208-21-015080-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821015080/xslF345X03/doc4.xml"}}
{"date": "2021-12-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-16 00:00:00", "acceptedDate": "2021-12-16 18:05:34", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821015079/0001225208-21-015079-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821015079/xslF345X03/doc4.xml"}}
{"date": "2021-12-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-16 00:00:00", "acceptedDate": "2021-12-16 18:05:28", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821015078/0001225208-21-015078-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821015078/xslF345X03/doc4.xml"}}
{"date": "2021-12-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-15 00:00:00", "acceptedDate": "2021-12-15 16:18:14", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000118/0000078003-21-000118-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000118/pfe-20211209.htm"}}
{"date": "2021-12-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-10 00:00:00", "acceptedDate": "2021-12-10 13:30:02", "formType": "UPLOAD", "link": "https://www.sec.gov/Archives/edgar/data/78003/000000000021014850/0000000000-21-014850-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000000000021014850/filename1.pdf"}}
{"date": "2021-12-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-06 00:00:00", "acceptedDate": "2021-12-06 17:18:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014513/0001225208-21-014513-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014513/xslF345X03/doc4.xml"}}
{"date": "2021-12-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-06 00:00:00", "acceptedDate": "2021-12-06 17:18:50", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014512/0001225208-21-014512-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014512/xslF345X03/doc4.xml"}}
{"date": "2021-12-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-01 00:00:00", "acceptedDate": "2021-12-01 16:50:24", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014282/0001225208-21-014282-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014282/xslF345X03/doc4.xml"}}
{"date": "2021-12-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-01 00:00:00", "acceptedDate": "2021-12-01 16:50:22", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014281/0001225208-21-014281-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014281/xslF345X03/doc4.xml"}}
{"date": "2021-12-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-01 00:00:00", "acceptedDate": "2021-12-01 16:50:18", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014280/0001225208-21-014280-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014280/xslF345X03/doc4.xml"}}
{"date": "2021-12-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-12-01 00:00:00", "acceptedDate": "2021-12-01 16:50:10", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014279/0001225208-21-014279-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014279/xslF345X03/doc4.xml"}}
{"date": "2021-11-30", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-30 00:00:00", "acceptedDate": "2021-11-30 16:30:36", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014220/0001225208-21-014220-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014220/xslF345X03/doc4.xml"}}
{"date": "2021-11-30", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-30 00:00:00", "acceptedDate": "2021-11-30 16:30:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014219/0001225208-21-014219-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821014219/xslF345X03/doc4.xml"}}
{"date": "2021-11-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-19 00:00:00", "acceptedDate": "2021-11-19 16:15:33", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000114/0000078003-21-000114-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000114/pfe-20211115.htm"}}
{"date": "2021-11-19", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-19 00:00:00", "acceptedDate": "2021-11-19 16:02:36", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000112/0000078003-21-000112-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000112/cardiff_form13gx11x21.htm"}}
{"date": "2021-11-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-16 00:00:00", "acceptedDate": "2021-11-16 17:37:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013903/0001225208-21-013903-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013903/xslF345X03/doc4.xml"}}
{"date": "2021-11-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-16 00:00:00", "acceptedDate": "2021-11-16 17:36:56", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013902/0001225208-21-013902-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013902/xslF345X03/doc4.xml"}}
{"date": "2021-11-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-16 00:00:00", "acceptedDate": "2021-11-16 17:36:49", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013901/0001225208-21-013901-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013901/xslF345X03/doc4.xml"}}
{"date": "2021-11-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-16 00:00:00", "acceptedDate": "2021-11-16 17:36:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013900/0001225208-21-013900-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013900/xslF345X03/doc4.xml"}}
{"date": "2021-11-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-15 00:00:00", "acceptedDate": "2021-11-15 17:40:30", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013883/0001225208-21-013883-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013883/xslF345X03/doc4.xml"}}
{"date": "2021-11-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-15 00:00:00", "acceptedDate": "2021-11-15 17:32:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013881/0001225208-21-013881-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013881/xslF345X03/doc4.xml"}}
{"date": "2021-11-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-12 00:00:00", "acceptedDate": "2021-11-12 18:08:08", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013850/0001225208-21-013850-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013850/xslF345X03/doc4.xml"}}
{"date": "2021-11-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-12 00:00:00", "acceptedDate": "2021-11-12 06:06:57", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000107/0000078003-21-000107-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000107/pfe-20211003.htm"}}
{"date": "2021-11-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-02 00:00:00", "acceptedDate": "2021-11-02 11:46:32", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013419/0001225208-21-013419-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013419/xslF345X03/doc4.xml"}}
{"date": "2021-11-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-02 00:00:00", "acceptedDate": "2021-11-02 11:46:26", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013418/0001225208-21-013418-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013418/xslF345X03/doc4.xml"}}
{"date": "2021-11-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-02 00:00:00", "acceptedDate": "2021-11-02 11:46:17", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013417/0001225208-21-013417-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013417/xslF345X03/doc4.xml"}}
{"date": "2021-11-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-02 00:00:00", "acceptedDate": "2021-11-02 11:46:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013416/0001225208-21-013416-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013416/xslF345X03/doc4.xml"}}
{"date": "2021-11-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-11-02 00:00:00", "acceptedDate": "2021-11-02 08:25:52", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000104/0000078003-21-000104-index.htm", "finalLink": ""}}
{"date": "2021-10-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-18 00:00:00", "acceptedDate": "2021-10-18 18:47:46", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013136/0001225208-21-013136-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013136/xslF345X03/doc4.xml"}}
{"date": "2021-10-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-18 00:00:00", "acceptedDate": "2021-10-18 18:47:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013134/0001225208-21-013134-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013134/xslF345X03/doc4.xml"}}
{"date": "2021-10-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-18 00:00:00", "acceptedDate": "2021-10-18 18:47:40", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013135/0001225208-21-013135-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013135/xslF345X03/doc4.xml"}}
{"date": "2021-10-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-18 00:00:00", "acceptedDate": "2021-10-18 18:47:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013133/0001225208-21-013133-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013133/xslF345X03/doc4.xml"}}
{"date": "2021-10-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-13 00:00:00", "acceptedDate": "2021-10-13 15:46:56", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013101/0001225208-21-013101-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013101/xslF345X03/doc4.xml"}}
{"date": "2021-10-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-13 00:00:00", "acceptedDate": "2021-10-13 15:46:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013100/0001225208-21-013100-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013100/xslF345X03/doc4.xml"}}
{"date": "2021-10-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-13 00:00:00", "acceptedDate": "2021-10-13 15:46:41", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013099/0001225208-21-013099-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013099/xslF345X03/doc4.xml"}}
{"date": "2021-10-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-13 00:00:00", "acceptedDate": "2021-10-13 15:46:34", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013098/0001225208-21-013098-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821013098/xslF345X03/doc4.xml"}}
{"date": "2021-10-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-04 00:00:00", "acceptedDate": "2021-10-04 17:30:15", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012800/0001225208-21-012800-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012800/xslF345X03/doc4.xml"}}
{"date": "2021-10-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-04 00:00:00", "acceptedDate": "2021-10-04 17:30:07", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012799/0001225208-21-012799-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012799/xslF345X03/doc4.xml"}}
{"date": "2021-10-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-04 00:00:00", "acceptedDate": "2021-10-04 17:30:04", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012798/0001225208-21-012798-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012798/xslF345X03/doc4.xml"}}
{"date": "2021-10-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-04 00:00:00", "acceptedDate": "2021-10-04 17:30:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012797/0001225208-21-012797-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012797/xslF345X03/doc4.xml"}}
{"date": "2021-10-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-01 00:00:00", "acceptedDate": "2021-10-01 15:43:01", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012643/0001225208-21-012643-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012643/xslF345X03/doc4.xml"}}
{"date": "2021-10-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-01 00:00:00", "acceptedDate": "2021-10-01 15:42:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012642/0001225208-21-012642-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012642/xslF345X03/doc4.xml"}}
{"date": "2021-10-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-01 00:00:00", "acceptedDate": "2021-10-01 15:42:51", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012641/0001225208-21-012641-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012641/xslF345X03/doc4.xml"}}
{"date": "2021-10-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-10-01 00:00:00", "acceptedDate": "2021-10-01 15:42:49", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012640/0001225208-21-012640-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012640/xslF345X03/doc4.xml"}}
{"date": "2021-09-20", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-20 00:00:00", "acceptedDate": "2021-09-20 16:25:45", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000101/0000078003-21-000101-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000101/a13g_arvinas.htm"}}
{"date": "2021-09-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-17 00:00:00", "acceptedDate": "2021-09-17 16:27:08", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000099/0000078003-21-000099-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000099/sch13d_axcere.htm"}}
{"date": "2021-09-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-17 00:00:00", "acceptedDate": "2021-09-17 16:17:55", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000098/0000078003-21-000098-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000098/sch13a_allo1.htm"}}
{"date": "2021-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-16 00:00:00", "acceptedDate": "2021-09-16 18:10:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012431/0001225208-21-012431-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012431/xslF345X03/doc4.xml"}}
{"date": "2021-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-16 00:00:00", "acceptedDate": "2021-09-16 18:10:08", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012430/0001225208-21-012430-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012430/xslF345X03/doc4.xml"}}
{"date": "2021-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-16 00:00:00", "acceptedDate": "2021-09-16 18:09:56", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012429/0001225208-21-012429-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012429/xslF345X03/doc4.xml"}}
{"date": "2021-09-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-16 00:00:00", "acceptedDate": "2021-09-16 18:09:45", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012428/0001225208-21-012428-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821012428/xslF345X03/doc4.xml"}}
{"date": "2021-09-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-02 00:00:00", "acceptedDate": "2021-09-02 16:14:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011947/0001225208-21-011947-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011947/xslF345X03/doc4.xml"}}
{"date": "2021-09-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-02 00:00:00", "acceptedDate": "2021-09-02 16:08:01", "formType": "3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011946/0001225208-21-011946-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011946/xslF345X02/doc3.xml"}}
{"date": "2021-09-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-01 00:00:00", "acceptedDate": "2021-09-01 16:03:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011910/0001225208-21-011910-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011910/xslF345X03/doc4.xml"}}
{"date": "2021-09-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-01 00:00:00", "acceptedDate": "2021-09-01 16:03:46", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011909/0001225208-21-011909-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011909/xslF345X03/doc4.xml"}}
{"date": "2021-09-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-01 00:00:00", "acceptedDate": "2021-09-01 16:03:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011908/0001225208-21-011908-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011908/xslF345X03/doc4.xml"}}
{"date": "2021-09-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-09-01 00:00:00", "acceptedDate": "2021-09-01 16:03:40", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011907/0001225208-21-011907-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011907/xslF345X03/doc4.xml"}}
{"date": "2021-08-18", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-18 00:00:00", "acceptedDate": "2021-08-18 16:06:08", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312521250347/0001193125-21-250347-index.htm", "finalLink": ""}}
{"date": "2021-08-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-17 00:00:00", "acceptedDate": "2021-08-17 16:02:34", "formType": "424B5", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312521249117/0001193125-21-249117-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312521249117/d195617d424b5.htm"}}
{"date": "2021-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-16 00:00:00", "acceptedDate": "2021-08-16 20:13:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011505/0001225208-21-011505-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011505/xslF345X03/doc4.xml"}}
{"date": "2021-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-16 00:00:00", "acceptedDate": "2021-08-16 20:13:11", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011504/0001225208-21-011504-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011504/xslF345X03/doc4.xml"}}
{"date": "2021-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-16 00:00:00", "acceptedDate": "2021-08-16 20:12:53", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011503/0001225208-21-011503-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011503/xslF345X03/doc4.xml"}}
{"date": "2021-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-16 00:00:00", "acceptedDate": "2021-08-16 20:12:45", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011502/0001225208-21-011502-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011502/xslF345X03/doc4.xml"}}
{"date": "2021-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-16 00:00:00", "acceptedDate": "2021-08-16 17:07:34", "formType": "FWP", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312521247924/0001193125-21-247924-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312521247924/d213610dfwp.htm"}}
{"date": "2021-08-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-16 00:00:00", "acceptedDate": "2021-08-16 08:52:52", "formType": "424B3", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312521247064/0001193125-21-247064-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312521247064/d195617d424b3.htm"}}
{"date": "2021-08-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-12 00:00:00", "acceptedDate": "2021-08-12 16:01:31", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000093/0000078003-21-000093-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000093/pfe-20210704.htm"}}
{"date": "2021-08-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-02 00:00:00", "acceptedDate": "2021-08-02 19:03:56", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011036/0001225208-21-011036-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011036/xslF345X03/doc4.xml"}}
{"date": "2021-08-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-02 00:00:00", "acceptedDate": "2021-08-02 19:03:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011035/0001225208-21-011035-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011035/xslF345X03/doc4.xml"}}
{"date": "2021-08-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-02 00:00:00", "acceptedDate": "2021-08-02 19:03:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011034/0001225208-21-011034-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011034/xslF345X03/doc4.xml"}}
{"date": "2021-08-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-08-02 00:00:00", "acceptedDate": "2021-08-02 19:02:32", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011033/0001225208-21-011033-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821011033/xslF345X03/doc4.xml"}}
{"date": "2021-07-28", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-28 00:00:00", "acceptedDate": "2021-07-28 08:04:28", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000090/0000078003-21-000090-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000090/pfe-20210728.htm"}}
{"date": "2021-07-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-16 00:00:00", "acceptedDate": "2021-07-16 16:14:03", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010712/0001225208-21-010712-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010712/xslF345X03/doc4.xml"}}
{"date": "2021-07-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-16 00:00:00", "acceptedDate": "2021-07-16 16:13:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010711/0001225208-21-010711-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010711/xslF345X03/doc4.xml"}}
{"date": "2021-07-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-16 00:00:00", "acceptedDate": "2021-07-16 16:13:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010710/0001225208-21-010710-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010710/xslF345X03/doc4.xml"}}
{"date": "2021-07-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-16 00:00:00", "acceptedDate": "2021-07-16 16:13:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010709/0001225208-21-010709-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010709/xslF345X03/doc4.xml"}}
{"date": "2021-07-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-14 00:00:00", "acceptedDate": "2021-07-14 15:49:30", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010644/0001225208-21-010644-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010644/xslF345X03/doc4.xml"}}
{"date": "2021-07-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-14 00:00:00", "acceptedDate": "2021-07-14 15:49:25", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010643/0001225208-21-010643-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010643/xslF345X03/doc4.xml"}}
{"date": "2021-07-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-14 00:00:00", "acceptedDate": "2021-07-14 15:49:21", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010642/0001225208-21-010642-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010642/xslF345X03/doc4.xml"}}
{"date": "2021-07-14", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-14 00:00:00", "acceptedDate": "2021-07-14 15:49:15", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010641/0001225208-21-010641-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010641/xslF345X03/doc4.xml"}}
{"date": "2021-07-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-09 00:00:00", "acceptedDate": "2021-07-09 16:38:25", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000087/0000078003-21-000087-index.htm", "finalLink": ""}}
{"date": "2021-07-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-09 00:00:00", "acceptedDate": "2021-07-09 16:25:02", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000085/0000078003-21-000085-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000085/sperosc13g.htm"}}
{"date": "2021-07-09", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-09 00:00:00", "acceptedDate": "2021-07-09 16:16:32", "formType": "SC 13D/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000083/0000078003-21-000083-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000083/cerevel_13dxa1.htm"}}
{"date": "2021-07-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-06 00:00:00", "acceptedDate": "2021-07-06 17:26:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010308/0001225208-21-010308-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010308/xslF345X03/doc4.xml"}}
{"date": "2021-07-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-06 00:00:00", "acceptedDate": "2021-07-06 17:25:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010307/0001225208-21-010307-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010307/xslF345X03/doc4.xml"}}
{"date": "2021-07-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-06 00:00:00", "acceptedDate": "2021-07-06 17:25:28", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010306/0001225208-21-010306-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010306/xslF345X03/doc4.xml"}}
{"date": "2021-07-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-06 00:00:00", "acceptedDate": "2021-07-06 17:25:18", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010305/0001225208-21-010305-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010305/xslF345X03/doc4.xml"}}
{"date": "2021-07-06", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-06 00:00:00", "acceptedDate": "2021-07-06 17:23:08", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010304/0001225208-21-010304-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821010304/xslF345X03/doc4.xml"}}
{"date": "2021-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-01 00:00:00", "acceptedDate": "2021-07-01 16:10:07", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009914/0001225208-21-009914-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009914/xslF345X03/doc4.xml"}}
{"date": "2021-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-01 00:00:00", "acceptedDate": "2021-07-01 16:10:01", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009913/0001225208-21-009913-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009913/xslF345X03/doc4.xml"}}
{"date": "2021-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-01 00:00:00", "acceptedDate": "2021-07-01 16:09:36", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009912/0001225208-21-009912-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009912/xslF345X03/doc4.xml"}}
{"date": "2021-07-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-07-01 00:00:00", "acceptedDate": "2021-07-01 16:08:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009911/0001225208-21-009911-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009911/xslF345X03/doc4.xml"}}
{"date": "2021-06-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-06-16 00:00:00", "acceptedDate": "2021-06-16 14:01:24", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009459/0001225208-21-009459-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009459/xslF345X03/doc4.xml"}}
{"date": "2021-06-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-06-16 00:00:00", "acceptedDate": "2021-06-16 14:01:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009458/0001225208-21-009458-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009458/xslF345X03/doc4.xml"}}
{"date": "2021-06-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-06-16 00:00:00", "acceptedDate": "2021-06-16 14:01:16", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009457/0001225208-21-009457-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009457/xslF345X03/doc4.xml"}}
{"date": "2021-06-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-06-16 00:00:00", "acceptedDate": "2021-06-16 14:01:12", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009456/0001225208-21-009456-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821009456/xslF345X03/doc4.xml"}}
{"date": "2021-06-07", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-06-07 00:00:00", "acceptedDate": "2021-06-07 14:47:50", "formType": "11-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000077/0000078003-21-000077-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000077/wyethunionsavingsplan2020.htm"}}
{"date": "2021-06-07", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-06-07 00:00:00", "acceptedDate": "2021-06-07 14:45:59", "formType": "11-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000075/0000078003-21-000075-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000075/pfizersavingsplanforemploy.htm"}}
{"date": "2021-06-07", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-06-07 00:00:00", "acceptedDate": "2021-06-07 14:44:20", "formType": "11-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000073/0000078003-21-000073-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000073/pfizersavingsplan2020.htm"}}
{"date": "2021-06-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-06-01 00:00:00", "acceptedDate": "2021-06-01 15:34:02", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008703/0001225208-21-008703-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008703/xslF345X03/doc4.xml"}}
{"date": "2021-06-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-06-01 00:00:00", "acceptedDate": "2021-06-01 15:34:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008702/0001225208-21-008702-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008702/xslF345X03/doc4.xml"}}
{"date": "2021-06-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-06-01 00:00:00", "acceptedDate": "2021-06-01 15:33:50", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008701/0001225208-21-008701-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008701/xslF345X03/doc4.xml"}}
{"date": "2021-06-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-06-01 00:00:00", "acceptedDate": "2021-06-01 15:33:46", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008700/0001225208-21-008700-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008700/xslF345X03/doc4.xml"}}
{"date": "2021-05-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-05-17 00:00:00", "acceptedDate": "2021-05-17 16:44:18", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008219/0001225208-21-008219-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008219/xslF345X03/doc4.xml"}}
{"date": "2021-05-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-05-17 00:00:00", "acceptedDate": "2021-05-17 16:44:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008218/0001225208-21-008218-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008218/xslF345X03/doc4.xml"}}
{"date": "2021-05-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-05-17 00:00:00", "acceptedDate": "2021-05-17 16:43:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008217/0001225208-21-008217-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008217/xslF345X03/doc4.xml"}}
{"date": "2021-05-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-05-17 00:00:00", "acceptedDate": "2021-05-17 16:43:49", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008216/0001225208-21-008216-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821008216/xslF345X03/doc4.xml"}}
{"date": "2021-05-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-05-13 00:00:00", "acceptedDate": "2021-05-13 11:32:26", "formType": "10-Q", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000065/0000078003-21-000065-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000065/pfe-20210404.htm"}}
{"date": "2021-05-07", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-05-07 00:00:00", "acceptedDate": "2021-05-07 16:10:01", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821007736/0001225208-21-007736-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821007736/xslF345X03/doc4.xml"}}
{"date": "2021-05-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-05-04 00:00:00", "acceptedDate": "2021-05-04 08:15:30", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000062/0000078003-21-000062-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000062/pfe-20210504.htm"}}
{"date": "2021-05-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-05-03 00:00:00", "acceptedDate": "2021-05-03 17:32:08", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821007395/0001225208-21-007395-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821007395/xslF345X03/doc4.xml"}}
{"date": "2021-05-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-05-03 00:00:00", "acceptedDate": "2021-05-03 17:32:01", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821007394/0001225208-21-007394-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821007394/xslF345X03/doc4.xml"}}
{"date": "2021-05-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-05-03 00:00:00", "acceptedDate": "2021-05-03 17:31:56", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821007393/0001225208-21-007393-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821007393/xslF345X03/doc4.xml"}}
{"date": "2021-05-03", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-05-03 00:00:00", "acceptedDate": "2021-05-03 17:31:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821007392/0001225208-21-007392-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821007392/xslF345X03/doc4.xml"}}
{"date": "2021-04-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-26 00:00:00", "acceptedDate": "2021-04-26 09:30:31", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000059/0000078003-21-000059-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000059/pfe-20210422.htm"}}
{"date": "2021-04-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-23 00:00:00", "acceptedDate": "2021-04-23 14:04:09", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006950/0001225208-21-006950-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006950/xslF345X03/doc4.xml"}}
{"date": "2021-04-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-23 00:00:00", "acceptedDate": "2021-04-23 14:04:05", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006949/0001225208-21-006949-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006949/xslF345X03/doc4.xml"}}
{"date": "2021-04-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-23 00:00:00", "acceptedDate": "2021-04-23 14:04:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006948/0001225208-21-006948-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006948/xslF345X03/doc4.xml"}}
{"date": "2021-04-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-23 00:00:00", "acceptedDate": "2021-04-23 14:03:48", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006947/0001225208-21-006947-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006947/xslF345X03/doc4.xml"}}
{"date": "2021-04-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-23 00:00:00", "acceptedDate": "2021-04-23 14:03:43", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006946/0001225208-21-006946-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006946/xslF345X03/doc4.xml"}}
{"date": "2021-04-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-23 00:00:00", "acceptedDate": "2021-04-23 14:02:37", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006945/0001225208-21-006945-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006945/xslF345X03/doc4.xml"}}
{"date": "2021-04-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-23 00:00:00", "acceptedDate": "2021-04-23 14:02:33", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006944/0001225208-21-006944-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006944/xslF345X03/doc4.xml"}}
{"date": "2021-04-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-23 00:00:00", "acceptedDate": "2021-04-23 14:02:27", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006943/0001225208-21-006943-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006943/xslF345X03/doc4.xml"}}
{"date": "2021-04-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-23 00:00:00", "acceptedDate": "2021-04-23 14:02:23", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006942/0001225208-21-006942-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006942/xslF345X03/doc4.xml"}}
{"date": "2021-04-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-23 00:00:00", "acceptedDate": "2021-04-23 14:02:18", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006941/0001225208-21-006941-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006941/xslF345X03/doc4.xml"}}
{"date": "2021-04-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-23 00:00:00", "acceptedDate": "2021-04-23 14:01:15", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006940/0001225208-21-006940-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006940/xslF345X03/doc4.xml"}}
{"date": "2021-04-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-16 00:00:00", "acceptedDate": "2021-04-16 17:51:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006821/0001225208-21-006821-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006821/xslF345X03/doc4.xml"}}
{"date": "2021-04-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-16 00:00:00", "acceptedDate": "2021-04-16 17:51:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006820/0001225208-21-006820-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006820/xslF345X03/doc4.xml"}}
{"date": "2021-04-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-16 00:00:00", "acceptedDate": "2021-04-16 17:51:31", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006819/0001225208-21-006819-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006819/xslF345X03/doc4.xml"}}
{"date": "2021-04-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-16 00:00:00", "acceptedDate": "2021-04-16 17:51:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006818/0001225208-21-006818-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006818/xslF345X03/doc4.xml"}}
{"date": "2021-04-15", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-15 00:00:00", "acceptedDate": "2021-04-15 14:50:11", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000055/0000078003-21-000055-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000055/defa_14coverxv1.htm"}}
{"date": "2021-04-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-13 00:00:00", "acceptedDate": "2021-04-13 17:35:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006739/0001225208-21-006739-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006739/xslF345X03/doc4.xml"}}
{"date": "2021-04-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-13 00:00:00", "acceptedDate": "2021-04-13 17:35:33", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006738/0001225208-21-006738-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006738/xslF345X03/doc4.xml"}}
{"date": "2021-04-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-13 00:00:00", "acceptedDate": "2021-04-13 17:35:29", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006737/0001225208-21-006737-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006737/xslF345X03/doc4.xml"}}
{"date": "2021-04-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-13 00:00:00", "acceptedDate": "2021-04-13 17:35:20", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006736/0001225208-21-006736-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006736/xslF345X03/doc4.xml"}}
{"date": "2021-04-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-02 00:00:00", "acceptedDate": "2021-04-02 14:47:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006306/0001225208-21-006306-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006306/xslF345X03/doc4.xml"}}
{"date": "2021-04-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-02 00:00:00", "acceptedDate": "2021-04-02 14:47:53", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006305/0001225208-21-006305-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006305/xslF345X03/doc4.xml"}}
{"date": "2021-04-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-02 00:00:00", "acceptedDate": "2021-04-02 14:47:50", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006304/0001225208-21-006304-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006304/xslF345X03/doc4.xml"}}
{"date": "2021-04-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-02 00:00:00", "acceptedDate": "2021-04-02 14:47:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006303/0001225208-21-006303-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006303/xslF345X03/doc4.xml"}}
{"date": "2021-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-01 00:00:00", "acceptedDate": "2021-04-01 17:49:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006236/0001225208-21-006236-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006236/xslF345X03/doc4.xml"}}
{"date": "2021-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-01 00:00:00", "acceptedDate": "2021-04-01 17:49:34", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006235/0001225208-21-006235-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006235/xslF345X03/doc4.xml"}}
{"date": "2021-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-01 00:00:00", "acceptedDate": "2021-04-01 17:49:28", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006234/0001225208-21-006234-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006234/xslF345X03/doc4.xml"}}
{"date": "2021-04-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-04-01 00:00:00", "acceptedDate": "2021-04-01 17:45:54", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006227/0001225208-21-006227-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821006227/xslF345X03/doc4.xml"}}
{"date": "2021-03-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-29 00:00:00", "acceptedDate": "2021-03-29 14:46:34", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000093041321000675/0000930413-21-000675-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000093041321000675/c101335_defa14a.htm"}}
{"date": "2021-03-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-25 00:00:00", "acceptedDate": "2021-03-25 16:17:36", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000051/0000078003-21-000051-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000051/cortexyme_13gax3x25.htm"}}
{"date": "2021-03-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-23 00:00:00", "acceptedDate": "2021-03-23 11:46:32", "formType": "PX14A6G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000121465921003342/0001214659-21-003342-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000121465921003342/r322210px14a6g.htm"}}
{"date": "2021-03-22", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-22 00:00:00", "acceptedDate": "2021-03-22 15:21:05", "formType": "PX14A6G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000121465921003315/0001214659-21-003315-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000121465921003315/p322211px14a6g.htm"}}
{"date": "2021-03-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-16 00:00:00", "acceptedDate": "2021-03-16 15:25:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821005373/0001225208-21-005373-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821005373/xslF345X03/doc4.xml"}}
{"date": "2021-03-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-16 00:00:00", "acceptedDate": "2021-03-16 15:25:38", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821005372/0001225208-21-005372-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821005372/xslF345X03/doc4.xml"}}
{"date": "2021-03-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-16 00:00:00", "acceptedDate": "2021-03-16 15:25:33", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821005371/0001225208-21-005371-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821005371/xslF345X03/doc4.xml"}}
{"date": "2021-03-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-16 00:00:00", "acceptedDate": "2021-03-16 15:25:31", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821005370/0001225208-21-005370-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821005370/xslF345X03/doc4.xml"}}
{"date": "2021-03-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-12 00:00:00", "acceptedDate": "2021-03-12 09:37:21", "formType": "DEFA14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000049/0000078003-21-000049-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000049/notice_pfex21.htm"}}
{"date": "2021-03-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-12 00:00:00", "acceptedDate": "2021-03-12 09:32:01", "formType": "DEF 14A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000047/0000078003-21-000047-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000047/proxystatement.htm"}}
{"date": "2021-03-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-02 00:00:00", "acceptedDate": "2021-03-02 19:00:19", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004333/0001225208-21-004333-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004333/xslF345X03/doc4.xml"}}
{"date": "2021-03-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-02 00:00:00", "acceptedDate": "2021-03-02 18:57:18", "formType": "4/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004332/0001225208-21-004332-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004332/xslF345X03/doc4a.xml"}}
{"date": "2021-03-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-02 00:00:00", "acceptedDate": "2021-03-02 18:00:01", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004320/0001225208-21-004320-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004320/xslF345X03/doc4.xml"}}
{"date": "2021-03-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-02 00:00:00", "acceptedDate": "2021-03-02 17:59:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004323/0001225208-21-004323-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004323/xslF345X03/doc4.xml"}}
{"date": "2021-03-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-02 00:00:00", "acceptedDate": "2021-03-02 17:59:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004322/0001225208-21-004322-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004322/xslF345X03/doc4.xml"}}
{"date": "2021-03-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-02 00:00:00", "acceptedDate": "2021-03-02 17:59:42", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004319/0001225208-21-004319-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004319/xslF345X03/doc4.xml"}}
{"date": "2021-03-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-02 00:00:00", "acceptedDate": "2021-03-02 17:59:39", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004321/0001225208-21-004321-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004321/xslF345X03/doc4.xml"}}
{"date": "2021-03-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-02 00:00:00", "acceptedDate": "2021-03-02 17:35:25", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004304/0001225208-21-004304-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004304/xslF345X03/doc4.xml"}}
{"date": "2021-03-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-02 00:00:00", "acceptedDate": "2021-03-02 17:35:25", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004302/0001225208-21-004302-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004302/xslF345X03/doc4.xml"}}
{"date": "2021-03-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-02 00:00:00", "acceptedDate": "2021-03-02 17:35:13", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004303/0001225208-21-004303-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004303/xslF345X03/doc4.xml"}}
{"date": "2021-03-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-02 00:00:00", "acceptedDate": "2021-03-02 17:35:11", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004301/0001225208-21-004301-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004301/xslF345X03/doc4.xml"}}
{"date": "2021-03-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-02 00:00:00", "acceptedDate": "2021-03-02 17:34:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004300/0001225208-21-004300-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004300/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 16:10:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004057/0001225208-21-004057-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004057/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 16:10:26", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004058/0001225208-21-004058-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004058/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 16:10:12", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004056/0001225208-21-004056-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004056/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 16:05:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004053/0001225208-21-004053-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004053/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 16:05:52", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004052/0001225208-21-004052-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004052/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 16:05:30", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004051/0001225208-21-004051-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004051/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 16:01:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004043/0001225208-21-004043-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004043/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 16:01:34", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004042/0001225208-21-004042-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004042/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 16:01:21", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004041/0001225208-21-004041-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004041/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 15:58:16", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004033/0001225208-21-004033-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004033/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 15:58:08", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004032/0001225208-21-004032-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004032/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 15:58:02", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004031/0001225208-21-004031-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004031/xslF345X03/doc4.xml"}}
{"date": "2021-03-01", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-03-01 00:00:00", "acceptedDate": "2021-03-01 15:55:27", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004024/0001225208-21-004024-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821004024/xslF345X03/doc4.xml"}}
{"date": "2021-02-26", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-26 00:00:00", "acceptedDate": "2021-02-26 16:15:57", "formType": "S-3ASR", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312521060428/0001193125-21-060428-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312521060428/d115723ds3asr.htm"}}
{"date": "2021-02-25", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-25 00:00:00", "acceptedDate": "2021-02-25 13:59:00", "formType": "10-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000038/0000078003-21-000038-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000038/pfe-20201231.htm"}}
{"date": "2021-02-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-23 00:00:00", "acceptedDate": "2021-02-23 18:12:08", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821003547/0001225208-21-003547-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821003547/xslF345X03/doc4.xml"}}
{"date": "2021-02-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-23 00:00:00", "acceptedDate": "2021-02-23 18:06:30", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821003546/0001225208-21-003546-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821003546/xslF345X03/doc4.xml"}}
{"date": "2021-02-23", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-23 00:00:00", "acceptedDate": "2021-02-23 17:43:00", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821003544/0001225208-21-003544-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821003544/xslF345X03/doc4.xml"}}
{"date": "2021-02-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-17 00:00:00", "acceptedDate": "2021-02-17 20:08:09", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821002866/0001225208-21-002866-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821002866/xslF345X03/doc4.xml"}}
{"date": "2021-02-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-17 00:00:00", "acceptedDate": "2021-02-17 20:08:04", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821002865/0001225208-21-002865-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821002865/xslF345X03/doc4.xml"}}
{"date": "2021-02-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-17 00:00:00", "acceptedDate": "2021-02-17 20:07:59", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821002864/0001225208-21-002864-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821002864/xslF345X03/doc4.xml"}}
{"date": "2021-02-17", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-17 00:00:00", "acceptedDate": "2021-02-17 20:07:39", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821002863/0001225208-21-002863-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821002863/xslF345X03/doc4.xml"}}
{"date": "2021-02-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-16 00:00:00", "acceptedDate": "2021-02-12 18:37:42", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000035/0000078003-21-000035-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000035/a4dm_13gx2x21.htm"}}
{"date": "2021-02-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-16 00:00:00", "acceptedDate": "2021-02-12 18:00:20", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000030/0000078003-21-000030-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000030/bioatla_13gx2x21.htm"}}
{"date": "2021-02-16", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-16 00:00:00", "acceptedDate": "2021-02-12 17:37:46", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000028/0000078003-21-000028-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000028/cortexyme_13gax2x21.htm"}}
{"date": "2021-02-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-12 00:00:00", "acceptedDate": "2021-02-12 17:17:19", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000025/0000078003-21-000025-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000025/contrafect_13gax2x21.htm"}}
{"date": "2021-02-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-12 00:00:00", "acceptedDate": "2021-02-12 17:08:29", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000023/0000078003-21-000023-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000023/springworks_13gax2x21.htm"}}
{"date": "2021-02-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-12 00:00:00", "acceptedDate": "2021-02-12 16:31:41", "formType": "SC 13G", "link": "https://www.sec.gov/Archives/edgar/data/78003/000009375121000388/0000093751-21-000388-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000009375121000388/PFIZER_INC.txt"}}
{"date": "2021-02-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-12 00:00:00", "acceptedDate": "2021-02-12 16:28:41", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000016/0000078003-21-000016-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000016/morphic_13gxax2x21.htm"}}
{"date": "2021-02-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-12 00:00:00", "acceptedDate": "2021-02-12 16:17:42", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000014/0000078003-21-000014-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000014/mersana13g_ax2x21.htm"}}
{"date": "2021-02-10", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-10 00:00:00", "acceptedDate": "2021-02-10 11:40:10", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000110465921018858/0001104659-21-018858-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000110465921018858/tv01608-pfizerinc.htm"}}
{"date": "2021-02-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-02 00:00:00", "acceptedDate": "2021-02-02 18:46:01", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821001472/0001225208-21-001472-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821001472/xslF345X03/doc4.xml"}}
{"date": "2021-02-02", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-02-02 00:00:00", "acceptedDate": "2021-02-02 08:34:49", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000003/0000078003-21-000003-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000007800321000003/pfe-20210202.htm"}}
{"date": "2021-01-29", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-29 00:00:00", "acceptedDate": "2021-01-29 17:22:55", "formType": "SC 13G/A", "link": "https://www.sec.gov/Archives/edgar/data/78003/000083423721004790/0000834237-21-004790-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000083423721004790/us7170811035_012921.txt"}}
{"date": "2021-01-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-13 00:00:00", "acceptedDate": "2021-01-13 17:24:44", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000804/0001225208-21-000804-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000804/xslF345X03/doc4.xml"}}
{"date": "2021-01-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-13 00:00:00", "acceptedDate": "2021-01-13 17:24:40", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000803/0001225208-21-000803-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000803/xslF345X03/doc4.xml"}}
{"date": "2021-01-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-13 00:00:00", "acceptedDate": "2021-01-13 17:24:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000802/0001225208-21-000802-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000802/xslF345X03/doc4.xml"}}
{"date": "2021-01-13", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-13 00:00:00", "acceptedDate": "2021-01-13 17:24:32", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000801/0001225208-21-000801-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000801/xslF345X03/doc4.xml"}}
{"date": "2021-01-12", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-12 00:00:00", "acceptedDate": "2021-01-12 10:59:02", "formType": "8-K", "link": "https://www.sec.gov/Archives/edgar/data/78003/000119312521006923/0001193125-21-006923-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000119312521006923/d102109d8k.htm"}}
{"date": "2021-01-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-04 00:00:00", "acceptedDate": "2021-01-04 19:31:35", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000113/0001225208-21-000113-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000113/xslF345X03/doc4.xml"}}
{"date": "2021-01-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-04 00:00:00", "acceptedDate": "2021-01-04 19:31:30", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000112/0001225208-21-000112-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000112/xslF345X03/doc4.xml"}}
{"date": "2021-01-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-04 00:00:00", "acceptedDate": "2021-01-04 19:31:25", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000111/0001225208-21-000111-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000111/xslF345X03/doc4.xml"}}
{"date": "2021-01-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-04 00:00:00", "acceptedDate": "2021-01-04 19:31:21", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000110/0001225208-21-000110-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000110/xslF345X03/doc4.xml"}}
{"date": "2021-01-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-04 00:00:00", "acceptedDate": "2021-01-04 17:01:01", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000077/0001225208-21-000077-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000077/xslF345X03/doc4.xml"}}
{"date": "2021-01-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-04 00:00:00", "acceptedDate": "2021-01-04 17:00:57", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000076/0001225208-21-000076-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000076/xslF345X03/doc4.xml"}}
{"date": "2021-01-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-04 00:00:00", "acceptedDate": "2021-01-04 17:00:51", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000075/0001225208-21-000075-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000075/xslF345X03/doc4.xml"}}
{"date": "2021-01-04", "symbol": "PFE", "type": "sec_filings", "result": {"symbol": "PFE", "cik": "0000078003", "filingDate": "2021-01-04 00:00:00", "acceptedDate": "2021-01-04 17:00:47", "formType": "4", "link": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000074/0001225208-21-000074-index.htm", "finalLink": "https://www.sec.gov/Archives/edgar/data/78003/000122520821000074/xslF345X03/doc4.xml"}}
{"date": "2025-12-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-22 03:38:00", "publisher": "The Motley Fool", "title": "Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?", "image": "https://images.financialmodelingprep.com/news/should-you-forget-novo-nordisk-and-buy-this-magnificent-20251222.jpg", "site": "fool.com", "text": "The pole position in the GLP-1 weight loss space is currently held by Eli Lilly. Novo Nordisk was the early leader, showing that being first doesn't always mean you stay at the head of the pack.", "url": "https://www.fool.com/investing/2025/12/22/forget-novo-nordisk-buy-high-yield-drug-stock/"}}
{"date": "2025-12-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-19 15:00:00", "publisher": "The Motley Fool", "title": "Better Buy in 2026: Pfizer or Merck?", "image": "https://images.financialmodelingprep.com/news/better-buy-in-2026-pfizer-or-merck-20251219.jpg", "site": "fool.com", "text": "Pfizer has at least two key candidates in the pipeline that look like future winners. Merck has launched several products in preparation for a massive upcoming patent cliff.", "url": "https://www.fool.com/investing/2025/12/19/better-buy-in-2026-pfizer-or-merck/"}}
{"date": "2025-12-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-19 11:50:20", "publisher": "Zacks Investment Research", "title": "Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock", "image": "https://images.financialmodelingprep.com/news/pfizer-down-after-it-issues-muted-2026-outlook-how-20251219.jpg", "site": "zacks.com", "text": "Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.", "url": "https://www.zacks.com/stock/news/2806863/pfizer-down-after-it-issues-muted-2026-outlook-how-to-play-the-stock?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2806863"}}
{"date": "2025-12-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-19 11:45:00", "publisher": "Seeking Alpha", "title": "Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound", "image": "https://images.financialmodelingprep.com/news/pfizer-isnt-dead-money-pipeline-execution-can-spark-a-20251219.jpg", "site": "seekingalpha.com", "text": "Pfizer (PFE) remains materially undervalued, with a forward yield near 7% and a Buy rating maintained despite recent underperformance and guidance revisions. PFE's discounted valuation reflects worrying execution risks tied to COVID franchise headwinds, loss of exclusivity, and the need for robust pipeline execution in oncology and obesity. Management's focus is on advancing multiple Phase III studies and commercializing new assets, but near-term valuation upside is unlikely until clearer growth visibility emerges.", "url": "https://seekingalpha.com/article/4854578-pfizer-stock-isnt-dead-money-pipeline-execution-can-spark-a-rebound"}}
{"date": "2025-12-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-19 10:45:00", "publisher": "Market Watch", "title": "Trump to announce new drug-pricing deals later today", "image": "https://images.financialmodelingprep.com/news/trump-to-announce-new-drugpricing-deals-later-today-20251219.jpg", "site": "marketwatch.com", "text": "The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.", "url": "https://www.marketwatch.com/story/trump-to-announce-new-drug-pricing-deals-later-today-8261bdfe"}}
{"date": "2025-12-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-19 03:22:52", "publisher": "Defense World", "title": "Addenda Capital Inc. Boosts Stock Position in Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/addenda-capital-inc-boosts-stock-position-in-pfizer-inc-20251219.png", "site": "defenseworld.net", "text": "Addenda Capital Inc. grew its holdings in shares of Pfizer Inc. (NYSE: PFE) by 26.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 322,379 shares of the biopharmaceutical company's stock after buying an additional 68,176 shares during the period. Addenda Capital", "url": "https://www.defenseworld.net/2025/12/19/addenda-capital-inc-boosts-stock-position-in-pfizer-inc-pfe.html"}}
{"date": "2025-12-18", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-18 20:30:00", "publisher": "The Motley Fool", "title": "3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now", "image": "https://images.financialmodelingprep.com/news/3-absurdly-cheap-stocks-you-can-buy-for-less-20251218.jpg", "site": "fool.com", "text": "These top healthcare companies all have strong underlying businesses. Their low valuations can make them attractive for bargain hunters.", "url": "https://www.fool.com/investing/2025/12/18/3-absurdly-cheap-stocks-you-can-buy-for-less-than/"}}
{"date": "2025-12-18", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-18 11:45:00", "publisher": "The Motley Fool", "title": "Better Buy in 2026: Pfizer or Eli Lilly?", "image": "https://images.financialmodelingprep.com/news/better-buy-in-2026-pfizer-or-eli-lilly-20251218.jpg", "site": "fool.com", "text": "Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer's acquisitions haven't paid off yet and the company is still struggling to grow its sales.", "url": "https://www.fool.com/investing/2025/12/18/better-buy-in-2026-pfizer-or-eli-lilly/"}}
{"date": "2025-12-18", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-18 10:00:00", "publisher": "Business Wire", "title": "Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts", "image": "https://images.financialmodelingprep.com/news/pfizer-invites-public-to-view-and-listen-to-webcast-20251218.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Fourth Quarter and Full Year 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.c.", "url": "https://www.businesswire.com/news/home/20251218182032/en/Pfizer-Invites-Public-to-View-and-Listen-to-Webcast-of-February-3-Conference-Call-with-Analysts/"}}
{"date": "2025-12-18", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-18 06:58:07", "publisher": "Benzinga", "title": "Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun", "image": "https://images.financialmodelingprep.com/news/pfizer-plays-catchup-in-obesity-market-licenses-weightloss-drug-20251218.jpg", "site": "benzinga.com", "text": "Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal", "url": "https://www.benzinga.com/Opinion/25/12/49473561/pfizer-plays-catchup-in-obesity-market-licenses-weight-loss-drug-from-fosun"}}
{"date": "2025-12-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-17 14:36:32", "publisher": "Forbes", "title": "Pfizer Stock Can Sink More. Here Is How", "image": "https://images.financialmodelingprep.com/news/pfizer-stock-can-sink-more-here-is-how-20251217.jpg", "site": "forbes.com", "text": "Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune.", "url": "https://www.forbes.com/sites/greatspeculations/2025/12/17/pfizer-stock-can-sink-more-here-is-how/"}}
{"date": "2025-12-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-17 11:47:00", "publisher": "The Motley Fool", "title": "If I Could Only Buy and Hold a Single Stock, This Would Be It", "image": "https://images.financialmodelingprep.com/news/if-i-could-only-buy-and-hold-a-single-20251217.jpg", "site": "fool.com", "text": "Lower demand for COVID-19 treatments has been hurting Pfizer's revenue. Pfizer also has major products losing patent protection over the next couple of years.", "url": "https://www.fool.com/investing/2025/12/17/if-i-could-only-buy-and-hold-a-single-stock-this/"}}
{"date": "2025-12-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-17 11:01:10", "publisher": "Zacks Investment Research", "title": "Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future?", "image": "https://images.financialmodelingprep.com/news/pfizer-issues-soft-2026-view-what-does-it-mean-20251217.jpg", "site": "zacks.com", "text": "PFE's soft 2026 outlook spooks investors, with revenue and EPS guidance trailing expectations as COVID-19 demand fades and patent losses mount.", "url": "https://www.zacks.com/stock/news/2805652/pfizer-issues-soft-2026-view-what-does-it-mean-for-the-stock-s-future?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2805652"}}
{"date": "2025-12-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-17 10:14:31", "publisher": "Benzinga", "title": "Pfizer, Merck Are Boring Again  And That's Exactly Why 2026 Investors Are Circling Back", "image": "https://images.financialmodelingprep.com/news/pfizer-merck-are-boring-again-and-thats-exactly-why-20251217.jpg", "site": "benzinga.com", "text": "Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) aren't exciting stocks anymore  and after a bruising reset, that's starting to look intentional. Pfizer's stock has been back in focus this month after the company laid out a cautious 2026 outlook, acknowledging that the post-COVID reset isn't over yet.", "url": "https://www.benzinga.com/markets/biotech/25/12/49451490/pfizer-merck-are-boring-again-and-thats-exactly-why-2026-investors-are-circling-back"}}
{"date": "2025-12-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-17 06:45:00", "publisher": "PRNewsWire", "title": "PADCEV Plus Keytruda Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility", "image": "https://images.financialmodelingprep.com/news/padcev-plus-keytruda-significantly-improves-survival-for-patients-with-20251217.jpg", "site": "prnewswire.com", "text": "PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with muscle-invasive bladder cancer Positive EV-304 data, combined with the recent unprecedented results from the EV-303 trial, highlight the potential of this combination to become a new platinum-free standard of care in an earlier stage of bladder cancer Results from the Phase 3 EV-304 trial will be presented at an upcoming medical meeting and discussed with global health authorities for potential regulatory filings TOKYO and NEW YORK , Dec. 17, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEV (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda(pembrolizumab), a PD-1 inhibitor. This pivotal study is evaluating the combination as neoadjuvant and adjuvant treatment (before and after surgery) versus standard of care neoadjuvant chemotherapy (gemcitabine and cisplatin) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy.", "url": "https://www.prnewswire.com/news-releases/padcev-plus-keytruda-significantly-improves-survival-for-patients-with-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility-302644184.html"}}
{"date": "2025-12-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-17 05:22:44", "publisher": "Defense World", "title": "Pfizer Inc. $PFE Shares Sold by Canandaigua National Bank & Trust Co.", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-pfe-shares-sold-by-canandaigua-national-bank-20251217.png", "site": "defenseworld.net", "text": "Canandaigua National Bank and Trust Co. lessened its stake in Pfizer Inc. (NYSE: PFE) by 13.1% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 190,139 shares of the biopharmaceutical company's stock after selling 28,742 shares during the period. Canandaigua National Bank and Trust Co.'s holdings", "url": "https://www.defenseworld.net/2025/12/17/pfizer-inc-pfe-shares-sold-by-canandaigua-national-bank-trust-co.html"}}
{"date": "2025-12-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-17 03:52:59", "publisher": "Defense World", "title": "Corient Private Wealth LLC Sells 179,789 Shares of Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/corient-private-wealth-llc-sells-179789-shares-of-pfizer-20251217.png", "site": "defenseworld.net", "text": "Corient Private Wealth LLC lowered its position in shares of Pfizer Inc. (NYSE: PFE) by 8.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,054,574 shares of the biopharmaceutical company's stock after selling 179,789 shares during", "url": "https://www.defenseworld.net/2025/12/17/corient-private-wealth-llc-sells-179789-shares-of-pfizer-inc-pfe.html"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 18:46:10", "publisher": "Zacks Investment Research", "title": "Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note", "image": "https://images.financialmodelingprep.com/news/pfizer-pfe-registers-a-bigger-fall-than-the-market-20251216.jpg", "site": "zacks.com", "text": "In the latest trading session, Pfizer (PFE) closed at $25.57, marking a -3.27% move from the previous day.", "url": "https://www.zacks.com/stock/news/2805231/pfizer-pfe-registers-a-bigger-fall-than-the-market-important-facts-to-note?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2805231"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 17:43:41", "publisher": "The Motley Fool", "title": "Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast", "image": "https://images.financialmodelingprep.com/news/stock-market-today-dec-16-pfizer-falls-after-cutting-20251216.jpg", "site": "fool.com", "text": "Expand NYSE: PFE Pfizer Today's Change (-3.40%) $-0.90 Current Price $25.53 Key Data Points Market Cap $150B Day's Range $24.92 - $26.50 52wk Range $20.91 - $27.69 Volume 112M Avg Vol 68M Gross Margin 69.12% Dividend Yield 6.51% Pfizer (PFE 3.40%), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 million shares, almost 60% above its three-month average.", "url": "https://www.fool.com/coverage/stock-market-today/2025/12/16/stock-market-today-dec-16-pfizer-falls-after-cutting-2025-revenue-forecast/"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 17:36:00", "publisher": "GuruFocus", "title": "Market Today: Jobs Cool, EU Eases Engine Ban, Oil Hits 2021 Lows", "image": "https://images.financialmodelingprep.com/news/market-today-jobs-cool-eu-eases-engine-ban-oil-20251216.png", "site": "gurufocus.com", "text": "Stock News U.S. labor market cools: The U.S. added 64,000 jobs in November after a 105,000 decline in October as unemployment rose to 4.6%, the highest since 20", "url": "https://www.gurufocus.com/news/4072538/market-today-jobs-cool-eu-eases-engine-ban-oil-hits-2021-lows"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 14:39:04", "publisher": "Seeking Alpha", "title": "Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-pfe-q4-2026-guidance-call-transcript-20251216.jpg", "site": "seekingalpha.com", "text": "Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript", "url": "https://seekingalpha.com/article/4853812-pfizer-inc-pfe-q4-2026-guidance-call-transcript"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 12:33:55", "publisher": "CNBC Television", "title": "Pfizer falls on disappointing guidance", "image": "https://images.financialmodelingprep.com/news/pfizer-falls-on-disappointing-guidance-20251216.jpg", "site": "youtube.com", "text": "CNBC's Annika Kim Constantino reports on Pfizer's 2026 guidance.", "url": "https://www.youtube.com/watch?v=NjBEpJVJNgg"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 12:16:29", "publisher": "Proactive Investors", "title": "Pfizer shares fall after it forecasts 2026 revenue below estimates", "image": "https://images.financialmodelingprep.com/news/pfizer-shares-fall-after-it-forecasts-2026-revenue-below-20251216.jpg", "site": "proactiveinvestors.com", "text": "Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly below Wall Street estimates, as sales of COVID-19 products fall and generic competition rises. The company forecast revenue between $59.5 billion and $62.5 billion for 2026, with adjusted earnings per share of $2.80 to $3.", "url": "https://www.proactiveinvestors.com/companies/news/1084539"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 11:36:00", "publisher": "GuruFocus", "title": "Why Pfizer (PFE) Stock Is Sliding Today", "image": "https://images.financialmodelingprep.com/news/why-pfizer-pfe-stock-is-sliding-today-20251216.png", "site": "gurufocus.com", "text": "Pfizer (PFE) shares slid about 5% on Tuesday morning after the company lowered its earnings and revenue forecasts for 2026.The pharmaceutical giant now expects", "url": "https://www.gurufocus.com/news/4071513/why-pfizer-pfe-stock-is-sliding-today"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 11:20:00", "publisher": "Proactive Investors - Finance", "title": "Nasdaq closes higher as tech, Tesla leads market despite sluggish jobs data", "image": "https://images.financialmodelingprep.com/news/nasdaq-closes-higher-as-tech-tesla-leads-market-despite-20251216.jpeg", "site": "proactiveinvestors.com", "text": "4:15pm:Tesla soars to record high US stocks wrapped up Tuesday on a mixed note, with investors weighing fresh labor market signals that offered reassurance...", "url": "https://www.proactiveinvestors.com/companies/news/1084512/nasdaq-closes-higher-as-tech-tesla-leads-market-despite-sluggish-jobs-data-1084512.html"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 11:14:00", "publisher": "GuruFocus", "title": "Pfizer Adjusts Revenue Outlook Amid Increased R&D Spending", "image": "https://images.financialmodelingprep.com/news/pfizer-adjusts-revenue-outlook-amid-increased-rd-spending-20251216.png", "site": "gurufocus.com", "text": "Pfizer (PFE) has reaffirmed its FY25 EPS guidance but lowered its revenue outlook, while issuing FY26 EPS guidance that falls short of Wall Street expectations.", "url": "https://www.gurufocus.com/news/4071777/pfizer-adjusts-revenue-outlook-amid-increased-rd-spending"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 11:10:00", "publisher": "GuruFocus", "title": "Pfizer Sees 2026 Profit Below Estimates as COVID Sales Decline", "image": "https://images.financialmodelingprep.com/news/pfizer-sees-2026-profit-below-estimates-as-covid-sales-20251216.png", "site": "gurufocus.com", "text": "Pfizer (PFE, Financials) estimated 2026 earnings below analyst projections due to a sharp drop in COVID-19 sales and medicine patent expiration.The pharmaceutic", "url": "https://www.gurufocus.com/news/4071087/pfizer-sees-2026-profit-below-estimates-as-covid-sales-decline"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 10:22:00", "publisher": "GuruFocus", "title": "PFE: Pfizer Stock Slides 3% After Lower 2026 Forecast", "image": "https://images.financialmodelingprep.com/news/pfe-pfizer-stock-slides-3-after-lower-2026-forecast-20251216.png", "site": "gurufocus.com", "text": "Pfizer (PFE) shares slid about 3% on Tuesday morning after the company lowered its earnings and revenue forecasts for 2026.The pharmaceutical giant now expects", "url": "https://www.gurufocus.com/news/4071513/pfe-pfizer-stock-slides-3-after-lower-2026-forecast"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 10:12:25", "publisher": "CNBC", "title": "Pfizer's modest 2026 outlook shows its big investments will take time to pay off", "image": "https://images.financialmodelingprep.com/news/pfizers-modest-2026-outlook-shows-its-big-investments-will-20251216.jpg", "site": "cnbc.com", "text": "Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit of $2.80 to $3 per share next year, and revenue of $59.5 billion to $62.5 billion.", "url": "https://www.cnbc.com/2025/12/16/pfizer-2026-guidance-metsera-seagen-deals.html"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 10:08:44", "publisher": "Investors Business Daily", "title": "Why Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise'", "image": "https://images.financialmodelingprep.com/news/why-pfizers-2026-guidance-miss-is-not-a-major-20251216.jpg", "site": "investors.com", "text": "Pfizer issued a light outlook for 2026 on Tuesday, missing Wall Street's earnings forecast following a suite of acquisitions.", "url": "https://www.investors.com/news/technology/pfizer-stock-pfizer-guidance-2026/"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 07:47:00", "publisher": "Market Watch", "title": "Here's why Pfizer is revising its revenue forecasts", "image": "https://images.financialmodelingprep.com/news/heres-why-pfizer-is-revising-its-revenue-forecasts-20251216.jpg", "site": "marketwatch.com", "text": "The drugmaker revised its revenue guidance for 2025, saying it now expects $62 billion in revenue for the year.", "url": "https://www.marketwatch.com/story/heres-why-pfizer-is-revising-its-revenue-forecasts-c6ed3e12"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 07:38:00", "publisher": "GuruFocus", "title": "First Look: Ford EV pivot, AI infra slump, Uber suit", "image": "https://images.financialmodelingprep.com/news/first-look-ford-ev-pivot-ai-infra-slump-uber-20251216.png", "site": "gurufocus.com", "text": "Stock News Ford pivots from pure EVs, takes $19.5B charge: Ford Motor (F) will record about $19.5 billion in special items tied to a pullback from all-electric", "url": "https://www.gurufocus.com/news/4071086/first-look-ford-ev-pivot-ai-infra-slump-uber-suit"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 07:25:00", "publisher": "Barrons", "title": "Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.", "image": "https://images.financialmodelingprep.com/news/pfizer-stock-edges-higher-on-2026-guidance-expect-a-20251216.jpg", "site": "barrons.com", "text": "Pfizer expects revenue and earnings to fall in 2026.", "url": "https://www.barrons.com/articles/pfizer-stock-2026-earnings-revenue-guidance-covid-85c66750"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 07:16:00", "publisher": "WSJ", "title": "Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings", "image": "https://images.financialmodelingprep.com/news/pfizer-expects-decline-in-covid19-drug-demand-to-hurt-20251216.jpg", "site": "wsj.com", "text": "Pfizer projected 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Wall Street is forecasting 2026 revenue of $61.6 billion and adjusted earnings of $3.05 a share.", "url": "https://www.wsj.com/business/earnings/pfizer-expects-decline-in-covid-19-drug-demand-to-hurt-2026-earnings-9b92553b"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 07:14:00", "publisher": "Proactive Investors - Finance", "title": "Pfizer shares fall after it forecasts 2026 revenue below estimates", "image": "https://images.financialmodelingprep.com/news/pfizer-shares-fall-after-it-forecasts-2026-revenue-below-20251216.jpeg", "site": "proactiveinvestors.com", "text": "Pfizer Inc (NYSE:PFE, XETRA:PFE) said on Tuesday that its 2026 revenue and profit are expected to come in slightly below Wall Street estimates, as sales of...", "url": "https://www.proactiveinvestors.com/companies/news/1084539/pfizer-shares-fall-after-it-forecasts-2026-revenue-below-estimates-1084539.html"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 07:08:00", "publisher": "Proactive Investors - Finance", "title": "Nasdaq drops back as Wall Street digests slowing jobs data, retail sales", "image": "https://images.financialmodelingprep.com/news/nasdaq-drops-back-as-wall-street-digests-slowing-jobs-20251216.jpeg", "site": "proactiveinvestors.com", "text": "12:05pm: Pfizer cuts revenue targets Pfizer Inc (NYSE:PFE, XETRA:PFE)said on Tuesday that its 2026 revenue and profit are expected to come in slightly...", "url": "https://www.proactiveinvestors.com/companies/news/1084512/nasdaq-drops-back-as-wall-street-digests-slowing-jobs-data-retail-sales-1084512.html"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 07:03:50", "publisher": "MarketBeat", "title": "Pfizer Adds to Its Big Bet on Weight Loss Drugs", "image": "https://images.financialmodelingprep.com/news/pfizer-adds-to-its-big-bet-on-weight-loss-20251216.jpg", "site": "marketbeat.com", "text": "Health care stocks have been on a run lately, leading the S&P 500's 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not included all of the Big Pharma mainstays.", "url": "https://www.marketbeat.com/originals/pfizer-adds-to-its-big-bet-on-weight-loss-drugs/"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 06:54:47", "publisher": "Reuters", "title": "Pfizer forecasts 2026 profit below expectations on lower COVID product sales", "image": "https://images.financialmodelingprep.com/news/pfizer-forecasts-2026-profit-below-expectations-on-lower-covid-20251216.jpg", "site": "reuters.com", "text": "Pfizer on Tuesday forecast 2026 profit below Wall Street estimates as it expects lower sales of its COVID products, sending its shares down 1.6% in premarket trading.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-forecasts-2026-profit-below-expectations-2025-12-16/"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 06:45:00", "publisher": "Business Wire", "title": "Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance", "image": "https://images.financialmodelingprep.com/news/pfizer-reaffirms-fullyear-2025-eps-guidance-and-provides-fullyear-20251216.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other components of full-year 2025 financial guidance(2). The accompanying presentation can be found at www.pfizer.com/investors. FULL-YEAR 2026 REVENUE GUIDANCE(2) Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion, while full-year 2025 revenue guidance(2) is revised to app.", "url": "https://www.businesswire.com/news/home/20251216635323/en/Pfizer-Reaffirms-Full-Year-2025-EPS-Guidance-and-Provides-Full-Year-2026-Guidance/"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 06:16:43", "publisher": "Defense World", "title": "Capital Asset Advisory Services LLC Has $2.79 Million Stock Holdings in Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/capital-asset-advisory-services-llc-has-279-million-stock-20251216.png", "site": "defenseworld.net", "text": "Capital Asset Advisory Services LLC grew its holdings in Pfizer Inc. (NYSE: PFE) by 51.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 109,430 shares of the biopharmaceutical company's stock after acquiring an additional 37,402 shares during the quarter. Capital", "url": "https://www.defenseworld.net/2025/12/16/capital-asset-advisory-services-llc-has-2-79-million-stock-holdings-in-pfizer-inc-pfe.html"}}
{"date": "2025-12-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-16 01:30:54", "publisher": "Defense World", "title": "Pfizer (NYSE:PFE) Stock Price Up 2.3% Following Dividend Announcement", "image": "https://images.financialmodelingprep.com/news/pfizer-nysepfe-stock-price-up-23-following-dividend-announcement-20251216.png", "site": "defenseworld.net", "text": "Shares of Pfizer Inc. (NYSE: PFE - Get Free Report) rose 2.3% during mid-day trading on Monday after the company announced a dividend. The company traded as high as $26.65 and last traded at $26.4470. Approximately 60,076,835 shares were traded during trading, an increase of 17% from the average daily volume of 51,170,094 shares. The stock", "url": "https://www.defenseworld.net/2025/12/16/pfizer-nysepfe-stock-price-up-2-3-following-dividend-announcement.html"}}
{"date": "2025-12-15", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-15 10:01:31", "publisher": "Zacks Investment Research", "title": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know", "image": "https://images.financialmodelingprep.com/news/investors-heavily-search-pfizer-inc-pfe-here-is-what-20251215.jpg", "site": "zacks.com", "text": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.", "url": "https://www.zacks.com/stock/news/2804267/investors-heavily-search-pfizer-inc-pfe-here-is-what-you-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2804267"}}
{"date": "2025-12-15", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-15 08:24:18", "publisher": "Reuters", "title": "Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million", "image": "https://images.financialmodelingprep.com/news/adaptive-biotechnologies-signs-nonexclusive-deals-with-pfizer-worth-up-20251215.jpg", "site": "reuters.com", "text": "Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/adaptive-biotechnologies-signs-non-exclusive-deals-with-pfizer-worth-up-890-2025-12-15/"}}
{"date": "2025-12-15", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-15 08:00:00", "publisher": "GlobeNewsWire", "title": "Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer", "image": "https://images.financialmodelingprep.com/news/adaptive-biotechnologies-announces-two-immune-receptor-licensing-agreements-with-20251215.jpg", "site": "globenewswire.com", "text": "A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive's proprietary TCR-antigen datasets for research and development in multiple immunology applications SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced two non-exclusive agreements with Pfizer Inc. (NYSE: PFE) to leverage Adaptive's proprietary T-cell receptor (TCR) discovery capabilities and large-scale immune receptor antigen mapping data. Discovering disease-causing TCRs in rheumatoid arthritis Adaptive has identified autoreactive or offender' TCRs that could potentially cause disease in patients with autoimmune indications.", "url": "https://www.globenewswire.com/news-release/2025/12/15/3205383/0/en/Adaptive-Biotechnologies-Announces-Two-Immune-Receptor-Licensing-Agreements-with-Pfizer.html"}}
{"date": "2025-12-15", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-15 05:10:50", "publisher": "Defense World", "title": "Cullen Capital Management LLC Has $88.32 Million Position in Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/cullen-capital-management-llc-has-8832-million-position-in-20251215.png", "site": "defenseworld.net", "text": "Cullen Capital Management LLC decreased its holdings in Pfizer Inc. (NYSE: PFE) by 22.9% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,643,578 shares of the biopharmaceutical company's stock after selling 1,079,744 shares during the quarter. Cullen Capital Management LLC", "url": "https://www.defenseworld.net/2025/12/15/cullen-capital-management-llc-has-88-32-million-position-in-pfizer-inc-pfe.html"}}
{"date": "2025-12-14", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-14 15:27:00", "publisher": "The Motley Fool", "title": "Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?", "image": "https://images.financialmodelingprep.com/news/should-you-forget-teva-pharmaceutical-and-buy-these-unstoppable-20251214.jpg", "site": "fool.com", "text": "Shares of Teva -- a generic-drug maker with a history of losses and high leverage -- have rallied strongly. Pfizer and Merck, which make branded drugs, are financially strong and are rebuilding their drug pipelines.", "url": "https://www.fool.com/investing/2025/12/14/should-you-forget-teva-and-buy-these-stock-instead/"}}
{"date": "2025-12-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-13 06:53:00", "publisher": "The Motley Fool", "title": "Forget Teladoc and Buy This Healthcare Stock Instead", "image": "https://images.financialmodelingprep.com/news/forget-teladoc-and-buy-this-healthcare-stock-instead-20251213.jpg", "site": "fool.com", "text": "Teladoc and Pfizer have both faced challenges over the past few years. While the latter has a clear path to recovery, the former doesn't seem to.", "url": "https://www.fool.com/investing/2025/12/13/forget-teladoc-buy-this-healthcare-stock-instead/"}}
{"date": "2025-12-12", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-12 13:51:10", "publisher": "Benzinga", "title": "FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back", "image": "https://images.financialmodelingprep.com/news/fda-weighs-black-box-warning-for-covid-vaccines-experts-20251212.jpeg", "site": "feeds.benzinga.com", "text": "FDA officials are weighing a black box warning for Covid vaccines, a proposal that has drawn strong criticism from outside experts citing lack of evidence.", "url": "https://www.benzinga.com/news/health-care/25/12/49371146/fda-weighs-black-box-warning-for-covid-vaccines-experts-push-back"}}
{"date": "2025-12-12", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-12 12:00:00", "publisher": "Business Wire", "title": "Pfizer Declares First-Quarter 2026 Dividend", "image": "https://images.financialmodelingprep.com/news/pfizer-declares-firstquarter-2026-dividend-20251212.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to holders of the Common Stock of record at the close of business on January 23, 2026. The first-quarter 2026 cash dividend will be the 349th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to brin.", "url": "https://www.businesswire.com/news/home/20251212838171/en/Pfizer-Declares-First-Quarter-2026-Dividend/"}}
{"date": "2025-12-12", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-12 11:32:00", "publisher": "The Motley Fool", "title": "Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026.", "image": "https://images.financialmodelingprep.com/news/pfizer-is-still-struggling-to-replace-its-covid-revenue-20251212.jpg", "site": "fool.com", "text": "Pfizer's coronavirus-related sales have fallen sharply -- and they may decline even further next year. The company is developing some promising products, including a flu vaccine and a weight loss therapy.", "url": "https://www.fool.com/investing/2025/12/12/pfizer-is-struggling-to-replace-its-covid-revenue/"}}
{"date": "2025-12-12", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-12 10:15:00", "publisher": "The Motley Fool", "title": "The Best Turnaround Stock to Invest $1,000 in Right Now", "image": "https://images.financialmodelingprep.com/news/the-best-turnaround-stock-to-invest-1000-in-right-20251212.jpg", "site": "fool.com", "text": "Bristol Myers Squibb's stock is down 35% from its 2022 highs as it faces patent cliffs. Pfizer is down 55% from its 2021 highs as it contends with similar challenges.", "url": "https://www.fool.com/investing/2025/12/12/the-best-turnaround-stock-to-invest-1000-in-right/"}}
{"date": "2025-12-12", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-12 08:45:00", "publisher": "Seeking Alpha", "title": "Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends", "image": "https://images.financialmodelingprep.com/news/dividend-harvesting-portfolio-week-249-24900-allocated-264653-in-20251212.jpg", "site": "seekingalpha.com", "text": "The Dividend Harvesting Portfolio remains up 32.60% on invested capital, yielding 8.02%, despite a temporary dip in dividend income from the MSTY reverse split. A dovish Fed rate cut and bullish GDP projections support expectations for a year-end market rally, favoring income-generating, rate-sensitive holdings. Recent capital was allocated to AMLP for high-yield, fee-based energy exposure, and to VZ, citing turnaround potential and robust EBITDA.", "url": "https://seekingalpha.com/article/4852843-dividend-harvesting-portfolio-week-249-24900-allocated-2646-53-in-projected-dividends"}}
{"date": "2025-12-12", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-12 07:24:55", "publisher": "Reuters", "title": "Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial", "image": "https://images.financialmodelingprep.com/news/health-rounds-pfizer-drug-delays-progression-of-advanced-breast-20251212.jpg", "site": "reuters.com", "text": "Pfizer's Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive metastatic breast cancer who had responded well to initial treatment, according to results of a late-stage trial.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/health-rounds-pfizer-drug-delays-progression-advanced-breast-cancer-trial-2025-12-12/"}}
{"date": "2025-12-11", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-11 14:03:00", "publisher": "GuruFocus", "title": "Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?", "image": "https://images.financialmodelingprep.com/news/moderna-sounds-the-alarm-is-china-about-to-seize-20251211.png", "site": "gurufocus.com", "text": "Investors watching the global biotech race may be sensing a shift after Moderna (MRNA) co-founder and chairman Noubar Afeyan suggested the US could be losing mo", "url": "https://www.gurufocus.com/news/3245468/moderna-sounds-the-alarm-is-china-about-to-seize-the-biotech-crown-from-the-us"}}
{"date": "2025-12-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-10 18:46:09", "publisher": "Zacks Investment Research", "title": "Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider", "image": "https://images.financialmodelingprep.com/news/pfizer-pfe-exceeds-market-returns-some-facts-to-consider-20251210.jpg", "site": "zacks.com", "text": "The latest trading day saw Pfizer (PFE) settling at $25.78, representing a +1.78% change from its previous close.", "url": "https://www.zacks.com/stock/news/2802572/pfizer-pfe-exceeds-market-returns-some-facts-to-consider?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2802572"}}
{"date": "2025-12-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-10 11:38:11", "publisher": "Reuters", "title": "Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports", "image": "https://images.financialmodelingprep.com/news/pfizer-to-cut-hundreds-of-jobs-in-switzerland-to-20251210.jpg", "site": "reuters.com", "text": "Pfizer will cut hundreds of jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on Wednesday, citing people familiar with the matter.", "url": "https://www.reuters.com/sustainability/pfizer-cut-hundreds-jobs-switzerland-reduce-costs-bloomberg-news-reports-2025-12-10/"}}
{"date": "2025-12-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-10 08:46:05", "publisher": "Zacks Investment Research", "title": "PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence", "image": "https://images.financialmodelingprep.com/news/pfe-buys-oral-glp1-drug-from-china-biotech-to-20251210.jpg", "site": "zacks.com", "text": "Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.", "url": "https://www.zacks.com/stock/news/2802063/pfe-buys-oral-glp-1-drug-from-china-biotech-to-boost-obesity-presence?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2802063"}}
{"date": "2025-12-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-10 08:35:55", "publisher": "Zacks Investment Research", "title": "JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?", "image": "https://images.financialmodelingprep.com/news/jnj-vs-pfe-which-bluechip-drug-stock-is-the-20251210.jpg", "site": "zacks.com", "text": "JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.", "url": "https://www.zacks.com/stock/news/2802052/jnj-vs-pfe-which-blue-chip-drug-stock-is-the-better-investment-now?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2802052"}}
{"date": "2025-12-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-10 08:15:00", "publisher": "Business Wire", "title": "TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer", "image": "https://images.financialmodelingprep.com/news/tukysa-added-to-firstline-maintenance-therapy-extends-median-progressionfree-20251210.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA (tucatinib) as part of an investigational first-line maintenance treatment combination, following chemotherapy-based induction, in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). The primary endpoint analysis showed a 35.9% reduction in the risk of disease progression or death amon.", "url": "https://www.businesswire.com/news/home/20251209535533/en/TUKYSA-Added-to-First-Line-Maintenance-Therapy-Extends-Median-Progression-Free-Survival-by-Over-8-Months-in-Patients-with-HER2-Metastatic-Breast-Cancer/"}}
{"date": "2025-12-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-10 03:26:59", "publisher": "Defense World", "title": "Arrow Capital Pty Ltd Acquires New Shares in Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/arrow-capital-pty-ltd-acquires-new-shares-in-pfizer-20251210.png", "site": "defenseworld.net", "text": "Arrow Capital Pty Ltd purchased a new position in Pfizer Inc. (NYSE: PFE) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 192,329 shares of the biopharmaceutical company's stock, valued at approximately $4,662,000. Pfizer makes up about 3.4% of", "url": "https://www.defenseworld.net/2025/12/10/arrow-capital-pty-ltd-acquires-new-shares-in-pfizer-inc-pfe.html"}}
{"date": "2025-12-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-09 16:15:00", "publisher": "The Motley Fool", "title": "Down 50%, Should You Buy the Dip on Pfizer?", "image": "https://images.financialmodelingprep.com/news/down-50-should-you-buy-the-dip-on-pfizer-20251209.jpg", "site": "fool.com", "text": "Pfizer is one of the world's largest drugmakers. It has long managed to produce new blockbuster drugs to replace drugs losing patent protection.", "url": "https://www.fool.com/investing/2025/12/09/down-50-should-you-buy-the-dip-on-pfizer/"}}
{"date": "2025-12-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-09 15:30:08", "publisher": "Invezz", "title": "Will Pfizer's YaoPharma deal deliver a powerful new oral obesity pill?", "image": "https://images.financialmodelingprep.com/news/will-pfizers-yaopharma-deal-deliver-a-powerful-new-oral-20251209.jpg", "site": "invezz.com", "text": "Pfizer is rolling the dice again on an oral obesity pill. The pharmaceutical giant signed an exclusive global license agreement with YaoPharma, a subsidiary of China's Fosun Pharma.", "url": "https://invezz.com/news/2025/12/09/will-pfizers-yaopharma-deal-deliver-a-powerful-new-oral-obesity-pill/"}}
{"date": "2025-12-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-09 12:30:00", "publisher": "GuruFocus", "title": "Pfizer Expands Obesity Pipeline With Up to $2.1 Billion Deal for YaoPharma Pill", "image": "https://images.financialmodelingprep.com/news/pfizer-expands-obesity-pipeline-with-up-to-21-billion-20251209.png", "site": "gurufocus.com", "text": "Pfizer (PFE, Financials) on Tuesday signed an agreement worth up to $2.1 billion with China-based YaoPharma to develop and commercialize the company's oral obes", "url": "https://www.gurufocus.com/news/3239673/pfizer-expands-obesity-pipeline-with-up-to-21-billion-deal-for-yaopharma-pill"}}
{"date": "2025-12-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-09 11:14:32", "publisher": "CNBC", "title": "Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill", "image": "https://images.financialmodelingprep.com/news/pfizer-adds-to-obesity-bet-with-up-to-21-20251209.jpg", "site": "cnbc.com", "text": "Pfizer said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharma company's push into the weight loss space. YaoPharma's oral drug works by targeting the same gut hormone, GLP-1, as Novo Nordisk's blockbuster weight loss injection Wegovy, but the pill is still in early-stage development.", "url": "https://www.cnbc.com/2025/12/09/pfizer-deal-yaopharma-obesity-pill.html"}}
{"date": "2025-12-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-09 10:59:00", "publisher": "GlobeNewsWire", "title": "Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons", "image": "https://images.financialmodelingprep.com/news/undisclosed-deaths-in-the-pfizer-mrna-covid19-vaccine-trial-20251209.jpg", "site": "globenewswire.com", "text": "In the rushed emergency use approval of Covid vaccines, deaths were undisclosed. Thousands received shots before warnings of heart damage were released.", "url": "https://www.globenewswire.com/news-release/2025/12/09/3202613/22503/en/Undisclosed-Deaths-in-the-Pfizer-mRNA-COVID-19-Vaccine-Trial-Discussed-in-the-Journal-of-American-Physicians-and-Surgeons.html"}}
{"date": "2025-12-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-09 10:45:08", "publisher": "Seeking Alpha", "title": "Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains", "image": "https://images.financialmodelingprep.com/news/pfizer-the-most-powerful-drug-pipeline-in-pharma-could-20251209.jpg", "site": "seekingalpha.com", "text": "Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds. PFE maintains strong free cash flow and improved guidance, targeting $61$64 billion in 2025 revenue and $3$3.15 adjusted EPS, while managing leverage post-acquisitions. Patent expirations threaten $17$18 billion in annual revenue by 20262028, but aggressive acquisitions, R&D investments and cost savings aim to offset losses and drive long-term growth.", "url": "https://seekingalpha.com/article/4851568-pfizer-the-most-powerful-drug-pipeline-in-pharma-could-deliver-major-long-term-gains"}}
{"date": "2025-12-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-09 10:15:33", "publisher": "Seeking Alpha", "title": "Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500", "image": "https://images.financialmodelingprep.com/news/heres-12-ideal-safer-december-dividend-dogs-of-the-20251209.jpg", "site": "seekingalpha.com", "text": "S&P 500 high-yield 'safer' dividend stocks offer attractive upside, with twelve currently meeting the dogcatcher ideal of dividends exceeding share prices. Analyst targets forecast 21.14% to 44.05% net gains for top-ten S&P 500 dividend dogs by December 2026, with an average 28.35% gain and lower-than-market volatility. Stocks with negative free cash flow marginsfifteen of the top fiftyare flagged as unsafe for dividend sustainability despite high yields.", "url": "https://seekingalpha.com/article/4851554-12-ideal-safer-december-dividend-dogs-of-sp500"}}
{"date": "2025-12-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-09 06:55:00", "publisher": "PRNewsWire", "title": "Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement", "image": "https://images.financialmodelingprep.com/news/fosun-pharmas-subsidiary-yao-pharma-and-pfizer-enter-into-20251209.jpg", "site": "prnewswire.com", "text": "SHANGHAI , Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. (\"Yao Pharma\"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement.", "url": "https://www.prnewswire.com/news-releases/fosun-pharmas-subsidiary-yao-pharma-and-pfizer-enter-into-exclusive-collaboration-and-license-agreement-302636496.html"}}
{"date": "2025-12-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-09 06:38:38", "publisher": "Reuters", "title": "Pfizer partners with YaoPharma for weight management treatment", "image": "https://images.financialmodelingprep.com/news/pfizer-partners-with-yaopharma-for-weight-management-treatment-20251209.jpg", "site": "reuters.com", "text": "Pfizer said on Tuesday it had entered into an exclusive licensing agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, for the development and commercialization of an experimental weight management treatment.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-partners-with-yaopharma-weight-management-treatment-2025-12-09/"}}
{"date": "2025-12-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-09 06:30:00", "publisher": "Business Wire", "title": "Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma", "image": "https://images.financialmodelingprep.com/news/pfizer-enters-into-exclusive-collaboration-and-license-agreement-with-20251209.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight manag.", "url": "https://www.businesswire.com/news/home/20251209536063/en/Pfizer-Enters-into-Exclusive-Collaboration-and-License-Agreement-with-YaoPharma/"}}
{"date": "2025-12-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-06 17:15:00", "publisher": "Business Wire", "title": "HYMPAVZI (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors", "image": "https://images.financialmodelingprep.com/news/hympavzi-marstacimab-reduced-bleeds-by-93-compared-to-ondemand-20251206.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no tr.", "url": "https://www.businesswire.com/news/home/20251206552218/en/HYMPAVZI%C2%AE-marstacimab-Reduced-Bleeds-by-93-Compared-to-On-Demand-Treatment-in-Adults-and-Adolescents-with-Hemophilia-A-or-B-with-Inhibitors/"}}
{"date": "2025-12-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-06 08:52:37", "publisher": "24/7 Wall Street", "title": "Teva Crushes Earnings as Pfizer Struggles to Replace COVID Revenue", "image": "https://images.financialmodelingprep.com/news/teva-crushes-earnings-as-pfizer-struggles-to-replace-covid-20251206.jpg", "site": "247wallst.com", "text": "Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two pharmaceutical companies moving in opposite directions.", "url": "https://247wallst.com/investing/2025/12/06/teva-crushes-earnings-as-pfizer-struggles-to-replace-covid-revenue/"}}
{"date": "2025-12-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-05 16:05:00", "publisher": "The Motley Fool", "title": "Do These 3 Healthcare Stocks Need a Checkup?", "image": "https://images.financialmodelingprep.com/news/do-these-3-healthcare-stocks-need-a-checkup-20251205.jpg", "site": "fool.com", "text": "Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb has a 5% yield and is off its 2023 highs by nearly 40%.", "url": "https://www.fool.com/investing/2025/12/05/do-these-3-healthcare-stocks-need-a-checkup/"}}
{"date": "2025-12-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-05 10:05:00", "publisher": "The Motley Fool", "title": "2 Headwinds Facing Pfizer Stock Going Into 2026", "image": "https://images.financialmodelingprep.com/news/2-headwinds-facing-pfizer-stock-going-into-2026-20251205.jpg", "site": "fool.com", "text": "Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs next year.", "url": "https://www.fool.com/investing/2025/12/05/2-headwinds-facing-pfizer-stock-going-into-2026/"}}
{"date": "2025-12-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-05 09:00:00", "publisher": "Seeking Alpha", "title": "Pfizer: The Market Is Still Wrong About It", "image": "https://images.financialmodelingprep.com/news/pfizer-the-market-is-still-wrong-about-it-20251205.jpg", "site": "seekingalpha.com", "text": "Pfizer's stock rebounded from April lows yet still trades as if COVID and patent cliffs equal business ruin, despite resilient nonCOVID franchises and pipeline optionality. Q3 looked weak, with revenue and EPS down year-over-year, yet both beat estimates as Vyndaqel, Nurtec, and Padcev collectively offset fading COVID contributions. Pfizer's adjusted margin stayed near seventysix percent, and OPEX fell, while a $1.5 billion manufacturing optimization program should expand margins and earnings by 2027.", "url": "https://seekingalpha.com/article/4850616-pfizer-the-market-is-still-wrong-about-it"}}
{"date": "2025-12-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-04 12:36:48", "publisher": "Zacks Investment Research", "title": "Pfizer (PFE) Up 3.9% Since Last Earnings Report: Can It Continue?", "image": "https://images.financialmodelingprep.com/news/pfizer-pfe-up-39-since-last-earnings-report-can-20251204.jpg", "site": "zacks.com", "text": "Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?", "url": "https://www.zacks.com/stock/news/2799727/pfizer-pfe-up-3-9-since-last-earnings-report-can-it-continue?cid=CS-STOCKNEWSAPI-FT-realtime_blog-2799727"}}
{"date": "2025-12-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-04 08:00:04", "publisher": "24/7 Wall Street", "title": "Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (December 2025)", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-nyse-pfe-price-prediction-and-forecast-20252030-20251204.jpg", "site": "247wallst.com", "text": "Shares of Pfizer ( NYSE: PFE )gained 3.69% over the past month after gaining 9.90% the month prior.", "url": "https://247wallst.com/investing/2025/12/04/pfizer-inc-nyse-pfe-price-prediction-and-forecast-2025-2030-april-2025/"}}
{"date": "2025-12-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-04 07:38:00", "publisher": "GuruFocus", "title": "First Look: Insurers, Auto Rules, AI and Fed Jitters", "image": "https://images.financialmodelingprep.com/news/first-look-insurers-auto-rules-ai-and-fed-jitters-20251204.png", "site": "gurufocus.com", "text": "Stock News Insurers under pressure, prior auth pledges stall: UnitedHealth Group (UNH) and peers Cigna (CI), Humana (HUM), CVS Health (CVS) and Elevance Health", "url": "https://www.gurufocus.com/news/3233331/first-look-insurers-auto-rules-ai-and-fed-jitters"}}
{"date": "2025-12-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-03 18:22:57", "publisher": "Seeking Alpha", "title": "3 Potential Mid-Cap Biotech Buyout Targets In 2026", "image": "https://images.financialmodelingprep.com/news/3-potential-midcap-biotech-buyout-targets-in-2026-20251203.jpg", "site": "seekingalpha.com", "text": "The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday. The sector has bounced back since. However, small biotech stocks have been on a huge run since mid-September, due primarily to a notable uptick in M&A activity across the industry. Numerous small and midcap biotech/biopharma stocks have been purchased for significant buyout premiums in recent months.", "url": "https://seekingalpha.com/article/4850021-3-potential-mid-cap-biotech-buyout-targets-in-2026"}}
{"date": "2025-12-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-02 12:11:00", "publisher": "Market Watch", "title": "17 dividend-stock bargains from a value manager with a stellar track record", "image": "https://images.financialmodelingprep.com/news/17-dividendstock-bargains-from-a-value-manager-with-a-20251202.jpg", "site": "marketwatch.com", "text": "John Buckingham, editor of the Prudent Speculator, reminds investors to be willing to stomach volatility.", "url": "https://www.marketwatch.com/story/17-dividend-stock-bargains-from-a-value-manager-with-a-stellar-track-record-6df0e310"}}
{"date": "2025-12-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-02 11:26:06", "publisher": "Zacks Investment Research", "title": "Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure", "image": "https://images.financialmodelingprep.com/news/pfizers-cancer-drugs-deliver-growth-amid-competitive-pressure-20251202.jpg", "site": "zacks.com", "text": "Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.", "url": "https://www.zacks.com/stock/news/2798391/pfizer-s-cancer-drugs-deliver-growth-amid-competitive-pressure?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2798391"}}
{"date": "2025-12-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-02 10:01:18", "publisher": "Zacks Investment Research", "title": "Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock", "image": "https://images.financialmodelingprep.com/news/here-is-what-to-know-beyond-why-pfizer-inc-20251202.jpg", "site": "zacks.com", "text": "Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.", "url": "https://www.zacks.com/stock/news/2798162/here-is-what-to-know-beyond-why-pfizer-inc-pfe-is-a-trending-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2798162"}}
{"date": "2025-12-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-02 08:42:30", "publisher": "24/7 Wall Street", "title": "Our December High-Yield 6% Dividend Stocks Have Big Total Return Potential", "image": "https://images.financialmodelingprep.com/news/our-december-highyield-6-dividend-stocks-have-big-total-20251202.jpg", "site": "247wallst.com", "text": "Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.", "url": "https://247wallst.com/investing/2025/12/02/our-december-high-yield-6-dividend-stocks-have-big-total-return-potential/"}}
{"date": "2025-12-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-02 05:18:44", "publisher": "Defense World", "title": "Beacon Pointe Advisors LLC Sells 607,423 Shares of Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/beacon-pointe-advisors-llc-sells-607423-shares-of-pfizer-20251202.png", "site": "defenseworld.net", "text": "Beacon Pointe Advisors LLC decreased its holdings in shares of Pfizer Inc. (NYSE: PFE) by 40.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 909,383 shares of the biopharmaceutical company's stock after selling 607,423 shares during the quarter.", "url": "https://www.defenseworld.net/2025/12/02/beacon-pointe-advisors-llc-sells-607423-shares-of-pfizer-inc-pfe.html"}}
{"date": "2025-12-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-01 20:00:43", "publisher": "Investopedia", "title": "Dow Jones Today: Stock Indexes Close Lower to Begin December Trading; Big Tech, Crypto-Tied Shares Drop Amid Risk-Off Sentiment", "image": "https://images.financialmodelingprep.com/news/dow-jones-today-stock-indexes-close-lower-to-begin-20251201.jpg", "site": "investopedia.com", "text": "Major stock indexes pulled back as the final trading month of the year began, with shares of big tech and cryptocurrency-tied firms falling amid risk-off sentiment.", "url": "https://www.investopedia.com/dow-jones-today-12012025-11859204"}}
{"date": "2025-12-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-01 15:50:42", "publisher": "Investopedia", "title": "FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks", "image": "https://images.financialmodelingprep.com/news/fda-plans-to-tighten-vaccine-approvals-weigh-on-these-20251201.jpg", "site": "investopedia.com", "text": "A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.", "url": "https://www.investopedia.com/possible-vaccine-rule-changes-send-moderna-shares-tumbling-mrna-pfe-bntx-11859304"}}
{"date": "2025-12-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-01 12:35:00", "publisher": "Market Watch", "title": "Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men", "image": "https://images.financialmodelingprep.com/news/vaccine-stocks-take-a-hit-as-fda-official-points-20251201.jpg", "site": "marketwatch.com", "text": "Memo also reportedly mentions vaccines for flu and pneumonia.", "url": "https://www.marketwatch.com/story/vaccine-stocks-take-a-hit-as-fda-official-points-to-link-between-covid-19-vaccines-and-rare-heart-condition-in-young-men-265ab5ab"}}
{"date": "2025-12-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-01 10:00:00", "publisher": "Business Wire", "title": "Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance", "image": "https://images.financialmodelingprep.com/news/pfizer-invites-public-to-view-and-listen-to-webcast-20251201.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025. The purpose of the call is to provide Pfizer's full-year 2026 financial guidance. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning tod.", "url": "https://www.businesswire.com/news/home/20251201362747/en/Pfizer-Invites-Public-to-View-and-Listen-to-Webcast-of-December-16-Conference-Call-with-Analysts-to-Provide-Full-Year-2026-Financial-Guidance/"}}
{"date": "2025-12-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-01 09:59:00", "publisher": "Barrons", "title": "Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals", "image": "https://images.financialmodelingprep.com/news/moderna-and-novavax-stocks-drop-as-fda-proposes-stricter-20251201.jpg", "site": "barrons.com", "text": "The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.", "url": "https://www.barrons.com/articles/moderna-and-novavax-stocks-drop-as-fda-proposes-stricter-vaccine-approvals-beba1a96"}}
{"date": "2025-12-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-12-01 07:37:00", "publisher": "GuruFocus", "title": "First Look: Airbus drops, Crypto slides, Cyber Monday", "image": "https://images.financialmodelingprep.com/news/first-look-airbus-drops-crypto-slides-cyber-monday-20251201.png", "site": "gurufocus.com", "text": "Stock News Airbus shares sink on fresh A320 quality snag: Airbus (EADSY) fell after reports of an industrial quality issue affecting fuselage panels on dozens o", "url": "https://www.gurufocus.com/news/3227948/first-look-airbus-drops-crypto-slides-cyber-monday"}}
{"date": "2025-11-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-30 21:05:00", "publisher": "The Motley Fool", "title": "2 Undervalued, High-Quality Companies to Buy Now and Hold Forever", "image": "https://images.financialmodelingprep.com/news/2-undervalued-highquality-companies-to-buy-now-and-hold-20251130.jpg", "site": "fool.com", "text": "Drug companies face fairly normal industry dynamics that can leave them unloved on Wall Street over short periods of time. Pfizer is facing a patent cliff and is making a big move to revamp its drug pipeline.", "url": "https://www.fool.com/investing/2025/11/30/2-undervalued-high-quality-companies-to-buy-now-an/"}}
{"date": "2025-11-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-30 16:04:00", "publisher": "The Motley Fool", "title": "This 7% Yielder Could Be a Top AI Play", "image": "https://images.financialmodelingprep.com/news/this-7-yielder-could-be-a-top-ai-play-20251130.jpg", "site": "fool.com", "text": "A looming patent cliff in which Pfizer will lose patent exclusivity to a handful of drugs has combined with cratering revenue from COVID-19 treatments to drive Pfizer shares down 50% since 2022. Pfizer has two important catalysts that can help it not only survive but also thrive amid these these challenges.", "url": "https://www.fool.com/investing/2025/11/30/this-7-yielder-could-be-a-top-ai-play/"}}
{"date": "2025-11-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-30 06:30:00", "publisher": "The Motley Fool", "title": "3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio", "image": "https://images.financialmodelingprep.com/news/3-stocks-to-buy-and-hold-the-longterm-play-20251130.jpg", "site": "fool.com", "text": "Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for long-term investors.", "url": "https://www.fool.com/investing/2025/11/30/stocks-buy-and-hold-long-term-pfe-mdt-jnj/"}}
{"date": "2025-11-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-30 06:13:02", "publisher": "Seeking Alpha", "title": "Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters", "image": "https://images.financialmodelingprep.com/news/pfizer-the-patent-cloud-is-an-opportunity-for-bargain-20251130.jpg", "site": "seekingalpha.com", "text": "Pfizer remains a compelling bargain, supported by a strong dividend yield and undervalued financial metrics, despite post-pandemic headwinds. PFE's acquisition of Metsera positions it for growth in the obesity market, though the deal will be dilutive to earnings through 2030. Recent FDA approval of the PADCEV/Keytruda combination and a robust oncology pipeline are expected to drive future revenue and margin expansion.", "url": "https://seekingalpha.com/article/4848781-pfizer-the-patent-cloud-is-an-opportunity-for-bargain-hunters"}}
{"date": "2025-11-29", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-29 23:59:00", "publisher": "Seeking Alpha", "title": "Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December", "image": "https://images.financialmodelingprep.com/news/pfizer-mastercard-among-24-companies-to-announce-annual-increases-20251129.jpg", "site": "seekingalpha.com", "text": "This is my latest article, where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Most of the dividend increases announced in the last two weeks of November were in the low-to-mid single-digit percentages, including a 5% boost from Merck. My expectations are high for December's increases, with at least five companies announcing 10%+ boosts, including Mastercard.", "url": "https://seekingalpha.com/article/4848760-pfizer-mastercard-among-24-companies-to-announce-annual-increases-in-december"}}
{"date": "2025-11-29", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-29 14:52:21", "publisher": "Benzinga", "title": "FDA's Prasad Cites Alleged Child COVID Shot Deaths in Push for Stricter Rules", "image": "https://images.financialmodelingprep.com/news/fdas-prasad-cites-alleged-child-covid-shot-deaths-in-20251129.jpeg", "site": "feeds.benzinga.com", "text": "FDA's new vaccine strategy tightens approval rules after internal findings linked COVID-19 shots to several child deaths.", "url": "https://www.benzinga.com/markets/biotech/25/11/49125806/fdas-prasad-cites-alleged-child-covid-shot-deaths-in-push-for-stricter-rules"}}
{"date": "2025-11-28", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-28 11:00:11", "publisher": "Seeking Alpha", "title": "8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills", "image": "https://images.financialmodelingprep.com/news/8-safer-dividend-buys-in-barrons-23-better-november-20251128.jpg", "site": "seekingalpha.com", "text": "Eight of the top fifteen Barron's Better Bets (BBB) 'Safer' dividend stocks, including Conagra, Altria, and Verizon, are currently attractively priced for income investors. Analyst forecasts project net gains of 18.44% to 29.95% for the top ten BBB Dogs by November 2026, with an average estimated gain of 22.01%. Stocks are considered 'dogs' when their reliable dividends and lower prices result in higher yields; eight of the top ten are already at ideal pricing levels.", "url": "https://seekingalpha.com/article/4848559-8-safer-dividend-buys-barrons-better-november-bets-than-t-bills"}}
{"date": "2025-11-28", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-28 05:30:00", "publisher": "The Motley Fool", "title": "8 Dividend Stocks Every Investor Should Consider", "image": "https://images.financialmodelingprep.com/news/8-dividend-stocks-every-investor-should-consider-20251128.jpg", "site": "fool.com", "text": "Dividend investing isn't just about yield -- payout ratio and growth potential matter too. Several of these companies have increased dividends for decades without interruption.", "url": "https://www.fool.com/investing/2025/11/28/8-dividend-stocks-every-investor-should-consider/"}}
{"date": "2025-11-28", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-28 03:45:02", "publisher": "Defense World", "title": "Clarkston Capital Partners LLC Buys 15,000 Shares of Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/clarkston-capital-partners-llc-buys-15000-shares-of-pfizer-20251128.png", "site": "defenseworld.net", "text": "Clarkston Capital Partners LLC boosted its stake in Pfizer Inc. (NYSE: PFE) by 22.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 81,688 shares of the biopharmaceutical company's stock after purchasing an additional 15,000 shares during the", "url": "https://www.defenseworld.net/2025/11/28/clarkston-capital-partners-llc-buys-15000-shares-of-pfizer-inc-pfe.html"}}
{"date": "2025-11-27", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-27 12:55:51", "publisher": "Zacks Investment Research", "title": "Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?", "image": "https://images.financialmodelingprep.com/news/novo-nordisk-or-pfizer-which-healthcare-giant-is-the-20251127.jpg", "site": "zacks.com", "text": "PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.", "url": "https://www.zacks.com/stock/news/2796713/novo-nordisk-or-pfizer-which-healthcare-giant-is-the-better-bet?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2796713"}}
{"date": "2025-11-27", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-27 04:01:00", "publisher": "The Motley Fool", "title": "Have $2,000 to Invest? Here Are 4 of My Favorite Dividend Stocks for the Next 5 Years", "image": "https://images.financialmodelingprep.com/news/have-2000-to-invest-here-are-4-of-my-20251127.jpeg", "site": "fool.com", "text": "Pfizer and Johnson & Johnson are healthcare leaders and faithful dividend payers. Home Depot is facing a difficult operating environment, but its core business remains strong.", "url": "https://www.fool.com/investing/2025/11/27/4-of-my-favorite-dividend-stocks-for-next-5-years/"}}
{"date": "2025-11-27", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-27 03:52:50", "publisher": "Defense World", "title": "Baltimore Washington Financial Advisors Inc. Invests $368,000 in Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/baltimore-washington-financial-advisors-inc-invests-368000-in-pfizer-20251127.png", "site": "defenseworld.net", "text": "Baltimore Washington Financial Advisors Inc. acquired a new stake in Pfizer Inc. (NYSE: PFE) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,190 shares of the biopharmaceutical company's stock, valued at approximately $368,000. A number of other large investors", "url": "https://www.defenseworld.net/2025/11/27/baltimore-washington-financial-advisors-inc-invests-368000-in-pfizer-inc-pfe.html"}}
{"date": "2025-11-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-26 12:30:25", "publisher": "Benzinga", "title": "Valneva Posts Positive Lyme Vaccine Booster Results  Pfizer Targeting 2026 Regulatory Filings", "image": "https://images.financialmodelingprep.com/news/valneva-posts-positive-lyme-vaccine-booster-results-pfizer-targeting-20251126.jpg", "site": "benzinga.com", "text": "Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.", "url": "https://www.benzinga.com/news/fda/25/11/49090533/valneva-posts-positive-lyme-vaccine-booster-results-pfizer-targeting-2026-regulatory-filings"}}
{"date": "2025-11-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-26 11:45:58", "publisher": "Zacks Investment Research", "title": "AbbVie and Pfizer: A Closer Look at Two Pharma Heavyweights", "image": "https://images.financialmodelingprep.com/news/abbvie-and-pfizer-a-closer-look-at-two-pharma-20251126.jpg", "site": "zacks.com", "text": "ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.", "url": "https://www.zacks.com/stock/news/2796033/abbvie-and-pfizer-a-closer-look-at-two-pharma-heavyweights?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2796033"}}
{"date": "2025-11-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-26 05:11:45", "publisher": "Benzinga", "title": "Medicare Announces Price Cuts For 15 Drugs Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month", "image": "https://images.financialmodelingprep.com/news/medicare-announces-price-cuts-for-15-drugs-novo-nordisks-20251126.jpeg", "site": "feeds.benzinga.com", "text": "The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its highestcost medications.", "url": "https://www.benzinga.com/news/health-care/25/11/49078768/medicare-announces-price-cuts-for-15-drugs-novo-nordisks-wegovy-and-ozempic-to-cost-274-a-month"}}
{"date": "2025-11-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-26 04:15:00", "publisher": "The Motley Fool", "title": "Did Pfizer Just Say \"Checkmate\" to Novo Nordisk?", "image": "https://images.financialmodelingprep.com/news/did-pfizer-just-say-checkmate-to-novo-nordisk-20251126.jpg", "site": "fool.com", "text": "Pfizer has been trying to get in on the billion-dollar weight loss drug market. Novo Nordisk initially dominated this market but has been losing ground to Eli Lilly.", "url": "https://www.fool.com/investing/2025/11/26/did-pfizer-just-say-checkmate-to-novo-nordisk/"}}
{"date": "2025-11-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-26 01:00:00", "publisher": "GlobeNewsWire", "title": "Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate", "image": "https://images.financialmodelingprep.com/news/valneva-announces-positive-final-phase-2-results-for-lyme-20251126.jpg", "site": "globenewswire.com", "text": "Saint-Herblain (France), November 26, 2025 Valneva SE(Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed strong anamnestic immune response and favorable safety profile six months after a third booster dose (month 48) in all age groups, confirming compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season. Pfizer and Valneva entered into a collaboration agreement in April 2020 for the development and commercialization of VLA15 by Pfizer.", "url": "https://www.globenewswire.com/news-release/2025/11/26/3194845/0/en/Valneva-Announces-Positive-Final-Phase-2-Results-for-Lyme-Disease-Vaccine-Candidate.html"}}
{"date": "2025-11-25", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-25 06:24:00", "publisher": "The Motley Fool", "title": "Is This the Best Value Stock to Buy While Markets Are Volatile?", "image": "https://images.financialmodelingprep.com/news/is-this-the-best-value-stock-to-buy-while-20251125.jpg", "site": "fool.com", "text": "Pfizer possesses several qualities that make it attractive when market volatility is high. The stock has a low forward earnings multiple and a higher -- yet still attractive -- EV-to-EBITDA ratio.", "url": "https://www.fool.com/investing/2025/11/25/is-this-the-best-value-stock-to-buy-while-markets/"}}
{"date": "2025-11-25", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-25 05:30:00", "publisher": "The Motley Fool", "title": "Want Over $7,000 in Annual Dividends? Invest $25,000 in Each of These 4 Stocks.", "image": "https://images.financialmodelingprep.com/news/want-over-7000-in-annual-dividends-invest-25000-in-20251125.jpg", "site": "fool.com", "text": "Income investors have been forced to seek yield in new places as stocks bump up against all-time highs. This diversified basket of blue chip names currently delivers over 7% annual yield.", "url": "https://www.fool.com/investing/2025/11/25/want-over-7000-in-annual-dividends-invest-25000-in/"}}
{"date": "2025-11-25", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-25 05:20:12", "publisher": "Forbes", "title": "JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?", "image": "https://images.financialmodelingprep.com/news/jnj-stock-vs-pfe-stock-which-pharmaceutical-giant-is-20251125.jpg", "site": "forbes.com", "text": "The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by 6%, greatly exceeding the S&P 500's 13% increase.", "url": "https://www.forbes.com/sites/greatspeculations/2025/11/25/jnj-stock-vs-pfe-stock-which-pharmaceutical-giant-is-a-better-buy/"}}
{"date": "2025-11-25", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-25 04:36:53", "publisher": "Defense World", "title": "AXQ Capital LP Buys Shares of 12,829 Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/axq-capital-lp-buys-shares-of-12829-pfizer-inc-20251125.png", "site": "defenseworld.net", "text": "AXQ Capital LP purchased a new position in Pfizer Inc. (NYSE: PFE) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm purchased 12,829 shares of the biopharmaceutical company's stock, valued at approximately $311,000. A number of other institutional investors have also made changes to their positions", "url": "https://www.defenseworld.net/2025/11/25/axq-capital-lp-buys-shares-of-12829-pfizer-inc-pfe.html"}}
{"date": "2025-11-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-22 13:07:45", "publisher": "Benzinga", "title": "First-Ever Human H5N5 Case Turns Fatal In Washington State", "image": "https://images.financialmodelingprep.com/news/firstever-human-h5n5-case-turns-fatal-in-washington-state-20251122.jpeg", "site": "feeds.benzinga.com", "text": "Washington reports world's first fatal human H5N5 bird flu case; officials say risk to public remains low, monitoring continues closely.", "url": "https://www.benzinga.com/markets/equities/25/11/49021169/first-ever-human-h5n5-case-turns-fatal-in-washington-state"}}
{"date": "2025-11-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-22 09:20:00", "publisher": "The Motley Fool", "title": "2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon", "image": "https://images.financialmodelingprep.com/news/2-healthcare-stocks-for-beginner-investors-with-a-20year-20251122.jpg", "site": "fool.com", "text": "If you want to invest in top healthcare stocks, both of these are worth consideration. Pfizer is moving past the pandemic era, and tremendous growth could be ahead.", "url": "https://www.fool.com/investing/2025/11/22/2-healthcare-stocks-for-beginner-investors/"}}
{"date": "2025-11-21", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-21 13:24:00", "publisher": "Business Wire", "title": "U.S. FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer", "image": "https://images.financialmodelingprep.com/news/us-fda-approves-padcev-plus-keytruda-for-certain-patients-with-20251121.jpg", "site": "businesswire.com", "text": "NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, Astellas) today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy.", "url": "https://www.businesswire.com/news/home/20251117031627/en/U.S.-FDA-Approves-PADCEV%C2%AE-plus-Keytruda%C2%AE-for-Certain-Patients-with-Bladder-Cancer/"}}
{"date": "2025-11-21", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-21 10:01:29", "publisher": "Zacks Investment Research", "title": "Is Trending Stock Pfizer Inc. (PFE) a Buy Now?", "image": "https://images.financialmodelingprep.com/news/is-trending-stock-pfizer-inc-pfe-a-buy-now-20251121.jpg", "site": "zacks.com", "text": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.", "url": "https://www.zacks.com/stock/news/2794077/is-trending-stock-pfizer-inc-pfe-a-buy-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2794077"}}
{"date": "2025-11-21", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-21 08:46:14", "publisher": "Zacks Investment Research", "title": "PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms", "image": "https://images.financialmodelingprep.com/news/pfes-new-acquired-drugs-drive-noncovid-comeback-as-loe-20251121.jpg", "site": "zacks.com", "text": "Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.", "url": "https://www.zacks.com/stock/news/2794004/pfe-s-new-acquired-drugs-drive-non-covid-comeback-as-loe-test-looms?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2794004"}}
{"date": "2025-11-21", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-21 08:00:00", "publisher": "The Motley Fool", "title": "This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase", "image": "https://images.financialmodelingprep.com/news/this-7yielding-dividend-stock-is-about-to-enter-an-20251121.jpg", "site": "fool.com", "text": "Pfizer is pursuing a potentially lucrative area of the vast oncology market. The drugmaker is also targeting the fast-growing weight loss space.", "url": "https://www.fool.com/investing/2025/11/21/this-7-yielding-dividend-stock-is-about-to-enter/"}}
{"date": "2025-11-21", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-21 04:11:12", "publisher": "Defense World", "title": "Bank Julius Baer & Co. Ltd Zurich Sells 41,351 Shares of Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/bank-julius-baer-co-ltd-zurich-sells-41351-shares-of-20251121.png", "site": "defenseworld.net", "text": "Bank Julius Baer and Co. Ltd Zurich reduced its position in shares of Pfizer Inc. (NYSE: PFE) by 5.3% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 742,418 shares of the biopharmaceutical company's stock after selling 41,351 shares during the quarter. Bank", "url": "https://www.defenseworld.net/2025/11/21/bank-julius-baer-co-ltd-zurich-sells-41351-shares-of-pfizer-inc-pfe.html"}}
{"date": "2025-11-20", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-20 16:05:04", "publisher": "Forbes", "title": "Pfizer Crosses Below Key Moving Average Level", "image": "https://images.financialmodelingprep.com/news/pfizer-crosses-below-key-moving-average-level-20251120.jpg", "site": "forbes.com", "text": "In trading on Thursday, shares of Pfizer crossed below their 200 day moving average of $24.58, changing hands as low as $24.28 per share. Pfizer shares are currently trading off about 1.6% on the day.", "url": "https://www.forbes.com/sites/dividendchannel/2025/11/20/pfizer-crosses-below-key-moving-average-level/"}}
{"date": "2025-11-20", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-20 09:30:00", "publisher": "The Motley Fool", "title": "Is Pfizer's 6.9%-Yielding Dividend Still Safe?", "image": "https://images.financialmodelingprep.com/news/is-pfizers-69yielding-dividend-still-safe-20251120.jpg", "site": "fool.com", "text": "A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years.", "url": "https://www.fool.com/investing/2025/11/20/is-pfizers-69-yielding-dividend-still-safe/"}}
{"date": "2025-11-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-19 17:43:09", "publisher": "Seeking Alpha", "title": "October Readers Identified 10 Ideal \"Safer\" Dividends In 39 Dogs", "image": "https://images.financialmodelingprep.com/news/october-readers-identified-10-ideal-safer-dividends-in-39-20251119.jpg", "site": "seekingalpha.com", "text": "This article highlights the October 2025 ReFa/Ro Dogs, focusing on high-yield, low-priced dividend stocks for contrarian income investors. Top projected net gainers include MFA, CIM, HAFN, IPG, and LYB, with analysts forecasting 30.84% to 70.61% upside by October 2026. Nine of the top ten ReFa/Ro Dogs meet the 'ideal' criterion: dividends from $1,000 invested exceed their share price, emphasizing value and income.", "url": "https://seekingalpha.com/article/4845789-october-readers-identified-10-ideal-safer-dividends-in-39-dogs"}}
{"date": "2025-11-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-19 15:51:23", "publisher": "Seeking Alpha", "title": "Pfizer: Is This Pharma Giant Finally A Bargain", "image": "https://images.financialmodelingprep.com/news/pfizer-is-this-pharma-giant-finally-a-bargain-20251119.jpg", "site": "seekingalpha.com", "text": "Following Pfizer's victory over Novo Nordisk in the \"war\" for Metsera, its stock resumed its upward momentum. But before the deal was completed, it again beat Wall Street analysts' consensus EPS and revenue estimates by a wide margin. Lorbrena, an ALK inhibitor against non-small cell lung cancer, brought in $268 million for Pfizer in Q3, up 30.1% year-on-year.", "url": "https://seekingalpha.com/article/4845752-pfizer-is-this-pharma-giant-finally-bargain"}}
{"date": "2025-11-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-19 10:31:45", "publisher": "Reuters", "title": "Pfizer in $41.5 million settlement with Texas over ADHD drug", "image": "https://images.financialmodelingprep.com/news/pfizer-in-415-million-settlement-with-texas-over-adhd-20251119.jpg", "site": "reuters.com", "text": "Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve claims over alleged quality control lapses in medicine to treat attention deficit hyperactivity disorder in children, Texas Attorney General Ken Paxton said on Wednesday.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-415-million-settlement-with-texas-over-adhd-drug-2025-11-19/"}}
{"date": "2025-11-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-19 06:58:45", "publisher": "Seeking Alpha", "title": "Pfizer Inc. (PFE) Presents at Jefferies London Healthcare Conference 2025 Transcript", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-pfe-presents-at-jefferies-london-healthcare-conference-20251119.jpg", "site": "seekingalpha.com", "text": "Pfizer Inc. ( PFE ) Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM EST Company Participants David Denton - Executive VP & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Good morning, everyone. I hope you're all doing well.", "url": "https://seekingalpha.com/article/4845517-pfizer-inc-pfe-presents-at-jefferies-london-healthcare-conference-2025-transcript"}}
{"date": "2025-11-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-19 03:08:50", "publisher": "Defense World", "title": "America First Investment Advisors LLC Buys 12,373 Shares of Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/america-first-investment-advisors-llc-buys-12373-shares-of-20251119.png", "site": "defenseworld.net", "text": "America First Investment Advisors LLC lifted its position in Pfizer Inc. (NYSE: PFE) by 1.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 796,840 shares of the biopharmaceutical company's stock after purchasing an additional 12,373 shares during the period. Pfizer accounts for about", "url": "https://www.defenseworld.net/2025/11/19/america-first-investment-advisors-llc-buys-12373-shares-of-pfizer-inc-pfe.html"}}
{"date": "2025-11-18", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-18 12:01:08", "publisher": "Zacks Investment Research", "title": "Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?", "image": "https://images.financialmodelingprep.com/news/pfizer-trading-above-50day-sma-is-it-a-good-20251118.jpg", "site": "zacks.com", "text": "PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.", "url": "https://www.zacks.com/stock/news/2792603/pfizer-trading-above-50-day-sma-is-it-a-good-time-to-buy-the-stock?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2792603"}}
{"date": "2025-11-18", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-18 06:45:00", "publisher": "The Motley Fool", "title": "2 No-Brainer Healthcare Stocks to Buy Now", "image": "https://images.financialmodelingprep.com/news/2-nobrainer-healthcare-stocks-to-buy-now-20251118.jpg", "site": "fool.com", "text": "Pfizer's acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach $130 billion by 2030. Viking Therapeutics has both injectable and oral versions of its dual-action, weight-loss drug in advanced testing, making it an attractive acquisition target.", "url": "https://www.fool.com/investing/2025/11/18/2-no-brainer-healthcare-stocks-to-buy-now/"}}
{"date": "2025-11-18", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-18 05:10:44", "publisher": "Defense World", "title": "Avantax Advisory Services Inc. Buys 54,086 Shares of Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/avantax-advisory-services-inc-buys-54086-shares-of-pfizer-20251118.png", "site": "defenseworld.net", "text": "Avantax Advisory Services Inc. raised its stake in Pfizer Inc. (NYSE: PFE) by 14.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 423,497 shares of the biopharmaceutical company's stock after buying an additional 54,086 shares during the period. Avantax Advisory Services", "url": "https://www.defenseworld.net/2025/11/18/avantax-advisory-services-inc-buys-54086-shares-of-pfizer-inc-pfe.html"}}
{"date": "2025-11-18", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-18 04:24:54", "publisher": "Defense World", "title": "Pfizer Inc. $PFE Stake Lowered by Bridger Management LLC", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-pfe-stake-lowered-by-bridger-management-llc-20251118.png", "site": "defenseworld.net", "text": "Bridger Management LLC cut its stake in Pfizer Inc. (NYSE: PFE) by 12.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 408,728 shares of the biopharmaceutical company's stock after selling 57,331 shares during the quarter. Pfizer makes up 5.8% of Bridger Management", "url": "https://www.defenseworld.net/2025/11/18/pfizer-inc-pfe-stake-lowered-by-bridger-management-llc.html"}}
{"date": "2025-11-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-17 21:10:00", "publisher": "The Motley Fool", "title": "Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy?", "image": "https://images.financialmodelingprep.com/news/pfizers-ceo-sends-a-warning-to-eli-lilly-is-20251117.jpg", "site": "fool.com", "text": "Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon.", "url": "https://www.fool.com/investing/2025/11/17/pfizers-ceo-sends-a-warning-to-eli-lilly-is-the-st/"}}
{"date": "2025-11-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-17 18:54:09", "publisher": "Reuters", "title": "US-Saudi event to include CEOs from Chevron, Qualcomm, Pfizer, source says", "image": "https://images.financialmodelingprep.com/news/ussaudi-event-to-include-ceos-from-chevron-qualcomm-pfizer-source-20251117.jpg", "site": "reuters.com", "text": "The U.S.-Saudi Arabia investment forum to take place in Washington during the visit of Saudi Crown Prince Mohammed bin Salman this week is expected to include CEOs from Chevron, Qualcomm, Cisco, General Dynamics and Pfizer, according to a source familiar with the event.", "url": "https://www.reuters.com/world/middle-east/us-saudi-event-include-ceos-chevron-qualcomm-pfizer-source-says-2025-11-17/"}}
{"date": "2025-11-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-17 16:05:39", "publisher": "Seeking Alpha", "title": "3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List", "image": "https://images.financialmodelingprep.com/news/3-best-healthcare-stocks-quant-strong-buys-from-goldmans-20251117.jpg", "site": "seekingalpha.com", "text": "The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in the Russell 1000 universe with positive recent consensus revisions to 2026 EPS estimates and that trade at attractive valuations. Goldman sees \"more opportunity for alpha than beta\" as wide return dispersion and increasing M&A activity in healthcare may favor selected winners.", "url": "https://seekingalpha.com/article/4844747-3-best-healthcare-stocks-quant-strong-buys-from-goldmans-alpha-list"}}
{"date": "2025-11-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-17 04:35:00", "publisher": "The Motley Fool", "title": "Down 55%, Should You Buy the Dip on Pfizer?", "image": "https://images.financialmodelingprep.com/news/down-55-should-you-buy-the-dip-on-pfizer-20251117.jpg", "site": "fool.com", "text": "Pfizer is a $145 billion pharmaceutical industry giant with a long history of success behind it. Wall Street bid the stock up during the COVID-19 pandemic, but now investors have soured on the shares.", "url": "https://www.fool.com/investing/2025/11/17/down-55-buy-the-dip-pfizer-stock/"}}
{"date": "2025-11-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-17 04:32:54", "publisher": "Defense World", "title": "Campbell & CO Investment Adviser LLC Has $347,000 Stock Position in Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/campbell-co-investment-adviser-llc-has-347000-stock-position-20251117.png", "site": "defenseworld.net", "text": "Campbell and CO Investment Adviser LLC cut its holdings in Pfizer Inc. (NYSE: PFE) by 75.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,332 shares of the biopharmaceutical company's stock after selling 43,434 shares during the quarter. Campbell and CO", "url": "https://www.defenseworld.net/2025/11/17/campbell-co-investment-adviser-llc-has-347000-stock-position-in-pfizer-inc-pfe.html"}}
{"date": "2025-11-15", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-15 05:45:00", "publisher": "The Motley Fool", "title": "Is Pfizer Stock a Buy After This $10 Billion Acquisition?", "image": "https://images.financialmodelingprep.com/news/is-pfizer-stock-a-buy-after-this-10-billion-acquisition-20251115.jpg", "site": "fool.com", "text": "Pfizer is buying out Metsera for up to $10 billion after an acquisition battle with another pharma giant. Metsera's leading candidate could be an excellent way for Pfizer to enter the weight-loss drug market.", "url": "https://www.fool.com/investing/2025/11/15/is-pfizer-a-buy-after-this-10-billion-acquisition/"}}
{"date": "2025-11-14", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-14 18:33:12", "publisher": "Reuters", "title": "Activist Starboard sells Pfizer stake after pushing for changes", "image": "https://images.financialmodelingprep.com/news/activist-starboard-sells-pfizer-stake-after-pushing-for-changes-20251114.jpg", "site": "reuters.com", "text": "Activist investor Starboard Value has liquidated its position in Pfizer , according to a regulatory filing on Friday, ending its push for changes aimed at boosting the drugmaker's share price.", "url": "https://www.reuters.com/sustainability/sustainable-finance-reporting/activist-starboard-sells-pfizer-stake-after-pushing-changes-2025-11-14/"}}
{"date": "2025-11-14", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-14 15:19:12", "publisher": "CNBC Television", "title": "Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman", "image": "https://images.financialmodelingprep.com/news/biopharma-companies-have-confidence-in-their-ability-to-do-20251114.jpg", "site": "youtube.com", "text": "Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.", "url": "https://www.youtube.com/watch?v=X24CQW_cpss"}}
{"date": "2025-11-14", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-14 07:01:00", "publisher": "GuruFocus", "title": "Prem Watsa's Strategic Moves: BlackBerry Ltd Sees a -1.32% Portfolio Impact", "image": "https://images.financialmodelingprep.com/news/prem-watsas-strategic-moves-blackberry-ltd-sees-a-132-portfolio-20251114.png", "site": "gurufocus.com", "text": "Exploring the Latest 13F Filing and Investment Adjustments Prem Watsa (Trades, Portfolio) recently submitted the 13F filing for the third quarter of 2025, prov", "url": "https://www.gurufocus.com/news/3209057/prem-watsas-strategic-moves-blackberry-ltd-sees-a-132-portfolio-impact"}}
{"date": "2025-11-14", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-14 06:41:00", "publisher": "GuruFocus", "title": "Pfizer Cuts BioNTech Stake by More Than Half", "image": "https://images.financialmodelingprep.com/news/pfizer-cuts-biontech-stake-by-more-than-half-20251114.png", "site": "gurufocus.com", "text": "Pfizer Inc. (PFE, Financials) has reduced its ownership in German partner BioNTech SE by 54.7%, according to a regulatory filing released Thursday. The transact", "url": "https://www.gurufocus.com/news/3208789/pfizer-cuts-biontech-stake-by-more-than-half"}}
{"date": "2025-11-14", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-14 04:45:02", "publisher": "Defense World", "title": "Arvest Bank Trust Division Has $1.38 Million Stake in Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/arvest-bank-trust-division-has-138-million-stake-in-20251114.png", "site": "defenseworld.net", "text": "Arvest Bank Trust Division reduced its position in Pfizer Inc. (NYSE: PFE) by 22.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,719 shares of the biopharmaceutical company's stock after selling 16,695 shares during the period. Arvest", "url": "https://www.defenseworld.net/2025/11/14/arvest-bank-trust-division-has-1-38-million-stake-in-pfizer-inc-pfe.html"}}
{"date": "2025-11-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-13 18:19:22", "publisher": "Reuters", "title": "Pfizer's ex-R&D chief Dolsten withdraws from Novo Nordisk board race", "image": "https://images.financialmodelingprep.com/news/pfizers-exrd-chief-dolsten-withdraws-from-novo-nordisk-board-20251113.jpg", "site": "reuters.com", "text": "Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing personal reasons, the Danish drugmaker said on Thursday.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizers-ex-rd-chief-dolsten-withdraws-novo-nordisk-board-race-2025-11-13/"}}
{"date": "2025-11-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-13 17:20:40", "publisher": "Reuters", "title": "Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up", "image": "https://images.financialmodelingprep.com/news/pfizer-sheds-biontech-stake-years-after-blockbuster-covid-vaccine-20251113.jpg", "site": "reuters.com", "text": "Pfizer Inc said on Thursday said that it will sell 54.7% of its stake in German drugmaker BioNTech SE , over five years after both firms formed an alliance that yielded a vaccine to combat the deadly COVID-19 pandemic.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-sheds-biontech-stake-years-after-blockbuster-covid-vaccine-tie-up-2025-11-13/"}}
{"date": "2025-11-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-13 14:16:18", "publisher": "Yahoo Finance", "title": "Pfizer CEO: RFK Jr. \"clearly\" was not his HHS Secretary choice", "image": "https://images.financialmodelingprep.com/news/pfizer-ceo-rfk-jr-clearly-was-not-his-hhs-20251113.jpg", "site": "youtube.com", "text": "Pfizer CEO Albert Bourla doesn't think RFK Jr.'s views on vaccines will have long-term risks: \"Vaccines have saved the world and we will continue doing that.\" About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.", "url": "https://www.youtube.com/shorts/872oxpkrXqU"}}
{"date": "2025-11-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-13 13:07:49", "publisher": "Yahoo Finance", "title": "Pfizer CEO: AI will help with medicine's next big breakthrough", "image": "https://images.financialmodelingprep.com/news/pfizer-ceo-ai-will-help-with-medicines-next-big-20251113.jpg", "site": "youtube.com", "text": "Fresh off Pfizer's (PFE) $10 billion battle to acquire Metsera (MTSR), Pfizer chairman and CEO Albert Bourla tells Yahoo Finance Executive Editor Brian Sozzi that the future for the pharmaceutical giant is bright. The company plans to enter the GLP-1 space by 2028 and aims to become a leader in the obesity market.", "url": "https://www.youtube.com/watch?v=qNV6MMLpu98"}}
{"date": "2025-11-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-13 11:26:00", "publisher": "Business Wire", "title": "Pfizer Completes Acquisition of Metsera", "image": "https://images.financialmodelingprep.com/news/pfizer-completes-acquisition-of-metsera-20251113.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. This strategic milestone represents more than a transactionit's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth ther.", "url": "https://www.businesswire.com/news/home/20251112938725/en/Pfizer-Completes-Acquisition-of-Metsera/"}}
{"date": "2025-11-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-13 11:10:21", "publisher": "Benzinga", "title": "Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run", "image": "https://images.financialmodelingprep.com/news/pfizer-seeks-to-exit-biontech-investment-after-lucrative-covid-20251113.jpg", "site": "benzinga.com", "text": "Pfizer (NYSE: PFE) is reportedly offloading its remaining stake in Covid-19 vaccine partner BioNTech SE (NASDAQ: BNTX).", "url": "https://www.benzinga.com/m-a/25/11/48839297/pfizer-seeks-to-exit-biontech-investment-after-lucrative-covid-vaccine-run"}}
{"date": "2025-11-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-13 09:18:56", "publisher": "Reuters", "title": "Metsera shareholders vote for $10 billion acquisition by Pfizer", "image": "https://images.financialmodelingprep.com/news/metsera-shareholders-vote-for-10-billion-acquisition-by-pfizer-20251113.jpg", "site": "reuters.com", "text": "Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing the U.S. pharmaceutical giant re-entry into the lucrative obesity treatment market after a fierce bidding war with Wegovy-maker Novo Nordisk.", "url": "https://www.reuters.com/legal/transactional/metsera-shareholders-vote-10-billion-acquisition-by-pfizer-2025-11-13/"}}
{"date": "2025-11-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-13 08:17:11", "publisher": "Reuters", "title": "BioNTech says collaboration with Pfizer remains unchanged", "image": "https://images.financialmodelingprep.com/news/biontech-says-collaboration-with-pfizer-remains-unchanged-20251113.jpg", "site": "reuters.com", "text": "BioNTech said on Thursday that its collaboration with Pfizer has not changed, when asked to comment on a report that Pfizer is looking to sell its stake in the German biotech firm.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-says-collaboration-with-pfizer-remains-unchanged-2025-11-13/"}}
{"date": "2025-11-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-13 04:55:00", "publisher": "The Motley Fool", "title": "Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead?", "image": "https://images.financialmodelingprep.com/news/should-you-forget-pfizer-and-buy-this-magnificent-drug-20251113.jpg", "site": "fool.com", "text": "Pfizer and Merck are two of the largest drug companies on the planet. Both companies are dealing with upcoming patent expirations.", "url": "https://www.fool.com/investing/2025/11/13/forget-pfizer-buy-magnificent-drug-stock/"}}
{"date": "2025-11-12", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-12 20:27:00", "publisher": "The Motley Fool", "title": "3 Healthcare Stocks Topping a 2025 List of Dividend Yields", "image": "https://images.financialmodelingprep.com/news/3-healthcare-stocks-topping-a-2025-list-of-dividend-20251113.jpg", "site": "fool.com", "text": "Bristol Myers Squibb has a high dividend yield, is very cheap, and may have better growth prospects than it might seem at first glance. Pfizer now has a 7% yield, and may have found a solution to its patent cliff issue.", "url": "https://www.fool.com/investing/2025/11/12/3-healthcare-stocks-topping-a-2025-list-of-dividen/"}}
{"date": "2025-11-12", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-12 10:15:00", "publisher": "The Motley Fool", "title": "2 Strong Healthcare Stock Picks for Value Investors", "image": "https://images.financialmodelingprep.com/news/2-strong-healthcare-stock-picks-for-value-investors-20251112.jpg", "site": "fool.com", "text": "These two tried-and-tested healthcare giants have compelling portfolios and pipelines. Pfizer is moving on from the pandemic era, and a stream of acquisitions has bolstered its pipeline.", "url": "https://www.fool.com/investing/2025/11/12/2-strong-healthcare-stock-picks-for-value-investor/"}}
{"date": "2025-11-12", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-12 10:00:00", "publisher": "Business Wire", "title": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference", "image": "https://images.financialmodelingprep.com/news/pfizer-invites-public-to-view-and-listen-to-webcast-20251112.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 a.m. GMT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginnin.", "url": "https://www.businesswire.com/news/home/20251112707293/en/Pfizer-Invites-Public-to-View-and-Listen-to-Webcast-of-Pfizer-Discussion-at-Healthcare-Conference/"}}
{"date": "2025-11-12", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-12 04:38:55", "publisher": "Defense World", "title": "Advyzon Investment Management LLC Buys 4,774 Shares of Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/advyzon-investment-management-llc-buys-4774-shares-of-pfizer-inc-20251112.png", "site": "defenseworld.net", "text": "Advyzon Investment Management LLC grew its holdings in Pfizer Inc. (NYSE: PFE) by 34.2% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,715 shares of the biopharmaceutical company's stock after acquiring an additional 4,774 shares during the period. Advyzon", "url": "https://www.defenseworld.net/2025/11/12/advyzon-investment-management-llc-buys-4774-shares-of-pfizer-inc-pfe.html"}}
{"date": "2025-11-12", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-12 03:41:01", "publisher": "Defense World", "title": "Allworth Financial LP Acquires 66,209 Shares of Pfizer Inc. $PFE", "image": "https://images.financialmodelingprep.com/news/allworth-financial-lp-acquires-66209-shares-of-pfizer-inc-pfe-20251112.png", "site": "defenseworld.net", "text": "Allworth Financial LP raised its stake in Pfizer Inc. (NYSE: PFE) by 43.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 218,449 shares of the biopharmaceutical company's stock after acquiring an additional 66,209 shares during the quarter. Allworth Financial LP's", "url": "https://www.defenseworld.net/2025/11/12/allworth-financial-lp-acquires-66209-shares-of-pfizer-inc-pfe.html"}}
{"date": "2025-11-11", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-11 13:57:00", "publisher": "GlobeNewsWire", "title": "Johnson Fistel Investigates Fairness of Proposed Sale of Metsera", "image": "https://images.financialmodelingprep.com/news/johnson-fistel-investigates-fairness-of-proposed-sale-of-metsera-20251111.jpg", "site": "globenewswire.com", "text": "SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE).", "url": "https://www.globenewswire.com/news-release/2025/11/11/3185726/0/en/Johnson-Fistel-Investigates-Fairness-of-Proposed-Sale-of-Metsera.html"}}
{"date": "2025-11-11", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-11 10:07:00", "publisher": "The Motley Fool", "title": "Where Will Pfizer Be in 3 Years?", "image": "https://images.financialmodelingprep.com/news/where-will-pfizer-be-in-3-years-20251111.jpg", "site": "fool.com", "text": "Pfizer has a long history of success in the competitive and complex drug sector. The pharmaceutical giant has patent expirations coming in 2027 and 2028.", "url": "https://www.fool.com/investing/2025/11/11/where-will-pfizer-be-in-3-years/"}}
{"date": "2025-11-11", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-11 09:53:24", "publisher": "24/7 Wall Street", "title": "5 Highest Yielding Dividend Stocks in the S&P 500", "image": "https://images.financialmodelingprep.com/news/5-highest-yielding-dividend-stocks-in-the-sp-500-20251111.jpg", "site": "247wallst.com", "text": "The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and fastest-moving giants.", "url": "https://247wallst.com/investing/2025/11/11/5-highest-yielding-dividend-stocks-in-the-sp-500/"}}
{"date": "2025-11-11", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-11 04:25:00", "publisher": "The Motley Fool", "title": "Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?", "image": "https://images.financialmodelingprep.com/news/whos-winning-the-intense-battle-to-rule-the-whitehot-20251111.jpg", "site": "fool.com", "text": "Eli Lilly's GLP-1 drug is now the world's best-selling drug. Novo Nordisk is struggling with declining market share.", "url": "https://www.fool.com/investing/2025/11/11/win-intense-battle-rule-glp-1-drug-lly-nvo-pfe/"}}
{"date": "2025-11-11", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-11 04:10:00", "publisher": "The Motley Fool", "title": "Why a Strong Quarter Wasn't Enough to Send Shares of Pfizer Soaring", "image": "https://images.financialmodelingprep.com/news/why-a-strong-quarter-wasnt-enough-to-send-shares-20251111.jpg", "site": "fool.com", "text": "Pfizer's sales and profits came in better than expected for the third quarter. The stock, however, remains down for the year.", "url": "https://www.fool.com/investing/2025/11/11/why-strong-quarter-not-enough-help-pfizer-stock/"}}
{"date": "2025-11-11", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-11 03:31:36", "publisher": "Seeking Alpha", "title": "Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-pfe-discusses-clinical-development-strategy-for-4404-20251111.jpg", "site": "seekingalpha.com", "text": "Pfizer Inc. ( PFE ) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Jeff Legos Johanna Bendell - Chief Development Officer of Oncology Arati Rao Conference Call Participants Steve Scala - TD Cowen, Research Division Evan Seigerman - BMO Capital Markets Equity Research Jiexian Zhuang - Leerink Partners LLC, Research Division Ethan Brown - JPMorgan Chase & Co, Research Division Presentation Operator Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded.", "url": "https://seekingalpha.com/article/4841652-pfizer-inc-pfe-discusses-clinical-development-strategy-for-4404-bispecific-antibody-in"}}
{"date": "2025-11-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-10 11:53:15", "publisher": "Proactive Investors", "title": "Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk", "image": "https://images.financialmodelingprep.com/news/pfizer-to-acquire-metsera-after-winning-bidding-contest-against-20251110.jpg", "site": "proactiveinvestors.com", "text": "Metsera (NASDAQ:MTSR)announced that it has entered into an amended merger agreement with Pfizer Inc (NYSE:PFE, ETR:PFE), under which Pfizer will acquire the biotech company for up to $86.25 per share, valuing it at about $10 billion. The offer consists of $65.60 per share in cash and a contingent value right (CVR) for additional payments of up to $20.65 per share based on clinical and regulatory milestones.", "url": "https://www.proactiveinvestors.com/companies/news/1082181"}}
{"date": "2025-11-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-10 10:46:01", "publisher": "Zacks Investment Research", "title": "Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B", "image": "https://images.financialmodelingprep.com/news/pfizer-wins-obesity-war-against-nvo-to-buy-metsera-20251110.jpg", "site": "zacks.com", "text": "Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.", "url": "https://www.zacks.com/stock/news/2788491/pfizer-wins-obesity-war-against-nvo-to-buy-metsera-for-around-10b?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2788491"}}
{"date": "2025-11-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-10 10:30:40", "publisher": "CNBC Television", "title": "Pfizer to buy Metsera in deal worth up to $10 billion", "image": "https://images.financialmodelingprep.com/news/pfizer-to-buy-metsera-in-deal-worth-up-to-20251110.jpg", "site": "youtube.com", "text": "Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.", "url": "https://www.youtube.com/shorts/rw4c52sfFBE"}}
{"date": "2025-11-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-10 10:21:40", "publisher": "CNBC Television", "title": "Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs", "image": "https://images.financialmodelingprep.com/news/pfizer-ceo-metsera-deal-gives-us-one-of-the-20251110.jpg", "site": "youtube.com", "text": "Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer's strategy for clinical development and manufacturing.", "url": "https://www.youtube.com/watch?v=VfD_9yJJfUU"}}
{"date": "2025-11-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-10 10:00:57", "publisher": "Zacks Investment Research", "title": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-pfe-is-attracting-investor-attention-here-is-20251110.jpg", "site": "zacks.com", "text": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.", "url": "https://www.zacks.com/stock/news/2788373/pfizer-inc-pfe-is-attracting-investor-attention-here-is-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2788373"}}
{"date": "2025-11-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-10 09:10:41", "publisher": "Investopedia", "title": "5 Things to Know Before the Stock Market Opens", "image": "https://images.financialmodelingprep.com/news/5-things-to-know-before-the-stock-market-opens-20251110.jpg", "site": "investopedia.com", "text": "Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part of an agreement that could bring an end to the shutdown that has lasted nearly six weeks; President Donald Trump has proposed issuing $2,000 dividend checks to Americans that would be funded by revenue from tariffs; AI data center firm CoreWeave (CRWV) is set to release its quarterly results after the closing bell today; and shares of Metsera (MTSR) are plunging after the weight-loss drug maker announced that it would be acquired by Pfizer (PFE) after a bidding war with Novo Nordisk (NVO). Here's what you need to know today.", "url": "https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-november-10-2025-11846510"}}
{"date": "2025-11-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-10 09:09:00", "publisher": "Schaeffers Research", "title": "End of Shutdown Hopes Send Stock Futures Surging", "image": "https://images.financialmodelingprep.com/news/end-of-shutdown-hopes-send-stock-futures-surging-20251110.png", "site": "schaeffersresearch.com", "text": "Stock futures are surging as a possible end to the longest-ever government shutdown comes into play", "url": "https://www.schaeffersresearch.com/content/ezines/2025/11/10/end-of-shutdown-hopes-send-stock-futures-surging"}}
{"date": "2025-11-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-10 08:05:00", "publisher": "Market Watch", "title": "Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.", "image": "https://images.financialmodelingprep.com/news/pfizer-won-its-fight-to-buy-an-obesitydrug-maker-20251110.jpg", "site": "marketwatch.com", "text": "Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration.", "url": "https://www.marketwatch.com/story/pfizer-won-its-fight-to-buy-an-obesity-drug-maker-it-took-an-extra-1-7-billion-and-a-phone-call-a9670e80"}}
{"date": "2025-11-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-10 07:32:00", "publisher": "Barrons", "title": "Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.", "image": "https://images.financialmodelingprep.com/news/pfizer-is-buying-weightloss-drugmaker-metsera-why-novo-nordisk-20251110.jpg", "site": "barrons.com", "text": "The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.", "url": "https://www.barrons.com/articles/pfizer-is-buying-weight-loss-drugmaker-metsera-why-novo-nordisk-is-the-real-winner-b464be0a"}}
{"date": "2025-11-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-10 07:00:00", "publisher": "GlobeNewsWire", "title": "Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader RogerDansey, M.D., to Its Board of Directors", "image": "https://images.financialmodelingprep.com/news/nurix-therapeutics-appoints-accomplished-biopharmaceutical-leader-rogerdansey-md-to-20251110.jpg", "site": "globenewswire.com", "text": "Dr.Dansey, formerly of Pfizer and Seagen, strengthens the Board's research, drug development and commercialization expertise Dr.Dansey, formerly of Pfizer and Seagen, strengthens the Board's research, drug development and commercialization expertise", "url": "https://www.globenewswire.com/news-release/2025/11/10/3184355/0/en/Nurix-Therapeutics-Appoints-Accomplished-Biopharmaceutical-Leader-Roger-Dansey-M-D-to-Its-Board-of-Directors.html"}}
{"date": "2025-11-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-10 05:27:00", "publisher": "Seeking Alpha", "title": "Dividend Income: Lanny's September 2025 Summary", "image": "https://images.financialmodelingprep.com/news/dividend-income-lannys-september-2025-summary-20251110.jpg", "site": "seekingalpha.com", "text": "In September, we (my wife and I) received a dividend income total of $5,342.09. Our dividend income went up almost $1,000 from last year. We had more stocks increase last month, but the increases this month provided much more growth to the forward passive income stream.", "url": "https://seekingalpha.com/article/4841196-dividend-income-lanny-september-2025-summary"}}
{"date": "2025-11-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-10 03:45:13", "publisher": "CNBC International TV", "title": "U.S. Senate Makes Progress on Shutdown Deal, Novo Nordisk Loses Out to Pfizer", "image": "https://images.financialmodelingprep.com/news/us-senate-makes-progress-on-shutdown-deal-novo-nordisk-20251110.jpg", "site": "youtube.com", "text": "The U.S. Senate progressed a deal towards ending the longest U.S. Government shutdown in history. Eight democrats joined all but one republican in voting to move forward with a funding bill that will keep the U.S. Government liquid through January 30th, drawing rebuke from Democratic party leaders given the deal's lack of guarantees on healthcare.", "url": "https://www.youtube.com/watch?v=BeNRs_aFvAA"}}
{"date": "2025-11-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-09 13:31:06", "publisher": "Seeking Alpha", "title": "Wall Street Brunch: Here Come The 13Fs", "image": "https://images.financialmodelingprep.com/news/wall-street-brunch-here-come-the-13fs-20251109.jpg", "site": "seekingalpha.com", "text": "13F filings this week will reveal hedge fund and institutional moves, offering insight into smart money positioning amid recent market highs. Earnings season is winding down, with 90% of S&P 500 companies reporting; most beat estimates, but guidance remains cautious.", "url": "https://seekingalpha.com/article/4841061-wall-street-brunch-here-come-the-13fs"}}
{"date": "2025-11-08", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-08 16:14:29", "publisher": "New York Post", "title": "Pfizer wins $10 billion bidding war for obesity drug developer", "image": "https://images.financialmodelingprep.com/news/pfizer-wins-10-billion-bidding-war-for-obesity-drug-20251108.jpg", "site": "nypost.com", "text": "Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.", "url": "https://nypost.com/2025/11/08/business/pfizer-wins-10-billion-bidding-war-for-metsera-over-novo-nordisk/"}}
{"date": "2025-11-08", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-08 09:54:46", "publisher": "Invezz", "title": "Pfizer clinches $10 billion Metsera deal, outbidding Novo Nordisk", "image": "https://images.financialmodelingprep.com/news/pfizer-clinches-10-billion-metsera-deal-outbidding-novo-nordisk-20251108.jpg", "site": "invezz.com", "text": "Pfizer acquires Metsera for $10 billion, cementing their new obesity treatment strategy. The purchase concludes a weeklong bidding frenzy between the New York-based pharmaceutical company and Danish heavyweight Novo Nordisk, whose last-minute counterbid was finally rejected by US antitrust regulators.", "url": "https://invezz.com/news/2025/11/08/pfizer-clinches-10-billion-metsera-deal-outbidding-novo-nordisk/"}}
{"date": "2025-11-08", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-08 06:38:43", "publisher": "Seeking Alpha", "title": "Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer", "image": "https://images.financialmodelingprep.com/news/healthcare-q3-dividend-roundup-i-prefer-abbvie-over-pfizer-20251108.jpg", "site": "seekingalpha.com", "text": "AbbVie's and Pfizer's Q3 earnings and dividend updates prompt a rating upgrade to Hold for ABBV and reiteration of Sell for PFE. PFE's higher yield (almost 7%) and single-digit P/E (FY1 P/E is ~8x only) can be attractive for deep value investors. The high yield and cheap valuation are for good reasons.", "url": "https://seekingalpha.com/article/4840843-healthcare-q3-dividend-roundup-i-prefer-abbvie-over-pfizer"}}
{"date": "2025-11-07", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-07 22:07:00", "publisher": "WSJ", "title": "Pfizer has agreed to buy weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting rival Novo Nordisk following a heated bidding war", "image": "https://images.financialmodelingprep.com/news/pfizer-has-agreed-to-buy-weightloss-drug-startup-metsera-20251107.jpg", "site": "wsj.com", "text": "Pfizer prevails over rival Novo Nordisk after an unusual bidding war for the weight-loss startup.", "url": "https://www.wsj.com/health/pharma/pfizer-and-metsera-reach-deal-worth-up-to-10-billion-be5def52"}}
{"date": "2025-11-07", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-07 21:32:00", "publisher": "PRNewsWire", "title": "Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer", "image": "https://images.financialmodelingprep.com/news/pfizer-and-metsera-enter-into-merger-agreement-amendment-metseras-20251107.jpg", "site": "prnewswire.com", "text": "Revised transaction valuesMetsera at up to $86.25 per share Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger agreement and approve the merger with Pfizer Transaction creates real, certain and immediate value for Metsera's stockholders and ensures Metsera's important drug candidates can emerge as key competitors available to all patients NEW YORK , Nov. 7, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to $20.65 per share in cash. The Metsera Board of Directors has determined that the revised terms represent the best transaction for shareholders, both from the perspective of value and certainty of closing.", "url": "https://www.prnewswire.com/news-releases/pfizer-and-metsera-enter-into-merger-agreement-amendment-metseras-board-of-directors-reaffirms-support-of-merger-with-pfizer-302609256.html"}}
{"date": "2025-11-07", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-07 19:59:59", "publisher": "Reuters", "title": "Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports", "image": "https://images.financialmodelingprep.com/news/pfizer-sweetens-offer-for-metsera-in-bidding-war-against-novo-20251107.jpg", "site": "reuters.com", "text": "Pfizer has submitted a sweetened bid for obesity drug developer Metsera , as its fight against rival Novo Nordisk escalates, Bloomberg News reported on Friday.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-sweetens-offer-metsera-bidding-war-against-novo-bloomberg-news-reports-2025-11-08/"}}
{"date": "2025-11-07", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-07 13:00:00", "publisher": "GlobeNewsWire", "title": "National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry", "image": "https://images.financialmodelingprep.com/news/national-advertising-division-will-refer-bridgebio-pharma-to-government-20251107.png", "site": "globenewswire.com", "text": "Following a challenge submitted by Pfizer, Inc., BBB National Programs' National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enforcement action for failure to participate in the National Advertising Division (NAD) inquiry. Following a challenge submitted by Pfizer, Inc., BBB National Programs' National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enforcement action for failure to participate in the National Advertising Division (NAD) inquiry.", "url": "https://www.globenewswire.com/news-release/2025/11/07/3183894/0/en/National-Advertising-Division-Will-Refer-BridgeBio-Pharma-to-Government-Agencies-for-Failure-to-Participate-in-Inquiry.html"}}
{"date": "2025-11-07", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-07 12:31:08", "publisher": "Zacks Investment Research", "title": "Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call", "image": "https://images.financialmodelingprep.com/news/pfizer-discusses-drug-pricing-deal-metsera-buyout-dispute-on-20251107.jpg", "site": "zacks.com", "text": "Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.", "url": "https://www.zacks.com/stock/news/2787962/pfizer-discusses-drug-pricing-deal-metsera-buyout-dispute-on-q3-call?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2787962"}}
{"date": "2025-11-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-06 14:00:53", "publisher": "Seeking Alpha", "title": "Pfizer: The Storm Has Passed -- Tailwinds Ahead", "image": "https://images.financialmodelingprep.com/news/pfizer-the-storm-has-passed-tailwinds-ahead-20251106.jpg", "site": "seekingalpha.com", "text": "Pfizer Inc. remains a Strong Buy with a $33 price target, implying 33% upside over 12-18 months, driven by undervaluation and sector tailwinds. Despite Fiscal Q3 2025 revenue and EPS declines, PFE's future outlook is improving, with new product launches and acquisitions expected to offset losses of exclusivity. PFE's robust dividend yield near 7%, shareholder-friendly capital allocation, and potential Metsera acquisition offer downside protection and growth catalysts.", "url": "https://seekingalpha.com/article/4839345-pfizer-storm-has-passed-tailwinds-ahead"}}
{"date": "2025-11-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-06 12:01:58", "publisher": "Reuters", "title": "What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?", "image": "https://images.financialmodelingprep.com/news/what-is-metsera-the-target-in-pfizers-and-novo-20251106.jpg", "site": "reuters.com", "text": "Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market.", "url": "https://www.reuters.com/legal/transactional/what-is-metsera-target-pfizers-novo-nordisks-bidding-war-2025-11-06/"}}
{"date": "2025-11-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-06 11:40:34", "publisher": "Benzinga", "title": "Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal", "image": "https://images.financialmodelingprep.com/news/pfizer-to-raise-metsera-bid-after-court-denies-attempt-to-20251106.jpeg", "site": "benzinga.com", "text": "The Delaware Chancery Court denied Pfizer Inc.'s (NYSE:PFE) request for a temporary restraining order to prevent Metsera, Inc. (NASDAQ:MTSR) from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk A/S (NYSE:NVO).", "url": "https://www.benzinga.com/m-a/25/11/48693778/pfizer-to-raise-metsera-bid-after-court-denies-attempt-to-block-rival-deal"}}
{"date": "2025-11-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-06 11:36:41", "publisher": "24/7 Wall Street", "title": "No Brainer Dividend Stocks To Buy Now", "image": "https://images.financialmodelingprep.com/news/no-brainer-dividend-stocks-to-buy-now-20251106.jpg", "site": "247wallst.com", "text": "You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating cash income from their portfolio, but if you handle the income well, you can generate a higher total return through dividend reinvestment while boosting the long-term capital appreciation potential.", "url": "https://247wallst.com/investing/2025/11/06/no-brainer-dividend-stocks-to-buy-now/"}}
{"date": "2025-11-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-06 10:11:02", "publisher": "Investors Business Daily", "title": "'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera", "image": "https://images.financialmodelingprep.com/news/its-getting-ugly-analyst-says-as-pfizer-escalates-its-20251106.jpg", "site": "investors.com", "text": "Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.", "url": "https://www.investors.com/news/technology/metsera-stock-pfizer-novo-nordisk-bidding-battle/"}}
{"date": "2025-11-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-06 08:49:32", "publisher": "Reuters", "title": "Metsera weighs rival bids from Pfizer, Novo in $10 billion obesity drug battle", "image": "https://images.financialmodelingprep.com/news/metsera-weighs-rival-bids-from-pfizer-novo-in-10-20251106.jpg", "site": "reuters.com", "text": "A bidding war over U.S. biotech Metsera was coming to a head on Thursday, with Danish drugmaker Novo Nordisk locked in a $10 billion battle with U.S. rival Pfizer to win Metsera's obesity drug assets.", "url": "https://www.reuters.com/legal/transactional/metsera-weighs-rival-bids-pfizer-novo-10-billion-obesity-drug-battle-2025-11-06/"}}
{"date": "2025-11-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-06 07:20:50", "publisher": "Seeking Alpha", "title": "Pfizer's Slow Burn Comeback", "image": "https://images.financialmodelingprep.com/news/pfizers-slow-burn-comeback-20251106.jpg", "site": "seekingalpha.com", "text": "Pfizer offers a 7% dividend yield, providing steady income despite stagnant share performance in recent months. COVID-19 product sales have sharply declined, with Paxlovid down 55% and vaccine revenue falling 20% year-over-year. Pfizer is redirecting investment toward oncology and cardiometabolic markets, projected to exceed $70 billion by 2030.", "url": "https://seekingalpha.com/article/4839065-pfizers-slow-burn-comeback"}}
{"date": "2025-11-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-06 06:29:34", "publisher": "Seeking Alpha", "title": "Wall Street Breakfast Podcast: Government Shutdown Hits New Altitude", "image": "https://images.financialmodelingprep.com/news/wall-street-breakfast-podcast-government-shutdown-hits-new-altitude-20251106.jpg", "site": "seekingalpha.com", "text": "FAA will reduce air traffic by 10% across 40 major markets due to staffing shortages from the government shutdown, impacting 3,500-4,000 flights daily. Pfizer (PFE) has matched Novo Nordisk's bid for obesity biotech Metsera (MTSR), valuing it at $10 billion, intensifying the takeover battle.", "url": "https://seekingalpha.com/article/4839068-wall-street-breakfast-podcast-government-shutdown-hits-new-altitude"}}
{"date": "2025-11-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-06 04:44:00", "publisher": "The Motley Fool", "title": "Why Pfizer's 7%-Yielding Dividend Just Became Safer -- and More Tempting", "image": "https://images.financialmodelingprep.com/news/why-pfizers-7yielding-dividend-just-became-safer-and-more-20251106.jpg", "site": "fool.com", "text": "Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line.", "url": "https://www.fool.com/investing/2025/11/06/why-pfizers-7-yielding-dividend-just-got-safer/"}}
{"date": "2025-11-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-06 04:10:00", "publisher": "The Motley Fool", "title": "2 Dirt Cheap Stocks to Buy With $1,000 Right Now", "image": "https://images.financialmodelingprep.com/news/2-dirt-cheap-stocks-to-buy-with-1000-right-20251106.jpg", "site": "fool.com", "text": "Turnaround stocks often face a lot of negativity from investors until their turnaround efforts start bearing fruit. United Parcel Service is working to streamline its operations so it can become a more profitable business.", "url": "https://www.fool.com/investing/2025/11/06/2-dirt-cheap-stocks-to-buy-with-1000-right-now/"}}
{"date": "2025-11-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-05 19:17:00", "publisher": "PRNewsWire", "title": "Metsera Issues Statement in Response to Litigation Ruling", "image": "https://images.financialmodelingprep.com/news/metsera-issues-statement-in-response-to-litigation-ruling-20251105.jpg", "site": "prnewswire.com", "text": "NEW YORK , Nov. 5, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\" or the \"Company\") today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer: \"Metsera is gratified by the Delaware Court of Chancery's decision to deny Pfizer's request for a temporary restraining order to block Metsera's Board of Directors from acting in the best interests of shareholders. Separately, Pfizer has reiterated it will continue to spuriously litigate.", "url": "https://www.prnewswire.com/news-releases/metsera-issues-statement-in-response-to-litigation-ruling-302606389.html"}}
{"date": "2025-11-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-05 18:02:02", "publisher": "CNBC Television", "title": "Expect Pfizer bid to beat Novo for Metsera, says BMO's Evan David Seigerman", "image": "https://images.financialmodelingprep.com/news/expect-pfizer-bid-to-beat-novo-for-metsera-says-bmos-20251105.jpg", "site": "youtube.com", "text": "Evan David Seigerman, BMO, joins 'Fast Money' to talk bidding wars in the pharma space, Novo Nordisk dropping on earnings, and more.", "url": "https://www.youtube.com/watch?v=RnefdufufSg"}}
{"date": "2025-11-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-05 17:08:00", "publisher": "Business Wire", "title": "Pfizer Responds to Delaware Chancery Court Ruling", "image": "https://images.financialmodelingprep.com/news/pfizer-responds-to-delaware-chancery-court-ruling-20251105.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court's decision denying Pfizer's request for a temporary restraining order to prevent Metsera, Inc. from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk. We remain confident in the merits of our claims and our belief that Metsera has acted in breach of its contractual obligations and that Metsera's directors have breached the.", "url": "https://www.businesswire.com/news/home/20251105465243/en/Pfizer-Responds-to-Delaware-Chancery-Court-Ruling/"}}
{"date": "2025-11-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-05 17:02:09", "publisher": "Reuters", "title": "Pfizer preparing to raise its bid for Metsera, WSJ reports", "image": "https://images.financialmodelingprep.com/news/pfizer-preparing-to-raise-its-bid-for-metsera-wsj-20251105.jpg", "site": "reuters.com", "text": "Pfizer is preparing to sweeten its offer again for Metsera , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-preparing-raise-its-bid-metsera-wsj-reports-2025-11-05/"}}
{"date": "2025-11-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-05 16:52:00", "publisher": "WSJ", "title": "Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk", "image": "https://images.financialmodelingprep.com/news/pfizer-is-preparing-to-sweeten-its-offer-again-for-20251105.jpg", "site": "wsj.com", "text": "Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk.", "url": "https://www.wsj.com/health/pharma/pfizer-preps-improved-offer-in-metsera-bidding-war-33f5879b"}}
{"date": "2025-11-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-05 16:20:20", "publisher": "Reuters", "title": "Delaware judge says she will not block Metsera from ending Pfizer deal", "image": "https://images.financialmodelingprep.com/news/delaware-judge-says-she-will-not-block-metsera-from-20251105.jpg", "site": "reuters.com", "text": "A Delaware judge said on Wednesday she would reject a request by Pfizer to temporarily block Metsera from terminating its takeover deal with Pfizer, allowing Metsera to proceed instead with a higher $10 billion deal from Novo Nordisk.", "url": "https://www.reuters.com/sustainability/boards-policy-regulation/delaware-judge-says-she-will-not-block-metsera-ending-pfizer-deal-2025-11-05/"}}
{"date": "2025-11-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-05 14:19:47", "publisher": "Reuters", "title": "Pfizer says it removed some conditions from its Metsera bid", "image": "https://images.financialmodelingprep.com/news/pfizer-says-it-removed-some-conditions-from-its-metsera-20251105.jpg", "site": "reuters.com", "text": "Pfizer has removed some conditions in its bid for Metsera as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Delaware judge on Wednesday.", "url": "https://www.reuters.com/world/pfizer-says-it-removed-some-conditions-its-metsera-bid-2025-11-05/"}}
{"date": "2025-11-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-05 11:30:50", "publisher": "Seeking Alpha", "title": "Pfizer: Market Still Pricing It At Crisis Valuations", "image": "https://images.financialmodelingprep.com/news/pfizer-market-still-pricing-it-at-crisis-valuations-20251105.jpg", "site": "seekingalpha.com", "text": "Pfizer Inc. remains materially undervalued despite recent volatility, with its recovery momentum challenged by the ongoing Metsera bidding war. PFE's more stable guidance and robust pipeline offer multiple growth pathways, even if the Metsera acquisition turns out to be unsuccessful. The GLP-1 market's increasing competition and pricing pressures may weigh on PFE sentiment, but strong free cash flows and appealing dividend yield support a bullish view.", "url": "https://seekingalpha.com/article/4838272-pfizer-market-still-pricing-it-at-crisis-valuations"}}
{"date": "2025-11-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-05 10:07:33", "publisher": "CNBC", "title": "Healthy Returns: What to know about Pfizer and Novo Nordisk's bidding war over obesity biotech Metsera", "image": "https://images.financialmodelingprep.com/news/healthy-returns-what-to-know-about-pfizer-and-novo-20251105.jpg", "site": "cnbc.com", "text": "Pfizer and Novo Nordisk are in a takeover clash over the obesity biotech Metsera, while some House Republicans warm to extending tax credits.", "url": "https://www.cnbc.com/2025/11/05/healthy-returns-pfizer-novo-nordisk-escalate-metsera-bidding-war.html"}}
{"date": "2025-11-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-05 05:42:00", "publisher": "Market Watch", "title": "Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera", "image": "https://images.financialmodelingprep.com/news/novo-nordisk-downgrades-sales-outlook-again-amid-bidding-war-with-20251105.jpg", "site": "marketwatch.com", "text": "Management lowers full-year guidance, warns about competition, launches bid for Metsera.", "url": "https://www.marketwatch.com/story/novo-nordisk-downgrades-sales-outlook-again-amid-bidding-war-with-pfizer-for-metsera-2578299c"}}
{"date": "2025-11-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-05 03:06:00", "publisher": "The Motley Fool", "title": "3 Magnificent Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 8.5% -- to Buy With Confidence in November", "image": "https://images.financialmodelingprep.com/news/3-magnificent-ultrahighyield-dividend-stocks-sporting-an-average-yield-of-20251105.jpg", "site": "fool.com", "text": "Dividend stocks have more than doubled the average annual return of non-payers over the last 51 years. Phenomenal deals can be found among ultra-high-yield dividend stocks -- those with yields four or more times higher than the average yield of the S&P 500.", "url": "https://www.fool.com/investing/2025/11/05/3-ultra-high-yield-dividend-stocks-buy-in-november/"}}
{"date": "2025-11-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-05 01:18:50", "publisher": "Defense World", "title": "Traders Buy Large Volume of Pfizer Call Options (NYSE:PFE)", "image": "https://images.financialmodelingprep.com/news/traders-buy-large-volume-of-pfizer-call-options-nysepfe-20251105.png", "site": "defenseworld.net", "text": "Pfizer Inc. (NYSE: PFE - Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock traders bought 190,383 call options on the company. This is an increase of 16% compared to the typical daily volume of 163,526 call options. Pfizer Price Performance NYSE PFE opened at $24.32 on Wednesday. The business's fifty", "url": "https://www.defenseworld.net/2025/11/05/traders-buy-large-volume-of-pfizer-call-options-nysepfe.html"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 16:14:00", "publisher": "GuruFocus", "title": "Pfizer Inc (PFE) Q3 2025 Earnings Call Highlights: Navigating Revenue Declines and Strategic Milestones", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-pfe-q3-2025-earnings-call-highlights-navigating-revenue-20251104.png", "site": "gurufocus.com", "text": "Revenue: $16.7 billion for Q3 2025, a 7% operational decrease year-over-year.Adjusted Diluted EPS: $0.87, ahead of expectations.Reported Diluted EPS: $0.62 for", "url": "https://www.gurufocus.com/news/3182664/pfizer-inc-pfe-q3-2025-earnings-call-highlights-navigating-revenue-declines-and-strategic-milestones"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 15:56:33", "publisher": "Seeking Alpha", "title": "Pfizer Inc. (PFE) Q3 2025 Earnings Call Transcript", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-pfe-q3-2025-earnings-call-transcript-20251104.jpg", "site": "seekingalpha.com", "text": "Pfizer Inc. ( PFE ) Q3 2025 Earnings Call November 4, 2025 10:00 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Albert Bourla - Chairman of the Board & CEO David Denton - Executive VP & CFO Aamir Malik Andrew Baum - Chief Strategy & Innovation Officer, Executive VP Chris Boshoff - Chief Scientific Officer and President of Research & Development Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.", "url": "https://seekingalpha.com/article/4837578-pfizer-inc-pfe-q3-2025-earnings-call-transcript"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 15:04:42", "publisher": "Benzinga", "title": "Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss  But Viking Already Owns It", "image": "https://images.financialmodelingprep.com/news/novo-pfizer-are-battling-to-buy-the-future-of-20251104.jpg", "site": "benzinga.com", "text": "Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid.", "url": "https://www.benzinga.com/m-a/25/11/48634701/novo-pfizer-are-battling-to-buy-the-future-of-weight-loss-but-viking-already-owns-it"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 14:45:55", "publisher": "Benzinga", "title": "Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb", "image": "https://images.financialmodelingprep.com/news/pfizer-novo-nordisk-intensify-fight-for-metsera-as-buyout-20251104.jpg", "site": "benzinga.com", "text": "Adding more drama to Metsera Inc.'s (NASDAQ:MTSR) acquisition deal, Novo Nordisk A/S (NYSE:NVO) increased the deal proposal to $62.20 per share in cash, up from $56.50.", "url": "https://www.benzinga.com/m-a/25/11/48634093/pfizer-novo-nordisk-intensify-fight-for-metsera-as-buyout-offers-continue-to-climb"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 13:02:32", "publisher": "Invezz", "title": "Why Metsera stock's 20% surge signals a fierce Pfizer-Novo Nordisk bidding war", "image": "https://images.financialmodelingprep.com/news/why-metsera-stocks-20-surge-signals-a-fierce-pfizernovo-20251104.jpg", "site": "invezz.com", "text": "Metsera stock (NASDAQ: MTSR) surged roughly 20% on Tuesday after the obesity-focused biotech announced that Novo Nordisk's revised $10 billion acquisition proposal has been deemed superior to Pfizer's competing bid. The escalating bidding war underscores the pharmaceutical industry's unprecedented scramble to control innovative obesity treatments.", "url": "https://invezz.com/news/2025/11/04/why-metsera-stocks-20-surge-signals-a-fierce-pfizer-novo-nordisk-bidding-war/"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 12:27:08", "publisher": "Proactive Investors", "title": "Novo Nordisk tops Pfizer in bidding war for obesity startup Metsera", "image": "https://images.financialmodelingprep.com/news/novo-nordisk-tops-pfizer-in-bidding-war-for-obesity-20251104.jpg", "site": "proactiveinvestors.com", "text": "Novo Nordisk (NYSE:NVO) has outbid Pfizer Inc (NYSE:PFE, ETR:PFE) in a heated contest for obesity-focused biotech Metsera (NASDAQ:MTSR), with the Danish drugmaker's revised offer valuing the company at roughly $10 billion, compared with Pfizer's $8.1 billion proposal. Metsera's board on Tuesday declared Novo Nordisk's amended bid superior, setting the stage for a potential acquisition that could reshape the obesity treatment landscape.", "url": "https://www.proactiveinvestors.com/companies/news/1081781"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 12:18:18", "publisher": "CNBC Television", "title": "Pfizer and Novo Nordisk both raise bids for Metsera", "image": "https://images.financialmodelingprep.com/news/pfizer-and-novo-nordisk-both-raise-bids-for-metsera-20251104.jpg", "site": "youtube.com", "text": "CNBC's David Faber breaks down the latest details about a bidding war between Pfizer and Novo Nordisk for Metsera.", "url": "https://www.youtube.com/watch?v=tGNfcQ59m7M"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 12:15:46", "publisher": "Zacks Investment Research", "title": "Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools", "image": "https://images.financialmodelingprep.com/news/pfizer-q3-earnings-beat-estimates-sales-decline-as-covid-20251104.jpg", "site": "zacks.com", "text": "Pfizer posts Q3 earnings beat and raises EPS guidance, but weaker COVID product sales weigh on overall revenue momentum.", "url": "https://www.zacks.com/stock/news/2784764/pfizer-q3-earnings-beat-estimates-sales-decline-as-covid-demand-cools?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2784764"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 11:29:58", "publisher": "Reuters", "title": "Delaware judge does not see current need for court in Metsera bidding war between Pfizer and Novo", "image": "https://images.financialmodelingprep.com/news/delaware-judge-does-not-see-current-need-for-court-20251104.jpg", "site": "reuters.com", "text": "A Delaware judge said on Tuesday she did not see in a preliminary evaluation the need to involve the court in the bidding war for Metsera between Pfizer and Novo Nordisk, but did schedule another hearing for 3:15 pm ET on Wednesday to review the process.", "url": "https://www.reuters.com/sustainability/boards-policy-regulation/delaware-judge-does-not-see-current-need-court-metsera-bidding-war-between-2025-11-04/"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 11:25:01", "publisher": "Proactive Investors", "title": "Pfizer reports strong Q3 earnings, raises full-year profit guidance", "image": "https://images.financialmodelingprep.com/news/pfizer-reports-strong-q3-earnings-raises-fullyear-profit-guidance-20251104.jpg", "site": "proactiveinvestors.com", "text": "Pfizer Inc (NYSE:PFE, ETR:PFE)reported third quarter financial results that topped Wall Street expectations despite a year-over-year drop in earnings and sales, while raising its full-year profit guidance. The company reported Q3 revenue of $16.7 billion, slightly above analyst estimates of $16.55 billion, representing a 7%decline compared with the same period last year.", "url": "https://www.proactiveinvestors.com/companies/news/1081773"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 11:01:34", "publisher": "Zacks Investment Research", "title": "Here's What Key Metrics Tell Us About Pfizer (PFE) Q3 Earnings", "image": "https://images.financialmodelingprep.com/news/heres-what-key-metrics-tell-us-about-pfizer-pfe-20251104.jpg", "site": "zacks.com", "text": "While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.", "url": "https://www.zacks.com/stock/news/2784707/here-s-what-key-metrics-tell-us-about-pfizer-pfe-q3-earnings?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2784707"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 09:58:00", "publisher": "WSJ", "title": "Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bid", "image": "https://images.financialmodelingprep.com/news/metsera-said-it-received-a-revised-acquisition-offer-from-20251104.jpg", "site": "wsj.com", "text": "The new offer constitutes a superior company proposal to Pfizer's bid, Metsera said.", "url": "https://www.wsj.com/health/pharma/novo-nordisk-sweetens-offer-for-metsera-e6dc4c2b"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 09:54:29", "publisher": "24/7 Wall Street", "title": "Pfizer's Q3 Earnings Beat on Top and Bottom Lines", "image": "https://images.financialmodelingprep.com/news/pfizers-q3-earnings-beat-on-top-and-bottom-lines-20251104.jpg", "site": "247wallst.com", "text": "Pfizer (NYSE: PFE) beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 consensus and revenue of $16.65 billion versus $16.50 billion expected.", "url": "https://247wallst.com/investing/2025/11/04/pfizers-q3-earnings-beat-on-top-and-bottom-lines/"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 09:53:19", "publisher": "Benzinga", "title": "Dow Dips Over 400 Points; Pfizer Earnings Top Estimates", "image": "https://images.financialmodelingprep.com/news/dow-dips-over-400-points-pfizer-earnings-top-estimates-20251104.jpg", "site": "benzinga.com", "text": "U.S. stocks traded lower this morning, with the Dow Jones index falling more than 400 points on Tuesday.", "url": "https://www.benzinga.com/news/25/11/48621866/dow-dips-over-400-points-pfizer-earnings-top-estimates"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 09:40:06", "publisher": "CNBC", "title": "Metsera says Novo Nordisk's new bid for obesity drugmaker is superior' to revised Pfizer offer", "image": "https://images.financialmodelingprep.com/news/metsera-says-novo-nordisks-new-bid-for-obesity-drugmaker-20251104.jpg", "site": "cnbc.com", "text": "Metsera said Novo Nordisk's new bid for the obesity biotech is \"superior\" to a revised offer from Pfizer, escalating a heated tussle over the startup between the two pharmaceutical giants. Novo Nordisk's new proposal values Metsera at up to $86.20 per share, for a total of around $10 billion.", "url": "https://www.cnbc.com/2025/11/04/novo-nordisk-pfizer-metsera-acquisition.html"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 09:30:00", "publisher": "Market Watch", "title": "Pfizer's revenue falls as COVID sales and vaccine recommendations continue to fade", "image": "https://images.financialmodelingprep.com/news/pfizers-revenue-falls-as-covid-sales-and-vaccine-recommendations-20251104.jpg", "site": "marketwatch.com", "text": "The full-year outlook was lifted, but the stock lost ground.", "url": "https://www.marketwatch.com/story/pfizers-revenue-falls-as-covid-sales-and-vaccine-recommendations-continue-to-fade-27000fc0"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 09:26:07", "publisher": "Seeking Alpha", "title": "Pfizer's Q3: Stagnation Continues", "image": "https://images.financialmodelingprep.com/news/pfizers-q3-stagnation-continues-20251104.jpg", "site": "seekingalpha.com", "text": "Pfizer reported another quarter of stagnation, with Q3 2025 revenue and EPS both declining year-over-year despite beating consensus estimates. PFE's revenue mix remains weak, with Primary Care sales dropping 15.6% and only Oncology showing growth ahead of inflation; management guidance remains largely unchanged. The forward P/E ratio is expected to stagnate, and low valuation multiples reflect poor growth prospects, making sector comparisons misleading.", "url": "https://seekingalpha.com/article/4837356-pfizers-q3-stagnation-continues"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 09:20:32", "publisher": "Reuters", "title": "Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up", "image": "https://images.financialmodelingprep.com/news/novo-nordisk-pfizer-sweeten-bid-for-metsera-as-bidding-20251104.jpg", "site": "reuters.com", "text": "Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday.", "url": "https://www.reuters.com/legal/litigation/novo-nordisk-sweetens-bid-metsera-with-an-offer-up-10-billion-2025-11-04/"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 09:09:00", "publisher": "PRNewsWire", "title": "Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal \"Superior\"", "image": "https://images.financialmodelingprep.com/news/metsera-receives-amended-proposal-from-novo-nordisk-metsera-declares-20251104.jpg", "site": "prnewswire.com", "text": "Novo Nordisk Amended Proposal Values Metsera at up to $ 86.20 per Share, a Total of Approximately $ 10.0 Billion Superior to Revised Pfizer Proposal that Valued Metsera at up to $ 70.00 per Share, a Total of Approximately $ 8.1 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK , Nov. 4, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that a revised proposal that Metsera received from Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) (\"Novo Nordisk\") to acquire Metsera (the \"Novo Nordisk Amended Proposal\") constitutes a \"Superior Company Proposal\" as defined in Metsera's existing Merger Agreement with Pfizer (the \"Pfizer Merger Agreement\"). Novo Nordisk's Proposal is structured in two steps.", "url": "https://www.prnewswire.com/news-releases/metsera-receives-amended-proposal-from-novo-nordisk-metsera-declares-novo-nordisk-amended-proposal-superior-302604143.html"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 09:01:07", "publisher": "Zacks Investment Research", "title": "Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates", "image": "https://images.financialmodelingprep.com/news/pfizer-pfe-surpasses-q3-earnings-and-revenue-estimates-20251104.jpg", "site": "zacks.com", "text": "Pfizer (PFE) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.06 per share a year ago.", "url": "https://www.zacks.com/stock/news/2784295/pfizer-pfe-surpasses-q3-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2784295"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 08:00:04", "publisher": "24/7 Wall Street", "title": "Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (November 2025)", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-nyse-pfe-price-prediction-and-forecast-20252030-20251104.jpg", "site": "247wallst.com", "text": "Shares of Pfizer ( NYSE: PFE )lost 9.90% over the past month after gaining 10.02% the month prior.", "url": "https://247wallst.com/investing/2025/11/04/pfizer-inc-nyse-pfe-price-prediction-and-forecast-2025-2030-april-2025/"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 07:35:00", "publisher": "GuruFocus", "title": "Pfizer's $4.9 Billion Gamble: Inside Its Legal War to Reclaim the Obesity Market", "image": "https://images.financialmodelingprep.com/news/pfizers-49-billion-gamble-inside-its-legal-war-to-20251104.png", "site": "gurufocus.com", "text": "Pfizer (PFE) raised its 2025 profit outlook again, signaling that cost discipline may be starting to pay off after a bruising few years. The company now expects", "url": "https://www.gurufocus.com/news/3180403/pfizers-49-billion-gamble-inside-its-legal-war-to-reclaim-the-obesity-market"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 07:31:00", "publisher": "GuruFocus", "title": "Pfizer Inc (PFE) Q3 2025 Earnings: EPS of $0.62 Beats Estimates, Revenue Hits $16.7 Billion", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-pfe-q3-2025-earnings-eps-of-062-20251104.png", "site": "gurufocus.com", "text": "Revenue: $16.7 billion for Q3 2025, slightly surpassing the estimated $16.59 billion, despite a 6% year-over-year decline.Earnings Per Share (EPS): Reported di", "url": "https://www.gurufocus.com/news/3180473/pfizer-inc-pfe-q3-2025-earnings-eps-of-062-beats-estimates-revenue-hits-167-billion"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 07:04:00", "publisher": "WSJ", "title": "Pfizer Profit Falls Amid Lower Covid-19 Drug Demand", "image": "https://images.financialmodelingprep.com/news/pfizer-profit-falls-amid-lower-covid19-drug-demand-20251104.jpg", "site": "wsj.com", "text": "Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continue to decline.", "url": "https://www.wsj.com/business/earnings/pfizer-profit-falls-amid-lower-covid-19-drug-demand-f3ab3ca1"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 06:56:18", "publisher": "CNBC", "title": "Pfizer tops estimates, raises profit guidance even as sales fall", "image": "https://images.financialmodelingprep.com/news/pfizer-tops-estimates-raises-profit-guidance-even-as-sales-20251104.jpg", "site": "cnbc.com", "text": "Pfizer reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit outlook as it cuts costs, even as sales for the period fell. The results come weeks after Pfizer became the first drugmaker to strike a deal with President Donald Trump to voluntarily sell its medications for less.", "url": "https://www.cnbc.com/2025/11/04/pfizer-pfe-earnings-q3-2025.html"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 06:49:49", "publisher": "Reuters", "title": "Pfizer raises 2025 profit forecast for second time in a row", "image": "https://images.financialmodelingprep.com/news/pfizer-raises-2025-profit-forecast-for-second-time-in-20251104.jpg", "site": "reuters.com", "text": "Pfizer lifted its full-year profit forecast for the second time in a row on Tuesday, buoyed by strong demand for its blockbuster heart treatment and blood thinner.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-raises-2025-profit-forecast-second-time-row-2025-11-04/"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 06:45:00", "publisher": "Business Wire", "title": "Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance", "image": "https://images.financialmodelingprep.com/news/pfizer-reports-solid-thirdquarter-2025-results-raises-and-narrows-20251104.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Q3-25 Earnings Release.", "url": "https://www.businesswire.com/news/home/20251104921455/en/Pfizer-Reports-Solid-Third-Quarter-2025-Results-Raises-and-Narrows-2025-EPS-Guidance/"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 03:05:04", "publisher": "Defense World", "title": "Best Medical Stocks To Watch Today  November 2nd", "image": "https://images.financialmodelingprep.com/news/best-medical-stocks-to-watch-today-november-2nd-20251104.jpg", "site": "defenseworld.net", "text": "Eli Lilly and Company, Pfizer, UnitedHealth Group, AbbVie, and Johnson and Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. \"Medical stocks\" are shares of publicly traded companies that operate in the healthcare sector, including pharmaceutical and biotechnology firms, medical device makers, hospitals, diagnostic labs, and health services providers.", "url": "https://www.defenseworld.net/2025/11/04/best-medical-stocks-to-watch-today-november-2nd.html"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 03:05:01", "publisher": "Defense World", "title": "Top Pharmaceutical Stocks To Follow Now  November 2nd", "image": "https://images.financialmodelingprep.com/news/top-pharmaceutical-stocks-to-follow-now-november-2nd-20251104.jpg", "site": "defenseworld.net", "text": "Eli Lilly and Company, Pfizer, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and commercialize prescription drugs, vaccines, and related therapies. For investors, they offer exposure to significant R&D and regulatory risk-stock performance is heavily", "url": "https://www.defenseworld.net/2025/11/04/top-pharmaceutical-stocks-to-follow-now-november-2nd.html"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 02:49:05", "publisher": "Benzinga", "title": "Pfizer Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts", "image": "https://images.financialmodelingprep.com/news/pfizer-gears-up-for-q3-print-here-are-the-20251104.jpg", "site": "benzinga.com", "text": "Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4.", "url": "https://www.benzinga.com/analyst-stock-ratings/price-target/25/11/48612898/pfizer-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts"}}
{"date": "2025-11-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-04 01:03:26", "publisher": "Reuters", "title": "Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight", "image": "https://images.financialmodelingprep.com/news/novo-nordisk-ceo-faces-baptism-of-fire-amid-board-20251104.jpg", "site": "reuters.com", "text": "Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S. rival Pfizer.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-ceo-faces-baptism-fire-amid-board-shakeup-pfizer-fight-2025-11-04/"}}
{"date": "2025-11-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-03 13:23:00", "publisher": "The Motley Fool", "title": "Did Novo Nordisk Just Say \"Checkmate\" to Pfizer?", "image": "https://images.financialmodelingprep.com/news/did-novo-nordisk-just-say-checkmate-to-pfizer-20251103.jpg", "site": "fool.com", "text": "Novo Nordisk made a much higher offer to acquire a biotech Pfizer was already set to buy out. Losing this battle would be more damaging to Pfizer than to Novo Nordisk.", "url": "https://www.fool.com/investing/2025/11/03/did-novo-nordisk-just-say-checkmate-to-pfizer/"}}
{"date": "2025-11-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-03 12:42:25", "publisher": "Investors Business Daily", "title": "Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo", "image": "https://images.financialmodelingprep.com/news/metsera-calls-pfizers-claims-nonsense-in-latest-buyout-battle-20251103.jpg", "site": "investors.com", "text": "Metsera called Pfizer's claims \"nonsense\" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.", "url": "https://www.investors.com/news/technology/metsera-pfizer-novo-nordisk-takeover-litigation/"}}
{"date": "2025-11-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-03 11:39:32", "publisher": "CNBC", "title": "Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech", "image": "https://images.financialmodelingprep.com/news/pfizer-files-second-lawsuit-against-novo-nordisk-metsera-in-20251103.jpg", "site": "cnbc.com", "text": "Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. The new suit escalates a heated standoff between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors in the blockbuster weight loss drug market.", "url": "https://www.cnbc.com/2025/11/03/pfizer-files-second-lawsuit-against-novo-nordisk-metsera.html"}}
{"date": "2025-11-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-03 09:19:00", "publisher": "WSJ", "title": "Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera", "image": "https://images.financialmodelingprep.com/news/pfizer-files-antitrust-suit-to-block-novo-nordisk-acquisition-20251103.jpg", "site": "wsj.com", "text": "Lawsuit says the proposed merger of the weight-loss drugmakers could kill off a smaller competitor.", "url": "https://www.wsj.com/health/pharma/pfizer-files-antitrust-suit-to-block-novo-nordisk-acquisition-of-metsera-378823de"}}
{"date": "2025-11-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-03 08:15:50", "publisher": "Benzinga", "title": "How To Earn $500 A Month From Pfizer Stock Ahead Of Q3 Earnings", "image": "https://images.financialmodelingprep.com/news/how-to-earn-500-a-month-from-pfizer-stock-20251103.jpg", "site": "benzinga.com", "text": "Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4.", "url": "https://www.benzinga.com/trading-ideas/long-ideas/25/11/48587995/how-to-earn-500-a-month-from-pfizer-stock-ahead-of-q3-earnings"}}
{"date": "2025-11-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-03 08:07:29", "publisher": "Reuters", "title": "Pfizer files second lawsuit against Metsera, Novo Nordisk", "image": "https://images.financialmodelingprep.com/news/pfizer-files-second-lawsuit-against-metsera-novo-nordisk-20251103.jpg", "site": "reuters.com", "text": "Pfizer Inc said on Monday it has filed a second lawsuit against Metsera , its controlling shareholder, and Novo Nordisk in a Delaware federal court, accusing the Danish drugmaker of anticompetitive conduct.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-files-second-lawsuit-against-metsera-novo-nordisk-2025-11-03/"}}
{"date": "2025-11-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-03 07:57:00", "publisher": "Business Wire", "title": "Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk", "image": "https://images.financialmodelingprep.com/news/pfizer-files-federal-antitrust-claims-in-second-lawsuit-against-metsera-20251103.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware. The lawsuit asserts that Novo Nordisk's recent proposal to acquire Metsera constitutes an anticompetitive action by Novo Nordisk to protect its dominant market position in GLP-1s by capturing and killing a nascent American competitor before it gains the support of Pfiz.", "url": "https://www.businesswire.com/news/home/20251102755714/en/Pfizer-Files-Federal-Antitrust-Claims-in-Second-Lawsuit-Against-Metsera-its-Controlling-Stockholders-and-Novo-Nordisk/"}}
{"date": "2025-11-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-03 07:37:00", "publisher": "The Motley Fool", "title": "2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon", "image": "https://images.financialmodelingprep.com/news/2-healthcare-stocks-for-individual-investors-with-a-20year-20251103.jpg", "site": "fool.com", "text": "A former pandemic favorite and a lesser-known biopharmaceutical stock both have value to add to a long-term investor's portfolio. Pfizer's growth has slowed from a few years ago, but its tepid stock price is not telling the whole story of this innovative company.", "url": "https://www.fool.com/investing/2025/11/03/2-healthcare-stocks-for-investors-with-a-20-year/"}}
{"date": "2025-11-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-03 04:46:00", "publisher": "The Motley Fool", "title": "Meet the 7% Yield Dividend Stock That Could Soar in 2026", "image": "https://images.financialmodelingprep.com/news/meet-the-7-yield-dividend-stock-that-could-soar-20251103.jpg", "site": "fool.com", "text": "The big near-term headwind for this drug maker is upcoming patent expirations. The company is working to address the issue, with a sizable acquisition that will advance its efforts in the diet drug space.", "url": "https://www.fool.com/investing/2025/11/03/7-percent-yield-dividend-stock-could-soar-in-2026/"}}
{"date": "2025-11-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-03 04:00:00", "publisher": "The Motley Fool", "title": "1 Incredible Reason to Buy Pfizer Stock (PFE) in November", "image": "https://images.financialmodelingprep.com/news/1-incredible-reason-to-buy-pfizer-stock-pfe-in-20251103.jpg", "site": "fool.com", "text": "Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the stock price has fallen in recent years.", "url": "https://www.fool.com/investing/2025/11/03/reason-buy-pfizer-stock-pfe-november/"}}
{"date": "2025-11-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-02 14:00:00", "publisher": "Barrons", "title": "Palantir, AMD, Pfizer, and Many More Stocks to Watch", "image": "https://images.financialmodelingprep.com/news/palantir-amd-pfizer-and-many-more-stocks-to-watch-20251102.jpg", "site": "barrons.com", "text": "Vertex, Corteva, and many more will also report earnings. On the economic front, The Supreme Court will hear arguments on the legality of Trump's tariffs, and ADP will release October employment data.", "url": "https://www.barrons.com/articles/palantir-amd-pfizer-robinhood-mcdonalds-stocks-dfd8631b"}}
{"date": "2025-11-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-02 07:07:08", "publisher": "Seeking Alpha", "title": "Wall Street Week Ahead", "image": "https://images.financialmodelingprep.com/news/wall-street-week-ahead-20251102.jpg", "site": "seekingalpha.com", "text": "Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.", "url": "https://seekingalpha.com/article/4836754-wall-street-week-ahead"}}
{"date": "2025-11-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-02 05:30:00", "publisher": "WSJ", "title": "Heard on the Street: Novo Nordisk and Pfizer are showing some desperation in their gloves-off fight for the obesity-drug assets of Metsera", "image": "https://images.financialmodelingprep.com/news/heard-on-the-street-novo-nordisk-and-pfizer-are-20251102.jpg", "site": "wsj.com", "text": "Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.", "url": "https://www.wsj.com/health/pharma/why-pfizer-can-still-prevail-in-the-obesity-fight-with-novo-nordisk-3ecafe71"}}
{"date": "2025-11-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-02 04:20:00", "publisher": "The Motley Fool", "title": "Is It Time to Dump Your Shares of Pfizer?", "image": "https://images.financialmodelingprep.com/news/is-it-time-to-dump-your-shares-of-pfizer-20251102.jpg", "site": "fool.com", "text": "After reporting record revenue a few years ago, Pfizer has faced tougher times in recent quarters. Challenges include a decline in demand for coronavirus products and patent expirations on the horizon.", "url": "https://www.fool.com/investing/2025/11/02/is-it-time-to-dump-your-shares-of-pfizer/"}}
{"date": "2025-11-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-02 01:35:55", "publisher": "Defense World", "title": "Top Medical Stocks To Keep An Eye On  October 31st", "image": "https://images.financialmodelingprep.com/news/top-medical-stocks-to-keep-an-eye-on-october-31st-20251102.jpg", "site": "defenseworld.net", "text": "Eli Lilly and Company, Pfizer, and UnitedHealth Group are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies whose primary business is healthcare - including pharmaceutical and biotech firms, medical device and diagnostic manufacturers, and healthcare service providers like hospitals and insurers. Investors", "url": "https://www.defenseworld.net/2025/11/02/top-medical-stocks-to-keep-an-eye-on-october-31st.html"}}
{"date": "2025-11-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-01 08:15:00", "publisher": "Seeking Alpha", "title": "5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Nov. 2025)", "image": "https://images.financialmodelingprep.com/news/5-relatively-secure-and-cheap-dividend-stocks-yields-up-to-20251101.jpg", "site": "seekingalpha.com", "text": "This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.", "url": "https://seekingalpha.com/article/4835411-5-relatively-secure-and-cheap-dividend-stocks-yields-up-to-8-percent-nov-2025"}}
{"date": "2025-11-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-01 05:47:08", "publisher": "Defense World", "title": "Medical Stocks To Watch Now  October 30th", "image": "https://images.financialmodelingprep.com/news/medical-stocks-to-watch-now-october-30th-20251101.jpg", "site": "defenseworld.net", "text": "Eli Lilly and Company, UnitedHealth Group, and Pfizer are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies that develop, manufacture, or deliver medical products and services - including pharmaceutical and biotech firms, medical device makers, diagnostic companies, hospitals, and healthcare insurers. Investors", "url": "https://www.defenseworld.net/2025/11/01/medical-stocks-to-watch-now-october-30th.html"}}
{"date": "2025-11-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-11-01 05:15:34", "publisher": "Invezz", "title": "Pfizer sues to block Novo Nordisk's bid for Metsera in high-stakes pharma clash", "image": "https://images.financialmodelingprep.com/news/pfizer-sues-to-block-novo-nordisks-bid-for-metsera-20251101.jpg", "site": "invezz.com", "text": "Pfizer has escalated its fight for obesity biotech Metsera by filing suit against both Metsera and Novo Nordisk in the Delaware Court of Chancery on October 31. The litigation challenges Novo's bombshell $8.5 billion offer as legally superior to Pfizer's original $7.2 billion deal announced in September.", "url": "https://invezz.com/news/2025/11/01/pfizer-sues-to-block-novo-nordisks-bid-for-metsera-in-high-stakes-pharma-clash/"}}
{"date": "2025-10-31", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-31 18:24:00", "publisher": "PRNewsWire", "title": "Metsera Issues Statement in Response to Litigation", "image": "https://images.financialmodelingprep.com/news/metsera-issues-statement-in-response-to-litigation-20251031.jpg", "site": "prnewswire.com", "text": "NEW YORK , Oct. 31, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\" or the \"Company\") today issued the following statement in response to litigation filed against the Company by Pfizer: \"Metsera disagrees with the allegations in Pfizer's complaint and will address them in the Delaware Court of Chancery.\"  Disclosure Notice  This release contains forward-looking information about, among other topics, Pfizer's proposed acquisition ofMetsera, Pfizer's andMetsera'spipeline products, including their potential benefits, potential best-in-class status, differentiation, profile and dosing, potential clinical trials, and the anticipated timing of completion of the proposed acquisition, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.", "url": "https://www.prnewswire.com/news-releases/metsera-issues-statement-in-response-to-litigation-302601500.html"}}
{"date": "2025-10-31", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-31 17:26:53", "publisher": "Investors Business Daily", "title": "Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal", "image": "https://images.financialmodelingprep.com/news/pfizer-sues-novo-nordisk-and-metsera-to-block-the-20251031.jpg", "site": "investors.com", "text": "Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller obesity-focused company.", "url": "https://www.investors.com/news/technology/pfizer-novo-nordisk-metsera-lawsuit/"}}
{"date": "2025-10-31", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-31 17:12:00", "publisher": "WSJ", "title": "Pfizer has filed a lawsuit seeking to block Novo Nordisk from circumventing Pfizer's deal for weight-loss drug startup Metsera", "image": "https://images.financialmodelingprep.com/news/pfizer-has-filed-a-lawsuit-seeking-to-block-novo-20251031.jpg", "site": "wsj.com", "text": "The lawsuit says Novo Nordisk's offer for drug startup Metsera isn't reasonably likely to be completed.", "url": "https://www.wsj.com/health/pharma/pfizer-sues-seeking-to-block-novo-nordisks-effort-to-undo-weight-loss-drug-deal-929710b2"}}
{"date": "2025-10-31", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-31 16:43:30", "publisher": "Reuters", "title": "Pfizer sues Metsera, Novo Nordisk over breach of merger deal", "image": "https://images.financialmodelingprep.com/news/pfizer-sues-metsera-novo-nordisk-over-breach-of-merger-20251031.jpg", "site": "reuters.com", "text": "Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , accusing them of breaking a merger agreement and interfering with the deal.", "url": "https://www.reuters.com/legal/litigation/pfizer-sues-metsera-novo-nordisk-over-breach-merger-deal-2025-10-31/"}}
{"date": "2025-10-31", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-31 16:37:00", "publisher": "Business Wire", "title": "Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement", "image": "https://images.financialmodelingprep.com/news/pfizer-files-lawsuit-against-metsera-and-its-directors-and-20251031.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera's breach of its obligations under the merger agreement between Pfizer and Metsera. Pfizer alleges that the Novo Nordisk offer cannot qualify as a Superior Company Proposal u.", "url": "https://www.businesswire.com/news/home/20251031742790/en/Pfizer-Files-Lawsuit-Against-Metsera-and-its-Directors-and-Novo-Nordisk-for-Breach-of-Merger-Agreement/"}}
{"date": "2025-10-31", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-31 15:55:53", "publisher": "Reuters", "title": "Pfizer gets US antitrust clearance for Metsera deal", "image": "https://images.financialmodelingprep.com/news/pfizer-gets-us-antitrust-clearance-for-metsera-deal-20251031.jpg", "site": "reuters.com", "text": "Pfizer said on Friday it has received an early clearance from the U.S. Federal Trade Commission for its proposed acquisition of Metsera.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-gets-us-antitrust-clearance-metsera-deal-2025-10-31/"}}
{"date": "2025-10-31", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-31 15:50:00", "publisher": "Business Wire", "title": "Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition", "image": "https://images.financialmodelingprep.com/news/pfizer-receives-early-clearance-from-us-federal-trade-commission-20251031.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the HSR Act), with respect to Pfizer's pending acquisition of Metsera (NASDAQ: MTSR). The termination of the waiting period under the HSR Act satisfies the regulatory review requirements under the previously announced proposed acquisition of Metsera, which was set to.", "url": "https://www.businesswire.com/news/home/20251031089764/en/Pfizer-Receives-Early-Clearance-from-U.S.-Federal-Trade-Commission-for-Metsera-Acquisition/"}}
{"date": "2025-10-31", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-31 12:20:35", "publisher": "Zacks Investment Research", "title": "Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?", "image": "https://images.financialmodelingprep.com/news/pfizer-q3-earnings-loom-buy-sell-or-hold-pfe-20251031.jpg", "site": "zacks.com", "text": "Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.", "url": "https://www.zacks.com/stock/news/2782813/pfizer-q3-earnings-loom-buy-sell-or-hold-pfe-stock-ahead-of-results?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2782813"}}
{"date": "2025-10-31", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-31 08:40:03", "publisher": "Forbes", "title": "How Pfizer Stock Can Rebound", "image": "https://images.financialmodelingprep.com/news/how-pfizer-stock-can-rebound-20251031.jpg", "site": "forbes.com", "text": "Novo Nordisk has launched a rival bid for U.S. obesity biotech firm Metsera, directly challenging an existing offer from Pfizer.", "url": "https://www.forbes.com/sites/greatspeculations/2025/10/31/how-pfizer-stock-can-rebound/"}}
{"date": "2025-10-31", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-31 06:02:47", "publisher": "Reuters", "title": "Pfizer could hold a Trump card in its bid for Metsera", "image": "https://images.financialmodelingprep.com/news/pfizer-could-hold-a-trump-card-in-its-bid-20251031.jpg", "site": "reuters.com", "text": "U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm Metsera, analysts, investors and lawyers said on Thursday.", "url": "https://www.reuters.com/legal/litigation/pfizer-could-hold-trump-card-its-bid-metsera-2025-10-31/"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 14:19:09", "publisher": "Reuters", "title": "Novo Nordisk changes tack with bold raid on Pfizer obesity deal", "image": "https://images.financialmodelingprep.com/news/novo-nordisk-changes-tack-with-bold-raid-on-pfizer-20251030.jpg", "site": "reuters.com", "text": "Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market under a new CEO and board.", "url": "https://www.reuters.com/business/finance/novo-nordisk-changes-tack-with-bold-raid-pfizer-obesity-deal-2025-10-30/"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 13:13:54", "publisher": "Investors Business Daily", "title": "Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera", "image": "https://images.financialmodelingprep.com/news/novo-nordisk-kicks-off-bloody-battle-with-pfizer-bidding-20251030.jpg", "site": "investors.com", "text": "Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.", "url": "https://www.investors.com/news/technology/metsera-novo-nordisk-pfizer-acquisition/"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 12:40:12", "publisher": "Reuters", "title": "Metsera the US obesity biotech at centre of Novo, Pfizer bidding war", "image": "https://images.financialmodelingprep.com/news/metsera-the-us-obesity-biotech-at-centre-of-novo-20251030.jpg", "site": "reuters.com", "text": "Metsera has become the obesity drug market's hottest ticket.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/metsera-us-obesity-biotech-centre-novo-pfizer-bidding-war-2025-10-30/"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 11:51:29", "publisher": "Seeking Alpha", "title": "10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)", "image": "https://images.financialmodelingprep.com/news/10-ideal-safer-dividend-buys-from-38-of-68-20251030.jpg", "site": "seekingalpha.com", "text": "The article analyzes the top large-cap value (GASV) stocks using YCharts' Value Score and Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Ten of eighteen 'safer' lowest-priced GASV stocks, including ET, MPLX, YRD, VZ, BMY, TFC, T, SU, MFC, and BBVA, are considered buyable in October. Analyst projections suggest the top ten GASV stocks could deliver average net gains of 38.01% by October 2026, with Lexinfintech Holdings leading potential returns.", "url": "https://seekingalpha.com/article/4835512-10-ideal-saferdividend-buys-from-38-of-68-october-graham-value-all-stars-gvas"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 11:39:34", "publisher": "Benzinga", "title": "Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'", "image": "https://images.financialmodelingprep.com/news/pfizer-blasts-novo-nordisks-9-billion-counteroffer-for-metsera-20251030.jpg", "site": "benzinga.com", "text": "On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).", "url": "https://www.benzinga.com/m-a/25/10/48533502/pfizer-blasts-novo-nordisks-9-billion-counteroffer-for-metsera-as-reckless"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 10:16:10", "publisher": "Zacks Investment Research", "title": "What Analyst Projections for Key Metrics Reveal About Pfizer (PFE) Q3 Earnings", "image": "https://images.financialmodelingprep.com/news/what-analyst-projections-for-key-metrics-reveal-about-pfizer-20251030.jpg", "site": "zacks.com", "text": "Evaluate the expected performance of Pfizer (PFE) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.", "url": "https://www.zacks.com/stock/news/2781261/what-analyst-projections-for-key-metrics-reveal-about-pfizer-pfe-q3-earnings?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2781261"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 09:52:34", "publisher": "Reuters", "title": "Novo Nordisk says offer for Metsera adheres to restrictions under Pfizer deal", "image": "https://images.financialmodelingprep.com/news/novo-nordisk-says-offer-for-metsera-adheres-to-restrictions-20251030.jpg", "site": "reuters.com", "text": "Novo Nordisk said on Thursday that it had adhered to all restrictions under the Pfizer merger agreement in its unsolicited offer for drugmaker Metsera , and that the value of its proposal far exceeded Pfizer's offer.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-offer-metsera-adheres-restrictions-under-pfizer-deal-2025-10-30/"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 07:11:00", "publisher": "Barrons", "title": "Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.", "image": "https://images.financialmodelingprep.com/news/metsera-stock-soars-novo-nordisk-looks-to-outbid-pfizer-for-20251030.jpg", "site": "barrons.com", "text": "Denmark's Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.", "url": "https://www.barrons.com/articles/metsera-stock-price-novo-nordisk-pfizer-c4d11ef3"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 07:07:00", "publisher": "PRNewsWire", "title": "Metsera Receives Unsolicited Proposal from Novo Nordisk", "image": "https://images.financialmodelingprep.com/news/metsera-receives-unsolicited-proposal-from-novo-nordisk-20251030.jpg", "site": "prnewswire.com", "text": "Metsera Declares Novo Nordisk Proposal \"Superior\" Novo Nordisk Proposal Values Metsera at up to $77.75 per Share, a Total of Approximately $9 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments to Existing Transaction Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK , Oct.30, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that an unsolicited proposal that Metsera received from Novo Nordisk A/S (Nasdaq Copenhagen: NOVO B) (\"Novo Nordisk\") to acquire Metsera (the \"Novo Nordisk Proposal\") constitutes a \"Superior Company Proposal\" as defined inMetsera's existing Merger Agreement with Pfizer (the \"Pfizer Merger Agreement\"). Novo Nordisk's Proposal is structured in two steps.", "url": "https://www.prnewswire.com/news-releases/metsera-receives-unsolicited-proposal-from-novo-nordisk-302599741.html"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 06:57:00", "publisher": "Business Wire", "title": "Pfizer Addresses Proposal for Metsera", "image": "https://images.financialmodelingprep.com/news/pfizer-addresses-proposal-for-metsera-20251030.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger. It is also structured in a way to circumvent antitrust laws and carries substantial regulatory and executional risk. The proposal is illusory and cannot qualify as a sup.", "url": "https://www.businesswire.com/news/home/20251030787900/en/Pfizer-Addresses-Proposal-for-Metsera/"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 06:23:00", "publisher": "WSJ", "title": "Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer Metsera", "image": "https://images.financialmodelingprep.com/news/novo-nordisk-moves-to-outbid-pfizer-with-up-to-20251030.jpg", "site": "wsj.com", "text": "Novo Nordisk said the proposal is currently subject to review by Metsera's board of directors.", "url": "https://www.wsj.com/health/pharma/novo-nordisk-moves-to-outbid-pfizer-with-up-to-9-billion-offer-for-obesity-drug-developer-metsera-42420b97"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 06:06:54", "publisher": "Proactive Investors", "title": "Novo Nordisk gatecrashes Pfizer's takeover of obesity rival Metsera", "image": "https://images.financialmodelingprep.com/news/novo-nordisk-gatecrashes-pfizers-takeover-of-obesity-rival-metsera-20251030.jpeg", "site": "proactiveinvestors.co.uk", "text": "Novo Nordisk (NYSE:NVO)has attempted to gatecrash Pfizer Inc (NYSE:PFE, ETR:PFE)deal to buy obesity drug developer MetseraInc (NASDAQ:MTSR), with an unsolicitedoffer of $6.5 billion, rising to a potential $9 billion. The Danish drugmaker became Europe's largest company after being first to market with anti-obesity drugs but has lost its lead and its crown after being usurped by rival products.", "url": "https://www.proactiveinvestors.co.uk/companies/news/1081430"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 05:47:24", "publisher": "Reuters", "title": "Novo Nordisk saidto make higher bid for Metsera to challenge Pfizer, Bloomberg News reports", "image": "https://images.financialmodelingprep.com/news/novo-nordisk-saidto-make-higher-bid-for-metsera-to-20251030.jpg", "site": "reuters.com", "text": "Danish drugmaker Novo Nordisk has made a higher offer for Metsera seeking to trump an agreed deal with Pfizer so it can consolidate its position in weight-loss medications, Bloomberg News reported on Thursday citing people with knowledge of the matter.", "url": "https://www.reuters.com/legal/litigation/novo-nordisk-said-to-make-higher-bid-metsera-challenge-pfizer-bloomberg-news-2025-10-30/"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 04:15:00", "publisher": "The Motley Fool", "title": "Prediction: Putting $1,000 Into These Dividend Stocks Could Pay Off for Years", "image": "https://images.financialmodelingprep.com/news/prediction-putting-1000-into-these-dividend-stocks-could-pay-20251030.jpg", "site": "fool.com", "text": "Verizon has hiked its dividends for 19 consecutive years, and today boasts a yield of about 7%. Pfizer has been paying dividends for 87 straight years.", "url": "https://www.fool.com/investing/2025/10/30/prediction-1000-in-these-dividend-stocks-could-pay/"}}
{"date": "2025-10-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-30 02:09:35", "publisher": "Defense World", "title": "Pharmaceutical Stocks To Keep An Eye On  October 28th", "image": "https://images.financialmodelingprep.com/news/pharmaceutical-stocks-to-keep-an-eye-on-october-28th-20251030.jpeg", "site": "defenseworld.net", "text": "Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, Pfizer, Incyte, AbbVie, and Novo Nordisk A/S are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies whose primary business is researching, developing, manufacturing, and marketing prescription drugs and related therapies. For investors, these stocks", "url": "https://www.defenseworld.net/2025/10/30/pharmaceutical-stocks-to-keep-an-eye-on-october-28th.html"}}
{"date": "2025-10-29", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-29 19:00:00", "publisher": "The Motley Fool", "title": "2 High-Yield Stocks With Fresh Catalysts", "image": "https://images.financialmodelingprep.com/news/2-highyield-stocks-with-fresh-catalysts-20251029.jpg", "site": "fool.com", "text": "A tobacco giant shifting to smoke-free products just raised its dividend by 8.9% as next-generation nicotine wins an ever-increasing slice of revenue. A pharmaceutical company trades at 8 times forward earnings with a 7% yield as it raises revenue guidance and reenters the obesity drug market.", "url": "https://www.fool.com/investing/2025/10/29/2-high-yield-stocks-with-fresh-catalysts/"}}
{"date": "2025-10-28", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-28 18:46:13", "publisher": "Zacks Investment Research", "title": "Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note", "image": "https://images.financialmodelingprep.com/news/pfizer-pfe-stock-drops-despite-market-gains-important-facts-20251028.jpg", "site": "zacks.com", "text": "Pfizer (PFE) closed at $24.5 in the latest trading session, marking a -1.09% move from the prior day.", "url": "https://www.zacks.com/stock/news/2779529/pfizer-pfe-stock-drops-despite-market-gains-important-facts-to-note?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2779529"}}
{"date": "2025-10-28", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-28 14:15:17", "publisher": "24/7 Wall Street", "title": "5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade", "image": "https://images.financialmodelingprep.com/news/5-highyield-stocks-to-anchor-your-portfolio-for-half-20251028.jpg", "site": "247wallst.com", "text": "There's no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment.", "url": "https://247wallst.com/investing/2025/10/28/5-high-yield-stocks-to-anchor-your-portfolio-for-half-a-decade/"}}
{"date": "2025-10-28", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-28 11:06:18", "publisher": "Zacks Investment Research", "title": "Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline", "image": "https://images.financialmodelingprep.com/news/earnings-preview-pfizer-pfe-q3-earnings-expected-to-decline-20251028.jpg", "site": "zacks.com", "text": "Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.", "url": "https://www.zacks.com/stock/news/2779077/earnings-preview-pfizer-pfe-q3-earnings-expected-to-decline?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2779077"}}
{"date": "2025-10-27", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-27 14:00:00", "publisher": "The Motley Fool", "title": "3 Dividend-Paying Drug Stocks to Buy at a Discount", "image": "https://images.financialmodelingprep.com/news/3-dividendpaying-drug-stocks-to-buy-at-a-discount-20251027.jpg", "site": "fool.com", "text": "Pfizer currently has a 7% yield, and the company is making important business moves. Bristol Myers Squibb has a 5.6% yield and has been building its drug pipeline with acquisitions.", "url": "https://www.fool.com/investing/2025/10/27/3-dividend-paying-drug-stocks-to-buy-at-a-discount/"}}
{"date": "2025-10-27", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-27 12:21:22", "publisher": "The Motley Fool", "title": "What Is 1 of the Best Pharmaceutical Stocks to Buy Now?", "image": "https://images.financialmodelingprep.com/news/what-is-1-of-the-best-pharmaceutical-stocks-to-20251027.jpg", "site": "fool.com", "text": "Anti-obesity drugs are being considered for a range of addictive behaviors. Pfizer just acquired a next-generation, clinical-stage maker of obesity treatments.", "url": "https://www.fool.com/investing/2025/10/27/what-is-1-of-best-pharmaceutical-stocks-buy-now/"}}
{"date": "2025-10-27", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-27 12:15:00", "publisher": "The Motley Fool", "title": "Should You Buy Pfizer Stock Before Nov. 4?", "image": "https://images.financialmodelingprep.com/news/should-you-buy-pfizer-stock-before-nov-4-20251027.jpg", "site": "fool.com", "text": "Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock.", "url": "https://www.fool.com/investing/2025/10/27/should-you-buy-pfizer-stock-before-nov-4/"}}
{"date": "2025-10-27", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-27 04:30:00", "publisher": "The Motley Fool", "title": "3 Healthcare Stocks Paying the Highest Dividends of 2025", "image": "https://images.financialmodelingprep.com/news/3-healthcare-stocks-paying-the-highest-dividends-of-2025-20251027.jpg", "site": "fool.com", "text": "Kenvue was spun off from Johnson & Johnson in mid-2023, and its life is starting out a little rough. Pfizer is working through typical drug industry issues, but there's a notable dividend risk to consider.", "url": "https://www.fool.com/investing/2025/10/27/healthcare-stocks-paying-highest-dividends-2025/"}}
{"date": "2025-10-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-26 10:26:53", "publisher": "24/7 Wall Street", "title": "3 Dividend Stocks Every Boomer Should Own for Reliable Income", "image": "https://images.financialmodelingprep.com/news/3-dividend-stocks-every-boomer-should-own-for-reliable-20251026.jpg", "site": "247wallst.com", "text": "Boomers today are between 60 and 79 years old.", "url": "https://247wallst.com/investing/2025/10/26/3-dividend-stocks-every-boomer-should-own-for-reliable-income/"}}
{"date": "2025-10-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-26 09:19:41", "publisher": "24/7 Wall Street", "title": "More Rate Cuts Are Coming: Grab 6% High-Yield S&P 500 Stocks Now", "image": "https://images.financialmodelingprep.com/news/more-rate-cuts-are-coming-grab-6-highyield-sp-20251026.jpg", "site": "247wallst.com", "text": "Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.", "url": "https://247wallst.com/investing/2025/10/26/more-rate-cuts-are-coming-grab-6-high-yield-sp-500-stocks-now/"}}
{"date": "2025-10-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-26 04:00:00", "publisher": "The Motley Fool", "title": "Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever.", "image": "https://images.financialmodelingprep.com/news/got-1000-3-highyield-healthcare-stocks-to-buy-and-hold-20251026.jpg", "site": "fool.com", "text": "Kenvue owns Johnson & Johnson's former over-the-counter brands. Medtronic has a diversified medical-device portfolio and is closing in on \"Dividend King\" status.", "url": "https://www.fool.com/investing/2025/10/26/got-1000-high-yield-healthcare-stocks-to-buy-hold/"}}
{"date": "2025-10-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-26 02:40:50", "publisher": "Defense World", "title": "Pharmaceutical Stocks To Watch Now  October 24th", "image": "https://images.financialmodelingprep.com/news/pharmaceutical-stocks-to-watch-now-october-24th-20251026.jpg", "site": "defenseworld.net", "text": "Eli Lilly and Company, Wellgistics Health, Pfizer, AbbVie, and Gilead Sciences are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies engaged in the research, development, manufacturing, and sale of prescription drugs, biologics, and vaccines. For investors, these stocks are typically driven by factors like", "url": "https://www.defenseworld.net/2025/10/26/pharmaceutical-stocks-to-watch-now-october-24th.html"}}
{"date": "2025-10-25", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-25 07:00:00", "publisher": "The Motley Fool", "title": "2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever", "image": "https://images.financialmodelingprep.com/news/2-unstoppable-dividend-stocks-yielding-more-than-4-that-incomeseeking-20251025.jpg", "site": "fool.com", "text": "One is a pharmaceutical industry powerhouse that has fallen out of favor with investors. The other is a top REIT that cranks out a dividend far more often than the usual U.S. business.", "url": "https://www.fool.com/investing/2025/10/25/2-unstoppable-dividend-stocks-yielding-more-than-4/"}}
{"date": "2025-10-24", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-24 12:45:54", "publisher": "Seeking Alpha", "title": "Why Pfizer's Headwinds May Already Be In The Price", "image": "https://images.financialmodelingprep.com/news/why-pfizers-headwinds-may-already-be-in-the-price-20251024.jpg", "site": "seekingalpha.com", "text": "Pfizer faces significant revenue headwinds from patent expiries, COVID product declines, and generic competition, but these risks are largely priced in. PFE's valuation is historically low at ~8x earnings, reflecting aggressive patent cliff assumptions and conservative growth projections for existing products. Pipeline and acquisition success, especially in obesity/diabetes, could drive capital appreciation, with even partial wins supporting a rerating toward historical multiples.", "url": "https://seekingalpha.com/article/4833169-why-pfizers-headwinds-may-already-be-in-the-price"}}
{"date": "2025-10-24", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-24 12:30:44", "publisher": "Zacks Investment Research", "title": "PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?", "image": "https://images.financialmodelingprep.com/news/pfe-versus-bmy-which-large-oncology-drugmaker-is-a-20251024.jpg", "site": "zacks.com", "text": "Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space.", "url": "https://www.zacks.com/stock/news/2776578/pfe-versus-bmy-which-large-oncology-drugmaker-is-a-better-pick-now?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2776578"}}
{"date": "2025-10-24", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-24 10:01:31", "publisher": "Zacks Investment Research", "title": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-pfe-is-a-trending-stock-facts-to-20251024.jpg", "site": "zacks.com", "text": "Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.", "url": "https://www.zacks.com/stock/news/2776209/pfizer-inc-pfe-is-a-trending-stock-facts-to-know-before-betting-on-it?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2776209"}}
{"date": "2025-10-24", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-24 07:54:40", "publisher": "Seeking Alpha", "title": "Buy 9 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 October Dividend Dogs", "image": "https://images.financialmodelingprep.com/news/buy-9-barrons-better-bets-than-tbills-from-15-20251024.jpg", "site": "seekingalpha.com", "text": "Nine of fifteen Barron's Better Bets (BBB) 'safer' high-yield dividend stocks are currently attractively priced, including CAG, VZ, MO, BMY, TFC, UDR, KEY, KIM, and RF. Analyst forecasts project top-ten BBB Dogs could deliver average net gains of 26.33% by October 2026, with lower volatility than the overall market. ONEOK stands out as the only stock ranking in the top ten for yield, target, and total return, but caution is advised for cash-poor stocks with negative free cash flow margins.", "url": "https://seekingalpha.com/article/4833034-buy-9-barrons-better-bets-than-t-bills-from-15-safer-of-23-october-dividend-dogs"}}
{"date": "2025-10-23", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-23 12:15:00", "publisher": "Business Wire", "title": "Metsera Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR", "image": "https://images.financialmodelingprep.com/news/metsera-investor-alert-by-the-former-attorney-general-of-20251023.jpg", "site": "businesswire.com", "text": "NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Metsera, Inc. (NasdaqGS: MTSR) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Metsera will receive $47.50 per share in cash at closing, plus a non-transferable contingent value right entitling holders to potential additional payments of up to $22.50 per shar.", "url": "https://www.businesswire.com/news/home/20251023294252/en/Metsera-Investor-Alert-By-The-Former-Attorney-General-Of-Louisiana-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Metsera-Inc.---MTSR/"}}
{"date": "2025-10-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-22 11:04:47", "publisher": "24/7 Wall Street", "title": "2 Safer High-Yield Stocks That Can Pay Boomers for Life", "image": "https://images.financialmodelingprep.com/news/2-safer-highyield-stocks-that-can-pay-boomers-for-20251022.jpg", "site": "247wallst.com", "text": "Baby Boomers should be looking to play things a bit more cautiously as stock valuations begin to climb across the board.", "url": "https://247wallst.com/investing/2025/10/22/2-safer-high-yield-stocks-that-can-pay-boomers-for-life/"}}
{"date": "2025-10-20", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-20 11:38:23", "publisher": "Seeking Alpha", "title": "My Top 3 Pharma Stocks", "image": "https://images.financialmodelingprep.com/news/my-top-3-pharma-stocks-20251020.jpg", "site": "seekingalpha.com", "text": "Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.", "url": "https://seekingalpha.com/article/4831152-my-top-3-pharma-stocks"}}
{"date": "2025-10-20", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-20 11:15:14", "publisher": "Zacks Investment Research", "title": "Pfizer's Q3 Non-Oncology Performance: Here's What to Expect", "image": "https://images.financialmodelingprep.com/news/pfizers-q3-nononcology-performance-heres-what-to-expect-20251020.jpg", "site": "zacks.com", "text": "Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.", "url": "https://www.zacks.com/stock/news/2772374/pfizer-s-q3-non-oncology-performance-here-s-what-to-expect?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2772374"}}
{"date": "2025-10-20", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-20 04:15:00", "publisher": "GlobeNewsWire", "title": "Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy", "image": "https://images.financialmodelingprep.com/news/patientreported-outcomes-from-veritac2-clinical-trial-support-clinical-benefit-20251020.jpeg", "site": "globenewswire.com", "text": " Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including pain, compared to fulvestrant  NEW HAVEN, Conn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant, which are being presented in a mini oral session at the 2025 European Society for Medical Oncology (ESMO) Congress.", "url": "https://www.globenewswire.com/news-release/2025/10/20/3169130/0/en/Patient-Reported-Outcomes-from-VERITAC-2-Clinical-Trial-Support-Clinical-Benefit-of-Vepdegestrant-in-Patients-with-ESR1-Mutated-ER-HER2-Advanced-or-Metastatic-Breast-Cancer-Previou.html"}}
{"date": "2025-10-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-19 10:57:00", "publisher": "The Motley Fool", "title": "2 High-Yield Dividend Stocks Too Cheap to Ignore", "image": "https://images.financialmodelingprep.com/news/2-highyield-dividend-stocks-too-cheap-to-ignore-20251019.jpg", "site": "fool.com", "text": "What's even better than a solid, reliable dividend stock? A solid, reliable, high-yield dividend stock.", "url": "https://www.fool.com/investing/2025/10/19/2-high-yield-dividend-stocks-too-cheap-to-ignore/"}}
{"date": "2025-10-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-19 04:15:00", "publisher": "Business Wire", "title": "XTANDI Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer", "image": "https://images.financialmodelingprep.com/news/xtandi-plus-leuprolide-reduced-risk-of-death-by-40-vs-20251019.jpg", "site": "businesswire.com", "text": "NEW YORK & NORTHBROOK, Ill.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, \"Astellas\") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) a.", "url": "https://www.businesswire.com/news/home/20251019277268/en/XTANDI%C2%AE-Plus-Leuprolide-Reduced-Risk-of-Death-by-40-vs-Leuprolide-Alone-in-Men-with-a-Type-of-Advanced-Prostate-Cancer/"}}
{"date": "2025-10-19", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-19 02:30:00", "publisher": "Business Wire", "title": "Pfizer's BRAFTOVI + MEKTOVI Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer", "image": "https://images.financialmodelingprep.com/news/pfizers-braftovi-mektovi-shows-sustained-longterm-survival-in-patients-with-20251019.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-nave patients, the median overall survival (OS) was 47.6 months (95% confidence interval [CI], 31.3, not estimable) after a median follow-up of 52.3 months. In previously treated pati.", "url": "https://www.businesswire.com/news/home/20251017611442/en/Pfizer%E2%80%99s-BRAFTOVI%C2%AE-MEKTOVI%C2%AE-Shows-Sustained-Long-Term-Survival-in-Patients-with-Advanced-Lung-Cancer/"}}
{"date": "2025-10-18", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-18 10:37:48", "publisher": "Reuters", "title": "Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients", "image": "https://images.financialmodelingprep.com/news/astellaspfizers-combination-therapy-halves-risk-of-death-in-bladder-20251018.jpg", "site": "reuters.com", "text": "Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, progression or death in patients suffering from a type of bladder cancer, the companies said on Saturday.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/astellas-pfizers-combination-therapy-halves-risk-death-bladder-cancer-patients-2025-10-18/"}}
{"date": "2025-10-18", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-18 10:30:40", "publisher": "Investors Business Daily", "title": "Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients", "image": "https://images.financialmodelingprep.com/news/pfizer-merck-and-astellas-have-an-enormous-new-hope-for-20251018.jpg", "site": "investors.com", "text": "Pharma titans Merck, Pfizer and Astellas Pharma are delivering an \"enormous new hope\" for patients with an aggressive form of bladder cancer.", "url": "https://www.investors.com/news/technology/bladder-cancer-padcev-keytruda-merck-pfizer-astellas/"}}
{"date": "2025-10-18", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-18 10:30:00", "publisher": "PRNewsWire", "title": "PADCEV Plus KEYTRUDA, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer", "image": "https://images.financialmodelingprep.com/news/padcev-plus-keytruda-given-before-and-after-surgery-cuts-20251018.jpg", "site": "prnewswire.com", "text": "First and only combination regimen to improve survival when used before and after surgical cystectomy in cisplatin-ineligible patients with muscle-invasive bladder cancer Unprecedented survival results from pivotal Phase 3 EV-303 trial show potential for PADCEV plus KEYTRUDA to redefine standard of care TOKYO and NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as KEYNOTE-905) for PADCEV(enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA(pembrolizumab), a PD-1 inhibitor. The study evaluated the combination in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or declined cisplatin-based chemotherapy.", "url": "https://www.prnewswire.com/news-releases/padcev-plus-keytruda-given-before-and-after-surgery-cuts-the-risk-of-recurrence-progression-or-death-by-60-and-the-risk-of-death-by-50-for-certain-patients-with-bladder-cancer-302587853.html"}}
{"date": "2025-10-18", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-18 08:36:00", "publisher": "Seeking Alpha", "title": "Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential", "image": "https://images.financialmodelingprep.com/news/pfizer-worldleading-drug-pipeline-sets-stage-for-major-longterm-potential-20251018.jpg", "site": "seekingalpha.com", "text": "Pfizer is rated a buy due to its robust drug pipeline, focus on improving financials, and significant long-term growth potential despite near-term headwinds. PFE delivered strong results in H1, with 10% revenue growth, 30% higher adjusted income, and raised EPS guidance, with H2 expected to be even stronger. Risks include upcoming patent expirations, high dividend payout ratio, and political pressure on drug pricing, but the company is actively managing these challenges.", "url": "https://seekingalpha.com/article/4830964-pfizer-world-leading-drug-pipeline-sets-stage-for-major-long-term-potential"}}
{"date": "2025-10-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-17 19:49:51", "publisher": "24/7 Wall Street", "title": "Interest Rates Tumble: Grab Our 5 All-Time Favorite Safe 6%+ Dividend Stocks", "image": "https://images.financialmodelingprep.com/news/interest-rates-tumble-grab-our-5-alltime-favorite-safe-20251017.jpg", "site": "247wallst.com", "text": "Investors love dividend stocks, especially those with safe high yields, because they provide a substantial income stream and offer significant total return potential.", "url": "https://247wallst.com/investing/2025/10/17/interest-rates-tumble-grab-our-5-all-time-favorite-safe-6-dividend-stocks/"}}
{"date": "2025-10-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-17 18:45:39", "publisher": "Zacks Investment Research", "title": "Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know", "image": "https://images.financialmodelingprep.com/news/pfizer-pfe-beats-stock-market-upswing-what-investors-need-20251017.jpg", "site": "zacks.com", "text": "Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.", "url": "https://www.zacks.com/stock/news/2771460/pfizer-pfe-beats-stock-market-upswing-what-investors-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2771460"}}
{"date": "2025-10-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-17 14:57:56", "publisher": "New York Post", "title": "Popular birth control is linked to brain tumors in new study  as over 1,000 women sue Pfizer over health risks", "image": "https://images.financialmodelingprep.com/news/popular-birth-control-is-linked-to-brain-tumors-in-new-20251017.jpg", "site": "nypost.com", "text": "One Louisiana woman, Robin Phillip, said she developed anintracranial meningioma that caused her to lose vision in her left eye and struggle to walk.", "url": "https://nypost.com/2025/10/17/health/popular-birth-control-linked-to-brain-tumors-in-new-study-as-over-1000-women-sue-pfizer-over-health-risks/"}}
{"date": "2025-10-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-17 10:19:58", "publisher": "Benzinga", "title": "Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?", "image": "https://images.financialmodelingprep.com/news/novo-vs-lilly-vs-pfizer-who-wins-if-trump-slashes-20251017.jpeg", "site": "benzinga.com", "text": "President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordabilityit's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare valuations from Eli Lilly And Co (NYSE:LLY) to Pfizer Inc (NYSE:PFE).", "url": "https://www.benzinga.com/trading-ideas/long-ideas/25/10/48275949/novo-vs-lilly-vs-pfizer-who-wins-if-trump-slashes-the-price-of-weight-loss-drugs"}}
{"date": "2025-10-17", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-17 09:55:09", "publisher": "Forbes", "title": "What's Behind The Slump In Pfizer Stock?", "image": "https://images.financialmodelingprep.com/news/whats-behind-the-slump-in-pfizer-stock-20251017.jpg", "site": "forbes.com", "text": "Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of 11% of its value over that period. This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around $138 billion.", "url": "https://www.forbes.com/sites/greatspeculations/2025/10/17/whats-behind-the-slump-in-pfizer-stock/"}}
{"date": "2025-10-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-16 15:27:26", "publisher": "The Motley Fool", "title": "ASSET PLANNING Exits Full Stake in Pfizer Worth $2.7 Million", "image": "https://images.financialmodelingprep.com/news/asset-planning-exits-full-stake-in-pfizer-worth-27-million-20251016.png", "site": "fool.com", "text": "On October 16, 2025, ASSET PLANNING SERVICES INC /LA/ /ADV disclosed in an SEC filing that it sold out of Pfizer (PFE -0.57%) , with an estimated $2.66 million trade.", "url": "https://www.fool.com/coverage/filings/2025/10/16/asset-planning-exits-full-stake-in-pfizer-worth-usd2-7-million/"}}
{"date": "2025-10-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-16 11:35:07", "publisher": "The Motley Fool", "title": "QSM Asset Management Buys $6.8 Million of Pfizer Stock as Pharma Giant Lags Market", "image": "https://images.financialmodelingprep.com/news/qsm-asset-management-buys-68-million-of-pfizer-stock-20251016.jpg", "site": "fool.com", "text": "On Thursday, QSM Asset Management disclosed a significant buy of Pfizer (PFE -0.04%), adding shares worth an estimated $6.8 million in the third quarter.", "url": "https://www.fool.com/coverage/filings/2025/10/16/qsm-asset-management-buys-usd6-8-million-of-pfizer-stock-as-pharma-giant-lags-market/"}}
{"date": "2025-10-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-16 08:12:00", "publisher": "The Motley Fool", "title": "A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years", "image": "https://images.financialmodelingprep.com/news/a-onceinadecade-investment-opportunity-1-pharmaceutical-stock-to-buy-20251016.jpg", "site": "fool.com", "text": "Over the past decade, pharmaceutical maker Pfizer (PFE -0.53%)has severely lagged the market. Dividends reinvested aside, the stock is in the red over this period, while the S&P 500 is up by almost 230%.", "url": "https://www.fool.com/investing/2025/10/16/a-once-in-a-decade-investment-opportunity-1-pharma/"}}
{"date": "2025-10-16", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-16 05:08:23", "publisher": "Seeking Alpha", "title": "Pfizer: Don't Forget About Value During AI Frenzy", "image": "https://images.financialmodelingprep.com/news/pfizer-dont-forget-about-value-during-ai-frenzy-20251016.jpg", "site": "seekingalpha.com", "text": "Pfizer is rated a Strong Buy, offering a nearly 7% forward dividend yield, which is highly likely safe. PFE's revenue has stabilized, management is delivering cost savings, and a recent drug pricing deal with the U.S. government reduces political uncertainty. The company's improving balance sheet, aggressive R&D, and undervalued stock price support long-term upside potential, despite sector headwinds.", "url": "https://seekingalpha.com/article/4830326-pfizer-do-not-forget-about-value-during-ai-frenzy"}}
{"date": "2025-10-15", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-15 15:31:30", "publisher": "CNBC", "title": "CEOs of Wells Fargo and Pfizer caution the U.S. could lose its edge to China without innovation", "image": "https://images.financialmodelingprep.com/news/ceos-of-wells-fargo-and-pfizer-caution-the-us-could-20251015.jpg", "site": "cnbc.com", "text": "Wells Fargo CEO Charlie Scharf said AI is boosting productivity but will likely reduce workforce size. Pfizer CEO Albert Bourla warned China is closing the biotech and pharmaceutical patent gap rapidly and said the U.S. needs to focus on innovation.", "url": "https://www.cnbc.com/2025/10/15/wells-fargo-pfizer-ceos-china-innovation.html"}}
{"date": "2025-10-15", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-15 09:41:08", "publisher": "Zacks Investment Research", "title": "Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?", "image": "https://images.financialmodelingprep.com/news/pharma-ma-activity-picks-up-pace-what-does-it-20251015.jpg", "site": "zacks.com", "text": "Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.", "url": "https://www.zacks.com/stock/news/2769007/pharma-m-a-activity-picks-up-pace-what-does-it-signal-for-2026?cid=CS-STOCKNEWSAPI-FT-analyst_blog|industry_focus-2769007"}}
{"date": "2025-10-14", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-14 22:58:05", "publisher": "Reuters", "title": "Pfizer CEO says US pharma industry needs to collaborate with China", "image": "https://images.financialmodelingprep.com/news/pfizer-ceo-says-us-pharma-industry-needs-to-collaborate-20251014.jpg", "site": "reuters.com", "text": "Pfizer Chief Executive Albert Bourla said on Tuesday that the U.S. pharmaceutical industry needs to collaborate with China's, where speedy processes have vaulted it to 30% of global drug development over the past decade.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-ceo-says-us-pharma-industry-needs-collaborate-with-china-2025-10-15/"}}
{"date": "2025-10-14", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-14 14:45:37", "publisher": "24/7 Wall Street", "title": "Top Dividend Stocks Delivering Over 5% for True Financial Freedom", "image": "https://images.financialmodelingprep.com/news/top-dividend-stocks-delivering-over-5-for-true-financial-20251014.jpg", "site": "247wallst.com", "text": "It is possible to achieve financial freedom through stock investing. If you pick the right companies, stay invested for the long term, and reinvest the dividends, you can build a solid portfolio for retirement.", "url": "https://247wallst.com/investing/2025/10/14/top-dividend-stocks-delivering-over-5-for-true-financial-freedom/"}}
{"date": "2025-10-14", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-14 10:45:17", "publisher": "24/7 Wall Street", "title": "3 Sizzling Ultra-High-Yield Stocks Under $50 With Upside Potential", "image": "https://images.financialmodelingprep.com/news/3-sizzling-ultrahighyield-stocks-under-50-with-upside-potential-20251014.jpg", "site": "247wallst.com", "text": "Investors can have their higher yields and capital appreciation potential, too. But, of course, there are always added risks to consider, and when it comes to the hard-hit higher-yielders out there, the fundamentals and growth narrative have taken a turn for the worse.", "url": "https://247wallst.com/investing/2025/10/14/3-sizzling-ultra-high-yield-stocks-under-50-with-upside-potential/"}}
{"date": "2025-10-14", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-14 06:45:00", "publisher": "Business Wire", "title": "TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial", "image": "https://images.financialmodelingprep.com/news/tukysa-combination-significantly-improves-progressionfree-survival-as-firstline-maintenance-20251014.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA (tucatinib) in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). HER2CLIMB-05 is evaluating TUKYSA versus placebo, both in combination with first-line standard-of-care maintenance therapy (trastuzumab plus pertuzumab) following chemotherapy.", "url": "https://www.businesswire.com/news/home/20251014543396/en/TUKYSA-Combination-Significantly-Improves-Progression-Free-Survival-as-First-Line-Maintenance-in-HER2-Metastatic-Breast-Cancer-in-HER2CLIMB-05-Trial/"}}
{"date": "2025-10-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-13 10:00:48", "publisher": "Zacks Investment Research", "title": "Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know", "image": "https://images.financialmodelingprep.com/news/investors-heavily-search-pfizer-inc-pfe-here-is-what-20251013.jpg", "site": "zacks.com", "text": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.", "url": "https://www.zacks.com/stock/news/2767265/investors-heavily-search-pfizer-inc-pfe-here-is-what-you-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2767265"}}
{"date": "2025-10-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-13 08:45:00", "publisher": "The Motley Fool", "title": "Where Will Pfizer Be in 5 Years?", "image": "https://images.financialmodelingprep.com/news/where-will-pfizer-be-in-5-years-20251013.jpg", "site": "fool.com", "text": "The 6.7% dividend yield on offer from Pfizer (PFE -1.72%) is both a sign of opportunity and risk. A lot will happen over the next five years that will determine if that dividend is sustainable.", "url": "https://www.fool.com/investing/2025/10/13/where-will-pfizer-be-in-5-years/"}}
{"date": "2025-10-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-13 06:45:00", "publisher": "Business Wire", "title": "Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025", "image": "https://images.financialmodelingprep.com/news/pfizer-to-highlight-advancements-in-respiratory-health-and-infectious-disease-20251013.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, Pfizer) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases. IDWeek 2025 offers a critical opportunity to highlight our cutting-edge scientific progress and collaborate with global health experts in our ongoin.", "url": "https://www.businesswire.com/news/home/20251013078360/en/Pfizer-to-Highlight-Advancements-in-Respiratory-Health-and-Infectious-Disease-Research-at-IDWeek-2025/"}}
{"date": "2025-10-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-13 05:35:59", "publisher": "Proactive Investors", "title": "IP Group shares climb 9% on potential royalties from Pfizer's $7.3bn Metsera deal", "image": "https://images.financialmodelingprep.com/news/ip-group-shares-climb-9-on-potential-royalties-from-pfizers-20251013.jpeg", "site": "proactiveinvestors.co.uk", "text": "Shares in IP Group PLC (LSE:IPO) rose 9% on Monday after investors welcomed the potential for future royalty income from Metsera, a biotech company that Pfizer has agreed to acquire for up to $7.3 billion. The agreement, announced in September, includes $4.9 billion in upfront cash and gives Pfizer control of Metsera's portfolio of next-generation obesity treatments.", "url": "https://www.proactiveinvestors.co.uk/companies/news/1080202"}}
{"date": "2025-10-13", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-13 02:43:50", "publisher": "Proactive Investors", "title": "IP Group in line for future royalties from Pfizer's drug deal", "image": "https://images.financialmodelingprep.com/news/ip-group-in-line-for-future-royalties-from-pfizers-20251013.jpg", "site": "proactiveinvestors.co.uk", "text": "IP Group PLC (LSE:IPO) could see future royalty income from a new wave of obesity drugs being developed by Metsera, a biotech company that Pfizer Inc (NYSE:PFE, ETR:PFE)has agreed to buy for up to $7.3 billion. The deal, announced in late September, includes $4.9 billion in upfront cash and gives the US pharmaceutical giant control of a portfolio of next-generation obesity treatments.", "url": "https://www.proactiveinvestors.co.uk/companies/news/1080184"}}
{"date": "2025-10-12", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-12 14:28:00", "publisher": "The Motley Fool", "title": "4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer", "image": "https://images.financialmodelingprep.com/news/4-dividend-stocks-to-double-up-on-right-now-including-20251012.jpg", "site": "fool.com", "text": "Sometimes, things are going great for a stock with potentially more good news on the way. In other cases, things are going so badly for a stock that it almost has nowhere to go but up.", "url": "https://www.fool.com/investing/2025/10/12/4-dividend-stocks-to-double-up-on-right-now-includ/"}}
{"date": "2025-10-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-10 10:15:34", "publisher": "Reuters", "title": "Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly", "image": "https://images.financialmodelingprep.com/news/next-medicine-deal-after-pfizer-analysts-shares-point-to-20251010.jpg", "site": "reuters.com", "text": "Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to lower drug prices last week.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/next-medicine-deal-after-pfizer-analysts-shares-point-astrazeneca-eli-lilly-2025-10-10/"}}
{"date": "2025-10-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-10 09:00:21", "publisher": "Seeking Alpha", "title": "Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)", "image": "https://images.financialmodelingprep.com/news/pfizers-q3-the-catalyst-for-a-bullish-resurgence-earnings-preview-20251010.jpg", "site": "seekingalpha.com", "text": "Pfizer's stock is poised for recovery, driven by recent corporate news and a three-year reprieve on drug-import tariffs from the Trump administration, strengthening the bullish case despite prior market reactions. Upcoming Q3 earnings on November 4, 2025, are expected to provide clarity on oncology progress and the impact of the Trump administration's tariff decision, potentially leading to meaningful earnings revisions. Pfizer's deal with TrumpRx, offering drug discounts and committing $70 billion in U.S. manufacturing/R&D, reduces regulatory uncertainty and should attract new investors as guidance is met.", "url": "https://seekingalpha.com/article/4829048-pfizer-stock-q3-catalyst-for-bullish-resurgence-earnings-preview"}}
{"date": "2025-10-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-10 06:45:00", "publisher": "The Motley Fool", "title": "2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now", "image": "https://images.financialmodelingprep.com/news/2-pharmaceutical-stocks-that-look-like-nobrainer-buys-right-now-20251010.jpg", "site": "fool.com", "text": "There are several compelling reasons to invest in pharmaceutical companies, especially when the economy isn't doing well. Since they belong to a defensive industry, drugmakers tend to perform better than most companies even in the worst economic downturns.", "url": "https://www.fool.com/investing/2025/10/10/2-pharmaceutical-stocks-that-look-like-no-brainer/"}}
{"date": "2025-10-10", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-10 03:18:00", "publisher": "The Motley Fool", "title": "Here's How This Pharmaceutical Giant Is Protecting Itself From President Trump's Tariffs. Should It Matter to Investors?", "image": "https://images.financialmodelingprep.com/news/heres-how-this-pharmaceutical-giant-is-protecting-itself-from-20251010.jpg", "site": "fool.com", "text": "As President Donald Trump's escalating tariff policies threaten to raise costs across global supply chains, one pharmaceutical giant is taking steps to protect its bottom line. On Sept. 30, Pfizer (PFE -1.81%) became the first big pharma company to agree to implement most-favored-nation pricing for the U.S.", "url": "https://www.fool.com/investing/2025/10/10/heres-how-this-pharmaceutical-giant-is-protecting/"}}
{"date": "2025-10-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-09 18:46:12", "publisher": "Zacks Investment Research", "title": "Here's Why Pfizer (PFE) Fell More Than Broader Market", "image": "https://images.financialmodelingprep.com/news/heres-why-pfizer-pfe-fell-more-than-broader-market-20251009.jpg", "site": "zacks.com", "text": "In the latest trading session, Pfizer (PFE) closed at $25.24, marking a -1.71% move from the previous day.", "url": "https://www.zacks.com/stock/news/2765789/here-s-why-pfizer-pfe-fell-more-than-broader-market?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2765789"}}
{"date": "2025-10-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-09 16:30:00", "publisher": "Business Wire", "title": "Pfizer Declares Fourth-Quarter 2025 Dividend", "image": "https://images.financialmodelingprep.com/news/pfizer-declares-fourthquarter-2025-dividend-20251009.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company's common stock, payable December 1, 2025, to holders of the Common Stock of record at the close of business on November 7, 2025. The fourth-quarter 2025 cash dividend will be the 348th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to.", "url": "https://www.businesswire.com/news/home/20251009128496/en/Pfizer-Declares-Fourth-Quarter-2025-Dividend/"}}
{"date": "2025-10-09", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-09 11:35:17", "publisher": "The Motley Fool", "title": "Wilsey Discloses $2.9 Million Purchase of Pfizer Stock Amid Landmark Trump Deal", "image": "https://images.financialmodelingprep.com/news/wilsey-discloses-29-million-purchase-of-pfizer-stock-amid-20251009.png", "site": "fool.com", "text": "Wilsey Asset Management disclosed the purchase of Pfizer shares valued at an estimated $2.9 million during the third quarter, according to an SEC filing released Wednesday.", "url": "https://www.fool.com/coverage/filings/2025/10/09/wilsey-discloses-usd2-9-million-purchase-of-pfizer-stock-amid-landmark-trump-deal/"}}
{"date": "2025-10-08", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-08 10:15:00", "publisher": "The Motley Fool", "title": "Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead", "image": "https://images.financialmodelingprep.com/news/healthcare-stocks-are-rising-here-are-2-with-even-20251008.jpg", "site": "fool.com", "text": "On Sept. 30, Pfizer announced a deal with the U.S. government that will allow the pharmaceutical leader to avoid President Donald Trump's tariffs for three years in exchange for slashing the prices of certain drugs in the U.S. and investing in local manufacturing efforts. This deal lifted not only Pfizer, but also much of the healthcare sector, especially the company's drugmaking peers, as Wall Street expects more deals along those lines.", "url": "https://www.fool.com/investing/2025/10/08/healthcare-stocks-are-rising-here-are-2-with-even/"}}
{"date": "2025-10-08", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-08 09:50:34", "publisher": "Zacks Investment Research", "title": "Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings", "image": "https://images.financialmodelingprep.com/news/heres-what-to-expect-from-pfizers-oncology-drugs-in-20251008.jpg", "site": "zacks.com", "text": "Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.", "url": "https://www.zacks.com/stock/news/2764294/here-s-what-to-expect-from-pfizer-s-oncology-drugs-in-q3-earnings?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2764294"}}
{"date": "2025-10-08", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-08 09:46:10", "publisher": "Zacks Investment Research", "title": "3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal", "image": "https://images.financialmodelingprep.com/news/3-large-drug-stocks-to-watch-as-industry-recovers-20251008.jpg", "site": "zacks.com", "text": "Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.", "url": "https://www.zacks.com/stock/news/2764279/3-large-drug-stocks-to-watch-as-industry-recovers-after-pfe-trump-deal?cid=CS-STOCKNEWSAPI-FT-analyst_blog|investment_ideas-2764279"}}
{"date": "2025-10-08", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-08 07:00:00", "publisher": "Business Wire", "title": "Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman", "image": "https://images.financialmodelingprep.com/news/mikael-dolsten-md-phd-joins-trio-pharmaceuticals-as-chairman-20251008.jpg", "site": "businesswire.com", "text": "SAN CARLOS, Calif.--(BUSINESS WIRE)---- $PFE #ADCs--Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman.", "url": "https://www.businesswire.com/news/home/20251008112766/en/Mikael-Dolsten-M.D.-Ph.D.-Joins-TRIO-Pharmaceuticals-as-Chairman/"}}
{"date": "2025-10-07", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-07 12:32:08", "publisher": "Proactive Investors", "title": "Life sciences sentiment rises as Pfizer deal eases tariff concerns", "image": "https://images.financialmodelingprep.com/news/life-sciences-sentiment-rises-as-pfizer-deal-eases-tariff-concerns-20251007.jpeg", "site": "proactiveinvestors.com", "text": "Sentiment towards life sciences tools and diagnostics firms in North America is turning positive after an agreement between the Trump Administration and Pfizer Inc (NYSE:PFE, ETR:PFE) has significantly eased the uncertainty around Most Favored Nation (MFN) tariffs on pharmaceuticals and related products, Citi analysts have highlighted. Under the deal announced late last month, Pfizer agreed to lower drug prices for Medicaid, sell discounted medicines directly to Americans, make significant investments in the US, and avoid tariffs for three years.", "url": "https://www.proactiveinvestors.com/companies/news/1079871"}}
{"date": "2025-10-07", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-07 09:30:00", "publisher": "The Motley Fool", "title": "Down 50%, Should You Buy the Dip on Pfizer?", "image": "https://images.financialmodelingprep.com/news/down-50-should-you-buy-the-dip-on-pfizer-20251007.jpg", "site": "fool.com", "text": "Pfizer (PFE -0.60%) has a huge 6.3% dividend yield. That's actually a lot lower than it was not too long ago, thanks to a large stock advance in recent days based on news.", "url": "https://www.fool.com/investing/2025/10/07/down-50-should-you-buy-the-dip-on-pfizer/"}}
{"date": "2025-10-07", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-07 08:16:06", "publisher": "Zacks Investment Research", "title": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? (Revised)", "image": "https://images.financialmodelingprep.com/news/will-pfizer-pfe-beat-estimates-again-in-its-next-earnings-20251007.jpg", "site": "zacks.com", "text": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "url": "https://www.zacks.com/stock/news/2763338/will-pfizer-pfe-beat-estimates-again-in-its-next-earnings-report-revised?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_7-2763338"}}
{"date": "2025-10-07", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-07 03:15:00", "publisher": "The Motley Fool", "title": "Worried About Tariffs? 2 Safe Haven Stocks to Buy on the Dip With $500", "image": "https://images.financialmodelingprep.com/news/worried-about-tariffs-2-safe-haven-stocks-to-buy-on-20251007.jpg", "site": "fool.com", "text": "Earlier this year, all three major indexes -- the S&P 500, the Nasdaq, and the Dow Jones Industrial Average -- slid as President Donald Trump announced his plan to impose tariffs on imports. Investors worried this would result in higher costs for U.S. companies as they import their goods made abroad -- and this might sink earnings.", "url": "https://www.fool.com/investing/2025/10/07/worried-about-tariffs-2-safe-haven-stocks-to-buy/"}}
{"date": "2025-10-07", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-07 01:16:40", "publisher": "Seeking Alpha", "title": "Pfizer Offers High Yield And Capital Appreciation Opportunities (Technical Analysis)", "image": "https://images.financialmodelingprep.com/news/pfizer-offers-high-yield-and-capital-appreciation-opportunities-technical-analysis-20251007.jpg", "site": "seekingalpha.com", "text": "Pfizer surged 15% last week on positive news, including a direct-to-consumer deal and a three-year tariff reprieve. PFE offers a high 6.28% yield, with a forward PE of 8.87, and its dividend is considered safe by Seeking Alpha. Technical analysis shows PFE above its 30-week EMA, with bullish short- and long-term momentum and strong buying volume from institutional investors.", "url": "https://seekingalpha.com/article/4828199-pfizer-offers-high-yield-capital-appreciation-opportunities-technical-analysis"}}
{"date": "2025-10-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-06 19:35:08", "publisher": "MarketBeat", "title": "Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal", "image": "https://images.financialmodelingprep.com/news/eli-lilly-stock-soars-on-trump-tariff-hopes-and-20251006.png", "site": "marketbeat.com", "text": "After tanking in early August, the world's most valuable pharmaceutical stock has roared back with a vengeance. That firm is Eli Lilly and Company NYSE: LLY, the maker of the wildly popular weight loss and diabetes drugs Zepbound and Mounjaro.", "url": "https://www.marketbeat.com/originals/eli-lilly-stock-soars-on-trump-tariff-hopes-and-pfizer-deal/"}}
{"date": "2025-10-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-06 14:21:31", "publisher": "MarketBeat", "title": "Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants", "image": "https://images.financialmodelingprep.com/news/trumps-drug-price-cuts-boom-or-bust-for-these-20251006.png", "site": "marketbeat.com", "text": "When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.", "url": "https://www.marketbeat.com/stock-ideas/trumps-drug-price-cuts-boom-or-bust-for-these-3-pharma-giants/"}}
{"date": "2025-10-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-06 13:29:00", "publisher": "Seeking Alpha", "title": "My Top 5 Biotech Stocks Big Pharma Could Buy Next", "image": "https://images.financialmodelingprep.com/news/my-top-5-biotech-stocks-big-pharma-could-buy-20251006.jpg", "site": "seekingalpha.com", "text": "While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck andPfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.", "url": "https://seekingalpha.com/article/4828107-my-top-5-biotech-stocks-big-pharma-could-buy-next"}}
{"date": "2025-10-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-06 13:11:26", "publisher": "Zacks Investment Research", "title": "Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?", "image": "https://images.financialmodelingprep.com/news/will-pfizer-pfe-beat-estimates-again-in-its-next-earnings-20251006.jpg", "site": "zacks.com", "text": "Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.", "url": "https://www.zacks.com/stock/news/2762958/will-pfizer-pfe-beat-estimates-again-in-its-next-earnings-report?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_7-2762958"}}
{"date": "2025-10-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-06 10:32:54", "publisher": "24/7 Wall Street", "title": "3 High-Yield Dividend Stocks to Buy in October", "image": "https://images.financialmodelingprep.com/news/3-highyield-dividend-stocks-to-buy-in-october-20251006.jpg", "site": "247wallst.com", "text": "To investors, the stock market is considered one of if not the greatest ways to build wealth.", "url": "https://247wallst.com/investing/2025/10/06/3-high-yield-dividend-stocks-to-buy-in-october/"}}
{"date": "2025-10-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-06 09:51:14", "publisher": "Zacks Investment Research", "title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar", "image": "https://images.financialmodelingprep.com/news/these-2-medical-stocks-could-beat-earnings-why-they-should-20251006.jpg", "site": "zacks.com", "text": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.", "url": "https://www.zacks.com/stock/news/2762513/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|zacks_education_earnings_esp-2762513"}}
{"date": "2025-10-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-06 08:00:00", "publisher": "Seeking Alpha", "title": "Pfizer: TrumpRx Unlocks Opportunities With Drug Discounts", "image": "https://images.financialmodelingprep.com/news/pfizer-trumprx-unlocks-opportunities-with-drug-discounts-20251006.jpg", "site": "seekingalpha.com", "text": "Pfizer delivered strong 2Q25 results with double-digit revenue growth, margin expansion, and robust earnings driven by Comirnaty, Paxlovid, and Vyndaqel. The TrumpRx deal offers discounted direct-to-consumer drug sales, tariff relief, and pricing clarity but introduces margin and execution risks. PFE trades at a significant discount to sector peers, with attractive valuation multiples and a high 6.28% dividend yield, making it a compelling value play.", "url": "https://seekingalpha.com/article/4827798-pfizer-trumprx-unlocks-opportunities-with-drug-discounts"}}
{"date": "2025-10-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-06 07:15:00", "publisher": "The Motley Fool", "title": "Great News for Pfizer Stock Investors", "image": "https://images.financialmodelingprep.com/news/great-news-for-pfizer-stock-investors-20251006.jpg", "site": "fool.com", "text": "Pfizer (PFE 1.03%) made a deal with the White House to avoid paying tariffs on imported products.", "url": "https://www.fool.com/investing/2025/10/06/great-news-for-pfizer-stock-investors/"}}
{"date": "2025-10-06", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-06 04:59:00", "publisher": "The Motley Fool", "title": "3 Reasons to Buy Pfizer Stock Now", "image": "https://images.financialmodelingprep.com/news/3-reasons-to-buy-pfizer-stock-now-20251006.jpg", "site": "fool.com", "text": "Pfizer (PFE 1.03%) continues to lag the market. Over the past few years, the company has generally reported declining revenue and profits, resulting in a substantial decline in market value.", "url": "https://www.fool.com/investing/2025/10/06/3-reasons-to-buy-pfizer-stock-now/"}}
{"date": "2025-10-05", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-05 09:15:00", "publisher": "The Motley Fool", "title": "Can Pfizer's Stock Break This Disappointing Streak?", "image": "https://images.financialmodelingprep.com/news/can-pfizers-stock-break-this-disappointing-streak-20251005.jpg", "site": "fool.com", "text": "Pfizer (PFE 1.03%) is one of the largest healthcare companies in the world. It was founded in 1849 and has since become an iconic name in healthcare.", "url": "https://www.fool.com/investing/2025/10/05/can-pfizers-stock-break-this-disappointing-streak/"}}
{"date": "2025-10-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-04 08:15:00", "publisher": "Seeking Alpha", "title": "5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Oct. 2025)", "image": "https://images.financialmodelingprep.com/news/5-relatively-secure-and-cheap-dividend-stocks-yields-up-20251004.jpg", "site": "seekingalpha.com", "text": "This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 3.56%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.", "url": "https://seekingalpha.com/article/4827004-5-relatively-secure-and-cheap-dividend-stocks-yields-8-percent-oct-2025"}}
{"date": "2025-10-04", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-04 08:00:04", "publisher": "24/7 Wall Street", "title": "Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (October 2025)", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-nyse-pfe-price-prediction-and-forecast-20252030-20251004.jpg", "site": "247wallst.com", "text": "Shares of Pfizer ( NYSE: PFE )gained 10.02% over the past month after gaining 4.50% the month prior.", "url": "https://247wallst.com/investing/2025/10/04/pfizer-inc-nyse-pfe-price-prediction-and-forecast-2025-2030-april-2025/"}}
{"date": "2025-10-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-03 17:17:00", "publisher": "WSJ", "title": "The Score: Pfizer, Tesla, Electronic Arts and More Stocks That Defined the Week", "image": "https://images.financialmodelingprep.com/news/the-score-pfizer-tesla-electronic-arts-and-more-stocks-20251003.jpg", "site": "wsj.com", "text": "Here are some of the major companies whose stocks moved on the week's news", "url": "https://www.wsj.com/finance/stocks/pfizer-tesla-electronic-arts-nike-meta-occidental-c27758e4"}}
{"date": "2025-10-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-03 16:20:59", "publisher": "Seeking Alpha", "title": "Pharmaceutical Stocks: Valuations And Pipelines Are Only Beginning To Be Appreciated", "image": "https://images.financialmodelingprep.com/news/pharmaceutical-stocks-valuations-and-pipelines-are-only-beginning-to-20251003.jpg", "site": "seekingalpha.com", "text": "Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, especially from LLY and NVO, provide powerful tailwinds for the sector. Advances in oncology, hematology, and new cardiology drugs like Lp(a) inhibitors create multi-billion dollar opportunities for AZN, LLY, and PFE.", "url": "https://seekingalpha.com/article/4827772-pharmaceutical-stocks-valuations-and-pipelines-are-only-beginning-to-be-appreciated"}}
{"date": "2025-10-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-03 11:01:09", "publisher": "Zacks Investment Research", "title": "Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?", "image": "https://images.financialmodelingprep.com/news/is-pfe-stock-a-buy-after-14-rise-post-20251003.jpg", "site": "zacks.com", "text": "Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.", "url": "https://www.zacks.com/stock/news/2761564/is-pfe-stock-a-buy-after-14-rise-post-drug-pricing-deal-with-trump?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2761564"}}
{"date": "2025-10-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-03 04:20:00", "publisher": "The Motley Fool", "title": "These 3 Stocks Pay More Than 6%. Are Their Dividend Yields Too Good to Be True?", "image": "https://images.financialmodelingprep.com/news/these-3-stocks-pay-more-than-6-are-their-20251003.jpg", "site": "fool.com", "text": "Did you know that if you have a reliable income stock that yields 6%, you would only need to invest about $16,700 in it to collect $1,000 in dividends over the course of a full year? The average stock on the S&P 500, meanwhile, yields just 1.2%, and it would take an investment of more than $83,000 to generate that same level of dividend income.", "url": "https://www.fool.com/investing/2025/10/03/stocks-pay-6-dividend-yields-too-good/"}}
{"date": "2025-10-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-03 03:48:00", "publisher": "The Motley Fool", "title": "2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 in October", "image": "https://images.financialmodelingprep.com/news/2-reliable-dividend-stocks-with-yields-above-6-that-20251003.jpg", "site": "fool.com", "text": "Does the government shutdown have you feeling queasy about investing in stocks? It's understandable, but history says your portfolio's going to be just fine.", "url": "https://www.fool.com/investing/2025/10/03/reliable-dividend-stocks-with-yields-above-that-yo/"}}
{"date": "2025-10-03", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-03 03:15:00", "publisher": "The Motley Fool", "title": "Pfizer Just Made a Landmark Drug Pricing Agreement with President Donald Trump. Is the Stock a Buy?", "image": "https://images.financialmodelingprep.com/news/pfizer-just-made-a-landmark-drug-pricing-agreement-with-20251003.jpg", "site": "fool.com", "text": "The biggest risks facing pharmaceutical companies in recent times haven't had to do with clinical trials or winning regulatory approval. Instead, investors have worried about President Donald Trump's intention to lower drug prices and slap a tariff on pharma imports.", "url": "https://www.fool.com/investing/2025/10/03/pfizer-just-made-a-landmark-drug-pricing-agreement/"}}
{"date": "2025-10-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-02 21:16:00", "publisher": "WSJ", "title": "The drug price deal between Pfizer and the Trump administration was built on down-to-the-wire team negotiations, building on a relationship between CEO Albert Bourla and President Trump", "image": "https://images.financialmodelingprep.com/news/the-drug-price-deal-between-pfizer-and-the-trump-20251002.jpg", "site": "wsj.com", "text": "Down-to-the wire team negotiations capped a long dance between President Trump and CEO Albert Bourla.", "url": "https://www.wsj.com/health/pharma/trump-pfizer-drug-price-tariff-deal-455be9b7"}}
{"date": "2025-10-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-02 09:00:00", "publisher": "Seeking Alpha", "title": "Pfizer: The Long Suffering Is Finally Over (Rating Upgrade)", "image": "https://images.financialmodelingprep.com/news/pfizer-the-long-suffering-is-finally-over-rating-upgrade-20251002.jpg", "site": "seekingalpha.com", "text": "Pfizer Inc. has secured an MFN pricing deal with the White House, easing recent tariff and drug repricing concerns while affording a win for Trump. PFE's solid dividend yield of >6% provides a robust anchor for income investors to accumulate. The deal allows management to refocus on integrating its Metsera M&A while advancing its oncology and obesity drug pipelines, overcoming LOE worries.", "url": "https://seekingalpha.com/article/4827401-pfizer-long-suffering-finally-over"}}
{"date": "2025-10-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-02 07:02:00", "publisher": "The Motley Fool", "title": "3 Things You Need to Know if You Buy Pfizer Today", "image": "https://images.financialmodelingprep.com/news/3-things-you-need-to-know-if-you-buy-20251002.jpg", "site": "fool.com", "text": "The big draw for most investors with Pfizer (PFE 6.77%) today is likely to be its lofty 7.2% dividend yield. That compares to 1.2% for the S&P 500 index and about 1.3% for the average pharmaceutical stock.", "url": "https://www.fool.com/investing/2025/10/02/3-things-you-need-to-know-if-you-buy-pfizer-today/"}}
{"date": "2025-10-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-02 07:00:00", "publisher": "WSJ", "title": "Heard on the Street: Pfizer's accord on price cuts with President Trump clears a cloud over the whole pharma industry", "image": "https://images.financialmodelingprep.com/news/heard-on-the-street-pfizers-accord-on-price-cuts-20251002.jpg", "site": "wsj.com", "text": "The company's accord with the president clears a cloud over the whole sector.", "url": "https://www.wsj.com/health/pharma/why-pfizers-trump-deal-is-good-news-for-all-of-big-pharma-7e2724f4"}}
{"date": "2025-10-02", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-02 05:11:00", "publisher": "The Motley Fool", "title": "3 Mega Dividend Stocks With Yields as High as 13.4%", "image": "https://images.financialmodelingprep.com/news/3-mega-dividend-stocks-with-yields-as-high-as-134-20251002.jpg", "site": "fool.com", "text": "Dividend yields are historically low these days. The S&P 500 yields less than 1.2%, which is near its lowest level on record.", "url": "https://www.fool.com/investing/2025/10/02/3-mega-dividend-stocks-with-yields-as-high-as-134/"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 19:46:10", "publisher": "Zacks Investment Research", "title": "Government Shutdown, Government Shmutdown", "image": "https://images.financialmodelingprep.com/news/government-shutdown-government-shmutdown-20251001.jpg", "site": "zacks.com", "text": "Market indexes were ultimately unbothered by this latest federal government shutdown today, to say nothing of the negative private-sector payroll report this morning.", "url": "https://www.zacks.com/stock/news/2760532/government-shutdown-government-shmutdown?cid=CS-STOCKNEWSAPI-FT-ahead_of_wall_street-2760532"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 17:55:59", "publisher": "MarketBeat", "title": "Top 3 Dividend Achievers for October: High Yields, Growth Ahead", "image": "https://images.financialmodelingprep.com/news/top-3-dividend-achievers-for-october-high-yields-growth-ahead-20251001.png", "site": "marketbeat.com", "text": "These stocks are attractive investments due to their proven models, stable cash flow, and ability to sustain capital returns, which may also lead to share price increases and capital gains.", "url": "https://www.marketbeat.com/stock-ideas/top-3-dividend-achievers-for-october-high-yields-growth-ahead/"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 17:08:42", "publisher": "The Motley Fool", "title": "Why Pfizer Stock Trounced the Market Today", "image": "https://images.financialmodelingprep.com/news/why-pfizer-stock-trounced-the-market-today-20251001.jpg", "site": "fool.com", "text": "Still basking in the glow of a likely advantageous deal it signed with the government the previous day, Pfizer's (PFE 6.77%) stock was extremely healthy on Hump Day. That positive sentiment was boosted by a positive analyst take, to the point where Pfizer's share price rose by almost 7%.", "url": "https://www.fool.com/investing/2025/10/01/why-pfizer-stock-trounced-the-market-today/"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 16:30:10", "publisher": "Forbes", "title": "Pfizer's Art Of The Deal", "image": "https://images.financialmodelingprep.com/news/pfizers-art-of-the-deal-20251001.jpg", "site": "forbes.com", "text": "President Trump and Pfizer announced a deal to cut drug pricing yeseterday. And it looks like the pharmaceutical giant got the better end of it.", "url": "https://www.forbes.com/sites/alexknapp/2025/10/01/pfizers-art-of-the-deal/"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 15:20:00", "publisher": "Seeking Alpha", "title": "All Cap Investing With Kirk Spano", "image": "https://images.financialmodelingprep.com/news/all-cap-investing-with-kirk-spano-20251001.jpg", "site": "seekingalpha.com", "text": "Kirk Spano runs Margin of Safety Investing and shares what this moment means for all cap investors. Stock picking and options strategies like covered calls and cash-secured puts to generate income and manage risk.", "url": "https://seekingalpha.com/article/4827309-all-cap-investing-with-kirk-spano"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 12:52:16", "publisher": "24/7 Wall Street", "title": "This 6.75%-Yielding Dividend Stock Can Gain 33%", "image": "https://images.financialmodelingprep.com/news/this-675yielding-dividend-stock-can-gain-33-20251001.jpg", "site": "247wallst.com", "text": "Pfizer (NYSE:PFE) shares are finally starting to attract attention after gaining close to 7% in a single trading session on news that it's reached a pricing deal with the Trump administration.", "url": "https://247wallst.com/investing/2025/10/01/this-6-75-yielding-dividend-stock-can-gain-33/"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 12:13:39", "publisher": "Benzinga", "title": "Stock Of The Day: Will Pfizer Head Higher?", "image": "https://images.financialmodelingprep.com/news/stock-of-the-day-will-pfizer-head-higher-20251001.jpeg", "site": "benzinga.com", "text": "Shares of Pfizer Inc.(NYSE:PFE) continue to head higher on Wednesday, a day after the company announced that it has secured a three-year grace period from President Donald Trump's tariffs on pharmaceuticals. This will enable Pfizer to offer its medication at significantly discounted prices compared to current rates.", "url": "https://www.benzinga.com/trading-ideas/technicals/25/10/47974840/stock-of-the-day-will-pfizer-head-higher"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 11:42:09", "publisher": "The Motley Fool", "title": "Pfizer Just Announced a Massive Deal with TrumpRx. Here's What Investors Need to Know", "image": "https://images.financialmodelingprep.com/news/pfizer-just-announced-a-massive-deal-with-trumprx-heres-20251001.jpg", "site": "fool.com", "text": "Pfizer (PFE 5.53%) announced on Tuesday that it had signed an agreement with the White House that will help Americans pay lower prices for prescription drugs and bolster U.S. leadership in biopharmaceutical innovation. The big pharmaceutical company will be involved in a website called \"TrumpRx\" that will help patients find discount prescription drugs and link them to manufacturers' direct-to-consumer websites.", "url": "https://www.fool.com/investing/2025/10/01/pfizer-just-announced-a-massive-deal-with-trumprx/"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 10:49:12", "publisher": "Benzinga", "title": "Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away", "image": "https://images.financialmodelingprep.com/news/pfizers-trumprx-pact-sends-shockwaves-why-unitedhealth-lilly-and-20251001.jpeg", "site": "benzinga.com", "text": "Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office  it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new TrumpRx platform at steep discounts and extend \"most favored nation\" (MFN) pricing to Medicaid, Pfizer bought itself a three-year tariff reprieve and plenty of goodwill.", "url": "https://www.benzinga.com/trading-ideas/long-ideas/25/10/47971458/pfizers-trumprx-pact-sends-shockwaves-why-unitedhealth-lilly-and-cvs-cant-look-away"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 09:55:11", "publisher": "Forbes", "title": "Pfizer Drug-Pricing Deal: More Upside For PFE Stock?", "image": "https://images.financialmodelingprep.com/news/pfizer-drugpricing-deal-more-upside-for-pfe-stock-20251001.jpg", "site": "forbes.com", "text": "Pfizer stock (NYSE: PFE) offers a compelling investment opportunity at its current price of around $25, supported by attractive valuations and recent policy changes that may present further upside potential.", "url": "https://www.forbes.com/sites/greatspeculations/2025/10/01/pfizer-drug-pricing-deal-more-upside-for-pfe-stock/"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 08:56:49", "publisher": "CNBC", "title": "Trump's pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers", "image": "https://images.financialmodelingprep.com/news/trumps-pharmaceutical-tariff-threat-loses-bite-after-pfizer-deal-20251001.jpeg", "site": "cnbc.com", "text": "President Donald Trump's long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer. Trump's agreement with Pfizer included a three-year exemption from pharmaceutical-specific tariffs, so long as the firm further invests in domestic manufacturing.", "url": "https://www.cnbc.com/2025/10/01/trump-pharmaceutical-tariffs-pfizer-deal.html"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 07:41:21", "publisher": "Proactive Investors", "title": "Drug pricing, politics and the cost of doing business in the US", "image": "https://images.financialmodelingprep.com/news/drug-pricing-politics-and-the-cost-of-doing-business-20251001.jpeg", "site": "proactiveinvestors.co.uk", "text": "Drug pricing politics in Washington just took a sharp turn. Pfizer Inc (NYSE:PFE, ETR:PFE)has struck a deal with President Trump to support his Most Favoured Nation (MFN) plan, which links US drug prices to those in other major markets.", "url": "https://www.proactiveinvestors.co.uk/companies/news/1079512"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 07:34:46", "publisher": "CNBC Television", "title": "Pres. Trump's deal with Pfizer is pretty devastating to PBMs and insurance companies: John Lamattina", "image": "https://images.financialmodelingprep.com/news/pres-trumps-deal-with-pfizer-is-pretty-devastating-to-20251001.jpg", "site": "youtube.com", "text": "John Lamattina, PureTech Health senior partner and former Pfizer Global R&D president, joins 'Squawk Box' to discuss President Trump's deal with Pfizer, impact on drug prices, what the deal means for drugmakers, and more.", "url": "https://www.youtube.com/watch?v=uWqXACRNSDE"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 07:09:43", "publisher": "Reuters", "title": "Swiss pharma companies likely to follow Pfizer-U.S. price deal, says business lobby", "image": "https://images.financialmodelingprep.com/news/swiss-pharma-companies-likely-to-follow-pfizerus-price-deal-20251001.jpg", "site": "reuters.com", "text": "Swiss pharma companies are likely to follow Pfizer's price deal with the U.S. following a demand from President Donald Trump's administration for lower drug prices, the head of a major Swiss chemical and pharmaceutical industry association said on Wednesday.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/swiss-pharma-companies-likely-follow-pfizer-us-price-deal-says-business-lobby-2025-10-01/"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 07:00:00", "publisher": "GlobeNewsWire", "title": "C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma", "image": "https://images.financialmodelingprep.com/news/c4-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-20251001.png", "site": "globenewswire.com", "text": "WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO), a B-cell maturation antigen CD3 targeted bispecific antibody (BCMAxCD3 bispecific), to C4T for its upcoming Phase 1b trial.", "url": "https://www.globenewswire.com/news-release/2025/10/01/3159347/0/en/C4-Therapeutics-Announces-Clinical-Trial-Collaboration-and-Supply-Agreement-with-Pfizer-for-the-Combination-of-Cemsidomide-and-Elranatamab-for-the-Treatment-of-Relapsed-Refractory-.html"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 05:10:00", "publisher": "The Motley Fool", "title": "Got $200? 2 Healthcare Stocks to Buy and Hold Forever", "image": "https://images.financialmodelingprep.com/news/got-200-2-healthcare-stocks-to-buy-and-hold-20251001.jpg", "site": "fool.com", "text": "You don't have to invest a fortune to get involved in an industry that could offer your portfolio growth along with safety. I'm talking about the field of healthcare, specifically companies that develop therapeutics.", "url": "https://www.fool.com/investing/2025/10/01/got-200-2-healthcare-stocks-to-buy-hold-forever/"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 03:51:00", "publisher": "The Motley Fool", "title": "3 Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 9.5% -- Which Are No-Brainer Buys in October", "image": "https://images.financialmodelingprep.com/news/3-ultrahighyield-dividend-stocks-sporting-an-average-yield-of-20251001.jpg", "site": "fool.com", "text": "For more than a century, the stock market has reigned supreme as the most-decorated wealth creator. No asset class has come close to matching the average annual return of stocks -- and with thousands of publicly traded companies to choose from, there's likely one or more securities that can help you reach your investment goals.", "url": "https://www.fool.com/investing/2025/10/01/3-ultra-high-yield-dividend-stocks-buy-in-october/"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 03:48:21", "publisher": "Reuters", "title": "European healthcare stocks surge as U.S. Pfizer deal reduces some uncertainty", "image": "https://images.financialmodelingprep.com/news/european-healthcare-stocks-surge-as-us-pfizer-deal-reduces-20251001.jpg", "site": "reuters.com", "text": "European healthcare stocks jumped on Wednesday, a day after Pfizer and U.S. President Donald Trump said the U.S.-based drugmaker agreed to lower prescription drug prices in the Medicaid program in exchange for tariff relief.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/european-healthcare-stocks-surge-us-pfizer-deal-reduces-some-uncertainty-2025-10-01/"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 03:29:57", "publisher": "Proactive Investors", "title": "AstraZeneca and other UK pharma boosted by Trump's first drug discount deal with Pfizer", "image": "https://images.financialmodelingprep.com/news/astrazeneca-and-other-uk-pharma-boosted-by-trumps-first-20251001.jpeg", "site": "proactiveinvestors.co.uk", "text": "Shares in the UK's biggest drug companies led the way on Wednesday, following news overnight that the US government had agreed its first deal on \"most favoured nation\"drug pricing with Pfizer. Topping the FTSE 100,Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF)shares jumped 4% in early trading, withAstraZeneca PLC (LSE:AZN, NASDAQ:AZN)andGSK PLC (LSE:GSK, NYSE:GSK)rising 3.6% and 1.4%.", "url": "https://www.proactiveinvestors.co.uk/companies/news/1079490"}}
{"date": "2025-10-01", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-10-01 02:00:00", "publisher": "PRNewsWire", "title": "Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025", "image": "https://images.financialmodelingprep.com/news/astellas-to-present-pioneering-advances-across-its-portfolio-and-pipeline-20251001.jpg", "site": "prnewswire.com", "text": "- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs - - Results from the EV-303 trial (also known as KEYNOTE-905) in cisplatin-ineligible patients with muscle invasive bladder cancer selected for presentation in an ESMO Presidential Symposium - TOKYO , Oct. 1, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") will present ten abstracts from our portfolio and advancing pipeline at the European Society for Medical Oncology (ESMO) congress taking place from 17-21 October 2025, including new data for PADCEV (enfortumab vedotin) plus pembrolizumab in muscle-invasive bladder cancer (MIBC) which will be presented in an ESMO Presidential Symposium on 18 October. In prostate cancer, we are sharing finalbest-in-class overall survival data for XTANDI (enzalutamide) in high-risk, biochemically recurrent non-metastatic hormone sensitive disease, plus encouraging data for our next-generation bispecific T cell engager ASP2138 in solid tumors, demonstrating continued leadership in CLDN18.2-targeted precision medicine.", "url": "https://www.prnewswire.com/news-releases/astellas-to-present-pioneering-advances-across-its-portfolio-and-pipeline-at-esmo-2025-302571874.html"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 19:43:48", "publisher": "Reuters", "title": "Explainer: What does Trump's deal with Pfizer mean for drug prices?", "image": "https://images.financialmodelingprep.com/news/explainer-what-does-trumps-deal-with-pfizer-mean-for-drug-20250930.jpg", "site": "reuters.com", "text": "President Donald Trump, who has long argued that the U.S. pays more than it should for prescription medicines, on Tuesday said Pfizer had agreed to cut prices for drugs it sells to the Medicaid program for low-income Americans and to ensure the U.S. would not pay more for new medicines than other high-income nations. Trump said he expects other drugmakers to follow suit.", "url": "https://www.reuters.com/legal/litigation/what-does-trumps-deal-with-pfizer-mean-drug-prices-2025-09-30/"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 18:27:37", "publisher": "CNBC Television", "title": "Final Trade: PFE, PPH, CART, NKE", "image": "https://images.financialmodelingprep.com/news/final-trade-pfe-pph-cart-nke-20250930.jpg", "site": "youtube.com", "text": "The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.", "url": "https://www.youtube.com/watch?v=EpxVNGxmyMs"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 18:05:42", "publisher": "Yahoo Finance", "title": "Pfizer strikes deal with the White House to lower drug prices", "image": "https://images.financialmodelingprep.com/news/pfizer-strikes-deal-with-the-white-house-to-lower-20250930.jpg", "site": "youtube.com", "text": "The Trump administration announced a deal with pharmaceutical giant Pfizer (PFE) to lower drug prices while gaining an exemption from the president's tariff policies. Watch President Trump's remarks he delivered on this deal alongside Pfizer CEO Albert Bourla on Tuesday.", "url": "https://www.youtube.com/watch?v=pVzIMyz3NY4"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 16:55:43", "publisher": "Investopedia", "title": "S&P 500 Gains and Losses Today: Pfizer and Merck Jump; Payments Stocks Decline", "image": "https://images.financialmodelingprep.com/news/sp-500-gains-and-losses-today-pfizer-and-merck-20250930.jpg", "site": "investopedia.com", "text": "An agreement with the U.S. government and a favorable regulatory decision in Europe helped lift shares of large drugmakers. Meanwhile, the announcement of a collaboration that will integrate shopping functions into a popular chatbot dragged on several financial technology firms.", "url": "https://www.investopedia.com/s-and-p-500-gains-and-losses-today-pfizer-and-merck-jump-payments-stocks-decline-11821787"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 16:54:05", "publisher": "Yahoo Finance", "title": "Shutdown deadline ticks closer with no deal in sight, Pfizer & Trump ink deal to lower drug prices", "image": "https://images.financialmodelingprep.com/news/shutdown-deadline-ticks-closer-with-no-deal-in-sight-20250930.jpg", "site": "youtube.com", "text": "Market Domination host Josh Lipton breaks down the biggest market stories ahead of the closing bell on September 30, 2025. US lawmakers have failed to compromise on a deal and avert a government shutdown before the October 1 deadline.", "url": "https://www.youtube.com/watch?v=5Ey0vaGXGwo"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 16:38:00", "publisher": "WSJ", "title": "Stocks Post Late Rally After Trump Strikes Deal With Pfizer", "image": "https://images.financialmodelingprep.com/news/stocks-post-late-rally-after-trump-strikes-deal-with-20250930.jpg", "site": "wsj.com", "text": "Gains in pharmaceutical stocks lifted indexes, despite the threat of an imminent government shutdown.", "url": "https://www.wsj.com/finance/stocks/stocks-post-late-rally-after-trump-strikes-deal-with-pfizer-540c12b1"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 15:39:16", "publisher": "CNBC", "title": "Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug", "image": "https://images.financialmodelingprep.com/news/healthy-returns-pfizers-new-obesity-bet-metsera-releases-encouraging-20250930.jpeg", "site": "cnbc.com", "text": "Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.", "url": "https://www.cnbc.com/2025/09/30/healthy-returns-pfizers-new-obesity-bet-metsera-releases-drug-data.html"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 15:19:11", "publisher": "Schaeffers Research", "title": "3 Pharma Stocks Getting an Intraday Trump Bump", "image": "https://images.financialmodelingprep.com/news/3-pharma-stocks-getting-an-intraday-trump-bump-20250930.jpg", "site": "schaeffersresearch.com", "text": "Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed \"TrumpRX.", "url": "https://www.schaeffersresearch.com/content/news/2025/09/30/3-pharma-stocks-getting-an-intraday-trump-bump"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 14:27:00", "publisher": "Market Watch", "title": "Pfizer found a way to boost its ailing stock  agree with Trump on drug pricing", "image": "https://images.financialmodelingprep.com/news/pfizer-found-a-way-to-boost-its-ailing-stock-20250930.jpg", "site": "marketwatch.com", "text": "Pfizer's stock surged after CEO Albert Bourla announces an agreement with the Trump administration aimed at lowering drug prices in the U.S. and removing tariff uncertainty.", "url": "https://www.marketwatch.com/story/pfizer-found-a-way-to-boost-its-ailing-stock-agree-with-trump-on-drug-pricing-219908fa"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 14:11:04", "publisher": "CNBC Television", "title": "What Pfizer's lower drug price agreement may mean for the company", "image": "https://images.financialmodelingprep.com/news/what-pfizers-lower-drug-price-agreement-may-mean-for-the-20250930.jpg", "site": "youtube.com", "text": "CNBC's Angelica Peebles joins \"The Exchange\" to detail Pfizer's agreement with the Trump administration to voluntarily sell its medications at lower prices in the United States.", "url": "https://www.youtube.com/watch?v=vk2l5iG-HKA"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 14:00:02", "publisher": "CNBC Television", "title": "Pfizer CEO: 'The big winner of this deal clearly will be the American patient'", "image": "https://images.financialmodelingprep.com/news/pfizer-ceo-the-big-winner-of-this-deal-clearly-20250930.jpg", "site": "youtube.com", "text": "Pfizer CEO Albert Bourla, speaking in the Oval Office on Tuesday about the company's deal to lower drug prices, said the winner of the deal will \"clearly will be the American patient.\" Bourla said the company satisfied all four of the requests President Trump outlined.", "url": "https://www.youtube.com/shorts/1fSK0AOFBXU"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 13:40:40", "publisher": "Investopedia", "title": "Top Stock Movers Now: Spotify, Pfizer, CoreWeave, Lamb Weston, and More", "image": "https://images.financialmodelingprep.com/news/top-stock-movers-now-spotify-pfizer-coreweave-lamb-weston-20250930.jpg", "site": "investopedia.com", "text": "Major U.S. equities indexes edged lower Tuesday afternoon, as a potential government shutdown loomed.The Dow, S&P 500, and Nasdaq were all slightly lower.", "url": "https://www.investopedia.com/top-stock-movers-now-spotify-pfizer-coreweave-lamb-weston-and-more-11821350"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 13:37:00", "publisher": "Reuters", "title": "US drugmakers rise after Trump announces Pfizer price cuts, promises more deals", "image": "https://images.financialmodelingprep.com/news/us-drugmakers-rise-after-trump-announces-pfizer-price-cuts-20250930.jpg", "site": "reuters.com", "text": "Shares of Pfizer rose about 5% after U.S. President Donald Trump said on Tuesday the drugmaker will cut the price on all of its prescription drugs sold to the Medicaid insurance program and will introduce all new prescription drugs at a \"most favored nation\" price.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-drugmakers-rise-after-trump-announces-pfizer-price-cuts-promises-more-deals-2025-09-30/"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 13:30:25", "publisher": "CNBC Television", "title": "Trump announces agreement with Pfizer to lower Medicaid drug prices", "image": "https://images.financialmodelingprep.com/news/trump-announces-agreement-with-pfizer-to-lower-medicaid-drug-20250930.jpg", "site": "youtube.com", "text": "President Donald Trump on Tuesday announced an agreement with Pfizer to voluntarily sell its medications for less, as his administration pushes to link U.S. drug prices to cheaper ones abroad. Pfizer has agreed to take measures to reduce U.S. drug prices, including selling its existing drugs to Medicaid patients at the lowest price offered in other developed nations, or what Trump calls the most-favored-nation price, according to the president.", "url": "https://www.youtube.com/shorts/qAl0Ew3aNiw"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 13:12:46", "publisher": "Bloomberg Markets and Finance", "title": "Pfizer to Sell Some Drugs in US at 50% Average Discount After Reaching Deal With Trump", "image": "https://images.financialmodelingprep.com/news/pfizer-to-sell-some-drugs-in-us-at-50-20250930.jpg", "site": "youtube.com", "text": "Pfizer will not be subject to President Donald Trump's tariffs on pharmaceuticals for three years. In exchange, the company will sell some products at a 50% average discount on a direct-to-consumer website called TrumpRX.", "url": "https://www.youtube.com/watch?v=ERUd8z77OLs"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 12:46:39", "publisher": "CNBC Television", "title": "Trump: Pfizer agreed to heavily discount prices for some current drugs", "image": "https://images.financialmodelingprep.com/news/trump-pfizer-agreed-to-heavily-discount-prices-for-some-20250930.jpg", "site": "youtube.com", "text": "President Donald Trump speaks from the Oval Office to announce that Pfizer has agreed to take measures to lower U.S. drug prices, including selling its existing drugs to Medicaid patients at the lowest price offered in other developed nations.", "url": "https://www.youtube.com/watch?v=SwovmQoVyUo"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 12:45:00", "publisher": "Business Wire", "title": "Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients", "image": "https://images.financialmodelingprep.com/news/pfizer-reaches-landmark-agreement-with-us-government-to-lower-20250930.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced a historic agreement with the Trump Administration that will ensure U.S. patients pay lower prices for their prescription medicines while strengthening America's role as the global leader in biopharmaceutical innovation. In response to the four points covered in the President's July 31st letter, Pfizer has voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in o.", "url": "https://www.businesswire.com/news/home/20250930776824/en/Pfizer-Reaches-Landmark-Agreement-with-U.S.-Government-to-Lower-Drug-Costs-for-American-Patients/"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 12:16:25", "publisher": "Business Insider", "title": "Trump announces 'TrumpRx' drug-buying website alongside Pfizer CEO", "image": "https://images.financialmodelingprep.com/news/trump-announces-trumprx-drugbuying-website-alongside-pfizer-ceo-20250930.jpeg", "site": "businessinsider.com", "text": "Donald Trump announced a new government website for buying prescription drugs on Tuesday. The website will allow people to buy prescription drugs via a government website.", "url": "https://www.businessinsider.com/trumprx-website-announcement-white-house-pfizer-ceo-2025-9"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 12:16:04", "publisher": "Seeking Alpha", "title": "7 Ideal \"Safer\" Dividend Buys From 61 September Graham Value All-Stars (GVAS)", "image": "https://images.financialmodelingprep.com/news/7-ideal-safer-dividend-buys-from-61-september-graham-20250930.jpg", "site": "seekingalpha.com", "text": "The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-priced GASV DogsET, MPLX, YRD, VZ, BMY, BBVA, and MFCare highlighted as buyable for September 2025. Top ten GASV stocks are projected by analysts to deliver average net gains of 26.84% by September 2026, with Energy Transfer (ET) leading at 35.43%.", "url": "https://seekingalpha.com/article/4826955-7-ideal-safer-dividend-buys-from-61-september-graham-value-all-stars-gvas"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 12:13:52", "publisher": "Proactive Investors", "title": "Pfizer first to offer 'major discounts' to US customers via govt website, says Trump", "image": "https://images.financialmodelingprep.com/news/pfizer-first-to-offer-major-discounts-to-us-customers-20250930.jpeg", "site": "proactiveinvestors.com", "text": "Pfizer Inc (NYSE:PFE, ETR:PFE)shares jumped 3.5% after Donald Trump said the drugmaker would be the first company offeringlower prices on its prescription drugs. Under a new agreement with the White House, the company will offer \"major discounts\" under the \"most favoured nation\"drug pricing order established earlier this year.", "url": "https://www.proactiveinvestors.com/companies/news/1079461"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 12:01:59", "publisher": "The Motley Fool", "title": "Why Pfizer Stock Just Popped", "image": "https://images.financialmodelingprep.com/news/why-pfizer-stock-just-popped-20250930.jpg", "site": "fool.com", "text": "Pfizer (PFE 3.77%) stock was trading 3.6% higher as of 12:01 p.m. ET Tuesday after The Washington Post reported that the Trump administration had struck a deal with the pharmaceutical giant under which it will sell some drugs to Medicaid patients at reduced prices.", "url": "https://www.fool.com/investing/2025/09/30/why-pfizer-stock-just-popped/"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 11:45:01", "publisher": "CNBC Television", "title": "Trump, Pfizer to announce agreement to lower Medicaid drug prices", "image": "https://images.financialmodelingprep.com/news/trump-pfizer-to-announce-agreement-to-lower-medicaid-drug-20250930.jpg", "site": "youtube.com", "text": "President Donald Trump on Tuesday will announce an agreement with Pfizer to voluntarily sell its medications for less, as his administration pushes to link U.S. drug prices to cheaper ones abroad, CNBC's Angelica Peebles reports.", "url": "https://www.youtube.com/shorts/OF_vXyi9IAo"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 11:05:31", "publisher": "CNBC Television", "title": "President Trump to announce drug-pricing deal with Pfizer", "image": "https://images.financialmodelingprep.com/news/president-trump-to-announce-drugpricing-deal-with-pfizer-20250930.jpg", "site": "youtube.com", "text": "CNBC's Eamon Javers joins 'Squawk on the Street' with the latest news.", "url": "https://www.youtube.com/watch?v=gJoHslqun7M"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 11:02:00", "publisher": "Barrons", "title": "Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.", "image": "https://images.financialmodelingprep.com/news/metsera-posts-promising-weightloss-drug-results-it-could-be-20250930.jpg", "site": "barrons.com", "text": "Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.", "url": "https://www.barrons.com/articles/metsera-stock-pfizer-weight-loss-drug-results-dd23f044"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 10:31:48", "publisher": "Reuters", "title": "Trump to announce Pfizer drug price cuts", "image": "https://images.financialmodelingprep.com/news/trump-to-announce-pfizer-drug-price-cuts-20250930.jpg", "site": "reuters.com", "text": "President Donald Trump will announce on Tuesday that Pfizer plans to lower prices on several of its medications in the United States, a White House official said.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/trump-announce-pfizer-drug-price-cuts-2025-09-30/"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 10:28:10", "publisher": "CNBC", "title": "Trump, Pfizer to announce agreement to lower drug prices", "image": "https://images.financialmodelingprep.com/news/trump-pfizer-to-announce-agreement-to-lower-drug-prices-20250930.jpeg", "site": "cnbc.com", "text": "President Donald Trump will announce an agreement with Pfizer to voluntarily sell its medications at lower prices, as his administration pushes to link U.S. drug prices to the cheaper prices paid abroad. In this article PFE", "url": "https://www.cnbc.com/2025/09/30/trump-pfizer-drug-price-agreement.html"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 10:08:00", "publisher": "WSJ", "title": "White House to Announce TrumpRx' Drug-Buying Website, and Deal With Pfizer", "image": "https://images.financialmodelingprep.com/news/white-house-to-announce-trumprx-drugbuying-website-and-deal-20250930.jpg", "site": "wsj.com", "text": "President Trump is expected to unveil the measures with Pfizer's CEO on Tuesday", "url": "https://www.wsj.com/health/pharma/white-house-to-announce-trumprx-drug-buying-website-and-deal-with-pfizer-8c42e5cb"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 10:06:52", "publisher": "Reuters", "title": "Trump to announce deal with Pfizer to sell drugs at lower prices, Washington Post reports", "image": "https://images.financialmodelingprep.com/news/trump-to-announce-deal-with-pfizer-to-sell-drugs-20250930.jpg", "site": "reuters.com", "text": "U.S. President Donald Trump will announce an agreement with Pfizer on Tuesday to voluntarily sell the company's medications through Medicaid at lower prices, the Washington Post reported on Tuesday, citing sources.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/trump-announce-deal-with-pfizer-sell-drugs-lower-prices-washington-post-reports-2025-09-30/"}}
{"date": "2025-09-30", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-30 04:00:00", "publisher": "The Motley Fool", "title": "Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out", "image": "https://images.financialmodelingprep.com/news/pfizer-just-reminded-investors-why-you-should-never-count-20250930.jpg", "site": "fool.com", "text": "Pfizer (PFE 0.32%)'s stock just can't seem to get out of a tailspin. It faces question marks about its future growth, and investors have effectively given up on it.", "url": "https://www.fool.com/investing/2025/09/30/pfizer-remind-investors-why-not-count-stock/"}}
{"date": "2025-09-29", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-29 15:16:01", "publisher": "Seeking Alpha", "title": "Pfizer Is Likely To Pass The Drug Import Tariff Stress Test", "image": "https://images.financialmodelingprep.com/news/pfizer-is-likely-to-pass-the-drug-import-tariff-20250929.jpg", "site": "seekingalpha.com", "text": "President Trump's new 100% tariff on imported drugs creates a major new risk for the pharma sector. While competitors announce flashy, multi-billion-dollar U.S. investment plans, Pfizer appears vague in comparison. We argue this perception is misleading and overlooks the company's core strategic advantage. A deep dive into Pfizer's existing manufacturing footprint and management's plan to onshore new technologies reveals a powerful and underappreciated case for a tariff exemption.", "url": "https://seekingalpha.com/article/4826696-pfizer-likely-to-pass-drug-import-tariff-stress-test"}}
{"date": "2025-09-29", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-29 13:15:09", "publisher": "Seeking Alpha", "title": "3 Of My Favorite Biotech Stocks Under $10", "image": "https://images.financialmodelingprep.com/news/3-of-my-favorite-biotech-stocks-under-10-20250929.jpg", "site": "seekingalpha.com", "text": "Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.", "url": "https://seekingalpha.com/article/4826668-3-of-my-favorite-biotech-stocks-under-10"}}
{"date": "2025-09-29", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-29 10:01:24", "publisher": "Zacks Investment Research", "title": "Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock", "image": "https://images.financialmodelingprep.com/news/here-is-what-to-know-beyond-why-pfizer-inc-20250929.jpg", "site": "zacks.com", "text": "Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.", "url": "https://www.zacks.com/stock/news/2758704/here-is-what-to-know-beyond-why-pfizer-inc-pfe-is-a-trending-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2758704"}}
{"date": "2025-09-29", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-29 03:43:00", "publisher": "The Motley Fool", "title": "3 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income", "image": "https://images.financialmodelingprep.com/news/3-highyield-dividend-stocks-to-buy-now-for-a-lifetime-20250929.jpg", "site": "fool.com", "text": "Investors seeking passive income sources that grow steadily have a few interesting options to choose from right now. Shares of Brookfield Infrastructure Corp. (BIPC 2.58%), Realty Income (O 0.83%), and Pfizer (PFE 0.64%) are offering a rare combination of high yields and steady payout raises.", "url": "https://www.fool.com/investing/2025/09/29/3-high-yield-dividend-stocks-to-buy-now-for-a-life/"}}
{"date": "2025-09-28", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-28 13:28:00", "publisher": "The Motley Fool", "title": "Why Pfizer's Post-COVID Future Looks Brighter Than Ever", "image": "https://images.financialmodelingprep.com/news/why-pfizers-postcovid-future-looks-brighter-than-ever-20250928.jpg", "site": "fool.com", "text": "It's been a rough few years to be a Pfizer (PFE 0.68%) shareholder. Shares of the big pharma stock are down about 61% from a peak they set in late 2021.", "url": "https://www.fool.com/investing/2025/09/28/why-pfizers-post-covid-future-looks-brighter-than/"}}
{"date": "2025-09-28", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-28 11:15:58", "publisher": "Investors Business Daily", "title": "BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival", "image": "https://images.financialmodelingprep.com/news/bridgebio-up-80-this-year-just-unveiled-promising-news-20250928.jpg", "site": "investors.com", "text": "BridgeBio Pharma said Sunday its heart-disease drug, Attruby, cut the risk of death almost in half in an exploratory study.", "url": "https://www.investors.com/news/technology/bridgebio-attruby-acoramidis-cardiovascular-outcomes/"}}
{"date": "2025-09-28", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-28 10:58:00", "publisher": "The Motley Fool", "title": "Down 55%, Should You Buy the Dip on Pfizer?", "image": "https://images.financialmodelingprep.com/news/down-55-should-you-buy-the-dip-on-pfizer-20250928.jpg", "site": "fool.com", "text": "Pfizer (PFE 0.64%) has a huge 7.1% dividend yield. That certainly compares favorably to the broader market's 1.2% yield and the average healthcare stock's yield of 1.7%.", "url": "https://www.fool.com/investing/2025/09/28/down-55-should-you-buy-the-dip-on-pfizer/"}}
{"date": "2025-09-28", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-28 10:10:05", "publisher": "Seeking Alpha", "title": "Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs", "image": "https://images.financialmodelingprep.com/news/buy-7-barrons-better-bets-than-tbills-from-15-safer-20250928.jpg", "site": "seekingalpha.com", "text": "Seven of the top fifteen Barron's Better Bets (BBB) dividend 'dogs' - including CAG, PFE, VZ, BMY, UDR, KIM, and KEY - are attractively priced for income investors. Analyst forecasts project 17.61% to 34.78% net gains for top-ten BBB dogs by September 2026, with an average estimated gain of 23.96% and lower-than-market volatility. Five of the lowest-priced, highest-yield BBB stocks - CAG, PFE, VZ, BMY, and LYB - are expected to outperform higher-priced peers, offering a 16.89% advantage in projected returns.", "url": "https://seekingalpha.com/article/4826464-buy-7-barrons-better-bets-than-t-bills-from-15-safer-of-23-september-dividend-dogs"}}
{"date": "2025-09-28", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-28 10:00:00", "publisher": "The Motley Fool", "title": "5 Dividend Powerhouses to Buy and Never Sell", "image": "https://images.financialmodelingprep.com/news/5-dividend-powerhouses-to-buy-and-never-sell-20250928.jpg", "site": "fool.com", "text": "Here's a statistic that should reshape how you think about investing: Companies that consistently raise dividends have crushed the S&P 500 by 2.5 percentage points annually since 1972. Not tech highfliers.", "url": "https://www.fool.com/investing/2025/09/28/5-dividend-powerhouses-to-buy-and-never-sell/"}}
{"date": "2025-09-27", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-27 08:15:00", "publisher": "The Motley Fool", "title": "Is Pfizer Stock a Buy After Its $5 Billion GLP-1 Bet?", "image": "https://images.financialmodelingprep.com/news/is-pfizer-stock-a-buy-after-its-5-billion-glp1-20250927.jpeg", "site": "fool.com", "text": "The GLP-1 market has grabbed considerable attention in the past couple of years, and there's little doubt as to which pharmaceutical companies dominate this space. Eli Lilly is currently the leader, followed closely by Novo Nordisk.", "url": "https://www.fool.com/investing/2025/09/27/is-pfizer-stock-a-buy-after-5-billion-glp-1-bet/"}}
{"date": "2025-09-27", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-27 06:45:00", "publisher": "The Motley Fool", "title": "3 Magnificent Stocks Under $100 to Buy Right Now", "image": "https://images.financialmodelingprep.com/news/3-magnificent-stocks-under-100-to-buy-right-now-20250927.jpg", "site": "fool.com", "text": "Share price has nothing to do with whether a stock is fairly valued. However, it is nonetheless an important consideration for investors on tight budgets.", "url": "https://www.fool.com/investing/2025/09/27/3-magnificent-stocks-under-100-to-buy-right-now/"}}
{"date": "2025-09-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-26 16:33:03", "publisher": "MarketBeat", "title": "Pfizer is Locking in New Growth Through a New Acquisition", "image": "https://images.financialmodelingprep.com/news/pfizer-is-locking-in-new-growth-through-a-new-acquisition-20250926.jpg", "site": "marketbeat.com", "text": "In the United States'healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug manufacturing and distribution businesses are all the hype for this new growth wave taking over the industry.", "url": "https://www.marketbeat.com/stock-ideas/pfizer-is-locking-in-new-growth-through-a-new-acquisition/"}}
{"date": "2025-09-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-26 08:45:00", "publisher": "The Motley Fool", "title": "Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?", "image": "https://images.financialmodelingprep.com/news/did-pfizer-just-give-investors-7-billion-reasons-to-20250926.jpg", "site": "fool.com", "text": "In the pharmaceutical world, if you can't develop 'em, acquire 'em. That seems to be the philosophy behind Pfizer's (PFE -1.97%) latest big-ticket buy, specifically its purchase of clinical-stage biotech Metsera (MTSR 0.10%), which it announced on Monday.", "url": "https://www.fool.com/investing/2025/09/26/did-pfizer-just-give-investors-7-billion-reasons/"}}
{"date": "2025-09-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-26 08:15:00", "publisher": "Barrons", "title": "Eli Lilly, Pfizer Stocks Rise After Trump's 100% Pharma Tariff Threat. Here's Why.", "image": "https://images.financialmodelingprep.com/news/eli-lilly-pfizer-stocks-rise-after-trumps-100-pharma-20250926.jpg", "site": "barrons.com", "text": "Trump's threat of a 100% tariff on imported branded or patented drugs sounds dramatic, yet, pharma stocks were mostly in the green as the past few months have already seen a flurry of companies announcing plans to invest in the U.S.", "url": "https://www.barrons.com/articles/eli-lilly-pfizer-stock-trump-pharma-tariffs-2b9ddfb7"}}
{"date": "2025-09-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-26 05:45:00", "publisher": "The Motley Fool", "title": "2 Top Passive Income Stocks to Buy Now", "image": "https://images.financialmodelingprep.com/news/2-top-passive-income-stocks-to-buy-now-20250926.jpg", "site": "fool.com", "text": "Building passive income is one of the most reliable ways to secure financial freedom. Instead of relying on active work for every paycheck, investors can put their money to work in dividend-paying stocks that send regular cash distributions straight to their brokerage accounts.", "url": "https://www.fool.com/investing/2025/09/26/2-top-passive-income-stocks-to-buy-now/"}}
{"date": "2025-09-26", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-26 03:50:00", "publisher": "The Motley Fool", "title": "3 Absurdly Cheap Stocks You Can Buy for Less than $100 Right Now", "image": "https://images.financialmodelingprep.com/news/3-absurdly-cheap-stocks-you-can-buy-for-less-20250926.jpg", "site": "fool.com", "text": "Want to invest in some low-priced stocks that possess a lot of upside in the long run? The stocks listed below could be great options for bargain hunters, as each one trades at less than $100 per share and is deeply undervalued.", "url": "https://www.fool.com/investing/2025/09/26/absurdly-cheap-stocks-you-can-buy-nvo-pfe-tgt/"}}
{"date": "2025-09-25", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-25 15:37:00", "publisher": "Business Wire", "title": "Hearing Against Pfizer Set For 29 September In Contraceptive Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio", "image": "https://images.financialmodelingprep.com/news/hearing-against-pfizer-set-for-29-september-in-contraceptive-20250925.jpg", "site": "businesswire.com", "text": "PENSACOLA, Fla.--(BUSINESS WIRE)--A hearing in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Monday, 29 September at 9:00am CT in the United States Courthouse in Pensacola, Florida. The hearing will address oral arguments from the plaintiffs and defendants concerning the issue of pre-emption. The pre-emption defence is common in drug litigation. It involves the drug manufacturer arguing that they cannot be sued for failure to warn under state law, because chang.", "url": "https://www.businesswire.com/news/home/20250925193009/en/Hearing-Against-Pfizer-Set-For-29-September-In-Contraceptive-%E2%80%98Depo-Provera%E2%80%99-Multidistrict-Litigation-Overseen-By-Levin-Papantonio/"}}
{"date": "2025-09-25", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-25 15:22:34", "publisher": "Seeking Alpha", "title": "Pfizer: Invest For The Yield, Not The Weight-Loss Drug Chase", "image": "https://images.financialmodelingprep.com/news/pfizer-invest-for-the-yield-not-the-weightloss-drug-20250925.jpg", "site": "seekingalpha.com", "text": "Pfizer Inc. is acquiring Metsera for up to $7.2 billion, aiming to enter the weight-loss drug market despite late-stage entry and no ongoing Phase 3 trials. PFE's acquisition targets GLP-1-based obesity drugs but faces stiff competition from established players like Eli Lilly and Novo Nordisk and promising biotechs like Viking Therapeutics. The stock offers a compelling 7% dividend yield, supported by cost-saving initiatives and stable oncology/vaccine growth, despite declining Covid vaccine sales.", "url": "https://seekingalpha.com/article/4825980-pfizer-invest-for-the-yield-not-the-weight-loss-drug-chase"}}
{"date": "2025-09-25", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-25 09:30:00", "publisher": "The Motley Fool", "title": "Does This Acquisition Make Pfizer Stock a Great Buy?", "image": "https://images.financialmodelingprep.com/news/does-this-acquisition-make-pfizer-stock-a-great-buy-20250925.jpg", "site": "fool.com", "text": "Remember Pfizer (PFE -0.46%), the giant pharmaceutical company that developed a COVID-19 vaccine within weeks of the pandemic hitting U.S. shores and got it approved within a year? It was the fastest vaccine development in history and a miracle of modern science.", "url": "https://www.fool.com/investing/2025/09/25/does-this-acquisition-make-pfizer-stock-great-buy/"}}
{"date": "2025-09-25", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-25 06:45:00", "publisher": "Business Wire", "title": "Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025", "image": "https://images.financialmodelingprep.com/news/pfizer-highlights-momentum-in-redefining-standards-of-care-in-20250925.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--ESMO Curtain Raiser.", "url": "https://www.businesswire.com/news/home/20250925011729/en/Pfizer-Highlights-Momentum-in-Redefining-Standards-of-Care-in-Cancer-at-ESMO-2025/"}}
{"date": "2025-09-25", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-25 05:00:00", "publisher": "The Motley Fool", "title": "3 Top Dividend Stocks to Buy and Hold Forever", "image": "https://images.financialmodelingprep.com/news/3-top-dividend-stocks-to-buy-and-hold-forever-20250925.jpg", "site": "fool.com", "text": "Dividends have quietly driven the bulk of stock market returns for over a century. While share prices grab headlines, reinvested dividends account for the majority of total returns in global equity markets since 1900.", "url": "https://www.fool.com/investing/2025/09/25/3-top-dividend-stocks-to-buy-and-hold-forever/"}}
{"date": "2025-09-25", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-25 04:12:00", "publisher": "The Motley Fool", "title": "Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.", "image": "https://images.financialmodelingprep.com/news/pfizer-is-buying-weight-loss-biotech-metsera-heres-why-20250925.jpg", "site": "fool.com", "text": "Weight loss drugs have represented an enormous growth area for biotech and pharma companies over the past couple of years. Pharma giants Eli Lilly and Novo Nordisk dominate the market with their drugs and have brought in billions of dollars in revenue as demand skyrocketed.", "url": "https://www.fool.com/investing/2025/09/25/pfizer-is-buying-weight-loss-biotech-metsera-heres/"}}
{"date": "2025-09-24", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-24 07:45:00", "publisher": "The Motley Fool", "title": "The Smartest Dividend Stock to Buy With $1,000 Right Now", "image": "https://images.financialmodelingprep.com/news/the-smartest-dividend-stock-to-buy-with-1000-right-20250924.jpg", "site": "fool.com", "text": "The winds of political change have hit the healthcare industry, with drug makers seemingly taking the brunt of the gale. Industry-leading companies like Pfizer (PFE 0.33%), Merck (MRK -0.63%), and Bristol Myers Squibb (BMY -0.31%) have seen their stocks fall and their yields rise.", "url": "https://www.fool.com/investing/2025/09/24/the-smartest-dividend-stock-to-buy-with-1000-right/"}}
{"date": "2025-09-24", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-24 06:35:00", "publisher": "The Motley Fool", "title": "Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?", "image": "https://images.financialmodelingprep.com/news/should-you-forget-pfizer-and-buy-these-unstoppable-stocks-20250924.jpg", "site": "fool.com", "text": "Pfizer (PFE 0.33%) is highly likely to survive the current headwinds it faces in the pharmaceutical sector. It has a long history and a strong core business.", "url": "https://www.fool.com/investing/2025/09/24/should-you-forget-pfizer-and-buy-these-unstoppable/"}}
{"date": "2025-09-24", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-24 03:55:00", "publisher": "The Motley Fool", "title": "Where Will Pfizer Be in 5 Years?", "image": "https://images.financialmodelingprep.com/news/where-will-pfizer-be-in-5-years-20250924.jpg", "site": "fool.com", "text": "A few years ago, Pfizer (PFE 0.33%) saw revenue soar to record heights thanks to coronavirus-related sales, from its vaccine Comirnaty and its treatment Paxlovid. On top of this, the company's blockbuster drugs in other treatment areas were going strong.", "url": "https://www.fool.com/investing/2025/09/24/where-will-pfizer-be-in-5-years/"}}
{"date": "2025-09-23", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-23 19:56:05", "publisher": "Zacks Investment Research", "title": "Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?", "image": "https://images.financialmodelingprep.com/news/time-to-buy-pfizer-pfe-or-metsera-mtsr-stock-20250923.jpg", "site": "zacks.com", "text": "Making a major move in the obesity drug market, Pfizer (PFE) announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR).", "url": "https://www.zacks.com/stock/news/2756071/time-to-buy-pfizer-pfe-or-metsera-mtsr-stock?cid=CS-STOCKNEWSAPI-FT-stocks_in_the_news-2756071"}}
{"date": "2025-09-23", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-23 18:00:00", "publisher": "Business Wire", "title": "METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR", "image": "https://images.financialmodelingprep.com/news/metsera-investor-alert-by-the-former-attorney-general-of-20250923.jpg", "site": "businesswire.com", "text": "NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale Metsera, Inc. (NasdaqGS: MTSR) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Metsera will receive $47.50 per share in cash at closing, plus a non-transferable contingent value right entitling holders to potential additional payments of up to $22.50 per sh.", "url": "https://www.businesswire.com/news/home/20250923592889/en/METSERA-INVESTOR-ALERT-by-the-Former-Attorney-General-of-Louisiana-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-Metsera-Inc.---MTSR/"}}
{"date": "2025-09-23", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-23 13:21:17", "publisher": "Zacks Investment Research", "title": "Can PFE Successfully Return to the Obesity Space With Metsera Buyout?", "image": "https://images.financialmodelingprep.com/news/can-pfe-successfully-return-to-the-obesity-space-with-metsera-20250923.jpg", "site": "zacks.com", "text": "Pfizer strikes a $4.9B deal for Metsera, adding obesity drug candidates to its pipeline after scrapping danuglipron.", "url": "https://www.zacks.com/stock/news/2755892/can-pfe-successfully-return-to-the-obesity-space-with-metsera-buyout?cid=CS-STOCKNEWSAPI-FT-analyst_blog|quick_take-2755892"}}
{"date": "2025-09-23", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-23 10:47:26", "publisher": "Proactive Investors", "title": "Pfizer's Metsera buy raises competitive heat for Novo Nordisk", "image": "https://images.financialmodelingprep.com/news/pfizers-metsera-buy-raises-competitive-heat-for-novo-nordisk-20250923.jpeg", "site": "proactiveinvestors.co.uk", "text": "UBS has warned that Pfizer Inc's (NYSE:PFE, ETR:PFE)$7.3 billion acquisition of Metsera will sharpen competition for Novo Nordisk (NYSE:NVO) in the fast-growing obesity drug market, particularly towards the end of the decade. The bank kept its 'neutral' rating on Novo shares with a DKr340 price target, implying 12.5% downside from the current level.", "url": "https://www.proactiveinvestors.co.uk/companies/news/1078981"}}
{"date": "2025-09-23", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-23 07:12:15", "publisher": "24/7 Wall Street", "title": "Boomers Are Buying Our Safe High-Yield Dividend Picks for September Hand-Over-Fist", "image": "https://images.financialmodelingprep.com/news/boomers-are-buying-our-safe-highyield-dividend-picks-for-20250923.jpg", "site": "247wallst.com", "text": "Investors love dividend stocks, especially high-yield varieties, because they offer a significant income stream and have substantial total return potential.", "url": "https://247wallst.com/investing/2025/09/23/boomers-are-buying-our-safe-high-yield-dividend-picks-for-september-hand-over-fist/"}}
{"date": "2025-09-23", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-23 04:00:00", "publisher": "The Motley Fool", "title": "3 High-Yielding Dividend Stocks to Buy and Hold for the Long Haul -- Including United Parcel Service (UPS) and Pfizer", "image": "https://images.financialmodelingprep.com/news/3-highyielding-dividend-stocks-to-buy-and-hold-for-20250923.jpg", "site": "fool.com", "text": "It makes a lot of sense to seek dividend-paying stocks for your portfolio. That income, after all, can be reinvested into more shares of stock, and healthy dividend payers tend to increase their payouts over time, too.", "url": "https://www.fool.com/investing/2025/09/23/3-high-yielding-dividend-stocks-to-buy-and-hold-fo/"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 14:50:48", "publisher": "Fast Company", "title": "Pfizer bets $7.3 billion on obesity drugs with Metsera buy", "image": "https://images.financialmodelingprep.com/news/pfizer-bets-73-billion-on-obesity-drugs-with-metsera-20250922.jpg", "site": "fastcompany.com", "text": "Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications for obesity and cardiometabolic diseases, in a deal valued at as much as $7.3 billion.", "url": "https://www.fastcompany.com/91408265/pfizer-obesity-drugs-metsera-buy"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 14:01:23", "publisher": "CNBC Television", "title": "BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity", "image": "https://images.financialmodelingprep.com/news/bmos-seigerman-on-pfizermetsera-deal-bullish-as-weve-waited-on-20250922.jpg", "site": "youtube.com", "text": "Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'The Exchange' to discuss Pfizer's obesity drug prospects, competitors and much more.", "url": "https://www.youtube.com/watch?v=0zKdxwQtn_g"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 13:33:48", "publisher": "Seeking Alpha", "title": "Pfizer Inc. (PFE) M&A Call Transcript", "image": "https://images.financialmodelingprep.com/news/pfizer-inc-pfe-ma-call-transcript-20250922.png", "site": "seekingalpha.com", "text": "Pfizer Inc. (NYSE:PFE ) M&A Call September 22, 2025 8:00 AM EDT Company Participants Francesca DeMartino - Chief Investor Relations Officer Chris Boshoff - Chief Scientific Officer and President of Research & Development Andrew Baum - Chief Strategy & Innovation Officer, Executive VP Jim List Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division David Risinger - Leerink Partners LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Umer Raffat - Evercore ISI Institutional Equities, Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Terence Flynn - Morgan Stanley, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Rajesh Kumar - HSBC Global Investment Research Courtney Breen - Sanford C.", "url": "https://seekingalpha.com/article/4824826-pfizer-inc-pfe-m-and-a-call-transcript"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 13:28:03", "publisher": "The Motley Fool", "title": "Why Pfizer Stock Just Popped", "image": "https://images.financialmodelingprep.com/news/why-pfizer-stock-just-popped-20250922.jpg", "site": "fool.com", "text": "Pfizer (PFE 0.56%), the one-time COVID vaccine hero turned Ozempic craze zero, is marching higher Monday after announcing it will try to recover from its danuglipron setback by buying another drug company with weight loss dreams.", "url": "https://www.fool.com/investing/2025/09/22/why-pfizer-stock-just-popped/"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 12:20:00", "publisher": "GlobeNewsWire", "title": "Johnson Fistel Investigates Fairness of Proposed Sale of Metsera", "image": "https://images.financialmodelingprep.com/news/johnson-fistel-investigates-fairness-of-proposed-sale-of-metsera-20250922.jpeg", "site": "globenewswire.com", "text": "SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached their fiduciary duties in connection with the proposed sale of the Company to Pfizer, Inc. (NYSE: PFE).", "url": "https://www.globenewswire.com/news-release/2025/09/22/3154160/0/en/Johnson-Fistel-Investigates-Fairness-of-Proposed-Sale-of-Metsera.html"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 11:08:28", "publisher": "Schaeffers Research", "title": "Pfizer Stock Higher on Multi-Billion Dollar Metsera Buyout", "image": "https://images.financialmodelingprep.com/news/pfizer-stock-higher-on-multibillion-dollar-metsera-buyout-20250922.jpg", "site": "schaeffersresearch.com", "text": "Pfizer Inc(NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after thepharma giantrevealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion.", "url": "https://www.schaeffersresearch.com/content/news/2025/09/22/pfizer-stock-higher-on-multi-billion-dollar-metsera-buyout"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 09:49:03", "publisher": "Proactive Investors", "title": "Pfizer acquires Metsera in $7.3B deal to boost obesity drug pipeline", "image": "https://images.financialmodelingprep.com/news/pfizer-acquires-metsera-in-73b-deal-to-boost-obesity-20250922.jpg", "site": "proactiveinvestors.com", "text": "Pfizer Inc (NYSE:PFE, ETR:PFE)on Monday announced that it willacquireMetsera, Inc (NASDAQ: MTSR), a weight-loss drug developer,in a deal valued at up to $7.3 billion, or$47.50 per share in cash. Metserais also eligible to receive anadditional$22.50 per share contingent on the achievement of certain performance milestones.", "url": "https://www.proactiveinvestors.com/companies/news/1078913"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 09:16:09", "publisher": "Investopedia", "title": "Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal", "image": "https://images.financialmodelingprep.com/news/pfizer-jumps-into-weightloss-drug-segment-with-73-billion-20250922.jpg", "site": "investopedia.com", "text": "Metsera (MTSR) shares skyrocketed 60% in premarket trading after Pfizer (PFE) agreed to purchase the biopharma firm for up to $7.3 billion to jump into the lucrative weight-loss drug segment. Shares of Pfizer were up slightly.", "url": "https://www.investopedia.com/pfizer-jumps-into-weight-loss-drug-segment-with-7-3-billion-metsera-deal-11814311"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 09:09:33", "publisher": "Benzinga", "title": "Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal", "image": "https://images.financialmodelingprep.com/news/pfizer-tries-to-revitalize-obesity-portfolio-with-5-billion-20250922.jpg", "site": "benzinga.com", "text": "Pfizer Inc. PFE on Monday agreed to acquire Metsera, Inc. MTSR to accelerate the next generation of medicines for obesity and cardiometabolic diseases.", "url": "https://www.benzinga.com/m-a/25/09/47787042/pfizer-tries-to-revitalize-obesity-portfolio-with-5-billion-matsera-deal"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 08:59:20", "publisher": "CNBC", "title": "Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera", "image": "https://images.financialmodelingprep.com/news/pfizer-boosts-obesity-drug-prospects-with-73-billion-deal-20250922.jpeg", "site": "cnbc.com", "text": "Pfizer said it would acquire weight loss biotech Metsera in a deal valued at up to $7.3 billion, including future payments, as it scrambles to win a slice in the booming obesity drug market. The move comes after a string of setbacks for Pfizer on the obesity front, including a decision to scrap its own lead obesity pill in April due to safety concerns.", "url": "https://www.cnbc.com/2025/09/22/pfizer-to-buy-weight-loss-drug-developer-metsera.html"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 08:30:00", "publisher": "The Motley Fool", "title": "3 Dirt-Cheap Stocks to Buy Right Now", "image": "https://images.financialmodelingprep.com/news/3-dirtcheap-stocks-to-buy-right-now-20250922.jpg", "site": "fool.com", "text": "The major market indexes are bumping against all-time highs. It's not surprising, therefore, that many stocks are trading at steep valuations.", "url": "https://www.fool.com/investing/2025/09/22/3-dirt-cheap-stocks-to-buy-right-now/"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 08:14:00", "publisher": "Market Watch", "title": "Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal", "image": "https://images.financialmodelingprep.com/news/pfizer-makes-a-49-billion-bet-on-obesity-drugs-20250922.jpg", "site": "marketwatch.com", "text": "Metsera's shareholders could see significant bonuses if certain milestones are reached.", "url": "https://www.marketwatch.com/story/pfizer-makes-a-4-9-billion-bet-on-obesity-drugs-with-metsera-buyout-deal-273003e4"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 08:05:00", "publisher": "FXEmpire", "title": "Nasdaq 100 and S&P500: Intel Weakens, Metsera Spikes 59% on Pfizer Deal, Fed in Spotlight", "image": "https://images.financialmodelingprep.com/news/nasdaq-100-and-sp500-intel-weakens-metsera-spikes-59-on-20250922.jpg", "site": "fxempire.com", "text": "Dow, S&P500 futures pull back today as Metsera pops 59%, Intel drops, and markets question whether Fed policy will match rate cut forecasts.", "url": "https://www.fxempire.com/forecasts/article/nasdaq-100-and-sp500-intel-weakens-metsera-spikes-59-on-pfizer-deal-fed-in-spotlight-1550013"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 07:42:00", "publisher": "Barrons", "title": "This Anti-Obesity Stock Jumps 60% on $7.3 Billion Bid by Pfizer", "image": "https://images.financialmodelingprep.com/news/this-antiobesity-stock-jumps-60-on-73-billion-bid-by-20250922.jpg", "site": "barrons.com", "text": "Pfizer said it would buy a clinical stage biopharma company for up to $7 billion, as it eyes the lucrative weight-loss drug market currently dominated by Eli Lilly and Novo Nordisk.", "url": "https://www.barrons.com/articles/pfizer-metsera-stock-bid-obesity-44dca605"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 07:02:00", "publisher": "WSJ", "title": "Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion", "image": "https://images.financialmodelingprep.com/news/pfizer-to-buy-weightloss-drug-developer-metsera-for-up-20250922.jpg", "site": "wsj.com", "text": "Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that gets the New York drugmaker back into the burgeoning market for obesity drugs.", "url": "https://www.wsj.com/health/pharma/pfizer-to-buy-weight-loss-drug-developer-metsera-for-up-to-7-3-billion-6c8ff920"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 06:54:01", "publisher": "Reuters", "title": "Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion", "image": "https://images.financialmodelingprep.com/news/pfizer-to-buy-weightloss-drug-developer-metsera-for-up-to-49-20250922.jpg", "site": "reuters.com", "text": "Pfizer said on Monday it would acquire weight-loss drug developer Metsera for up to $4.9 billion to secure its position in the lucrative obesity treatment market.", "url": "https://www.reuters.com/legal/litigation/pfizer-buy-weight-loss-drug-developer-metsera-up-49-billion-2025-09-22/"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 06:45:00", "publisher": "Business Wire", "title": "Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio", "image": "https://images.financialmodelingprep.com/news/pfizer-to-acquire-metsera-and-its-nextgeneration-obesity-portfolio-20250922.jpg", "site": "businesswire.com", "text": "NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Metsera, Inc. (NASDAQ: MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portfolio of differentiated oral and injectable incretin, non-incretin and combination therapy candidates with potential best-in.", "url": "https://www.businesswire.com/news/home/20250922965053/en/Pfizer-to-Acquire-Metsera-and-its-Next-Generation-Obesity-Portfolio/"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 01:55:15", "publisher": "Invezz", "title": "Pfizer close to acquiring Metsera for $7.3B, targeting breakthrough obesity drug", "image": "https://images.financialmodelingprep.com/news/pfizer-close-to-acquiring-metsera-for-73b-targeting-breakthrough-obesity-20250922.jpg", "site": "invezz.com", "text": "Pfizer is making a bold move in the pharmaceutical world by closing in on a $7.3 billion deal to acquire Metsera, a biotech firm focused on next-generation anti-obesity drugs, news platform Financial Times reported on Monday.", "url": "https://invezz.com/news/2025/09/22/pfizer-close-to-acquiring-metsera-for-7-3b-targeting-breakthrough-obesity-drug/"}}
{"date": "2025-09-22", "symbol": "PFE", "type": "stock_news", "result": {"symbol": "PFE", "publishedDate": "2025-09-22 00:04:32", "publisher": "Reuters", "title": "Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports", "image": "https://images.financialmodelingprep.com/news/pfizer-closes-in-on-73-billion-takeover-of-antiobesity-drugmaker-20250922.jpg", "site": "reuters.com", "text": "Pfizer is closing in on a potential $7.3 billion takeover of anti-obesity drug developer Metsera , the Financial Times reported on Sunday, citing unidentified sources.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-closes-73-billion-takeover-anti-obesity-drugmaker-metsera-ft-reports-2025-09-22/"}}
